

Vetenskapliga arbeten:

K. FUXE

1. Preservation of cholinesterase and its histochemical demonstration after freeze-drying and polyethylene glycol embedding. Acta morph. Neerl. scand. III, 1107-1113, 1960. Tills. m. B. Fredricsson, B. Holmstedt o. F. Sjöqvist.
2. Cryostate sectioning of frozen tissue. Stain Techn. 37, 377-378, 1962. Tills. m. O. Nilsson.
3. Autofluorescent granules of the uterine epithelium in the spayed mouse. Zeitschr. Wissenschaftl. Mikr. mikroskop. Tech. 65, 292-300, 1963. Tills. m. O. Nilsson.
4. Histochemistry of the lipid granules in the uterine epithelium of the spayed mouse. J. Ultrastruct. Res. 8, 379-390, 1963. Tills. m. O. Nilsson.
5. Histochemistry of the decomposing lipid granules in the uterine epithelium during oestrogen stimulation. Exp. Cell Res. 32, 109-117, 1963.
6. The mouse uterine surface epithelium during the estrous cycle. Anat. Rec. 145, 541-548, 1963. Tills. m. O. Nilsson.
7. Cell culture of mouse uterine epithelium. Acta morphol. Neerl. Scand. 5, 380-384, 1963. Tills. m. O. Nilsson.
8. Cellular localization of monoamines in the median eminence and in infundibular stem of some mammals. Acta physiol. scand. 58, 383-384, 1963.
9. Chemical and histochemical evaluation of the distribution of catecholamines in the rabbit and guinea pig heart. Acta physiol. scand. 59, 184-192, 1963. Tills. m. E.A. Angelakos o. M.L. Torchiana.
10. Cellular localization of monoamines in the median eminence and infundibular stem of some mammals. Z. Zellforsch. 61, 710-724, 1964.
11. Mastcells and monoamines. Experientia 20, 80-82, 1964. Tills. m. J. Adams-Ray, A. Dahlström o. N.-Å. Hillarp.
12. Cellular localization of monoamines in the spinal cord. Acta physiol. scand. 60, 112-119, 1964. Tills. m. A. Carlsson, B. Falck o. N.-Å. Hillarp.
13. A histochemical and biochemical correlation evaluating the effect of reserpine on the storage mechanism of noradrenaline. Acta physiol. scand. 61, 121-130, 1964. Tills. m. G. Sedvall.
14. A method for the demonstration of adrenergic nerve fibres in peripheral nerves. Z. Zellforsch. 62, 602-607, 1964. Tills. m. A. Dahlström.
15. A method for the demonstration of monoamine containing neurons in the central nervous system. Acta physiol. scand. 60, 293-294, 1964. Tills. m. A. Dahlström.
16. Localization of monoamines in the lower brain stem. Experientia. 20, 398-399, 1964. Tills. m. A. Dahlström.
17. Evidence for the existence of monoamine containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta physiol. scand. 62. Suppl. 232. 1-55. Tills. m. A. Dahlström.

18. Demonstration and mapping out of nigrostriatal dopamine neurons. Life Sci. 3, 523-530, 1964. Tills. m. N.-E. Andén, A. Carlsson, A. Dahlström o. N.-Å. Hillarp.
19. Observations on the cellular localization of dopamine in the caudate nucleus of the rat. Z. Zellforsch. 63, 701-706, 1964. Tills. m. T. Hökfelt o. O. Nilsson.
20. Adrenergic mechanisms in the pupillary light - reflex path. Acta physiol. scand. 62, 119-124, 1964. Tills. m. A. Dahlström, N.-Å. Hillarp o. T. Malmfors.
21. Ascending catecholamine system from the lower brain stem. Acta physiol. scand. 62, 485-486, 1964. Tills. m. A. Dahlström, O. Larsson o. U. Ungerstedt.
22. The effect of certain psychopharmaca on the central monoamine neurons. Experientia 20, 690-691, 1964. Tills. m. V. Bartonicek o. A. Dahlström.
23. Uptake of L-dopa and noradrenaline by central adrenergic neurons. Life Sci. 13, 1403-1406, 1964. Tills. m. N.-Å. Hillarp.
24. Depletion of the amine stores in brain catecholamine terminals on amygdaloid stimulation. Acta physiol. scand. 62, 493-494, 1964. Tills. m. L.-M. Gunne.
25. The cellular localization of monoamines in the upper brain stem of the pigeon. J. Comp. Neurol. 125, 255-382, 1965. Tills. m. L. Ljunggren.
26. The cellular localization of monoamines in the area postrema of certain mammals. J. Comp. Neurol. 125, 337-354, 1965. Tills. m. Ch. Owman.
27. The adrenergic innervation of the nasal mucosa of certain mammals. Acta Oto-Laryngol. 59, 65-72, 1965. Tills. m. A. Dahlström.
28. The distribution of adrenergic nerve fibres to the blood-vessels of skeletal muscle. Acta physiol. scand. 64, 75-86, 1965. Tills. m. G. Sedvall.
29. Evidence for the existence of monoamine containing neurons in the central nervous system. II. Experimentally induced changes in the intra-neuronal amine levels. Acta physiol. scand. 64, Suppl. 247. 1-36, 1965. Tills. m. A. Dahlström.
30. Evidence for the existence of monoamine containing neurons in the central nervous system. III. Presence of monoamine containing terminals in the lower brain stem. Z. Zellforsch. 65, 573-596, 1965.
31. Further evidence for the presence of nigro-necstriatal dopamine neurons. Am. J. Anat. 116, 329-333, 1965. Tills. m. N.-E. Andén, A. Dahlström o. K. Larsson.
32. Evidence for the existence of monoamine containing neurons in the central nervous system. IV. The distribution of monoamine terminals in the central nervous system. Acta physiol. scand. 64, Suppl. 247. 39-85, 1965.

33. Site of action of reserpine. Acta pharmacol. 22, 277-292, 1965. Tills. m. A. Dahlström o. N.-Å. Hillarp.
34. Central monoamine neurons and monoamine neurotransmission. Proc. of the XIIIrd Internat. Congr. of Physiological Sciences, Tokyo, Sept. 1965. pp. 419-434.
35. Histochemical and biochemical detection of monoamine release from brain neurons. Life Sci. 4, 809-811, 1965. Tills. m. A. Carlsson, A. Dahlström o. M. Lindqvist.
36. Failure of reserpine to deplete noradrenaline neurons of  $\alpha$ -methyl-noradrenaline formed from  $\alpha$ -methyl-dopa. Acta pharmacol. 22, 270-276, 1965. Tills. m. A. Carlsson, A. Dahlström o. N.-Å. Hillarp.
37. Absence of monoamines in olivo-cochlear fibres in cat. Acta physiol. scand. 64, 259-262, 1965.
38. Reduction of the monoamine stores in the terminals of bulbospinal neurons following stimulation in the medulla oblongata. Life Sci. 4, 1207-1212, 1965. Tills. m. A. Dahlström.
39. A fluorescence and electronmicroscopic study on certain brain regions rich in monoamine terminals. Amer. J. Anat. 117, 33-46, 1965. Tills. m. T. Hökfelt o. O. Nilsson.
40. Mechanoreceptors and adrenergic nerve terminals. Experientia 21, 641-642, 1965. Tills. m. B.Y. Nilsson.
41. Evidence for the existence of outflow of noradrenaline nerve fibres in the ventral roots of the rat spinal cord. Experientia 21, 409, 1965. Tills. m. A. Dahlström.
42. Formation and storage of dopamine in hamster mast cells following the administration of L-DOPA. J. Pharm. Pharmacol. 17, 252-253, 1965. Tills. m. J. Adams-Ray, A. Dahlström o. J. Häggendal.
43. Evidence for the existence of monoamine neurons in the central nervous system. M.D. Thesis, Stockholm 1965.
44. Observations on the adrenergic innervation of the dog's heart. Amer. J. Physiol. 206, 689-692, 1965. Tills. m. A. Dahlström, M. Myatu o. B. Zetterström.
45. Mapping out of CA and 5-HT neuron systems innervating the diencephalon and the telencephalon. Life Sci. 4, 1275-1279, 1965. Tills. m. N.-E. Andén, A. Dahlström o. K. Fuxe.
46. Effects of the amphetamine group on the intraneuronal brain amines in vitro and in vivo. J. Pharm. Pharmacol. 16, 521-524, 1965. Tills. m. A. Carlsson, A. Dahlström, D. Masuoka o. M. Lindqvist.
47. The distribution and possible function of the monoamine nerve terminals of the rabbit olfactory bulb. Life Sci. 4, 2071-2074, 1965. Tills. m. A. Dahlström, L. Olson o. U. Ungerstedt.

48. Studies on central monoamine neurons with special reference to the nigro-neostriatal dopamine neuron system. Symposium on "On the biochemistry and pharmacology of the basal ganglia", New York, Nov. 29th, 1965. Tills. m. N.-E. Andén.
49. Monoamines and the pituitary gland. Acta endocrinol. (Kbh.) 51, 301-314, 1966. Tills. m. A. Dahlström.
50. Morphologic changes in the mouse uterine epithelium during decomposition of lipid granules. Meth. Achievm. Exp. Path. 1, 271-297, 1966. Tills. m. O. Nilsson.
51. Central monoamine neurons. In: Mechanisms on release of biogenic amines. Eds.: U.S. v. Euler, S. Rosell and B. Uvnäs, Pergamon Press, 1966, pp. 31-37. Tills. m. N.-Å. Hillarp o. A. Dahlström.
52. Demonstration and mapping out of central DA, NA and 5-HT neuron systems and their reaction to psychopharmaca. Pharm. Rev. 18, 727-741, 1966. Tills. m. A. Dahlström o. N.-Å. Hillarp.
53. A fluorescence and electronmicroscopic study on central monoamine nerve cells. Anat. Rec. 155, 33-40, 1966. Tills. m. T. Hökfelt, O. Nilsson o. S. Reinius.
54. Ascending NA neurons from the pons and the medulla oblongata. Experientia 22, 44-45, 1966. Tills. m. N.-E. Andén, A. Dahlström, L. Olson o. U. Ungerstedt.
55. Adrenergic innervation of the bronchial muscle of cat. Acta physiol. scand. 66, 507-508, 1966. Tills. m. A. Dahlström, T. Hökfelt o. K.-A. Norberg.
56. Refillment of the catecholamine stores with L-DOPA after depletion induced by tyrosine-hydroxylase inhibition. Life Sci. 5, 605-611, 1966. Tills. m. H. Corrodi o. T. Hökfelt.
57. Effects of tyrosine hydroxylase inhibition on the amine levels of central monoamine neurons. Life Sci. 5, 561-568, 1966. Tills. m. N.-E. Andén, H. Corrodi, A. Dahlström o. T. Hökfelt.
58. Functional role of the nigro-neostriatal dopamine neurons. Acta pharmacol. <sup>Toxicol.</sup> 24, 263-274, 1966. Tills. m. N.-E. Andén, A. Dahlström o. K. Larsson.
59. Histochemical and biochemical effects of diethyldithiocarbamate on tissue catecholamines. J. Pharm. Pharmacol. 18, 60-62, 1966. Tills. m. A. Carlsson, T. Hökfelt o. M. Lindqvist.
60. Further evidence for the existence of tubero-infundibular DA neurons. Acta physiol. scand. 66, 245-246, 1966. Tills. m. T. Hökfelt.
61. The effect of (+)-amphetamine on various central and peripheral catecholamine-containing neurons. Acta pharm. pharmacol. 18, 128-130, 1966. Tills. m. A. Carlsson, B. Hamberger o. M. Lindqvist.

62. Biochemical and histochemical studies on the effects of imipramine-like and (+)-amphetamine on central and peripheral catecholamine neurons. Acta physiol. scand. 67, 481-497, 1966. Tills. m. A. Carlsson, B. Hamberger o. M. Lindqvist.
63. Central catecholamine and 5-hydroxytryptamine neurons - their distribution and properties. Lecture held at the NRP session "On neuronal properties on biogenic amines", March 13th, 1966, Boston.
64. Hjärnans monoaminer - cellulär lokalisation. Nordisk Med. 75, 430, 1966.
65. Experimentally and pharmacologically induced changes in the amine levels of central monoamine neurons as studied with a histochemical technique. XII Scand. Congr. of Physiol., Turku 1966. Acta physiol. scand. 68, Suppl. 277, 55, 1966.
66. Inhibition of amine uptake in tubero-infundibular dopamine neurons and in catecholamine cell bodies of the area postrema. J. pharm. pharmacol. 18, 543-544, 1966. Tills. m. B. Hamberger o. T. Malmfors.
67. The effects of barbiturates on the activity of the catecholamine neurons in the rat brain. J. pharm. pharmacol. 18, 556-558, 1966. Tills. m. H. Corrodi o. T. Malmfors.
68. Responses of skeletal musculature and its vasculature during "diving" in the duck: Peculiarities of the adrenergic vasoconstrictor innervation. Acta physiol. scand. 67, 327-342, 1966. Tills. m. B. Folkow o. R. Sonnenschein.
69. Competition between vasoconstrictor and vasodilator metabolites in exercising skeletal muscle - A comparison between diving and non-diving animals. Presented at the "Symposium on muscle circulation", Bratislava, Sept. 1966. Tills. m. B. Folkow and R. Sonnenschein.
70. The effect of haloperidol and chlorpromazine on the amine levels of central monoamine neurons. Acta physiol. scand. 68, 419-420, 1966. Tills. m. N.-E. Andén, A. Dahlström o. T. Hökfelt.
71. Localization of catecholamine uptake in rat brain after intraventricular injection. Life Sci. 5, 1817-1824, 1966. Tills. m. U. Ungerstedt.
72. The importance of the nervous impulse flow for the depletion of the monoamines from central neurons by some drugs. J. pharm. pharmacol. 18, 630-632, 1966. Tills. m. N.-E. Andén o. T. Hökfelt.
73. Effect of large mesencephalic-diencephalic lesions on the noradrenaline, dopamine, and 5-hydroxytryptamine neurons of the central nervous system. Experientia 22, 842-847, 1966. Tills. m. N.-E. Andén o. K. Larsson.
74. The influence of central catecholamine neurons on the hormone secretion from the anterior and posterior pituitary. Proc. of the Fourth Internat. Symp. on Neurosecretion, Strassbourg, Jyly 1966. Tills. m. T. Hökfelt.

75. Changes in amine levels of the tubero-infundibular dopamine neuron system during implantation in rats. Presented at the Fifth World Congr. of Fertility and Sterility, Stockholm, June 1966. Tills. m. T. Hökfelt o. O. Nilsson. pp. 541-542.
76. The effect of ethanol on the activity of central catecholamine neurons in rat brain. J. Pharm. Pharmacol. 18, 821-823, 1966. Tills. m. H. Corrodi o. T. Hökfelt.
77. Ascending monoamine neurons to the telencephalon and diencephalon. Acta physiol. scand. 67, 313-326, 1966. Tills. m. N.-E. Andén, A. Dahlström, K. Larsson, L. Olson o. U. Ungerstedt.
78. A quantitative study on the nigro-neostriatal dopamine neuron system in rat. Acta physiol. scand. 67, 306-312, 1966. Tills. m. N.-E. Andén, B. Hamberger o. T. Hökfelt.
79. Studies on central monoamine neurons with special reference to the nigro-neostriatal dopamine neuron system. In: Biochemistry and Pharmacology of the Basal Ganglia. 2nd Symp. of the Parkinson's Disease Information and Research Center, New York, 1965. Eds.: E. Costa, L.J. Coté and M.D. Yahr, Raven Press, Hewlett, N.Y. 1966, pp. 123-129. Tills. m. N.-E. Andén.
80. Noradrenaline nerve terminals in the hippocampal region of the rat and the guinea-pig. Z. Zellforsch. 78, 463-473, 1967. Tills. m. T. Blackstad o. T. Hökfelt.
81. The effect of lithium on central monoamine neurons. Psychopharmacol. 11, 345-353, 1967. Tills. m. T. Hökfelt o. M. Schou.
82. The effect of neuroleptics on the activity of central catecholamine neurons. Life Sci. 6, 767-774, 1967. Tills. m. H. Corrodi o. T. Hökfelt.
83. Some observations on the site of action of oxypertin. Naunyn-Schmiedeberg's Arch. Pharmak. u. exp. Path. 256, 450-463, 1967. Tills. m. H. Grobecker, T. Hökfelt, J. Jonsson o. T. Malmfors.
84. Studies on reserpine-resistant uptake mechanisms in the central catecholamine neurons in vivo. Held at the "Fysiologföreningen", Stockholm, Dec. 16, 1967.
85. Failure of dopamine to accumulate in central noradrenaline neurons after depletion with diethyldithiocarbamate. J. Pharm. Pharmacol. 19, 481-483. 1967. Tills. m. A. Carlsson o. T. Hökfelt.
86. Replenishment by 5-hydroxytryptophane of the amine stores in the central 5-hydroxytryptamine neurons after depletion induced by reserpine or by an inhibition of monoamine synthesis. J. Pharm. Pharmacol. 19, 433-438, 1967. Tills. m. H. Corrodi.
87. The effect of drugs on accumulation of amines in tubero-infundibular dopamine neurons. Europ. J. Pharmacol. 1, 334-341, 1967. Tills. m. B. Hamberger o. T. Malmfors.
88. Central catecholamine neurons and conditioned avoidance behaviour. Psychopharmacol. 11, 439-447, 1967. Tills. m. L. Hansson.
89. Identification of dopamine, noradrenaline and 5-hydroxytryptamine varicosities in a fraction containing nerve ending particles. Brain Res. 6, 475-480, 1967. Tills. m. H. Grobecker o. G. Jonsson.

90. Uptake and storage of catecholamines in rabbit brain after chronic reserpine treatment. J. Pharm. Pharmacol. 19, 345-349, 1967. Tills. m. A. Dahlström, B. Hamberger o. T. Hökfelt.
91. Effect of some drugs on central monoamine nerve terminals lacking nerve impulse flow. Europ. J. Pharmacol. 1, 226-232, 1967. Tills. m. N.-E. Andén o. T. Hökfelt.
92. Monoamine pathways to the cerebellar and cerebral cortex. Experientia 23, 838-839, 1967. Tills. m. N.-E. Andén o. U. Ungerstedt.
93. The effect of catecholamine precursors and monoamineoxidase inhibition on the amine levels of central catecholamine neurons after reserpine treatment or tyrosine hydroxylase inhibition. Life Sci. 6, 1345-1350, 1967. Tills. m. H. Corrodi.
94. The effects of drugs interfering with the monoamine metabolism on the central monoamine neurons. IIIrd. Internat. Pharmacol. Congr., S. Paulo, Brazil, July 1966.
95. Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19, 627-629, 1967. Tills. m. N.-E. Andén, A. Rubensson o. T. Hökfelt.
96. Localization of 5-hydroxytryptamine uptake in rat brain after intraventricular injection. J. Pharm. Pharmacol. 19, 335-337, 1967. Tills. m. U. Ungerstedt.
97. Activity changes in the tubero-infundibular dopamine neurons of the rat during various states of the reproductive cycle. Life Sci. 6, 2057-2061, 1967. Tills. m. T. Hökfelt o. O. Nilsson.
98. A modification of the histochemical fluorescence method for the improved localization of 5-hydroxytryptamine. Histochemie 11, 161-166, 1967. Tills. m. G. Jonsson.
99. Oxotremorine and central monoamine neurons. Life Sci., 6, 2257-2266, 1967. Tills. m. H. Corrodi, W. Hammer, F. Sjöqvist o. U. Ungerstedt.
100. Possible role played by central monoamine neurons in thermo-regulation. Acta physiol. scand. 71, 224-232, 1967. Tills. m. H. Corrodi o. T. Hökfelt.
101. Increased impulse flow in bulbospinal noradrenaline neurons by catecholamine receptor blocking agents. Europ. J. Pharmacol. 2, 59-64, 1967. Tills. m. N.-E. Andén, H. Corrodi o. T. Hökfelt.
102. The effect of some psychoactive drugs on central monoamine neurons. Europ. J. Pharmacol. 1, 363-368, 1967. Tills. m. H. Corrodi o. T. Hökfelt.
103. The effect of beta-phenethylamine on the central and peripheral monoamine-containing neurons. Europ. J. Pharmacol. 2, 202-207, 1967. Tills. m. H. Corrodi o. J. Jonsson.
104. Studies on uptake mechanisms in central monoamine neurons. Acta pharmacol. et toxicol. 25, Suppl. 4, 8, 1967. Tills. m. T. Hökfelt o. U. Ungerstedt.
105. Effect of desmethylimipramine, protriptyline and (+)-amphetamine on fluorescence of central adrenergic neurons of rats pretreated with alpha-methyl-DOPA and tetrabenazine or reserpine. Europ. J. Pharmacol. 2, 196-201, 1967. Tills. m. A. Carlsson o. T. Hökfelt.

1968

106. The effect of immobilization stress on the activity of central monoamine neurons. Life Sci. 7, 107-112, 1968. Tills. m. H. Corrodi o. T. Hökfelt.
107. The effect of imipramine of central 5-hydroxytryptamine neurons. J. Pharm. Pharmacol. 20, 150-151, 1968. Tills. m. A. Carlsson o. U. Ungerstedt.
108. Distribution of noradrenaline nerve terminals in cortical areas of the rat. Brain Res. 8, 125-131, 1968. Tills. m. B. Hamberger o. T. Hökfelt.
109. Depletion of noradrenaline in brainstem neurons during sham rage behaviour produced by acute brainstem transection in cat. Brain Res. 7, 448-451, 1968. Tills. m. D. Reis.
110. Localization of indolealkylamines in CNS. Adv. in Pharmacol. 6A, 235-251, 1968. Tills. m. T. Hökfelt. o. U. Ungerstedt.
111. Histochemical studies on the distribution of catecholamines and 5-hydroxytryptamine after intraventricular injections. Histochemie 13, 16-28, 1968. Tills. m. U. Ungerstedt.
112. Central serotonin neurons and thermoregulation. Adv. in Pharmacol. 6B, 49-54, 1968. Tills. m. H. Corrodi o. T. Hökfelt.
113. The effect of imipramine on central monoamine neurons. J. Pharm. Pharmacol. 20, 230-231, 1968. Tills. m. H. Corrodi.
114. Histochemical studies on the effect of (+)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamines and 5-hydroxytryptamine. Europ. J. Pharmacol. 4, 135-144, 1968. Tills. m. U. Ungerstedt.
115. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Brit. J. Pharmacol. 34, 1-7, 1968. Tills. m. N.-E. Andén, H. Corrodi o. T. Hökfelt.
116. Studies on uptake of intraventricularly administered tritiated noradrenaline and 5-hydroxytryptamine with combined fluorescence histochemical and autoradiographic techniques. Histochemie 16, 186-194. Tills. m. T. Hökfelt, M. Ritzén o. U. Ungerstedt.



117. Adrenergic innervation of the carotid sinus. Amer. J. Physiol. 215, 1054-1057, 1968. Tills. m. D. Reis.
118. Evidence that brain noradrenaline release is essential for sham rage behaviour produced by acute brainstem transection in cat. Trans. Amer. Neurologic. Assoc. 93, 268-270, 1968. Tills. m. D. Reis.
119. The effect of phenylamine on central catecholamine and 5-hydroxytryptamine neurons. Biochim. Appl. 14, <sup>Suppl. 1,</sup> 97-107, 1968. Tills. m. H. Grobecker o. T. Hökfelt.

1969

120. Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res. 12, 456-460, 1969. Tills. m. A. Carlsson, J. Jonason o. M. Lindqvist.
121. Distribution of monoamines in the mammalian central nervous system by histochemical studies. In: Metabolism of Amines in the Brain. Proc. of the Symposium of the Brit. and Scand. Pharmacol. Societies, Edinburgh, July 1968. Ed.: G. Hooper, MacMillan, London, 1969, pp. 10-22. Tills. m. T. Hökfelt o. U. Ungerstedt.
122. Turnover studies using synthesis inhibition. In: Metabolism of Amines in the Brain. Proc. of the Symposium of the Brit. and Scand. Pharmacol. Soc., Edinburgh, July 1968. Ed.: G. Hooper, MacMillan, London, 1969, pp. 38-47. Tills. m. N.-E. Andén o. H. Corrodi.
123. Histokemiska studier över effekten av antidepressiva farmaka på upptag, <sup>ackumulation</sup> och frisättning av intraventrikulärt injicerade katekolaminer och 5-hydroxytryptamin. I boken: Studier över antidepressiva. November 1968. Tills. m. U. Ungerstedt.
124. Effects of morphine intoxication on brain catecholamine neurons. Europ. J. Pharmacol. 5, 338-342, 1969. Tills. m. L.-M. Gunne o. J. Jonsson.

125. 6-Hydroxytryptamine - a new tool in monoamine fluorescence histochemistry. Brain Res. 13, 190-195, 1969. Tills. m. G. Jonsson, B. Hamberger o. T. Hökfelt.
126. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl- $\alpha$ -ethyl-meta-tyramine. Europ. J. Pharmacol. 5, 357-366, 1969. Tills. m. A. Carlsson, H. Corrodi o. T. Hökfelt.
127. Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4, $\alpha$ -dimethyl-meta-tyramine. Europ. J. Pharmacol. 5, 367-373, 1969. Tills. m. A. Carlsson, H. Corrodi o. T. Hökfelt.
128. Effect of a new series of bicyclic compounds with potential thymoleptic properties on the reserpine-resistant uptake mechanism of central and peripheral monoamine neurones in vivo and in vitro. Brit. J. Pharmacol. 36, 18-28, 1969. Tills. m. A. Carlsson, B. Hamberger o. T. Malmfors.
129. Catecholamines in the hypothalamus and the pituitary gland. In: Frontiers in Neuroendocrinology, 1969. Eds.: W.F. Ganong and L. Martini, Oxford University Press, Inc., pp. 47-96. Tills. m. T. Hökfelt.
130. The effect of prolonged lithium administration on cerebral monoamine neurons in the rat. Life Sci. 8, 643-651, 1969. Tills. m. H. Corrodi o. M. Schou.
131. The effects of drugs and stereotaxic lesions on the nigro-neostriatal dopamine neurons. 3rd Symp. Parkinson's Disease, Edinburgh 1968. Eds.: F.J. Gillingham and I.M.L. Donaldson, E. & S. Livingstone, Edinburgh and London, 1969, pp. 40-47. Tills. m. T. Hökfelt, U. Ungerstedt, N.-E. Andén, L. Butcher o. A. Rubensson.
132. Cerebellar monoamine nerve terminals, a new type of afferent fibers to the cortex cerebelli. Exp. Brain Res. 9, 63-72, 1969. Tills. m. T. Hökfelt.
133. Decreased turnover in central 5-HT nerve terminals induced by antidepressant drugs of the imipramine type. Europ. J. Pharmacol. 7, 56-59, 1969. Tills. m. H. Corrodi.
134. Det dopaminhaltiga nigro-neostriatala neuronsystemet. Svenska Läkaresällskapet, sammankomst 4.11.1969. Särtryck ur Nordisk Medicin 82, 1130, 1969.

135. Castration, sex hormones, and tubero-infundibular dopamine neurons. Neuroendocrinology 5, 107-120, 1969. Tills. m. T. Hökfelt o. O. Nilsson.
136. Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat. Brain Res. 14, 461-471, 1969. Tills. m. U. Ungerstedt, L.L. Butcher, S.G. Butcher o. N.-E. Andén.
137. Monoamine afferent input to the hypothalamus and the dopamine afferent input to the median eminence. Excerpta Med. Int. Congr. Ser. No. 184, 1969, Progress in Endocrinology. Proc. 3rd Int. Congr. Endocrinology, Mexico 1968. Tills. m. T. Hökfelt.
138. Brain norepinephrine: evidence that neuronal release is essential for sham rage behavior following brainstem transection in cat. Proc. National Acad. Sci. 64, 108-112, 1969. Tills. m. D.J. Reis.
139. Mechanisms of noradrenaline and 5-hydroxytryptamine disappearance induced by  $\alpha$ -methyl-dopa and  $\alpha$ -methyl-metatyrosine. Europ. J. Pharmacol. 8, 302-309, 1969. Tills. m. N.-E. Andén o. M. Henning.
140. Factors involved in the control of the activity of the tubero-infundibular dopamine neurons during pregnancy and lactation. Neuroendocrinology 5, 257-270, 1969. Tills. m. T. Hökfelt o. O. Nilsson.
141. On the role of central monoamine neurons in neuroendocrine mechanisms. Acta physiol. scand. 77, Suppl. 330, 48, 1969. Tills. m. T. Hökfelt.

1970

142. Protection of the neostriatal dopamine stores against reserpine by local treatment with metatyramine. Acta pharmacol. et toxicol. 28, 39-48, 1970. Tills. m. N.-E. Andén o. S.G. Butcher.
143. Effects of antidepressant drugs of the imipramine type on central 5-hydroxytryptamine neurotransmission. Europ. J. Pharmacol. 9, 325-332, 1970. Tills. m. J. Meek o. N.-E. Andén.
144. Evidence for a central noradrenaline receptor stimulation by clonidine. Life Sci. 9, 513-523, 1970. Tills. m. N.-E. Andén, H. Corrodi, B. Hökfelt, T. Hökfelt, C. Rydin o. T. Svensson.
145. Central monoaminergic tracts. In: Principles of Psychopharmacology. Ed.: W.G. Clark & J. del Guidice. Academic Press, New York, 1970, pp. 87-96. Tills. m. T. Hökfelt o. U. Ungerstedt.
146. L-Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition. J. Pharm. Pharmacol. 22, 313-316, 1970. Tills. m. L. Butcher o. J. Engel.
147. Adrenergic and cholinergic nerve terminals in skeletal muscle vessels. Acta physiol. scand. 78, 52-59, 1970. Tills. m. P. Bolme.
148. Antiparkinsonian drugs and central dopamine neurons. Life Sci. 9, 811-824, 1970. Tills. m. M. Goldstein o. Å. Ljungdahl.
149. Central monoamine neurons and pituitary-adrenal activity. In: Progress in Brain Research. Vol.32, p.42-56. Ed.:D. de Wied & J.A.W.M. Weijnen. Elsevier Publ. Co., Amsterdam, 1970. Tills. m. H. Corrodi, T. Hökfelt o. G. Jonsson.
150. Histochemical, biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In: Amphetamines and Related Compounds. Proc. Mario Negri Inst. Pharmacol. Res., Milano. pp. 257-288. Ed.: E. Costa & S. Garattini. Raven Press, New York, 1970. Tills. m. U. Ungerstedt.
151. Behavioural effects of stimulation in the region of the substantia nigra. J. Physiol. 210, 61-62, 1970. Proc. Physiol. Soc. 6 June 1970. Tills. m. G.W. Arbuthnott, T.J. Crow o. U. Ungerstedt.
152. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Europ. J. Pharmacol. 11, 303-314, 1970. Tills. m. N.-E. Andén, S.G. Butcher, H. Corrodi o. U. Ungerstedt.

153. Participation of central monoamine neurons in the regulation of anterior pituitary function with special regard to the neuro-endocrine role of tubero-infundibular dopamine neurons. In: Aspects of Neuroendocrinology. Ed.: W. Bargmann & B. Scharrer. Springer-Verlag, Berlin, Heidelberg, New York, 1970, pp. 192-205. Tills. m. T. Hökfelt.
154. The effect of hormonal steroids on the tubero-infundibular DA neurons and central NA neurons. Excerpta Medica International Congress Series No. 210. No. 118. Abstract presented at the III International Congress on Hormonal Steroids, Hamburg, September 1970. Tills. m. T. Hökfelt.
155. Immunohistochemical localization of dopamine- $\beta$ -hydroxylase in the peripheral and central nervous system. Res. Comm. Chem. Pathol. Pharmacol. 1, 627-636, 1970. Tills. m. M. Goldstein, T. Hökfelt o. T.H. Joh.
156. Fluorescence microscopy in neuroanatomy. In: Contemporary Research Methods in Neuroanatomy. Ed.: W.J.H. Nauta & S.O.E. Ebbesson. Springer-Verlag, Berlin, Heidelberg, New York, 1970, pp. 275-314. Tills. m. T. Hökfelt, G. Jonsson o. U. Ungerstedt.
157. Studies on central and peripheral noradrenaline neurons using a new dopamine- $\beta$ -hydroxylase inhibitor. Europ. J. Pharmacol. 12, 145-155, 1970. Tills. m. H. Corrodi, B. Hamberger o. Å. Ljungdahl.
158. Effect of some antiparkinsonian drugs on catecholamine neurons. J. Pharm. Pharmacol. 22, 733-737, 1970. Tills. m. L.-O. Farnebo, B. Hamberger o. Å. Ljungdahl.
159. Morphological and functional aspects of central monoamine neurons. In: International Review of Neurobiology. Vol. 13, pp. 93-126. Academic Press, New York, 1970. Tills. m. T. Hökfelt o. U. Ungerstedt.
160. Effects of chronic morphine administration on the catecholamine depletion induced by reserpine. J. Pharm. Pharmacol. 22, 550-552, 1970. Tills. m. L.-M. Gunne o. J. Jonsson.
161. Depletion of catecholamines in vivo induced by electrical stimulation of central monoamine pathways. Brain Res. 24, 471-483, 1970. Tills. m. G.W. Arbuthnott, T.J. Crow, L. Olson o. U. Ungerstedt.

162. Histological and molecular biochemistry. In: The Neuroleptics. Mod. Probl. Pharmacopsychiat. Vol. 5, pp. 1-11. Ed.: D.P. Bobon, P.A.J. Janssen & J. Bobon. Karger, Basel-München-Paris-New York, 1970.
163. Biological and pharmacological theories. In: The Neuroleptics. Mod. Probl. Pharmacopsychiat. Vol. 5, pp. 119-122. Ed.: D.P. Bobon, P.A.J. Janssen & J. Bobon. Karger, Basel-München-Paris-New York, 1970.
164. Studies on the action of some psychoactive drugs on central noradrenaline neurones after inhibition of dopamine- $\beta$ -hydroxylase. Brain Res., 24, 451-470, 1970. Tills. m. H. Corrodi, Å. Ljungdahl o. S.-O. Ögren.
165. Central monoaminergic systems and hypothalamic function. In: The Hypothalamus. Ed.: L. Martini, M. Motta & F. Fraschini. Academic Press Inc., New York, 1970, pp. 1-16. Tills. m. T. Hökfelt.
166. Participation of central monoaminergic neurons in the regulation of anterior pituitary secretion. In: Neurochemical Aspects of Hypothalamic Function (L. Martini & J. Meites, eds.) Academic Press, New York, London, 1970, pp. 61-83. (Proc. from the 2nd International Meeting of the International Society for Neurochemistry, Milano 1969, Symp. on Neurochemistry of the Hypothalamus). Tills. m. T. Hökfelt o. G. Jonsson.

1971

167. Pharmacological studies on the hypotensive effects of clonidine. Europ. J. Pharmacol., 13, 168-174, 1971. P. Bösl o. K. Fuxe.
168. Serotonin accumulation after monoamine oxidase inhibition. Biochem. Pharmacol., 20, 693-706, 1971. J.L. Meek o. K. Fuxe.
169. Blockade of p-chlormethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem. Pharmacol., 20, 707-709, 1971. J.L. Meek, K. Fuxe o. A. Carlsson.
170. Central catecholamine turnover and self-stimulation behaviour. Brain Res., 27, 406-413, 1971. G. Arbuthnott, K. Fuxe o. U. Ungerstedt.
171. On the projections from the locus coeruleus noradrenaline neurons: The cerebellar innervation. Brain Res., 28, 165-171, 1971. L. Olson o. K. Fuxe.
172. Minor tranquillizers, stress and central catecholamine neurons. Brain Res., 29, 1-16, 1971. H. Corrodi, K. Fuxe, P. Lidbrink o. L. Olson.
173. DL-5-hydroxytryptophan-induced changes in central monoamine neurons after peripheral decarboxylase inhibition. J. Pharm. Pharmacol., 23, 420-424, 1971. K. Fuxe, L.L. Butcher o. J. Engel.
174. Origin of 5-hydroxytryptophan and l-dopa accumulating in brain following decarboxylase inhibition. Naunyn-Schmiedebergs Arch. Pharmak., 269, 1-6, 1971. P. Bédard, A. Carlsson, K. Fuxe o. M. Lindqvist.
175. The tubero-infundibular (TB) dopamine (DA) neurons and ovulation. Abstract reprinted from Federation Proceedings, Vol. 30, No. 2, 1971. K. Fuxe, T. Hökfelt o. C.D. Sundstedt.
176. Turnover changes in the tubero-infundibular dopamine neurons during the ovarian cycle of the rat. Endocrinology, 88, 1415-1424, 1971. K. Ahrén, K. Fuxe, L. Hamberger o. T. Hökfelt.
177. Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. Europ. J. Pharmacol., 15, 193-199, 1971. N.-E. Andén, H. Corrodi, K. Fuxe o. U. Ungerstedt.

178. Localization of monoamines in the central nervous system. Symposium Bel-Air IV, Genève, Sept. 1970. In "Monoamines Noyaux Gris Centraux et Syndrome de Parkinson" (J. de Ajuriaguerra & G. Gauthier, eds.), Georg & Cie. S.A., Genève, 1971, pp. 23-60. K. Fuxe, T. Hökfelt o. U. Ungerstedt.
179. The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology 10, 521-536, 1971. P. Lidbrink, G. Jonsson o. K. Fuxe.
180. Histochemical fluorescence detection of changes in central monoamine neurons provoked by drugs acting on the CNS. Triangle, Sandoz Journal of Medical Science, 10, 73-84, 1971. K. Fuxe o. T. Hökfelt.
181. Immunohistochemical studies on phenylethanolamine-N-methyltransferase, dopa-decarboxylase and dopamine- $\beta$ -hydroxylase. Experientia 27, 951-952, 1971. M. Goldstein, K. Fuxe, T. Hökfelt o. T.H. Joh.
182. Evidence for a new type of dopamine receptor stimulating agent. J. Pharm. Pharmacol. 23, 989-991, 1971. H. Corrodi, K. Fuxe & U. Ungerstedt.
183. Cellular localization of dopamine- $\beta$ -hydroxylase and phenylethanolamine-N-methyl transferase as revealed by immunohistochemistry. In "Progress in Brain Research" (O. Eränkö, ed.), Vol. 34, pp. 127-138, 1971. K. Fuxe, M. Goldstein, T. Hökfelt & T.H. Joh.
184. The influence of benzquinamide, oxypertine and prenylamine on monoamine levels and on monoamine effects in the spinal cord. Acta pharmacol. et toxicol. 30, 225-237, 1971. N.-E. Andén & K. Fuxe.
185. The effect of tetrahydrocannabinols on central monoamine neurons. Acta Pharmaceutica Suecica 8, 695, 1971. (Symp. on the chemistry and biological activity of Cannabis, Stockholm, Oct. 1971). K. Fuxe & G. Jonsson.
186. Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J. Pharmacol. Exp. Ther. 179, 236-249, 1971. N.-E. Andén, H. Corrodi & K. Fuxe.



187. Morfologia, fisiologia e farmacologia dei neuroni centrali monoaminergici. Aggiornamenti IFI No. 7. 10-16, 1971. K. Fuxe.
188. A new dopamine- $\beta$ -hydroxylase inhibitor: Effects on the noradrenaline concentration and on the action of l-dopa in the spinal cord. Brit. J. Pharmacol. 43; 747-756, 1971. N.-E. Andén & K. Fuxe
189. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: A possible mode of action in Parkinson's disease. Europ. J. Pharmacol. 16, 27-38, 1971. L.-O. Farnebo, K. Fuxe, M. Goldstein, B. Hamberger & U. Ungerstedt.
190. The effect of gonadal steroids on the tubero-infundibular dopamine neurons. In: Excerpta Med. Intern. Congr. Ser. No. 219, pp. 806-813, 1971. (Proc. of the Third Intern. Congr. on Hormonal Steroids, Hamburg, Sept. 1970). K. Fuxe, T. Hökfelt & G. Jonsson.

1972

191. On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Brain-Endocrine Interaction. Median Eminence: Structure and Function. Int. Symp. Munich 1971, pp. 181-223 (Karger, Basel 1972). T. Hökfelt & K. Fuxe.
192. Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Neuroendocrinology 9: 100-122, 1972. T. Hökfelt & K. Fuxe.
193. The effect of psychotomimetic glycolate esters on central monoamine neurons. Europ. J. Pharmacol. 17: 97-102, 1972. N.-E. Andén, H. Corrodi & K. Fuxe.
194. Effect of constant light and androgen-sterilization on the amine turnover of the tubero-infundibular dopamine neurons: Blockade of cyclic activity and induction of a persistent high dopamine turnover in the median eminence. Acta Endocrinol. 69: 625-639, 1972. K. Fuxe, T. Hökfelt & O. Nilsson.
195. Effects of caffeine on central monoamine neurons. J. Pharm. Pharmacol. 24: 155-158, 1972. H. Corrodi, K. Fuxe & G. Jonsson.
196. Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- $\beta$ -hydroxylase inhibitors. J. Pharm. Pharmacol. 24: 177-182, 1972. N.-E. Andén, H. Corrodi & K. Fuxe.
197. On the catecholamine innervation of the hypothalamus, with special reference to the median eminence. Brain Res. 40: 271-281, 1972. G. Jonsson, K. Fuxe & T. Hökfelt.
198. Dopamine- $\beta$ -hydroxylase activity in mouse neuroblastoma tumors and in cell cultures. Proc. Nat. Acad. Sci. USA 69: 1883-1886, 1972. B. Anagnoste, L.S. Freedman, M. Goldstein, J. Broome & K. Fuxe.
199. Early and selective increase in brain dopamine levels after axotomy. Experientia 28: 300-301, 1972. N.-E. Andén, P. Bédard, K. Fuxe & U. Ungerstedt.

200. Effect of tetrahydrocannabinols on central monoamine neurons. Acta Pharmacol. et Toxicol. 31, Suppl. I, 6, 1972. G. Jonsson & K. Fuxe.
201. Intracerebral injections of 5,6-dihydroxytryptamine (5,6-HT). Evidence for selective degeneration of central 5-hydroxytryptamine (5-HT) neurons. Acta Pharmacol. et Toxicol. 31, Suppl. I, 24, 1972. G. Jonsson, K. Fuxe & J. Daly
202. Degeneration processes in central NA neurons. Acta Pharmacol. et Toxicol. 31, Suppl. I, 26, 1972. P. Lidbrink, G. Jonsson & K. Fuxe.
203. Possible mechanism of the hypotensive action of 2,6-dichlorobenzylidene aminoguanidine acetate: Evidence for a central noradrenaline receptor stimulation. Acta Pharmacol. et Toxicol. 31, Suppl. I, 65, 1972. P. Bolme, H. Corrodi & K. Fuxe.
204. Behavioral, biochemical, and histochemical analyses of the central effects of monoamine precursors after peripheral decarboxylase inhibition. Brain Res. 41, 387-411, 1972. L.L. Butcher, J. Engel & K. Fuxe.
205. Immunohistochemical studies on the localization of three catecholamine synthesizing enzymes. In "Histochemistry and Cytochemistry" (T. Takeuchi, K. Ogawa & S. Fujita, eds.), Nakanishi Printing Co. Ltd., Kyoto, Japan, 1972, pp. 483-484. T. Hökfelt, K. Fuxe, M. Goldstein & T.H. Joh.
206. 5,6-Dihydroxytryptamine: A new tool in the mapping out of central 5-HT neurons. In "Histochemistry and Cytochemistry" (T. Takeuchi, K. Ogawa & S. Fujita, eds.), Nakanishi Printing Co. Ltd., Kyoto, Japan, 1972, pp. 487-488. J. Daly, K. Fuxe & G. Jonsson.
207. Further mapping out of central noradrenaline neuron systems: Projections of the "subcoeruleus" area. Brain Res. 43, 289-295, 1972. L. Olson & K. Fuxe.
208. Interaction between cholinergic and catecholaminergic neurones in rat brain. Brain Res. 43, 397-416, 1972. H. Corrodi, K. Fuxe & P. Lidbrink.

209. Mapping of central monoamine neurons in the monkey. Experientia 28, 688-690, 1972. A. Battista, K. Fuxe, M. Goldstein & M. Ogawa.
210. Effects of 5-methoxy-N,N-dimethyltryptamine on central monoamine neurons. Europ. J. Pharmacol. 19, 25-34, 1972. K. Fuxe, B. Holmstedt & G. Jonsson.
211. Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol. Rev. 24, 293-309, 1972. M. Goldstein, K. Fuxe & T. Hökfelt.
212. Farmakologiska studier över läkemedel vid parkinsonism. Nordiskt symposium, Symmetri<sup>®</sup> vid parkinsonism, Göteborg, 1972. L.-O. Farnebo & K. Fuxe.
213. On the role of central monoamine neurons in the regulation of sleep. Fifth International Congress on Pharmacology, San Francisco, Calif., July 23-28, 1972. K. Fuxe, P. Lidbrink & L. Olson.
214. Heterogeneity of striatal and limbic dopamine innervation: Highly fluorescent islands in developing and adult rats. Brain Res. 44, 283-288, 1972. L. Olson, Å. Seiger & K. Fuxe.
215. The effect of pituitary transplants on the tubero-infundibular dopamine neurons in various endocrine states. Acta Endocrinol. 71, 233-244, 1972. L. Olson, K. Fuxe & T. Hökfelt.
216. Hypothermic effect of apomorphine in the mouse. J. Pharm. Pharmacol. 24, 702-705, 1972. K. Fuxe & F. Sjöqvist.
217. Amine turnover changes in the tubero-infundibular dopamine (DA) neurons in immature rats injected with PMS. Neuroendocrinology 10, 282-300, 1972. K. Fuxe, T. Hökfelt, C.-D. Sundstedt, K. Ahrén & L. Hamberger.
218. Barbiturates and meprobamate: Decreases in catecholamine turnover of central dopamine and noradrenaline neuronal systems and the influence of immobilization stress. Brain Res. 45, 507-524, 1972. P. Lidbrink, H. Corrodi, K. Fuxe & L. Olson.
219. ET495 and brain catecholamine mechanisms: Evidence for stimulation of dopamine receptors. Europ. J. Pharmacol. 20, 195-204, 1972. H. Corrodi, L.-O. Farnebo, K. Fuxe, B. Hamberger & U. Ungerstedt.
220. On the function of central catecholamine neurons - their role in cardiovascular and arousal mechanisms. Res. Commun. Chem. Pathol. Pharmacol. 4, 657-697, 1972. P. Bolme, K. Fuxe & P. Lidbrink.

221. Monosynaptic NA and 5-HT projections to the cortex cerebri from the lower brain stem: their possible role in regulation of vigilance states. In "The Sleeping Brain", Perspectives in the Brain Sciences, Vol. 1, pp. 122-127, M.H. Chase, ed. Brain Information Service/Brain Research Institute, UCLA, Los Angeles 1972 (Symposium on Neural circuitry of sleep, Brügge, Belgium June 1971). K. Fuxe, P. Lidbrink & L. Olson.
222. On the effects of minor tranquilizers and barbiturates on central catecholamine neurons. In "The Sleeping Brain", Perspectives in the Brain Sciences, Vol. 1, pp. 158-160, M.H. Chase, ed. Brain Information Service/Brain Research Institute, UCLA, Los Angeles 1972 (Symposium on Neural circuitry of sleep, Brügge, Belgium, June 1971). K. Fuxe, P. Lidbrink, H. Corrodi & L. Olson.

1973

223. Immunohistochemical localization of three catecholamine synthesizing enzymes: Aspects on methodology. Histochemie 33, 231-254, 1973. T. Hökfelt, K. Fuxe, M. Goldstein & T.H. Joh.
224. Effects of intracerebral injections of 6-hydroxydopamine on sleep and waking in the rat. J. Pharm. Pharmacol. 25, 84-87, 1973. P. Lidbrink & K. Fuxe.
225. Tremor and involuntary movements in monkeys: Effect of L-dopa and of a dopamine receptor stimulating agent. Science 179, 816-817, 1973. M. Goldstein, A.F. Battista, T. Ohmoto, B. Anagnoste & K. Fuxe.
226. Effects of intracerebral injections of 5,6-dihydroxytryptamine on central monoamine neurons: Evidence for selective degeneration of central 5-hydroxytryptamine neurons. Brain Research 49, 476-482, 1973. J. Daly, K. Fuxe & G. Jonsson.
227. Action of m-tyrosine in experimental models: Evidence for possible anti-parkinsonian activity. Europ. J. Pharmacol. 21, 230-237, 1973. U. Ungerstedt, K. Fuxe, M. Goldstein, A. Battista, M. Ogawa & B. Anagnoste.
228. Effect of prostaglandin E<sub>2</sub> on central and peripheral catecholamine neurons. Europ. J. Pharmacol. 21, 362-368, 1973. S. Bergström, L.-O. Farnebo & K. Fuxe

229. Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat. Brain Res. 53, 175-180, 1973. T. Hökfelt, K. Fuxe & M. Goldstein.
230. Pharmacological studies on a possible role of central noradrenaline neurons in respiratory control. J. Pharm. Pharmacol. 25, 351-352, 1973. P. Bolme & K. Fuxe.
231. Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409-412, 1973. H. Corrodi, K. Fuxe, T. Hökfelt, P. Lidbrink & U. Ungerstedt
232. The effects of benzodiazepines, meprobamate, and barbiturates on central monoamine neurons. In "The Benzodiazepines" (S. Garattini, E. Mussini and L.O. Randall, eds.), Raven Press, New York, 1973, pp. 203-223. P. Lidbrink, H. Corrodi, K. Fuxe & L. Olson.
233. The histochemical fluorescence method for the demonstration of catecholamines. Theory, practice and application. J. Histochem. Cytochem. 21, 293-311, 1973. K. Fuxe & G. Jonsson.
234. Brain and pituitary-adrenal interactions. Studies on central monoamine neurons. In "Brain-Pituitary-Adrenal Interrelationships", Karger, Basel, 1973, pp. 239-269. K. Fuxe, T. Hökfelt, G. Jonsson, S. Levine, P. Lidbrink & A. Löfström.
235. On the role of central monoamine neurons in sleep mechanisms. In "Pharmacology and the Future of Man", Proc. 5th Int. Congr. Pharmacology, San Francisco 1972, vol. 4, Karger, Basel, 1973, pp. 90-102. P. Lidbrink, H. Corrodi, K. Fuxe & L. Olson.
236. Possible mechanism of the hypotensive action of 2,6-dichlorobenzylidene aminoguanidine: Evidence for central noradrenaline receptor stimulation. Europ. J. Pharmacol. 23, 175-182, 1973. P. Bolme, H. Corrodi & K. Fuxe.
237. Biogenic amine aspects of sleep and waking. In "Sleep: Physiology, Biochemistry, Psychology, Pharmacology, Clinical Implications", 1st European Congr. Sleep Res., Basel 1972, pp. 12-26, W.P. Koella & P. Levin, eds. Karger, Basel 1973. K. Fuxe & P. Lidbrink.

238. Tools in the treatment of Parkinson's disease: Studies on new types of dopamine receptor stimulating agents. In "Advances in Neurology, Vol. 3: Progress in the Treatment of Parkinsonism" (ed. D.B. Calne), Raven Press, New York, 1973, pp. 273-279. K. Fuxe.
239. Evidence for adrenaline neurons in the rat brain. Acta physiol. scand. 89, 286-288, 1973. T. Hökfelt, K. Fuxe, M. Goldstein & O. Johansson.
240. Immunohistochemical studies on monoamine-containing cell systems. Brain Research 62, 461-469, 1973. T. Hökfelt, K. Fuxe & M. Goldstein.
241. The biochemical mechanisms involved in experimentally induced involuntary movements. In "Parkinson's Disease. Rigidity, Akinesia, Behavior, Vol. 2: Selected Communications" (ed. J. Siegfried), Hans Huber Publishers, Bern, 1973, pp. 213-219. (Proceedings of the Fourth International Symposium on Parkinson's Disease, Zurich 1972). M. Goldstein, B. Anagnoste, A.F. Battista, T. Ohmoto & K. Fuxe.
242. Action of neuroleptics on the nigro-neostriatal dopaminergic pathway. In "Psychopharmacology, Sexual Disorders and Drug Abuse", North-Holland Publ. Co., Amsterdam-London, 1973, pp. 407-413. (Proceedings of the Symposia held at the VIII Congress of the Collegium International Neuro-Psychopharmacologicum, Copenhagen 1972). N.-E. Andén, H. Corrodi, K. Fuxe & U. Ungerstedt.
243. Brain-endocrine interaction: Are some effects of ACTH and adrenocortical hormones on neuroendocrine regulation and behaviour mediated via central catecholamine neurons? In "Hormones and Brain Function", Publishing House of the Hungarian Academy of Sciences, Budapest, 1973, pp. 409-425. (Budapest 1971). K. Fuxe, T. Hökfelt, G. Jonsson & P. Lidbrink.
244. Serum and tissue dopamine- $\beta$ -hydroxylase activity in hypophysectomized rats. Europ. J. Pharmacol. 24, 366-374, 1973. L.S. Freedman, M. Roffman, M. Goldstein, K. Fuxe & T. Hökfelt.
245. Central catecholamine neurons and gonadotrophin secretion. In "Endocrinology", (eds. R.O. Scow, F.J.G. Ebling & I.W. Henderson), Intern. Congr. Ser. No. 273, (Proc. Fourth Intern. Congr. Endocrinol., Washington 1972), Excerpta Medica, Amsterdam, 1973, pp. 138-143. T. Hökfelt, K. Fuxe, K. Ajika & A. Löfström.

246. Mapping of central noradrenaline pathways with 6-hydroxy-dopa. Brain Res. 63, 249-261, 1973. Ch. Sachs, G. Jonsson & K. Fuxe.
247. Characterization, localization and regulation of catecholamine synthesising enzymes. In "Frontiers in Catecholamine Research" (eds. E. Usdin & S. Snyder), Pergamon Press, New York 1973, pp. 69-78. M. Goldstein, B. Anagnoste, L.S. Freedman, M. Roffman, R.P. Ebstein, D.H. Park, K. Fuxe & T. Hökfelt.
248. Recent morphological and functional studies on hypothalamic dopaminergic and noradrenergic mechanisms. In "Frontiers in Catecholamine Research" (eds. E. Usdin & S. Snyder), Pergamon Press, New York 1973, pp. 787-794. K. Fuxe, T. Hökfelt, G. Jonsson & A. Löfström.



1974

249. Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain. Brain Research 66, 235-251, 1974. T. Hökfelt, K. Fuxe, M. Goldstein & O. Johansson.
250. Pharmaco-histochemical evidence of the existence of dopamine nerve terminals in the limbic cortex. Europ. J. Pharmacol. 25, 108-112, 1974. T. Hökfelt, K. Fuxe, O. Johansson & Å. Ljungdahl.
251. Selective reserpine-resistant accumulation of catecholamines in central dopamine neurones after dopa administration. Brain Research 67, 439-456, 1974. P. Lidbrink, G. Jonsson & K. Fuxe.
252. 5,7-Dihydroxytryptamine as a tool for the morphological and functional analysis of central 5-hydroxytryptamine neurons. Res. Comm. Chem. Pathol. Pharmacol. 7, 175-187, 1974. J. Daly, K. Fuxe & G. Jonsson.
253. Hallucinogenic phenylethylamines: Interactions with serotonin turnover and receptors. Europ. J. Pharmacol. 25, 176-184, 1974. N.-E. Andén, H. Corrodi, K. Fuxe and J.L. Meek.
254. Benzodiazepines and barbiturates: Turnover changes in central 5-hydroxytryptamine pathways. Europ. J. Pharmacol. 26, 35-40, 1974. P. Lidbrink, H. Corrodi & K. Fuxe.
255. Dopaminergic involvement in hypothalamic function: Extrahypothalamic and hypothalamic control. A neuroanatomical analysis. In "Advances in Neurology", Vol. 5, Raven Press, New York, 1974, pp. 405-419. K. Fuxe, M. Goldstein, T. Hökfelt, G. Jonsson & P. Lidbrink.
256. Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis. In "Advances in Neurology, Vol. 5" (eds. F. McDowell & A. Barbeau), Raven Press, New York, 1974, pp. 79-85. M. Goldstein, B. Anagnoste, A.F. Battista, T. Miyamoto & K. Fuxe.
257. Action of caffeine and theophyllamine on supersensitive dopamine receptors: Considerable enhancement of receptor response to treatment with dopa and dopamine receptor agonists. Med. Biol. 52, 48-54, 1974. K. Fuxe & U. Ungerstedt.

258. Effect of ventromedial tegmental lesions on central catecholamine neurons of monkey brain: Involvement of dopamine pathways in tremor and involuntary movements. Med. Biol. 52: 66-69, 1974. A. Battista, K. Fuxe, M. Goldstein & T. Miyamoto.
259. Dopamine nerve terminals in the rat limbic cortex: Aspects of the dopamine hypothesis of schizophrenia. Science 184, 177-179, 1974. T. Hökfelt, Å. Ljungdahl, K. Fuxe & O. Johansson.
260. Changes in the development of central noradrenaline neurones following neonatal administration of 6-hydroxydopamine. J. Neurochem. 22, 419-429, 1974. G. Jonsson, Ch. Pycock, K. Fuxe & Ch. Sachs.
261. Long-lasting anti-tremor activity induced by 2-Br- $\alpha$ -ergocryptine in monkeys. J. Pharm. Pharmacol. 26, 452-454, 1974. T. Miyamoto, A. Battista, M. Goldstein & K. Fuxe.
262. Studies on central 5-hydroxytryptamine neurons using dihydroxytryptamines: Evidence for regeneration of bulbospinal 5-hydroxytryptamine axons and terminals. In "Dynamics of Degeneration and Growth in Neurons" (eds. K. Fuxe, L. Olson & Y. Zotterman), Pergamon Press, Oxford 1974, pp. 169-179. K. Fuxe, G. Jonsson, L.-G. Nygren & L. Olson.
263. Enhanced sensitivity to the noradrenaline receptor stimulating agent, clonidine, following degeneration of noradrenaline pathways: Studies on arterial pressure, heart rate, and respiration. In "Dynamics of Degeneration and Growth in Neurons" (eds. K. Fuxe, L. Olson & Y. Zotterman), Pergamon Press, Oxford 1974, pp. 597-602. P. Bolme, K. Fuxe, L.-G. Nygren, L. Olson & Ch. Sachs.
264. Characterization of central dopamine neurons. In "Amine Fluorescence Histochemistry" (eds. M. Fujiwara & C. Tanaka), Igaku Shoin Ltd., Tokyo 1974, pp. 13-22. K. Fuxe & T. Hökfelt.
265. Further mapping of central 5-hydroxytryptamine neurons: Studies with the neurotoxic dihydroxytryptamines. In "Advances in Biochemical Psychopharmacology, Vol. 10: Serotonin-New Vistas. Histochemistry and Pharmacology" (eds. E. Costa, G.L. Gessa & M. Sandler), Raven Press, New York 1974, pp. 1-12. K. Fuxe & G. Jonsson.

266. The effect of ventromedial tegmental lesions on the disposition and biosynthesis of dopamine and serotonin. In "Advances in Biochemical Psychopharmacology, Vol. 10: Serotonin-New Vistas. Histochemistry and Pharmacology" (eds. E. Costa, G.L. Gessa & M. Sandler), Raven Press, New York 1974, pp. 45-53. M. Goldstein, A.F. Battista, B. Anagnoste, P.M. Ceasar, K. Fuxe & T. Hökfelt.
267. Microspectrofluorimetric studies on central 5-hydroxytryptamine neurons. In "Advances in Biochemical Psychopharmacology, Vol. 10: Serotonin-New Vistas. Histochemistry and Pharmacology" (eds. E. Costa, G.L. Gessa & M. Sandler), Raven Press, New York, 1974, pp. 55-65. G. Jonsson, P. Einarsson, K. Fuxe & H. Hallman.
268. Some aspects of the interrelationship between central 5-hydroxytryptamine neurons and hormones. In "Advances in Biochemical Psychopharmacology, Vol. 10: Serotonin-New Vistas. Histochemistry and Pharmacology" (eds. E. Costa, G.L. Gessa & M. Sandler), Raven Press, New York 1974, pp. 67-74. K. Fuxe, J. Schubert, T. Hökfelt & G. Jonsson.
269. Effects of piperoxane on sleep and waking in the rat. Evidence for increased waking by blocking inhibitory adrenaline receptors on the locus coeruleus. Acta physiol. scand. 91, 566-567, 1974. K. Fuxe, P. Lidbrink, T. Hökfelt, P. Bolme & M. Goldstein.
270. Functional regeneration of 5-hydroxytryptamine nerve terminals in the rat spinal cord following 5,6-dihydroxytryptamine induced degeneration. Brain Research 78, 377-394, 1974. L.-G. Nygren, K. Fuxe, G. Jonsson & L. Olson.
271. Aporphines. 11. Synthesis and dopaminergic activity of monohydroxyaporphines. Total synthesis of ( $\pm$ )-11-hydroxyaporphine, ( $\pm$ )-11-hydroxynoraporphine, and ( $\pm$ )-11-hydroxy-N-n-propylnoraporphine. J. Med. Chem. 17, 1090-1095, 1974. J.L. Neumeyer, F.E. Granchelli, K. Fuxe, U. Ungerstedt & H. Corrodi.
272. Possible involvement of central adrenaline neurons in vasomotor and respiratory control. Studies with clonidine and its interactions with piperoxane and yohimbine. Europ. J. Pharmacol. 28, 89-94, 1974. P. Bolme, H. Corrodi, K. Fuxe, T. Hökfelt, P. Lidbrink & M. Goldstein.

273. Ergocornine and 2-Br- $\alpha$ -ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52, 121-132, 1974. (K. Fuxe, H. Corrodi, T. Hökfelt, P. Lidbrink & U. Ungerstedt).
274. Inhibitory role of dopamine and 5-hydroxytryptamine in the sexual behaviour of female rats. Europ. J. Pharmacol. 29, 187-191, 1974. (B.J. Everitt, K. Fuxe & T. Hökfelt).
275. The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons. Brain Res. 82, 349-355, 1974. (K. Fuxe, T. Hökfelt, O. Johansson, G. Jonsson, P. Lidbrink & Å. Ljungdahl).
276. Learning, brain noradrenaline and the pituitary-adrenal axis. Med. Biol. 52, 399-405, 1974. (S.-O. Ögren & K. Fuxe).
277. New aspects on the catecholamine innervation of the hypothalamus and the limbic system. in: "Neurosecretion - The Final Neuroendocrine Pathway" (eds. F. Knowles & L. Vollrath), Springer-Verlag, Berlin, Heidelberg, New York, 1974, pp. 223-228. (K. Fuxe, M. Goldstein, T. Hökfelt, G. Jonsson & A. Löfström).
278. Aminergic mechanisms in neuroendocrine control. in: "Neurosecretion - The Final Neuroendocrine Pathway" (eds. F. Knowles & L. Vollrath), Springer-Verlag, Berlin, Heidelberg, New York, 1974, pp. 269-275. (K. Fuxe, T. Hökfelt, G. Jonsson & A. Löfström).
279. Quantitative comparisons of amine fluorescence in cortical noradrenaline terminals using smear preparations. J. Histochem. Cytochem. 22, 1122-1127, 1974. (L.F. Agnati & K. Fuxe).
280. Central catecholamine neurons, behaviour and neuroleptic drugs: An analysis to understand the involvement of catecholamines in schizophrenia. J. psychiat. Res. 11, 151-161, 1974. (K. Fuxe, M. Nyström, M. Tovi, R. Smith & S.-O. Ögren).
281. Recent developments in monoamine histochemistry. J. psychiat. Res., 11, 277-280 (Pergamon Press) (T. Hökfelt, K. Fuxe, M. Goldstein, O. Johansson & Å. Ljungdahl), 1974.
282. Centrala monoaminerga mekanismer, GABA och bensodiazepiner. "Symposium om bensodiazepiner i relation till andra dagsedativa", Roche-Produkter, Stockholm 1974, pp. 45-55. (K. Fuxe, L.F. Agnati, T. Hökfelt, P. Lidbrink, Å. Ljungdahl, M. Pérez de la Mora & S.-O. Ögren).

1975

283. Microspectrofluorimetric analysis of the formaldehyde induced fluorescence in midbrain raphe neurons. Med. Biol. 53, 25-39, 1975. (G. Jonsson, P. Einarsson, K. Fuxe & H. Hallman).
284. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgraduate Medical Journal 51, Suppl. 1, 35-45. (K. Fuxe, L.-O. Farnebo, B. Hamberger & S.-O. Ögren).
285. The possible involvement of GABA mechanisms in the action of benzodiazepines on central catecholamine neurons. In "Mechanism of Action of Benzodiazepines" (eds. E. Costa & P. Greengard), Raven Press, New York 1975, pp. 45-61. (K. Fuxe, L.F. Agnati, P. Bolme, T. Hökfelt, P. Lidbrink, Å. Ljungdahl, M. Pérez de la Mora & S.-O. Ögren).
286. Action of dopamine receptor agonists in forebrain and hypothalamus: Rotational behavior, ovulation, and dopamine turnover. In "Advances in Neurology", Vol. 9 (eds. D.B. Calne, T.N. Chase & A. Barbeau), Raven Press, New York 1975, pp. 223-242. (K. Fuxe, L.F. Agnati, H. Corrodi, B.J. Everitt, T. Hökfelt, A. Löfström & U. Ungerstedt).
287. Effect of ergot drugs on central 5-hydroxytryptamine neurons: Evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Europ. J. Pharmacol. 30, 172-181, 1975. (H. Corrodi, L.-O. Farnebo, K. Fuxe & B. Hamberger).
288. Evidence for involvement of central NA neurones in alcohol intake. Increased alcohol consumption after degeneration of the NA pathway to the cortex cerebri. Neuroscience Letters 1, 41-45, 1975. (K. Kiianmaa, K. Fuxe, G. Jonsson & L. Ahtee).

289. Applications of immunohistochemistry to studies on monoamine cell systems with special reference to nervous tissues. Ann. N.Y. Acad. Sci. 254, 407-432, 1975. (T. Hökfelt, K. Fuxe & M. Goldstein).
290. Studies on the role of monoamines in the hormonal regulation of sexual receptivity in the female rat. In "Sexual Behavior: Pharmacology and Biochemistry" (eds. M. Sandler & G.L. Gessa), Raven Press, New York 1975, pp. 147-159. (B.J. Everitt, K. Fuxe, T. Hökfelt & G. Jonsson).
291. Transmitter histochemistry of the central nervous system. In "Golgi Centennial Symposium. Proceedings" (ed. M. Santini), Raven Press, New York 1975, pp. 401-414. (T. Hökfelt, K. Fuxe, M. Goldstein, O. Johansson & Å. Ljungdahl).
292. Effect of antipsychotic drugs on central catecholamine neurons of rat brain. In "Antipsychotic Drugs, Pharmacodynamics & Pharmacokinetics" (ed. G. Sedvall), Pergamon Press, Oxford, New York 1975, pp. 117-132. (K. Fuxe, L. Agnati, K. Tsuchiya, T. Hökfelt, O. Johansson, G. Jonsson, P. Lidbrink, A. Löfström & U. Ungerstedt).
293. Possible involvement of GABA synapses in the action of neuroleptic drugs on dopamine neurons. In "Antipsychotic Drugs, Pharmacodynamics & Pharmacokinetics" (ed. G. Sedvall), Pergamon Press, Oxford, New York 1975, pp. 227-233. (T. Hökfelt, L. Agnati, K. Fuxe, O. Johansson, G. Jonsson, Å. Ljungdahl & A. Löfström).
294. Immunofluorescence mapping of central monoamine and releasing hormone (LHR) systems. In "Anatomical Neuroendocrinology" (eds. W.E. Stumpf & L.D. Grant), S. Karger, Basel 1975, pp. 381-392. (T. Hökfelt, K. Fuxe, M. Goldstein, O. Johansson, H. Fraser & S.L. Jeffcoate).
295. On the role of central catecholamine and 5-hydroxytryptamine neurons in neuroendocrine regulation. In "Anatomical Neuroendocrinology" (eds. W.E. Stumpf & L.D. Grant), S. Karger, Basel 1975, pp. 420-432. (K. Fuxe, A. Löfström, L. Agnati, B. Everitt, T. Hökfelt, G. Jonsson & F.-A. Wiesel).
296. The effect of dopamine receptor stimulating and blocking agents on the activity of supersensitive dopamine receptors and on the amine turnover in various dopamine nerve terminal systems in the rat brain. J. Pharmacol. (Paris) 6, 117-129, 1975. (K. Fuxe, L.F. Agnati, T. Hökfelt, G. Jonsson, P. Lidbrink, Å. Ljungdahl, A. Löfström & U. Ungerstedt).

297. Serotonin, catecholamines and sexual receptivity of female rats. Pharmacological findings. J. Pharmacol. (Paris) 6, 269-276, 1975. (B.J. Everitt, K. Fuxe & T. Hökfelt).
298. Role of monoamines in the control by hormones of sexual receptivity in the female rat. J. comp. physiol. Psychol. 89, 556-572, 1975. (B.J. Everitt, K. Fuxe, T. Hökfelt & G. Jonsson).
299. Anatomical and functional studies of monoamines in the limbic system. VIIth International Congress of Neuropathology, Budapest, Hungary, 1-7 Sept. 1974. Excerpta Medica, Amsterdam 1975, pp. 185-190. (K. Fuxe, T. Hökfelt, B.J. Everitt, O. Johansson, G. Jonsson, P. Lidbrink, Å. Ljungdahl & S.-O. Ögren).
300. The use of amine fluorescence histochemistry in the study of drugs, especially morphine, on the CNS. Neuropharmacology 14, 903-912, 1975. (K. Fuxe, L. Agnati, P. Bolme, B.J. Everitt, T. Hökfelt, G. Jonsson, Å. Ljungdahl & A. Löfström).
301. The topography of central catecholamine pathways in relation to their possible role in blood pressure control. In "Central Action of Drugs in Blood Pressure Regulation" (eds. D.S. Davies & J.S. Reid), Pitman Medical, London 1975, pp. 8-22. (K. Fuxe, T. Hökfelt, P. Bolme, M. Goldstein, O. Johansson, G. Jonsson, P. Lidbrink, Å. Ljungdahl & Ch. Sachs).
302. The effects of 5,7-dihydroxytryptamine lesions of ascending 5-hydroxytryptamine pathways on the sexual and aggressive behaviour of female rats. J. Pharmacol. (Paris) 6, 25-32, 1975. (B.J. Everitt, K. Fuxe & G. Jonsson).
303. Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: Possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs. Med. Biol. 53, 177-183, 1975. (K. Fuxe, T. Hökfelt, Å. Ljungdahl, L. Agnati, O. Johansson & M. Pérez de la Mora).
304. Effect of apomorphine on the GABA turnover in the DA cell group rich area of the mesencephalon. Evidence for the involvement of an inhibitory gabergic feedback control of the ascending DA neurons. Neuroscience Letters 1, 109-114, 1975. (M. Pérez de la Mora, K. Fuxe, T. Hökfelt & Å. Ljungdahl).

305. Thyrotropin releasing hormone (TRH)-containing nerve terminals in certain brain stem nuclei and in the spinal cord. Neuroscience Letters 1, 133-139, 1975. (T. Hökfelt, K. Fuxe, O. Johansson, S. Jeffcoate & N. White).
306. Distribution of thyrotropin-releasing hormone (TRH) in the central nervous system as revealed with immunohistochemistry. Europ. J. Pharmacol. 34, 389-392, 1975. (T. Hökfelt, K. Fuxe, O. Johansson, S. Jeffcoate & N. White).
307. Effects of methergoline on central monoamine neurones. Evidence for a selective blockade of central 5-HT receptors. Neuroscience Letters 1, 283-290, 1975. (K. Fuxe, L. Agnati & B. Everitt).
308. Effects of 6-OH-DA induced lesions of the ascending noradrenaline and adrenaline pathways to the tel- and diencephalon on FSH, LH and prolactin secretion in the ovariectomized female rat. In "Chemical Tools in Catecholamine Research, Vol 1", (eds. G. Jonsson, T. Malmfors & Ch. Sachs), North-Holland Publishing Company 1975, pp. 273-283. (K. Fuxe, P. Eneroth, J.Å. Gustavsson, T. Hökfelt, G. Jonsson, A. Löfström & P. Skett).
309. Mapping and relationship of hypothalamic neurotransmitters and hypothalamic hormones. In "Proceedings of the Sixth International Congress of Pharmacology, Vol. 3, CNS and Behavioural Pharmacology", (eds. J. Tuomisto & M.K. Paasonen), Finnish Pharmacological Society 1975, pp. 93-110. (T. Hökfelt, O. Johansson, K. Fuxe, A. Löfström, M. Goldstein, D. Park, R. Ebstein, H. Fraser, S. Jeffcoate, S. Efendic, R. Luft & A. Arimura).
310. The effects of hormones and psychoactive drugs on the tubero-infundibular neurons. In "Some Aspects of Hypothalamic Regulation of Endocrine Functions". F.K. Schattauer Verlag, Stuttgart, New York 1975, pp. 51-61. (K. Fuxe & T. Hökfelt).
311. On the neuropharmacology of ET 495. In "Proceedings of the First International Symposium on Piribedil", Servier Research Institute, Paris 1975, pp. 166-176. (K. Fuxe, H. Corrodi, L.-O. Farnebo, B. Hamberger and U. Ungerstedt).



1976

312. Microfluorimetric quantitation of catecholamine fluorescence of rat median eminence. I. Aspects on the distribution of dopamine and noradrenaline nerve terminals J. Histochem. Cytochem. 24, 415-426, 1976. (A. Löfström, G. Jonsson & K. Fuxe).
313. Microfluorimetric quantitation of catecholamine fluorescence in rat median eminence. II. Turnover changes in hormonal states. J. Histochem. Cytochem. 24, 430-442, 1976. (A. Löfström, G. Jonsson, F.-A. Wiesel & K. Fuxe).
314. Role of monoamines in the control of gonadotrophin secretion. In "Neuroendocrine Regulation of Fertility" (ed. T.C. Anand Kumar), Karger, Basel 1976, pp. 124-140. (K. Fuxe, T. Hökfelt, L. Agnati, A. Löfström, B.J. Everitt, O. Johansson, G. Jonsson, W. Wuttke & M. Goldstein).
315. Studies on the cholinergic and dopaminergic innervation of the neostriatum with the help of intraneostriatal injections of drugs. Pharmac. Ther. B, 2, 29-36, 1976. (K. Fuxe & U. Ungerstedt).
316. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: Studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour. Pharmac. Ther. B, 2, 41-47, 1976. (K. Fuxe & U. Ungerstedt).
317. The effect of mepiprazole on central monoamine neurons. Evidence for increased 5-hydroxytryptamine and dopamine receptor activity. Europ. J. Pharmacol. 35, 93-108, 1976. (K. Fuxe, L.F. Agnati & U. Ungerstedt).
318. Aporphines. 14. Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propyl-noraporphine. J. Med. Chem. 19, 25-29, 1976. (J.L. Neumeyr, J.H. Reinhard, W.P. Dafeldecker, J. Guarino, D.S. Kosersky, K. Fuxe & L. Agnati).
319. Behavioral effects of 5,7-dihydroxytryptamine lesions of ascending 5-hydroxytryptamine pathways. Brain Res. 107, 385-399, 1976. (K. Hole, K. Fuxe & G. Jonsson).

320. Further evidence that apomorphine increases GABA turnover in the DA cell body rich and DA nerve terminal rich areas of the brain. Neuroscience Letters 2, 239-242, 1976. (M. Pérez de la Mora, K. Fuxe, T. Hökfelt & Å. Ljungdahl).
321. The antiparkinsonian efficacy of bromocriptine. Neurology 26, 405-409, 1976. (A. Lieberman, M. Zolfaghari, D. Boal, H. Hassouri, B. Vogel, A. Battista, K. Fuxe & M. Goldstein).
322. Interactions between hypothalamic catecholamine nerve terminals and LRF containing neurons. Further evidence for an inhibitory dopaminergic and a facilitatory noradrenergic influence. In: Basic Applications and Clinical Uses of Hypothalamic Hormones. Excerpta Medica Intern. Congr. Ser. No. 374, pp. 165-177. Excerpta Medica, Amsterdam. (K. Fuxe, A. Löfström, P. Eneroth, J.-Å. Gustafsson, T. Hökfelt, P. Scett, W. Wuttke, H. Fraser & S. Jeffcoate).
323. Immunohistochemical evidence for the existence of angiotensin II-containing nerve terminals in the brain and spinal cord in the rat. Neuroscience Letters 2, 229-234, 1976. (K. Fuxe, D. Ganten, T. Hökfelt & P. Bolme).
324. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Europ. J. Pharmacol. 38, 31-38, 1976. (B.B. Fredholm, K. Fuxe & L. Agnati).
325. On the role of neurotransmitters and hypothalamic hormones and their interactions in hypothalamic and extrahypothalamic control of pituitary function and sexual behavior. In: Subcellular Mechanisms in Reproductive Neuroendocrinology (eds. F. Naftolin, K.J. Ryan & J. Davies), pp. 193-246. Elsevier Scientific Publishing Co., Amsterdam 1976. (K. Fuxe, T. Hökfelt, A. Löfström, O. Johansson, L. Agnati, B. Everitt, M. Goldstein, S. Jeffcoate, N. White, P. Eneroth, J.-Å. Gustafsson & P. Skett).
326. The effect of dl-, l- and d-propranolol on central monoamine neurones. I. Studies on dopamine mechanisms. Neuroscience Letters 3, 45-52, 1976. (K. Fuxe, P. Bolme, L. Agnati & B.J. Everitt).
327. The effect of dl-, l- and d-propranolol on central monoamine neurones. II. Studies on noradrenaline mechanisms. Neuroscience Letters 3, 53-60, 1976. (K. Fuxe, P. Bolme, L. Agnati & B.J. Everitt).

328. Distribution and properties of PNMT in the brain of various mammalian species. In: Trace Amines and the Brain (E. Usdin & M. Sandler, eds.), Psychopharmacology Series Vol. 1, pp. 191-208, Marcel Dekker, Inc., New York - Basel 1976. (M. Goldstein, J.Y. Lew, Y. Matsumoto, J. Pearson, K. Fuxe & T. Hökfelt).
329. On the biochemistry and pharmacology of hallucinogens. In: Schizophrenia Today (eds. D. Kemali, G. Bartholini & D. Richter), pp. 135-157. Pergamon Press 1976. (K. Fuxe, B.J. Everitt, L. Agnati, B. Fredholm & G. Jonsson).
330. A system for measuring the noradrenaline receptor contribution to the flexor reflex. Med. Biol. 54: 352-363, 1976. (J.H. Austin, L.G. Nygren & K. Fuxe).
331. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. I. Tyrosine hydroxylase in the mes- and diencephalon. Med. Biol. 54: 427-453. 1976. (T. Hökfelt, O. Johansson, K. Fuxe, M. Goldstein & D. Park).
332. Resistance of central phenylethanolamine-N-methyltransferase containing neurons to 6-hydroxydopamine. Med. Biol. 54: 421-426, 1976. (G. Jonsson, K. Fuxe, T. Hökfelt & M. Goldstein).
333. Monoamine neuron systems in the hypothalamus and their relation to the GABA and peptide containing neurons. In: Colloque de synthèse 1976, série Action Thématique Rapport No. 7: Action thématiques 22 et 35 Neuro-endocrinologie, pp. 17-40. INSERM, Paris 1976. (K. Fuxe, T. Hökfelt, O. Johansson, D. Ganten, M. Goldstein, M. Pérez de la Mora, L. Possani, R. Tapia, L. Teran, R. Palacios, S. Said & V. Mutt).
334. Central adrenaline receptors and blood pressure regulation: Evidence for an adrenergic vasodepressor system mediating the actions of clonidine. In: Recent Advances in Hypertension, Vol. 3 (eds. P. Milliez & M. Safar), pp. 72-80. Laboratoires Boehringer Ingelheim, Reims, France 1976. (K. Fuxe, P. Bolme, T. Hökfelt & M. Goldstein).
335. Evidence for a central inhibitory adrenaline mechanism in the blood pressure lowering effect of morphine, propranolol and  $\alpha$ -methyldopa. In: Recent Advances in Hypertension, Vol. 3 (eds. P. Milliez & M. Safar), pp. 86-93. Laboratoires Boehringer Ingelheim, Reims, France 1976. (P. Bolme, K. Fuxe, L. Agnati, T. Hökfelt & B. Everitt).

336. The effect of beta-adrenergic blocking agents on arterial blood pressure and central monoamine turnover: Possibility of agonist activity at central adrenaline receptors. In: Beta-Adrenergic Blockers and Hypertension (eds. D. Ganten, R. Dietz, B. Lüth & F. Gross), pp. 131-142. Georg Thieme Verlag, Stuttgart 1976. (K. Fuxe, P. Bolme & B. Everitt).
337. Special morphological features of the neostriatal dopamine innervation. In: Advances in Parkinsonism (eds. W. Birkmayer & O. Hornykiewicz), pp. 55-63. Editiones 'Roche', Basle 1976. (K. Fuxe, T. Hökfelt, M. Goldstein, O. Johansson & L. Agnati).
338. Pre- and postsynaptic effects of dopaminergic agonists: Antiparkinsonian efficacy and effects on dopamine synthesis. In: Advances in Parkinsonism (eds. W. Birkmayer & O. Hornykiewicz), pp. 236-243. Editiones 'Roche', Basle 1976. (M. Goldstein, A.F. Battista, Y. Matsumoto, R.L. Bronaugh, J.Y. Lew, K. Fuxe & T. Hökfelt).

1977

339. Localization and characterization of phenylethanolamine N-methyl transferase in the brain of various mammalian species. Brain Research 119: 199-210. (J.Y. Lew, Y. Matsumoto, J. Pearson, M. Goldstein, T. Hökfelt & K. Fuxe).
340. Dopamine in the nucleus accumbens: preferential increase of DA turnover by rat prolactin. Brain Research 122: 177-182, 1977. (K. Fuxe, P. Eneroth, J.-Å. Gustafsson, A. Löfström & P. Skett).
341. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. II. Tyrosine hydroxylase in the telencephalon. Med. Biol. 55: 21-40, 1977. (T. Hökfelt, O. Johansson, K. Fuxe, M. Goldstein & D. Park).
342. Dopamine and sexual behaviour in female rats. Effects of dopamine receptor agonists and sulpiride. Neuroscience Letters 4: 209-213, 1977. (B.J. Everitt & K. Fuxe).
343. Serotonin and sexual behaviour in female rats. Effects of hallucinogenic indolealkylamines and phenylethylamines. Neuroscience Letters 4: 215-220, 1977. (B.J. Everitt & K. Fuxe).
344. Functional morphology of the median eminence. On the involvement of catecholamines in the control of FSH, LH and prolactin secretion. In: Progress in Reproductive Biology. Vol. 2. Clinical Reproductive Neuroendocrinology (eds. P.O. Hubinont, M. L'Hermite & C. Robyn), pp. 41-53. Karger, Basel 1977. (K. Fuxe, A. Löfström, L. Agnati, T. Hökfelt, O. Johansson, P. Eneroth, J.-Å. Gustafsson, P. Skett, S. Jeffcoate & H. Fraser).
345. Effects of methionine-enkephalin on prolactin release and catecholamine levels and turnover in the median eminence. Europ. J. Pharmacol. 43: 89-90, 1977. (L. Ferland, K. Fuxe, P. Eneroth, J.-Å. Gustafsson & P. Skett).
346. Central monoaminergic pathways. Their role in control of lutropin, follitropin and prolactin secretion. In: Excerpta Medica International Congress Series No. 402, Endocrinology. Proc. Vth Intern. Congr. Endocrinol., Hamburg, Vol. 1 (ed. V.H.T. James), pp. 136-143. Excerpta Medica, Amsterdam 1977. (K. Fuxe, A. Löfström, L. Agnati, P. Eneroth, J.-Å. Gustafsson, T. Hökfelt & P. Skett).

347. Prolactin-like immunoreactivity: Localization in nerve terminals of rat hypothalamus. Science 196: 899-900, 1977. (K. Fuxe, T. Hökfelt, P. Eneroth, J.-Å. Gustafsson & P. Skett).
348. The brain isorenin-angiotensin system: Localization and biological function. In: Hypertension and Brain Mechanisms, Progress in Brain Research, Vol. 47 (eds. W. De Jong pp. 155-159. Elsevier/North-Holland Biomedical Press, Amsterdam 1977. (D. Ganten, K. Fuxe, U. Ganten, T. Hökfelt & P. Bolme).
349. Evidence for a nerve impulse-dependent GABA accumulation in the substantia nigra after treatment with  $\gamma$ -glutamylhydrazide. Neuroscience Letters 5: 75-82, 1977. (M. Pérez de la Mora, K. Fuxe, T. Hökfelt & Å. Ljungdahl).
350. On the catecholamine control of growth hormone regulation. Evidence for discrete changes in dopamine and noradrenaline turnover following growth hormone administration. Neuroscience Letters 5: 83-89, 1977. (K. Andersson, K. Fuxe, P. Eneroth, J.-Å. Gustafsson & P. Skett).
351. Regulation of the mesocortical dopamine neurons. In: Advances in Biochemical Psychopharmacology, Vol. 16 (eds. E. Costa & G.L. Gessa), pp. 47-55, Raven Press, New York 1977. (K. Fuxe, T. Hökfelt, L. Agnati, O. Johansson, Å. Ljungdahl & M. Pérez de la Mora).
352. Hypothalamic dopamine neurons and hypothalamic peptides. In: Advances in Biochemical Psychopharmacology, Vol. 16 (eds. E. Costa & G.L. Gessa), pp. 99-108. Raven Press, New York 1977. (T. Hökfelt, O. Johansson, K. Fuxe, R. Elde, M. Goldstein, D. Park, S. Efendic, R. Luft, H. Fraser & S. Jeffcoate).
353. Dopaminergic drugs and ovulation: Studies on PMS-induced ovulation and changes in median eminence DA and NE turnover in immature female rats. In: Advances in Biochemical Psychopharmacology, Vol. 16 (eds. E. Costa & G.L. Gessa), pp. 159-168. Raven Press, New York 1977. (L. Agnati, K. Fuxe, A. Löfström & T. Hökfelt).
354. Studies on the role of dopamine in cardiovascular and respiratory control: Central versus peripheral mechanisms. In: Advances in Biochemical Psychopharmacology, Vol. 16 (eds. E. Costa & G.L. Gessa), pp. 281-290. Raven Press, New York 1977. (P. Bolme, K. Fuxe, T. Hökfelt & M. Goldstein).

355. Effect of dopaminephilic agents and cAMP on tyrosine hydroxylase activity. In: *Advances in Biochemical Psychopharmacology*, Vol. 16 (eds. E. Costa & G.L. Gessa), pp. 447-453. Raven Press, New York 1977. (M. Goldstein, R.L. Bronaugh, J.Y. Lew, T. Ohashi, G.S. Drummond & K. Fuxe).
356. Action of  $\beta$ (4-chlorophenyl)GABA,  $\gamma$ -hydroxybutyrolactone, and apomorphine on central dopamine neurons. In: *Advances in Biochemical Psychopharmacology*, Vol. 16 (eds. E. Costa & G.L. Gessa), 489-494. Raven Press, New York 1977. (K. Fuxe, L. Agnati, B.J. Everitt, T. Hökfelt, Å. Ljungdahl & M. Pérez de la Mora).
357. GABA-DA interactions and their possible relation to schizophrenia. In: *Psychopathology and Brain Dysfunction* (eds. C. Shagass, S. Gershon & A.J. Friedhoff), pp. 97-111. Raven Press, New York 1977. (K. Fuxe, M. Perez de la Mora, T. Hökfelt, L. Agnati, Å. Ljungdahl & O. Johansson).
358. Immunohistochemical evidence for the existence of angiotensin II containing nerve terminals in the central nervous system of the rat. In: *Central Actions of Angiotensin and Related Hormones* (eds. J.P. Buckley, C.M. Ferrario & M.F. Lokhandwala), pp. 515-518. Pergamon Press Inc., New York-Oxford-Toronto-Sydney-Paris-Frankfurt 1977. (K. Fuxe, D. Ganten, T. Hökfelt & P. Bolme).
359. On the role of brain noradrenaline and the pituitary-adrenal axis in avoidance learning. I. Studies with corticosterone, Neurosci. Lett. 5, 291-296, 1977. (S.-O. Ögren & K. Fuxe).
360. The effects of 5,7-dihydroxytryptamine-induced lesions of the ascending 5-hydroxytryptamine pathways on the sleep-wakefulness cycle. Brain Res. 131, 287-301, 1977. (K. Kiianmaa & K. Fuxe).
361. Vasoactive intestinal polypeptide and the nervous system: Immunohistochemical evidence for localization in central and peripheral neurons, particularly intracortical neurons of the cerebral cortex. Neurosci. Lett. 5, 241-246, 1977. (K. Fuxe, T. Hökfelt, S.I. Said & V. Mutt).
362. Involvement of central catecholamines in the feedback actions of  $17\beta$ -estradiolbenzoate on luteinizing hormone secretion in the ovariectomized female rat. Psychoneuroendocrinology 2, 203-225, 1977. (K. Fuxe, A. Löfström, P. Eneroth, J.-Å. Gustafsson, P. Skett, T. Hökfelt, F.-A. Wiesel & L. Agnati).

363. Some attempts to explore possible central GABAergic mechanisms with special reference to control of dopamine neurons. In: *Neuroregulators and Psychiatric Disorders* (E. Usdin, D.A. Hamburg & J.D. Barchas, eds.), pp. 358-369. Oxford University Press, New York 1977. (T. Hökfelt, Å. Ljungdahl, K. Fuxe, O. Johansson, M. Perez de la Mora & L. Agnati).
364. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. I. Studies in the male rat. Med. Biol. 55, 148-157, 1977. (K. Fuxe, L. Agnati, P. Eneroth, J.-Å. Gustafsson, T. Hökfelt, A. Löfström, B. Skett & P. Skett).
365. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. II. Inhibitory influence of nicotine on LH, FSH and prolactin secretion in the ovariectomized female rat and its relation to regional changes in dopamine and noradrenaline levels and turnover. Med. Biol. 55, 158-166, 1977. (P. Eneroth, K. Fuxe, J.-Å. Gustafsson, T. Hökfelt, A. Löfström, P. Skett & L. Agnati).
366. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. III. Studies on prepubertal female rats treated with pregnant mare serum gonadotropin. Med. Biol. 55, 167-176, 1977. (P. Eneroth, K. Fuxe, J.-Å. Gustafsson, T. Hökfelt, A. Löfström, P. Skett & L. Agnati).
367. Studies on GABA accumulation induced by  $\gamma$ -glutamyl-hydrazide in regions of rat brain following treatment with a tyrosine hydroxylase inhibitor and 6-hydroxy-dopamine. Experientia 33, 945-947, 1977. (M. Pérez de la Mora & K. Fuxe).
368. Central monoaminergic pathways with emphasis on their relation to the so called 'extrapyramidal motor system'. Pharmac. Ther. B. 3, 169-210, 1977. (K. Fuxe, T. Hökfelt, L. Olson & U. Ungerstedt).
369. Brain GABA, dopamine and acetylcholine interactions. I. Studies with oxotremorine. Brain Research 135, 107-122, 1977. (M. Pérez de la Mora & K. Fuxe).
370. Enhancement of sexual behavior in the female rat by nicotine. Pharmacology Biochemistry & Behavior 7, 147-151, 1977. (K. Fuxe, B.J. Everitt & T. Hökfelt).
371. Possible involvement of GABA mechanisms in central cardiovascular and respiratory control. Studies on the interaction between diazepam, picrotoxin and clonidine. Med. Biol. 55, 301-309, 1977. (P. Bolme & K. Fuxe).



372. On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neurosci. Lett. 6, 339-343, 1977. (K. Fuxe, S.-O. Ögren, L. Agnati, J.-Å. Gustafsson & G. Jonsson).
373. Immunohistochemical evidence of vasoactive intestinal polypeptide-containing neurons and nerve fibers in sympathetic ganglia. Neuroscience 2, 885-896, 1977. (T. Hökfelt, L.-G. Elfvin, M. Schultzberg, K. Fuxe, S.I. Said, V. Mutt & M. Goldstein).
374. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. III. Three catecholamine synthesizing enzymes in the rhinencephalon. In: Rhinencéphale Neurotransmetteurs et Psychoses (Symposium Bel-Air V, Genève, 1976), (J. de Ajuriaguerra and R. Tissot, eds.), pp. 79-113. Georg & Cie., Genève 1977. (T. Hökfelt, O. Johansson, K. Fuxe, M. Goldstein & D. Park).
375. Possibilities of a differential blockade of central monoamine receptors. In: Rhinencéphale Neurotransmetteurs et Psychoses (Symposium Bel-Air V, Genève, 1976), (J. de Ajuriaguerra and R. Tissot, eds.), pp. 253-289. Georg & Cie., Genève 1977. (K. Fuxe, S.-O. Ögren, B. Fredholm, L. Agnati, T. Hökfelt & M. Perez de la Mora).
376. Evidence for an inhibitory dopaminergic and stimulatory noradrenergic hypothalamic influence of PMS-induced ovulation in the immature rat. I. Catecholamine turnover changes in relation to the critical period. Neuroendocrinology 24, 270-288, 1977. (A. Löfström, L.F. Agnati & K. Fuxe).
377. Evidence for an inhibitory dopaminergic and stimulatory noradrenergic hypothalamic influence on PMS-induced ovulation in the immature rat. II. A pharmacological analysis. Neuroendocrinology 24, 289-316, 1977. (A. Löfström, L.F. Agnati, K. Fuxe & T. Hökfelt).
378. Conclusions of pharmacology session. In: Rhinencéphale Neurotransmetteurs et Psychoses (Symposium Bel-Air V, Genève 1976), (J. de Ajuriaguerra and R. Tissot, eds.), pp. 335-339. Georg & Cie., Genève 1977. (K. Fuxe).
379. A method to measure the distribution pattern of specific nerve terminals in sampled regions. Studies on tyrosine hydroxylase LHRH, TRH and GIH immunofluorescence. J. Histochem. Cytochem. 25, 1222-1236, 1977. (L.F. Agnati, K. Fuxe, T. Hökfelt, M. Goldstein & S.L. Jeffcoate).

1978

380. Distribution of peptide-containing neurons. In: Psychopharmacology: A Generation of Progress (M.A. Lipton, A. DiMascio & K.F. Killam, eds.), pp. 39-66. Raven Press, New York 1978. (T. Hökfelt, R. Elde, O. Johansson, Å. Ljungdahl, M. Schultzberg, K. Fuxe, M. Goldstein, G. Nilsson, B. Pernow, L. Terenius, D. Ganten, S.L. Jeffcoate, J. Rehfeld & S. Said).
381. Mapping out central catecholamine neurons: Immunohistochemical studies on catecholamine-synthesizing enzymes. In: Psychopharmacology: A Generation of Progress (M.A. Lipton, A. DiMascio & K.F. Killam, eds.), pp. 67-94. Raven Press, New York 1978. (K. Fuxe, T. Hökfelt, L.F. Agnati, O. Johansson, M. Goldstein, M. Perez de la Mora, L. Possani, R. Tapia, L. Teran & R. Palacios).
382. Localization and function of PNMT in the central nervous system. In: Psychopharmacology: A Generation of Progress (M.A. Lipton, A. DiMascio & K.F. Killam, eds.), pp. 261-269. Raven Press, New York 1978. (M. Goldstein, J.Y. Lew, Y. Matsumoto, T. Hökfelt & K. Fuxe).
383. On the functional role of hypothalamic catecholamine neurons in control of the secretion of hormones from the anterior pituitary, particularly in the control of LH and prolactin secretion. In: Brain-Endocrine Interaction. III. Neural Hormones and Reproduction (D.E. Scott, G.P. Kozlowski & A. Weindl, eds.), pp. 172-182. Karger, Basel 1978. (K. Fuxe, L. Ferland, K. Andersson, P. Eneroth, J.-Å. Gustafsson & P. Skett).
384. Sexual behavior in male rats after intracerebral injection of 5,7-dihydroxytryptamine. Brain Research 141, 293-303, 1978. (K. Larsson, K. Fuxe, B.J. Everitt, M. Holmgren & P. Södersten).
385. Prolactin-monoamine interactions in rat brain and their importance in regulation of LH and prolactin secretion. In: Progress in Prolactin Physiology and Pathology (C. Robyn & M. Harter, eds.), pp. 95-109. Elsevier/North-Holland Biomedical Press, Amsterdam-New York 1978. (K. Fuxe, K. Andersson, T. Hökfelt, L.F. Agnati, S.-O. Ögren, P. Eneroth, J.-Å. Gustafsson & P. Skett).

386. Cardiovascular effects of morphine and opioid peptides following intracisternal administration in chloralose-anesthetized rats. Europ. J. Pharmacol. 48, 319-324, 1978. (P. Bolme, K. Fuxe, L.F. Agnati, R. Bradley & J. Smythies).
387. Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology 16 (Suppl. 1), 99-134, 1978. (K. Fuxe, B.B. Fredholm, L.F. Agnati, S.-O. Ögren, B.J. Everitt, G. Jonsson & J.-Å. Gustafsson).
388. Aminergic and peptidergic pathways in the nervous system with special reference to the hypothalamus. In: The Hypothalamus (S. Reichlin, R.J. Baldessarini & J.B. Martin, eds.), pp. 69-135. Raven Press, New York 1978. (T. Hökfelt, R. Elde, K. Fuxe, O. Johansson, Å. Ljungdahl, M. Goldstein, R. Luft, S. Efendic, G. Nilsson, L. Terenius, D. Ganten, S.L. Jeffcoate, J. Rehfeld, S. Said, M. Perez de la Mora, L. Possani, R. Tapia, L. Teran & R. Palacios).
389. Pharmacological and biochemical evidence for the dopamine agonistic effect of Bromocriptine. Acta Endocrinologica 88 (Suppl. 216), 27-56, 1978. (K. Fuxe, B.B. Fredholm, S.O. Ögren, L.F. Agnati, T. Hökfelt & J.Å. Gustafsson).
390. The brain isorenin-angiotensin system: Biochemistry, localization, and possible role in drinking and blood pressure regulation. In: Frontiers in Neuroendocrinology, Vol. 5 (W.F. Ganong & L. Martini, eds.), pp. 61-99. Raven Press, New York, 1978. (D. Ganten, K. Fuxe, M.I. Phillips, J.F.E. Mann & U. Ganten).
391. The effect of antidepressant drugs of the imipramine type on various monoamine systems and their relation to changes in behaviour and neuroendocrine function. In: Depressive Disorders (S. Garattini, ed.), pp. 67-94. F.K. Schattauer Verlag, Stuttgart-New York 1978. (K. Fuxe, S.-O. Ögren, B.J. Everitt, L.F. Agnati, P. Eneroth, J.-Å. Gustafsson, G. Jonsson, P. Skett & A.C. Holm).
392. The position of dopamine among the biogenic amines with neurotransmitter function. Triangle 17, 1-11, 1978. (K. Fuxe).

393. 5-Hydroxytryptamine neurons and the sleep-wakefulness cycle. Effects of methergoline and zimelidine. Neurosci. Lett. 8, 55-58, 1978. (K. Fuxe & K. Kiianmaa).
394. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors. Brain Research 146, 295-311, 1978. (K. Fuxe, B.B. Fredholm, L.F. Agnati & H. Corrodi).
395. Studies on dopamine turnover in ovariectomized or hypophysectomized female rats. Effects of  $17\beta$ -estradiol benzoate, ethynodioldiacetate and ovine prolactin. Brain Research 148, 399-411, 1978. (F.-A. Wiesel, K. Fuxe, T. Hökfelt & L.F. Agnati).
396. Influence of central catecholamines on LHRH-containing pathways. In: Clinics in Obstetrics and Gynaecology, Vol. 5, No. 2 (J.E. Tyson, ed.), pp. 251-269. W.B. Saunders Company Ltd., London 1978. (K. Fuxe, A. Löfström, T. Hökfelt, L. Ferland, K. Andersson, L. Agnati, P. Eneroth, J.-Å. Gustafsson & P. Skett).
397. 5,7-Dihydroxytryptamine as a tool to study the functional role of central 5-hydroxytryptamine neurons. In: Serotonin Neurotoxins, Ann. N.Y. Acad. Sci. Vol. 305 (J.H. Jacoby & L.D. Lytle, eds.), pp. 346-369. The New York Academy of Sciences, New York 1978. (K. Fuxe, S.-O. Ögren, L.F. Agnati, G. Jonsson & J.-Å. Gustafsson).
398. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis. Federation Proc. 37, 2181-2191, 1978. (K. Fuxe, B.B. Fredholm, S.-O. Ögren, L.F. Agnati, T. Hökfelt & J.-Å. Gustafsson).
399. Effect of antidepressant drugs on the secretion of anterior pituitary hormones. In: Biogena aminer och affektiv sjukdom. Symposium i Göteborg 21-22 november 1977, pp. 144-161. Ciba-Geigy Läkemedel, Mönldal 1978. (K. Fuxe, S.-O. Ögren, L.F. Agnati, P. Eneroth, J.-Å. Gustafsson, G. Jonsson & P. Skett).

400. Effects of Bromocriptine on  $^3\text{H}$ -spiroperidol binding sites in rat striatum. Evidence for actions of dopamine receptors not linked to adenylate cyclase. Life Sci. 23, 465-470, 1978. (R. Schwarcz, K. Fuxe, L.F. Agnati & J.-Å. Gustafsson).
401. Further evidence that methergoline is a central 5-hydroxytryptamine receptor blocking agent. Neurosci. Lett. 9, 195-200, 1978. (K. Fuxe, S.-O. Ögren, L.F. Agnati & G. Jonsson).
402. Transmitter-based mapping of central neurons. In: Principles of Psychopharmacology, Second Edition (W.G. Clark & J. del Guidice, eds.), pp. 71-95. Academic Press, New York 1978. (K. Fuxe & T. Hökfelt).
403. The transmitters of the hypothalamus. In: Pharmacology of the Hypothalamus (B. Cox, I.D. Morris & A.H. Weston, eds.), pp. 31-59. Macmillan, London 1978. (K. Fuxe, T. Hökfelt, K. Andersson, L. Ferland, O. Johansson, D. Ganten, P. Eneroth, J.-Å. Gustafsson, P. Skett, S.I. Said & V. Mutt).
404. Perforant path transections protect hippocampal granule cells from kainate lesion. Neurosci. Lett. 10, 241-246, 1978. (C. Köhler, R. Schwarcz & K. Fuxe).
405. Establecimiento de circuitos neuronales en el sistema nerviosa central de la rata. Enfoque bioquímico, farmacológico e histoquímico. In: Temas Bioquímicos de Actualidad (E. Piña, A. Peña, V. Chagoya de Spanchez & J. Martuscelli, eds.), pp. 239-256. Universidad Nacional Autónoma de México, México City 1978. (M. Pérez de la Mora, K. Fuxe, T. Hökfelt & Å. Ljungdahl).
406. Comparative topography of catecholamines and neuronal peptides in the hypothalamus. In: Biologie cellulaire des processus neurosécrétoires hypothalamiques, Colloques Internationaux du C.N.R.S. No. 280 (J.-D. Vincent & C. Kordon, eds.), pp. 415-432. Centre National de la Recherche Scientifique, Paris 1978. (T. Hökfelt, O. Johansson, R. Elde, Å. Ljungdahl, K. Fuxe & M. Goldstein).

1979

408. Dopamine receptor agonists in brain research and as therapeutic agents. Trends in Neurosciences 2, 1-4, 1979. (K. Fuxe).
409. GABA neurons and their interaction with monoamine neurons. An anatomical, pharmacological and functional analysis. In: GABA-Neurotransmitters. Pharmacochemical, Biochemical and Pharmacological Aspects (P. Krogsgaard-Larsen, J. Scheel-Krüger & H. Kofod, eds.), pp. 74-94. Munksgaard, Copenhagen 1979. (K. Fuxe, K. Andersson, S.-O. Ögren, M. Perez de la Mora, R. Schwarcz, T. Hökfelt, P. Eneroth, J.-Å. Gustafsson & P. Skett).
410. On the cardiovascular role of noradrenaline, adrenaline and peptide containing neuron systems in the brain. In: Nervous System and Hypertension (P. Meyer & H. Schmitt), pp. 1-17. Wiley-Flammarion, Paris 1979. (K. Fuxe, P. Bolme, G. Jonsson, L.F. Agnati, M. Goldstein, T. Hökfelt, R. Schwarcz & J. Engel).
411. Dopamine and Huntington's disease: assessment using the kainic acid model. In: Dopaminergic Ergot Derivatives and Motor Function (K. Fuxe & D.B. Calne, eds.), pp. 115-126. Pergamon Press, Oxford and New York 1979. (R. Schwarcz, K. Fuxe, T. Hökfelt, K. Andersson & J.T. Coyle).
412. Actions of ergot derivatives at dopamine synapses. In: Dopaminergic Ergot Derivatives and Motor Function (K. Fuxe & D.B. Calne, eds.), pp. 141-157. Pergamon Press, Oxford and New York 1979. (K. Fuxe, R. Schwarcz, L. Agnati, B. Fredholm, S.-O. Ögren, Ch. Köhler & J.-Å. Gustafsson).
413. Behavioural effects of ergot drugs. In: Dopaminergic Ergot Derivatives and Motor Function (K. Fuxe & D.B. Calne, eds.), pp. 187-205. Pergamon Press, Oxford and New York 1979. (S.-O. Ögren, Ch. Köhler, K. Fuxe and K. Angeby).
414. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors. Brain Research 170, 485-495, 1979. (R. Schwarcz, K. Fuxe, L.F. Agnati, T. Hökfelt & J.T. Coyle).

415. Peptide neurons. In: Brain Peptides: A New Endocrinology (A.M. Gotto, Jr., E.J. Peck, Jr. & A.E. Boyd, III, eds.), pp. 5-25. Elsevier/North-Holland Biomedical Press, Amsterdam 1979. (T. Hökfelt, O. Johansson, Å. Ljungdahl, J. Lundberg, M. Schultzberg, K. Fuxe, B. Pernow & M. Goldstein).
416. Identification of neurons on a transmitter histochemical basis. In: Neurobiology (M. Otsuka, ed.), pp. 185-203. John Wiley & Sons, Inc. 1979. (T. Hökfelt, O. Johansson, Å. Ljungdahl, M. Schultzberg, K. Fuxe & M. Goldstein).
417. On the role of ascending dopamine systems in the control of voluntary ethanol intake and ethanol intoxication. Pharmacology Biochemistry & Behavior, 10, 603-608, 1979. (K. Kiianmaa, K. Andersson & K. Fuxe).
418. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacology Biochemistry & Behavior, 10, 671-677, 1979. (K. Fuxe, B.J. Everitt & T. Hökfelt).
419. Neurotransmitters and neuropeptides: distribution patterns and cellular localization as revealed by immunocytochemistry. In: Central Regulation of the Endocrine System (K. Fuxe, T. Hökfelt & R. Luft, eds.), pp. 31-48. Plenum, New York 1979. (T. Hökfelt, O. Johansson, Å. Ljungdahl, J. Lundberg, M. Schultzberg, K. Fuxe, M. Goldstein, H. Steinbusch, A. Verhofstad & R. Elde).
420. Neurotransmitter mechanisms in the control of the secretion of hormones from the anterior pituitary. In: Central Regulation of the Endocrine System (K. Fuxe, T. Hökfelt & R. Luft, eds.), pp. 349-380. Plenum, New York 1979. (K. Fuxe, K. Andersson, A. Löfström, T. Hökfelt, L. Ferland, L.F. Agnati, M. Pérez de la Mora, R. Schwarcz, P. Eneroth, J.-Å. Gustafsson & P. Skett).
421. A method to determine dopamine levels and turnover rate in discrete dopamine nerve terminal systems by quantitative use of dopamine fluorescence obtained by Falck-Hillarp methodology. J. Neurosci. Methods 1, 365-373, 1979. (L. F. Agnati, K. Andersson, F. Wiesel & K. Fuxe).
422. Gyanilate cyclase activity increases after kainic acid lesion of rat striatum. Brain Research 171, 567-572, 1979. (M.-L. Tjörnhammar, R. Schwarcz, T. Bartfai & K. Fuxe).

423. Ibotenic Acid-induced Neuronal Degeneration: A Morphological and Neurochemical Study. Exp. Brain Res. 37, 199-216, 1979. (R. Schwarcz, T. Hökfelt, K. Fuxe, G. Jönsson, M. Goldstein & L. Terenius).
424. Evidence for in vivo binding of apomorphine and bromocriptine to receptor sites not labelled by <sup>3</sup>H-spiperone. Europ. J. Pharmacol. 58, 339-340, 1979. (C. Köhler, K. Fuxe, S.-O. Ögren & L.F. Agnati).
425. Evidence for an exclusive localization of <sup>3</sup>H-ADTN binding sites to postsynaptic nerve cells in the striatum of the rat. Europ. J. Pharmacol. 58, 515-517, 1979. (K. Fuxe, H. Hall & C. Köhler).
426. Localization and possible function of peptidergic neurons and their interactions with central catecholamine neurons, and the central actions of gut hormones. Federation Proc. 38, 2333-2340, 1979. (K. Fuxe, K. Andersson, T. Hökfelt, V. Mutt, L. Ferland, L.F. Agnati, D. Ganten, S. Said, P. Eneroth & J.-Å. Gustafsson).
427. The effects of chronic treatment with the 5-hydroxytryptamine uptake blocker zimelidine on central 5-hydroxytryptamine mechanisms. Evidence for the induction of a low affinity binding site for 5-hydroxytryptamine. Neurosci. Lett. 13, 307-312, 1979. (K. Fuxe, S.-O. Ögren & L.F. Agnati).
428. Immunocytochemical studies on catecholamine cell systems with aspects on relations to putative peptide transmitters. Fourth International Catecholamine Symposium, Section J: Neuroregulator Interactions, 1007-1019, 1979. (T. Hökfelt, K. Fuxe, M. Goldstein, O. Johansson, Å. Ljungdahl, J. Lundberg & M. Schultzberg).
429. Central catecholamine systems and neuroendocrine regulation. Controllers of anterior pituitary secretion. In: Catecholamines: Basic and Clinical Frontiers (E. Usdin, I.J. Kopin & J. Barchas, eds.) Vol. 2, 1187-1203. (K. Fuxe, K. Andersson, L.F. Agnati, L. Ferland, T. Hökfelt, P. Eneroth, J.-Å. Gustafsson & P. Skett)
430. Studies on interactions of epinephrine neuronal systems with other neuronal systems. In: Central Regulation of the Endocrine System (K. Fuxe, T. Hökfelt & R. Luft eds.), 209-222, 1979. (M. Goldstein, A. Sauter, F. Hata, J.Y. Lew, Y. Baba, J. Engel, K. Fuxe & T. Hökfelt). Plenum Press, New York.
431. Studies on GABA-Monoamine and GABA-Endorphin Interactions. In: Catecholamines: Basic and Clinical Frontiers (E. Usdin, I.J. Kopin & J. Barchas eds.) Vol. 2, 1032-1034, 1979. (M. Perez de la Mora, K. Fuxe, K. Andersson, T. Hökfelt, Å. Ljungdahl, L. Possani & R. Tapia). Pergamon Press.



432.  $\beta$ -Endorphin and Met-Enkephalin Induced Changes in Amine Turnover in Discrete DA Nerve Terminal Systems of the Neostriatum and the Limbic Forebrain. In: Catecholamines: Basic and Clinical Frontiers (E. Usdin, I.J. Kopin & J. Barchas eds.) Vol. 2, 1047-1049. (R. Schwarcz, K. Fuxe, K. Andersson & L. Ferland). Pergamon Press, New York.
433. On the Role of Noradrenaline and Adrenaline Neuron Systems in Control of Central Cardiovascular Functions. In: Catecholamines: Basic and Clinical Frontiers (E. Usdin, I.J. Kopin & J. Barchas eds.) Vol. 2, 1440-1442, 1979. (P. Bolme, K. Fuxe, G. Jonsson, D. Ganten, L.F. Agnati, K. Andersson, H. Hallman, M. Goldstein & T. Hökfelt). Pergamon Press, New York.
434. On the Mechanism of Selective Neuronal Degeneration in the Rat Brain: Studies with Ibotenic Acid. In: Advances in Neurology, Vol. 23, Huntington's Disease (T.N. Chase, N.S. Wexler & A. Barbeau, 655-668, 1979. (R. Schwarcz, C. Köhler, K. Fuxe, T. Hökfelt & M. Goldstein). Raven Press, New York.
435. <sup>3</sup>H-Kainic acid binding: Relevance for evaluating the neurotoxicity of kainic acid. Life Sciences, Vol. 24, 1471-1480, 1979. (R. Schwarcz & K. Fuxe).
436. Reevaluation of the Indoleamine Hypothesis of Depression. Evidence for a Reduction of Functional Activity of Central 5-HT Systems by Antidepressant Drugs. J. Neural Transmission 46, 85-103, 1979. (S.-O. Ögren, K. Fuxe, L. F. Agnati, J.-Å. Gustafsson, G. Jonsson & A.C. Holm).
437. Reduction of adrenaline turnover in cardiovascular areas of rat medulla oblongata by clonidine. Acta Physiol. Scand. 107, 177-179, 1979. (K. Fuxe, G. Jonsson, P. Bolme, K. Andersson, L. F. Agnati, M. Goldstein & T. Hökfelt).
438. Catecholamine turnover changes in hypothalamus and dorsal midline area of the caudal medulla oblongata of spontaneously hypertensive rats. Neurosci. Lett. 15, 283-288, 1979. (K. Fuxe, D. Ganten, G. Jonsson, L. F. Agnati, K. Andersson, T. Hökfelt, P. Bolme, M. Goldstein, H. Hallman, T. Unger & W. Rascher).
439. Evidence for a selective reduction of adrenaline turnover in the dorsal midline area of the caudal medulla oblongata of young spontaneous hypertensive rats. Acta Physiol. Scand. 107, 397-399, 1979. (K. Fuxe, D. Ganten, G. Jonsson, P. Bolme, L.F. Agnati, K. Andersson, M. Goldstein & T. Hökfelt)
440. Hippocampal lesions indicate differences between the excitotoxic properties of acidic amino acids. Brain Res. 175, 366-371, 1979. (C. Köhler, R. Schwarcz & K. Fuxe).
441. Intrahippocampal injections of ibotenic acid provide histological evidence for a neurotoxic mechanism different from kainic acid. Neurosci. Lett. 15, 223-228, 1979. (C. Köhler, R. Schwarcz & K. Fuxe)

442. Studies on different types of dopamine nerve terminals in the forebrain and their possible interactions with hormones and with neurons containing GABA, glutamate and opioid peptides. In: Advances in Neurology, Vol. 24, (L.J. Piorier, T.L. Sourkes & P.J. Bédard, eds.), pp. 199-214. Raven Press, New York, 1979. (K. Fuxe, K. Andersson, R. Schwarcz, L.F. Agnati, M. Pérez de la Mora, T. Hökfelt, M. Goldstein, L. Ferland, L. Possani & R. Tapia.

1980

443. Discrete changes in dopamine and noradrenaline levels and turnover in various hypothalamic nuclei following systemic treatment with the synthetic enkephalin analogue FK 33-824 in rats and their possible relationship to FK 33-824 induced changes in the secretion of adenohipophyseal hormones. Neuroendocrinology Letters 2(1), 7-18, 1980.
444. Mecamylamine induced blockade of nicotine induced inhibition of gonadotrophin and TSH secretion and of nicotine induced increases of catecholamine turnover in the rat hypothalamus. Acta Physiol. Scand. Suppl. 479: 27-29, 1980. (K. Andersson, K. Fuxe, P. Eneroth, J.-Å. Gustafsson & L.F. Agnati)
445. Central monoamine synapses as sites of action for ergot drugs. In: Ergot Compounds and Brain Function: Neuroendocrine and Neuro-psychiatric Aspects (M. Goldstein et al, eds.), pp. 41-62, Raven Press, New York 1980. (K. Fuxe, S.-O. Ögren, L.F. Agnati, K. Andersson, H. Hall, C. Köhler & B. Fredholm).
446. Compensatory bilateral changes in dopamine turnover after striatal kainate lesion. Nature Vol. 283, No. 5742, 94-96, 1980. (K. Andersson, Robert Schwarcz & K. Fuxe)
447. Toluene induced activation of certain hypothalamic and median eminence CA nerve terminal systems of the male rat and its effects on anterior pituitary hormone secretion. Toxicology Letters 5, 393-398, 1980. (K. Andersson, K. Fuxe, R. Toftgård, O. Nielsen, P. Eneroth & J.-Å. Gustafsson).
448. Effects of Chronic Treatment with 1-Sulpiride and Haloperidol on Central Monoaminergic Mechanisms. In: Long-Term Effects of Neuroleptics. (Adv. Biochem. Psychopharmacol. Vol. 24.) (F. Cattabeni et al, eds.) pp. 193 - 206, Raven Press, New York, 1980. (K. Fuxe, S.-O. Ögren, H. Hall, L.F. Agnati, K. Andersson, C. Köhler & R. Schwarcz).
449. Effects of Chronic Striatal Kainate Lesions on Some Dopaminergic Parameters and Enkephalin Immunoreactive Neurons in the Basal Ganglia. J. Neurochemistry 34(4), 772-778, 1980. (Robert Schwarcz, Kjell Fuxe, Tomas Hökfelt, Lars Terenius & Menek Goldstein).
450. On the Mechanism of the Antiparkinsonian Action of 1-DOPA and Bromocriptine: A Theoretical and Experimental Analysis of Dopamine Receptor Sub- and Super-sensitivity. J. Neural Transmission, Suppl 16, 69-81, 1980. (L. F. Agnati & K. Fuxe).

451. Hypothalamic monoamine pathways and their possible role in disturbances of the secretion of hormones from the anterior pituitary gland. In: Pituitary Microadenomas (G. Faglia, M.A. Giovanelli & R.M. MacLeod, eds.) pp. 15-35, Academic Press, 1980.  
(K. Fuxe, K. Andersson, L.F. Agnati, T. Hökfelt, P. Eneroth & J.-Å. Gustafsson).
452. Hypothalamic catecholamine neuron systems and neuroendocrine control: Effects of ergot drugs and neuropeptides. In: Neuroactive Drugs in Endocrinology (E.E. Müller, ed.) pp. 149-166, Elsevier/North-Holland Biomedical Press, Amsterdam, 1980.  
(K. Fuxe, K. Andersson, V. Locatelli, L.F. Agnati, V. Mutt & P. Eneroth).
453. Catecholamine-stimulated cyclic AMP formation in phenylethanolamine N-methyltransferase containing brain stem nuclei of normal rats and of rats with spontaneous genetic hypertension. Brain Res. 186, 133-143, 1980.  
(D. Wilkening, B. Dvorkin, M.H. Makman, L.Y. Lew, J. Matsumoto, Y. Baba, M. Goldstein & K. Fuxe).
454. The mesolimbic dopamine system: Evidence for a high amine turnover and for a heterogeneity of the dopamine neuron population. Neurosci. Lett. 18, 45-51, 1980.  
(L.F. Agnati, K. Fuxe, K. Andersson, F. Benfenati, P. Cortelli & R. D'Alessandro).
455. Evidence for the Existence of an Angiotensin II-like Immunoreactive Central Neuron System and Its Interactions with the Central Catecholamine Pathways. In: Enzymatic Release of Vasoactive Peptides (F. Gross & G. Vogel, eds.) pp. 161-170, 1980. Raven Press, New York.  
(K. Fuxe, K. Andersson, D. Ganten, T. Hökfelt & P. Eneroth).
456. Renin-like immunocytochemical activity in the rat and mouse brain. Neurosci. Lett. 18, 245-250, 1980.  
(K. Fuxe, D. Ganten, V. Locatelli, K. Poulsen, G. Stock, E. Rix & R. Taugner).
457. On the role of central adrenaline neurons in central cardiovascular regulation. In: Central Adrenaline Neurons: Basic Aspects and their Role in Cardiovascular Disease (K. Fuxe, M. Goldstein, B. Hökfelt & T. Hökfelt, eds.) pp. 161-182, Pergamon Press, Oxford & New York, 1980.  
(K. Fuxe, P. Bolme, L.F. Agnati, G. Jonsson, K. Andersson, C. Köhler & T. Hökfelt).
458. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. European J. Pharmacol. 67, 329-331, 1980.  
(K. Fuxe, K. Andersson, V. Locatelli, L.F. Agnati, T. Hökfelt, L. Skirboll & V. Mutt).
459. Peptidergic Neurons in the Nervous System with Special Reference to the Extrapyramidal System: Morphological and Functional Aspects. In: Parkinson's Disease: Current progress, problems and management (U.K. Rinne, M. Klingler & G. Stamm, eds.) pp. 29-48, 1980. Elsevier/North-Holland Biomedical Press, Amsterdam.  
(T. Hökfelt, O. Johansson, A. Ljungdahl, J.M. Lundberg, M. Schultzberg, K. Fuxe, L. Skirboll, R. Schwarcz & M. Goldstein).

460. Effects of Chronic Treatment with 1-Sulpiride and Haloperidol on Central Dopamine Turnover Evaluated in Dopamine Cell Body and Nerve Terminal-Rich Areas. In: Long-Term Effects of Neuroleptics (Adv. Biochem. Psychopharmacol., Vol. 24) (F. Cattabeni, G. Racagni, P.F. Spano & E. Costa, eds.) pp. 75-80, Raven Press, New York, 1980.  
(L.F. Agnati, K. Andersson, K. Fuxe, F. Benfenati, P. Cortelli, R. D'Alessandro & S.-O. Ögren).
461. Histochemical identification of adrenaline containing cells with special reference to neurons. In: Central Adrenaline Neurons: Basic Aspects and their Role in Cardiovascular Functions (K. Fuxe, M. Goldstein, B. Hökfelt & T. Hökfelt, eds.) pp. 19-47, Pergamon Press, Oxford & New York, 1980.  
(T. Hökfelt, M. Goldstein, K. Fuxe, O. Johansson, A. Verhofstad, H. Steinbusch, B. Penke & J. Vargas).
462. Distribution and characterization of PNMT and epinephrine in the CNS. In: Central Adrenaline Neurons: Basic Aspects and their Role in Cardiovascular Functions (K. Fuxe, M. Goldstein, B. Hökfelt & T. Hökfelt, eds.) pp. 49-55, Pergamon Press, Oxford & New York, 1980.  
(M. Goldstein, J. Pearson, A. Sauter, K. Ueta, T. Asano, J. Engel, P. Passeltiner, T. Hökfelt & K. Fuxe).
463. Catecholamine-stimulated cyclic AMP formation in brainstem nuclei of normal rats and rats with genetic hypertension. In: Central Adrenaline Neurons: Basic Aspects and their Role in Cardiovascular Functions (K. Fuxe, M. Goldstein, B. Hökfelt & T. Hökfelt, eds.) pp. 213-224, Pergamon Press, Oxford & New York, 1980.  
(M.H. Makman, D. Wilkening, B. Dvorkin, M. Goldstein, J.Y. Lew, Y. Matsumoto, Y. Baba & K. Fuxe).
464. The role of central catecholamine pathways in spontaneous and renal hypertension in rats. In: Central Adrenaline Neurons: Basic Aspects and their Role in Cardiovascular Functions (K. Fuxe, M. Goldstein, B. Hökfelt & T. Hökfelt, eds.) pp. 259-276, Pergamon Press, Oxford & New York, 1980.  
(K. Fuxe, D. Ganten, P. Bolme, L.F. Agnati, T. Hökfelt, K. Andersson, M. Goldstein, A. Härfstrand, T. Unger & W. Rascher).
465. Bromokriptinets Farmakologi. In: Pravidel (Bromokriptin) och Parkinsons Syndrom, pp. 49-59, Sandoz AB, Täby, 1980.  
(K. Fuxe & L.F. Agnati).
466. Concepts in neuroendocrinology with emphasis on neuropeptide-monoamine interactions in neuroendocrine regulation. In: Progress in Psychoneuroendocrinology (F. Brambilla, G. Racagni & D. de Wied, eds.) pp. 47-61, Elsevier/North-Holland Biomedical Press, Amsterdam, 1980.  
(K. Fuxe, L.F. Agnati, K. Andersson, V. Locatelli, P. Eneroth, T. Hökfelt, V. Mutt, T. McDonald, M.F. El Etreby, I. Zini & L. Calza).
467. Aspects on receptor regulation and isoreceptor identification. Medical Biology 58: 182-187, 1980.  
(L.F. Agnati, K. Fuxe, I. Zini, P. Lenzi & T. Hökfelt).
468. Estrogen induced increases of high affinity and especially low affinity <sup>3</sup>H-clonidine binding sites in the amygdaloid-entorhinal cortex of the ovariectomized rat. Neuroendocrinology Letters 2(5): 249-256, 1980.  
(L.F. Agnati, K. Fuxe, K. Andersson, P. Eneroth & J.-Å. Gustafsson).

469. Hypothalamic dopamine and noradrenaline nerve terminal systems and their reactivity to changes in pituitary-thyroid and pituitary-adrenal activity and to prolactin. In: Progress in Psychoneuroendocrinology (F. Brambilla, G. Racagni & D. de Wied, eds.) pp. 395-406. Elsevier/North-Holland Biomedical Press, Amsterdam, 1980.  
(K. Andersson, K. Fuxe, P. Eneroth, L.F. Agnati & V. Locatelli)
470. Neuropeptides and central catecholamine systems: Interactions in neuroendocrine and central cardiovascular regulation. In: Neural Peptides and Neuronal Communication (E. Costa & M. Trabucchi, eds.), pp. 37-50. Raven Press New York, 1980.  
(K. Fuxe, K. Andersson, V. Locatelli, V. Mutt, J. Lundberg, T. Hökfelt, L.F. Agnati, P. Eneroth & P. Bolme).
471. Evidence for differential localization of angiotensin-I converting enzyme and renin in the corpus striatum of rat. Acta Physiol. Scand. 110: 321-323, 1980.  
(K. Fuxe, D. Ganten, C. Köhler, B. Schüll & G. Speck).
472. Studies on the cardiovascular functions of the central catecholamine pathways. Evidence for a vasodepressor function of the central adrenaline neurons. In: Les Neuromédiateurs du Tronc Cérébral (Lyon October 26-27, 1979). pp. 13-35. Sandoz Editions, 1980. Paris  
(K. Fuxe, L.F. Agnati, D. Ganten, G. Jonsson, T. Hökfelt, P. Bolme, K. Andersson, M. Goldstein, T. Unger & W. Rascher).
473. Peptidergic and Catecholaminergic Mechanisms in Central Blood Pressure Control. In Contr. Nephrol., vol. 23, pp. 93-104, (Karger, Basel, 1980.  
(Ganten, D., Unger, Th, Rascher, K., Fuxe, K., Hökfelt, Th, Agnati, L.)

1981

474. Long-term treatment with zimelidine leads to a reduction in 5-hydroxytryptamine neurotransmission within the central system of the mouse and rat. Neurosci. Lett. 21, 57-62, 1981.  
(K. Fuxe, S.-O. Ögren, L.F. Agnati, P. Eneroth, A.C. Holm & K. Andersson).
475. Acute sino-aortic denervation in rats produces a selective increase of adrenaline turnover in the dorsal midline area of the caudal medulla oblongata and a reduction of adrenaline levels in the anterior and posterior hypothalamus. Eur. J. Pharmacol. 69: 361-365, 1981.  
(T. Yukimura, K. Fuxe, D. Ganten, K. Andersson, A. Härfstrand, T. Unger & L.F. Agnati).
476. GABA and Benzodiazepine Receptors. Studies on Their Localization in the Hippocampus and Their Interaction with Central Dopamine Neurons in the Rat Brain. In: GABA and Benzodiazepine Receptors (E. Costa et al., eds.), pp. 61-76. Raven Press, New York, 1981.  
(K. Fuxe, C. Köhler, L.F. Agnati, K. Andersson, S.-O. Ögren, P. Eneroth, M. Pérez de la Mora, M. Karobath & P. Krogsdaard-Larsen).
477. Acute changes in serum LH concentrations in catecholestrogen-treated ovariectomized rats - Effects of injection of synthetic LHRH. Neuroendocrinol. Lett. 3(1): 7-12, 1981.  
(C.A. Blake, K. Fuxe, K. Andersson, P. Eneroth, J.F. Rodriguez-Sierra & J.-A. Gustafsson).
478. Demonstration of central  $\gamma$ -aminobutyrate-containing nerve terminals by means of antibodies against glutamate decarboxylase. Neuroscience 6(5): 875-895, 1981.  
(M. Pérez de la Mora, L.D. Possani, R. Tapia, L. Teran, R. Palacios, K. Fuxe, T. Hökfelt & A. Ljungdahl).
479. Prolactin lowering drugs. In: Endocrinology of Human Infertility: New Aspects (R.G. Crosignani, ed.), pp. 93-128. Academic Press, New York, 1981.  
(K. Fuxe, K. Andersson, L.F. Agnati, C.A. Blake, P. Eneroth & J.F. Rodriguez-Sierra)
480. Characterization of normal and supersensitive dopamine receptors: Effects of ergot drugs and neuropeptides. J. Neural Trans. 51: 3-37, 1981.  
(K. Fuxe, L.F. Agnati, C. Köhler, D. Kuonen, S-O Ögren, K. Andersson & T. Hökfelt)
481. Effects of estrogen and combined treatment with estrogen and progesterone on central dopamine, noradrenaline and adrenaline nerve terminal systems of the ovariectomized rat. Relationship of changes in amine turnover to changes in LH and prolactin secretion and in sexual behaviour. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, J.-A. Gustafsson & L. Wetterberg eds.), pp. 73-92, Pergamon Press, Oxford & New York, 1981.  
(K. Fuxe, K. Andersson, C.A. Blake, P. Eneroth, J-A. Gustafsson & L.F. Agnati)
482. Glucocorticoids, catecholamines and avoidance learning. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, J-A. Gustafsson, L. Wetterberg eds.), pp. 355-378, Pergamon Press, Oxford, 1981.  
(Ögren, S-O., Archer, T., Fuxe, K., Eneroth, P)
483. Effects of adrogenic and adrenocortical steroids on hypothalamic and preoptic catecholamine nerve terminals and on the secretion of anterior pituitary hormones. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, J-A. Gustafsson, L. Wetterberg, eds.), pp. 117-133, Pergamon Press, Oxford, 1981.  
(K. Andersson, K. Fuxe, P. Eneroth, C.A. Blake, L.F. Agnati and J-A Gustafsson)

- 484.. The role of noradrenaline and adrenaline neuron systems and substance P in the control of central cardiovascular functions. In: Central Nervous System Mechanisms in Hypertension. (J.P. Buckley, C.M. Ferrario eds.), pp. 89-113, Raven Press, New York, 1981.  
(Fuxe, K., Agnati, L.F., Ganten, D., Goldstein, M., Yukimura, T., Jonsson, G., Bolme, P., Hökfelt, T., Andersson, K., Härfstrand, A., Unger, T., Rascher, W)
- 485.. Studies on the glucocorticoid receptor. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, L. Wetterberg, J-Å. Gustafsson, eds.), pp. 31-39, Pergamon Press, New York, 1981.  
Gustafsson, J-Å. Carlstedt-Duke, J., Fuxe, K., Carlström, K., Okret, S., Wrangé, Ö)
486. Effects of estrogen and progesterone on central  $\alpha$ - and  $\beta$  adrenergic receptors in ovariectomized rats. evidence for gonadal steroid receptor regulation of brain  $\alpha$ - and  $\beta$  adrenergic receptors. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, L. Wetterberg, J-Å Gustafsson, eds.), pp. 237-252, Pergamon Press, Oxford, 1981.  
(Agnati, L.F., Fuxe, K., Kuonen, D., Blake, C.A., Andersson, K., Eneroth, P., Gustafsson, J-Å., Battistini, N., Calza, L)
487. Acute effects of catecholestrogens on hypothalamic and median eminence catecholamines and anterior pituitary gland luteinizing hormone and prolactin secretion in the ovariectomized rat. In: Steroid Hormone Regulation of the Brain. (K. Fuxe, L. Wetterberg, J-Å. Gustafsson, eds.), pp.93-106, Pergamon Press, Oxford, 1981.  
(Blake, C.A., Fuxe, K., Andersson, K., Rodrigues-Sierra, J.F., Eneroth, P., Gustafsson, J-Å., Agnati, L.F.)
488. Regional in vivo binding of ( $^3$ H)N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Europ. J. Pharmacol. 72: 397-402, 1981.  
(Köhler, C., Fuxe, K. & Ross, S)
489. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta Physiol. Scand. 112:345-347, 1981.  
(Andersson, Kurt., Fuxe, K., Agnati, L.F.)
490. Renin: Immunocytochemistry in the rat and mouse brain. In: Central Nervous System Mechanisms in Hypertension. (J.P. Buckley and C.M. Ferrario, eds.) pp. 301-309, Raven Press, New York, 1981.  
(Rix, E., Fuxe, K., Ganten, D., Hökfelt, T., Locatelli, V., Poulsen, K., Stock, G., Taugner, R.)
491. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain. Evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems. Medical Biology 59: 170-176, 1981.  
(K. Andersson, K. Fuxe, L.F. Agnati and P. Eneroth)
492. Production of discrete changes in dopamine and noradrenaline levels and turnover in various parts of the rat brain following exposure to xylene, ortho-, meta-, and para-xylene, and ethylbenzene. Toxicology and Applied Pharmacol. 60: 535-548, 1981.  
(Andersson, K., Fuxe, K., Nilsen, O.G., Toftgård, R., Eneroth, P. and Gustafsson, J.-Å.)



493. Studies on the role of central 5HT neurons in avoidance learning: A behavioural and biochemical analysis. In: Serotonin: Current Aspects of Neurochemistry and Function (B. Harber, S. Gabay, M.R. Issidorides, S.G.A. Alivisatos, eds), pp. 681-705, Plenum Publishing Corporation, 1981.  
(Ögren, S.-O., Fuxe, K., Archer, T., Hall, H., Holm, A.-C., Köhler, C)
494. Rat prolactin and hypothalamic catecholamine nerve terminal systems. Evidence for rapid and discrete increases in dopamine and noradrenaline turnover in the hypophysectomized male rat. Eur. J. Pharmacol. 76: 261-265, 1981  
(Andersson, K., Fuxe, K., Eneroth, P., Nyberg, P., Roos, P)
495. GABAergic synapses: Distribution and interaction with other neurotransmitter systems in the brain. In: Regulatory Mechanisms of Synaptic Transmission (R. Tapia and C.W. Cotman, eds), pp. 71-101, Plenum Publishing Corporation, 1981.  
(Pérez de la Mora, M., Fuxe, K., Hökfelt, T., Andersson, K., Possani, L., Tapia, R)
496. Distribution of VIP neurons in the peripheral and central nervous system. Endocrinol. No. 1, 301-308, 1980.  
(Schultzberg, M., Hökfelt, T., Lundberg, J.M., Fuxe, K., Mutt, V., Said, S)
497. Pharmacological and clinical implications of chemical neurotransmission: Chairmen's overview. In: Chemical Neurotransmission (L. Stjärne, P. Hedqvist, H. Lagercranz, A. Wennmalm, eds), pp. 541-548, Academic Press, London, 1981.  
(Fuxe, K., Sedvall G)
498. Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: Evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand 113: 567-569, 1981.  
(K. Fuxe, L.F. Agnati, F. Benfenati, M. Cimmino, S. Algeri, T. Hökfelt, V. Mutt)
499. On the interactive role of central noradrenaline neurons and corticosterone in two-way active avoidance acquisition in the rat. Neurosci. Lett. 27: 341-346, 1981.  
(T. Archer, S.-O. Ögren, K. Fuxe, L.F. Agnati, P. Eneroth)
500. A new hypothesis on memory - a possible role of local circuits in the formation of the memory trace. Medical Biol. 59: 224-229, 1981.  
(L.F. Agnati, K. Fuxe, M. Ferrari, F. Benfenati, S.-O. Ögren)

1982

501. Distribution of vasoactive intestinal polypeptide in the central and peripheral nervous system as revealed by immunocytochemistry. In: Vasoactive Intestinal Peptide (S.I. Said, ed), pp. 65-90, Raven Press, New York, 1982. (Hökfelt, T., Schultzberg, M., Lundberg, J.M., Fuxe, K., Mutt, V., Fahrenkrug, J., Said, S)
502. Immunocytochemical demonstration of angiotensin II and renin-like immunoreactive nerve cells in the hypothalamus. Angiotensin peptides as comodulators in vasopressin and oxytocin neurons and their regulation of various types of central catecholamine nerve terminal systems. Exp. Brain Res. suppl. 4, 208-232. (K. Fuxe, D. Ganten, K. Andersson, L.F. Agnati, R.E. Lang, K. Poulsen, T. Hökfelt, P. Bernardi)
503. Vasopressor effects of substance P and C-terminal sequences after intracisternal injection to  $\alpha$ -chloralose-anaesthetized rats: blockade by a substance P antagonist. Eur. J. Pharmacol. 77: 171-176, 1982. (K. Fuxe, L.F. Agnati, S. Rosell, Anders Härfstrand, K. Folkers, J. Lundberg, K. Andersson, T. Hökfelt)
504. Selective reduction of adrenaline turnover in the dorsal midline area of the caudal medulla oblongata and increase of hypothalamic adrenaline levels in the Lyon strain of genetically hypertensive rats. Eur. J. Pharmacol. 77: 187-191, 1982. (K. Fuxe, M. Vincent, K. Andersson, A. Härfstrand, L.F. Agnati, J. Sassard, F. Benfenati, T. Hökfelt)
505. Neuroanatomical methods for the quantitative evaluation of coexistence of transmitters in nerve cells. Analysis of the ACTH- and betaendorphin immunoreactive nerve cell bodies of the mediobasal hypothalamus of the rat. J. Neurosci. Methods 5: 203-214, 1982. (L.F. Agnati, K. Fuxe, V. Locatelli, F. Benfenati, I. Zini, A.E. Panerai, M.F. El Etreby, T. Hökfelt)
506. Evidence for stabilization of cortical 5HT neurotransmission by chronic treatment with antidepressant drugs: induction of a high and a low affinity component in  $^3\text{H}$ -5HT binding sites. Acta Physiol Scand 114: 477-480, 1982. (K. Fuxe, S.-O. Ögren, L.F. Agnati, L. Calza)
507. I sistemi inibitori nell'ippocampo: studio mediante tecniche di binding dei recettori per il GABA e per le benzodiazepine. Boll Lega It Epil 37/38: 39-48, 1982. (F. Benfenati, L.F. Agnati, K. Fuxe, L. Calza, N. Battistini, M. Zoli)
508. Effects of acute central and peripheral administration of nicotine on hypothalamic catecholamine nerve terminal systems and on the secretion of adenohypophyseal hormones in the male rat. Med Biol. 60(2): 98-111. (K. Andersson, K. Fuxe, P. Eneroth, L.F. Agnati)

509. Toluene and telencephalic dopamine; selective reduction of amine turnover in discrete DA nerve terminal systems of the anterior caudate nucleus by low concentrations of toluene. Toxicol. Lett., 12: 115-123, 1982.  
(K. Fuxe, K. Andersson, O.G. Nilsen, R. Toftgård, P. Eneroth, J.-Å. Gustafsson)
510. Immunocytochemistry of central neurons. WHO organization "Scientific meeting on Neuroplasticity and Repair in the central Nervous System, Geneva, 28 June - 2 July, 1982."  
(K. Fuxe, L.F. Agnati, T. Hökfelt, L. Calza, F. Benfenati, M. Goldstein)
511. Effects of GM<sub>1</sub> gangliosides on the recovery of dopaminergic nigro-striatal neurons after lesion. WHO organization "Scientific meeting on Neuroplasticity and Repair in the central Nervous System, Geneva, 28 June - 2 July, 1982."  
(G. Savoini, K. Fuxe, L.F. Agnati, L. Calza, F. Moroni, M.G. Lombardi, M. Goldstein, G. Toffano)
512. New vistas on synaptic plasticity: mosaic hypothesis on the engram. Med Biol., 60: 183-190, 1982.  
(L.F. Agnati, K. Fuxe, M. Zoli, C. Rondanini, S.-O. Ögren)
513. Principles for the morphological characterization of transmitter-identified nerve cell groups. J. Neurosci. Meth., 6: 157-167, 1982.  
(L.F. Agnati, K. Fuxe, I. Zini, F. Benfenati, T. Hökfelt, J. De Mey)
514. Intracisternal administration of avian pancreatic polypeptide lowers respiration rate and enhances the clonidine induced reduction of respiration rate in  $\alpha$ -chloralose anaesthetized rats: Possible interactions with and  $\alpha_2$ -adrenergic receptor. Acta Physiol. Scand., 115: 381-384, 1982.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, J. Lundberg, T. Hökfelt, L. Calza, J. Kimmel, P. Bernardi)
515. On the mechanism of action of antidepressant drugs: Indications of reductions in 5-HT neurotransmission in some brain regions upon subchronic treatment. In: Advances in the Biosciences. New Vistas in Depression, (eds. S.Z. Langer et al.), vol. 40, pp. 49-63, Pergamon Press, Oxford and New York, 1982.  
(K. Fuxe, S.-O. Ögren, L.F. Agnati, K. Andersson, P. Eneroth)
516. Summary, Session 1: Relevant neurotransmitters in depression. Effects of antidepressants. In: Advances in the Biosciences. New Vistas in Depression, (eds. S.Z. Langer et al.), vol. 40, pp. 93-95, Pergamon Press, Oxford and New York, 1982.  
(K. Fuxe, T. Segawa)
517. Behavioural and biochemical studies on the effects of acute and chronic administration of antidepressant drugs on central serotonergic receptor mechanism. In: Advances in the Biosciences. New Vistas in Depression, (eds. S.Z. Langer et al.), vol. 40, pp. 11-19, Pergamon Press, Oxford and New York, 1982.  
(S.-O. Ögren, K. Fuxe, T. Archer, G. Johansson, A.C. Holm)

518. Effects of subchronic antidepressant drug treatment on central serotonergic mechanisms in the male rat. In: Typical and Atypical Antidepressant Mechanisms, (eds. E. Costa, G. Racagni), vol. 31, pp. 91-107, Raven Press, New York, 1982.  
(K. Fuxe, S.-O. Ögren, L.F. Agnati, K. Andersson, P. Eneroth)
519. The effects of subchronic antidepressant drug treatment on the secretion of adenohipophyseal hormones and of corticosterone in the male rat. In: Typical and Atypical Antidepressant Mechanisms, (eds. E. Costa, G. Racagni), vol. 31, pp. 109-120, Raven Press, New York, 1982.  
(K. Fuxe, S.-O. Ögren, K. Andersson, P. Eneroth, L.F. Agnati)
520. A new approach to quantitate the density and antigen contents of high densities of transmitter-identified terminals, immunocytochemical studies on different types of tyrosine hydroxylase immunoreactive nerve terminals in nucleus caudatus putamen of the rat. Neurosci. Lett., 32; 253-258, 1982.  
(L.F. Agnati, K. Fuxe, I. Zini, L. Calza, F. Benfenati, M. Zoli, T. Hökfelt, M. Goldstein)
521. Central and peripheral hormones and peptides: Focus on the involvement of noradrenaline and adrenaline neurons, opioid peptides, substance P and somatostatin in central cardiovascular regulation of the rat. In: Hypertensive Mechanisms. The Spontaneously Hypertensive Rat as a Model of Study Human Hypertension, (eds. W. Rascher, D. Clough and D. Ganten), pp. 417-441, Schattauer Verlag, Stuttgart and Berlin, 1982.  
(K. Fuxe, L.F. Agnati, D. Ganten, K. Andersson, L. Calza, M. Vincent, J. Sassard, T. Yukimura, P. Eneroth, M. Goldstein, T. Hökfelt, S. Rosell, A. Härfstrand, W. Vale, M. Brown, J. Rivier)
522. Morphometrical evaluation of the coexistence of renin-like and oxytocin-like immunoreactivity in nerve cells of the paraventricular hypothalamic nucleus of the rat. Neurosci. Lett., 33: 19-24, 1982.  
(K. Fuxe, L.F. Agnati, D. Ganten, R.E. Lang, L. Calza, K. Poulsen, F. Infatellina)
523. Presence of renin-like immunoreactivity in oxytocin immunoreactive nerve cells of the paraventricular and supraoptic nuclei in the rat hypothalamus. Acta Physiol Scand. 116: 313-316, 1982.  
(L. Calza, K. Fuxe, L.F. Agnati, I. Zini, D. Ganten, R.E. Lang, K. Poulsen, T. Hökfelt.)
524. Involvement of cholinergic nicotine-like receptors as modulators of amine turnover in various types of hypothalamic dopamine and noradrenaline nerve terminal systems and of prolactin, LH, FSH and TSH secretion in the castrated male rat. Acta Physiol. Scand. 116: 41-50, 1982.  
(K. Andersson, K. Fuxe, P. Eneroth, L.F. Agnati)

525. Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain. Acta Physiol. Scand. 116: 465-468, 1982.  
(C.A. Seyfried, K. Fuxe, H.-P. Wolf, L.F. Agnati)
526. Intraventricular injections of renin increase amine turnover in the tuberoinfundibular dopamine neurons and reduce the secretion of prolactin in the male rat. Acta Physiol. Scand. 116: 317-320, 1982.  
(K. Andersson, K. Fuxe, L.F. Agnati, D. Ganten, I. Zini, P. Eneroth, F. Mascagni, F. Infantillina).
527. A morphometric analysis of transmitter identified dendrites and nerve terminals. Brain Res. Bull. 9: 53-60, 1982.  
(L.F. Agnati, K. Fuxe, L. Calza, T. Hökfelt, O. Johansson, F. Benfenati, M. Goldstein)
528. Morphometric characterization of transmitter-identified nerve cell groups. Analysis of mesencephalic 5-HT nerve cell bodies. Brain Res. Bull. 9: 45-51, 1982.  
(L.F. Agnati, K. Fuxe, T. Hökfelt, F. Benfenati, L. Calza, O. Johansson, J. De Mey)
529. Interactions of nicotine and pentobarbitone in the regulation of telencephalic and hypothalamic catecholamine levels and turnover and of adenohipophyseal hormone secretion in the normal male rat. Arch. Pharmacol. 321: 287-292, 1982  
(K. Andersson, K. Fuxe, L.F. Agnati, J.-Å. Gustafsson)

Eneroth P,

1983

530. Heterogeneity of brain dopamine systems: Possible discrimination of different types of dopamine systems and receptors by ergot drugs. In: Lisuride and Other Dopamine Agonists (D.B. Calne et al., eds.), pp. 11-31, Raven Press, New York, 1983.  
(K. Fuxe, L.F. Agnati, C. Köhler, K. Andersson, P. Eneroth, L. Calza, S.-O. Ögren)
531. Effects of chronic sino-aortic denervation in male rats on regional catecholamine levels and turnover and on neuroendocrine function. Eur. J. Pharmacol. 87: 145-149, 1983.  
(K. Fuxe, T. Yukimura, D. Ganten, A. Härfstrand, K. Andersson, P. Eneroth, I. Zini, L.F. Agnati, T. Unger)
532. Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22: 389-400, 1983.  
(K. Fuxe, S.-O. Ögren, L.F. Agnati, F. Benfenati, B. Fredholm, K. Andersson, I. Zini, P. Eneroth)
533. Differential modulation by CCK-8 and CCK-4 of <sup>3</sup>H-spiroperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the rat. Neurosci. Lett. 35: 179-183, 1983.  
(L.F. Agnati, K. Fuxe, F. Benfenati, M.F. Celani, N. Battistini, V. Mutt, L. Cavicchioli, G. Galli, T. Hökfelt)
534. Evidence for interactions between <sup>3</sup>H-glutamate and <sup>3</sup>H-kainic acid binding sites in rat striatal membranes. Possible relevance for kainic acid neurotoxicity. Neurosci. Lett. 35: 233-238, 1983  
(K. Fuxe, L.F. Agnati, M.F. Celani)
535. Ergot drugs and cholecystokinin peptides as modulators of dopamine synapses in the brain. In: Aging. vol. 23: Aging Brain and Ergot Alkaloids, (eds. A. Agnoli et al.), Raven Press, New York, 1983.  
(K. Fuxe, L.F. Agnati, C. Köhler, S.-O. Ögren, K. Andersson, F. Benfenati, L. Calza, M. Cimino)
536. On the functional role of coexistence of 5-HT and substance P in bulbospinal 5-HT neurons. Substance P reduces affinity and increases density of <sup>3</sup>H-5-HT binding sites. Acta Physiol. Scand. 117: 299-301, 1983.  
(L.F. Agnati, K. Fuxe, F. Benfenati, I. Zini, T. Hökfelt)
537. Interactions of partial ergoline with dopamine receptors in vivo and in vitro. Acta Physiol. Scand. 177: 303-305, 1983.  
(K. Fuxe, M. Goldstein, L.F. Agnati, C. Köhler, J.Y. Lew and K. Okada)

538. Selective modulation of  $^3\text{H}$ -spiperone labeled 5-HT receptors by subchronic treatment with the ganglioside GM1 in the rat. Acta Physiol. Scand. 117: 311-314, 1983.  
(L.F. Agnati, F. Benfenati, N. Battistini, L. Caviocchioli, K. Fuxe, G. Toffano)
539. Immobilization stress-induced changes in discrete hypothalamic catecholamine levels and turnover, their modulation by nicotine and relationship to neuroendocrine function. Acta Physiol. Scand. 117: 421-426, 1983.  
(K. Fuxe, K. Andersson, P. Eneroth, R.A. Siegel, L.F. Agnati)
540. Neurobiology of central monoamine neurotransmission: Functional neuroanatomy and noradrenaline and 5-hydroxytryptamine involvement in learning and memory. In: Neural Transmission, Learning and Memory, (eds. R. Caputto & C.A. Marsan), pp. 237-255, Raven Press, New York, 1983.  
(K. Fuxe, L.F. Agnati, S.-O. Ögren, K. Andersson, F. Benfenati)
541. The Heterogeneity of the Dopamine Systems in Relation to the Actions of Dopamine Agonists. In: Symposium on Dopamine Receptor Agonists (eds. A. Carlsson & J.L.G. Nilsson), pp. 60-79, Acta Pharmaceutica Suecica, Suppl. 1983:1, Stockholm.  
(K. Fuxe, L.F. Agnati, S.-O. Ögren, C. Köhler, L. Calza, F. Benfenati, M. Goldstein, K. Andersson & P. Eneroth)
542. Chronic treatment with l-dopa plus carbidopa in hemitranssected rats: Preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity. Acta Physiol. Scand. 118: 27-34, 1983.  
(L.F. Agnati, K. Fuxe, L. Calza, I. Zini, F. Benfenati, C. Farabegoli, M. Goldstein)
543. Cholecystokinin peptides in vitro modulate the characteristics of the striatal  $^3\text{H}$ -N-propylnorapomorphine sites. Acta Physiol. Scand. 118: 79-81, 1983.  
(L.F. Agnati, M.F. Celani, K. Fuxe)
544. Evidence for interactions between striatal cholecystokinin and glutamate receptors. CCK-8 in vitro produces a marked downregulation of  $^3\text{H}$ -glutamate binding sites in striatal membranes. Acta Physiol. Scand. 118: 75-77, 1983.  
(K. Fuxe, L.F. Agnati, M.F. Celani)
545. Intravenous injections of nicotine induce very rapid and discrete reductions of hypothalamic catecholamine levels associated with increases of ACTH, vasopressin and prolactin secretion. Acta Physiol. Scand. 118: 35-40, 1983.  
(K. Andersson, R.A. Siegel, K. Fuxe, P. Eneroth)

546. Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuroleptics. *J. Neuronal Trans.* 18: 165-179, 1983. (K. Fuxe, L.F. Agnati, F. Benfenati, M.F. Celani, I. Zini, M. Zoli, V. Mutt)
547. Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons in the human medulla oblongata. *Neurosci. Lett.* 36: 217-222. (T. Hökfelt, J. M. Lundberg, H. Lagercrantz, K. Tatemoto, V. Mutt, J. Lindberg, L. Terenius, B.J. Everitt, K. Fuxe., L. Agnati, M. Goldstein)
548. Immunohistochemical indications of gastrin releasing peptide- bombesin-like immunoreactivity in the nervous system of the rat. Codistribution with substance P-like immunoreactive nerve terminal systems and co-existence with substance P-like immunoreactivity in dorsal root ganglion cell bodies. *Neurosci. Lett.* 37: 17-22. (K. Fuxe, L.F. Agnati, T. McDonald, V. Locatelli, T. Hökfelt, C.-J. Dalsgaard, N. Battistini, N. Yanaiharu, V. Mutt, A.C. Cuello)
549. The influence of cholecystokinin peptides and PYY on the amine turnover in discrete hypothalamic dopamine and noradrenaline nerve terminal systems and possible relationship to neuroendocrine function. *INSERM* 110: 65-86 (1982). (K. Fuxe, K. Andersson, L.F. Agnati, P. Eneroth, V. Locatelli, L. Cavicchioli, F. Mascagni, K. Tatemoto, V. Mutt)
550. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. *Acta Physiol. Scand.* 118: 189-192. (K. Fuxe, L.F. Agnati, A. Härfstrand, I. Zini, K. Tatemoto, E. Merlo Pich, T. Hökfelt, V. Mutt, L. Terenius)
551. Effects of subacute treatment with toluene on central monoamine receptors in the rat. Reduced affinity in (<sup>3</sup>H)5-hydroxytryptamine binding sites and in (<sup>3</sup>H)spiperone binding sites linked to dopamine receptors. *Toxicol. Lett.* 17: 275-281. (M.F. Celani, K. Fuxe, L.F. Agnati, K. Andersson, T. Hansson, J.-Å. Gustafsson, N. Battistini, P. Eneroth)
552. Morphometrical characterization of the ACTH -endorphin and dopamine neuron systems of the mediobasal hypothalamus of the rat. Effects of neonatal monosodium glutamate treatment. *INSERM*, vol. 110: 87-102. (L.F. Agnati, K. Fuxe, C. Blake, L. Calza, J. Rodriguez-Sierra, V. Locatelli, F. Benfenati, G. Galli & M. Goldstein)
553. Neuropeptide Y in vitro selectively increases the number of  $\alpha_2$ -adrenergic binding sites in membranes of the medulla oblongata of the rat. *Acta Physiol. Scand.* 118: 293-295. (L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini, A. Härfstrand, K. Tatemoto, T. Hökfelt & V. Mutt)
554. Rapid and discrete changes in hypothalamic catecholamine nerve terminal systems induced by audiogenic stress, and their modulation by nicotine-relationship to neuroendocrine function. *Eur J Pharmacol* 91: 49-56. (R.A. Siegel, K. Andersson, K. Fuxe, P. Eneroth, L.-O. Lindbom & L.F. Agnati)



555. Analysis of transmitter-identified neurons by morphometry and quantitative microfluorimetry. Evaluation of the actions of psychoactive drugs, especially sulpiride. In: Special Aspects of Psychopharmacology (M. Ackenheil & N. Matussek, eds.) Expansion Scientifique Francaise, Paris, pp. 13-32.  
(K. Fuxe, L.F. Agnati, K. Andersson, L. Calza, F. Benfenati, I. Zini, N. Battistini, C. Köhler, S.-O. Ögren & T. Hökfelt)
556. The position of the serotonin re-uptake blocker zimelidine as an antidepressant drug. In: Symposium Depression and Anti-depressants - Recent Events. Excerpta Medica, Amsterdam, pp. 63-76.  
(S.-O. Ögren, K. Fuxe & L.F. Agnati)
557. Quantitative autoradiographic localization of (<sup>3</sup>H)imipramine binding sites in the brain of the rat: Relationship to ascending 5-hydroxytryptamine neuron systems. Proc. Natl. Acad. Sci. USA 80: 3836-3840.  
(K. Fuxe, L. Calza, F. Benfenati, I. Zini & L.F. Agnati)
558. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment. Neurosci. Lett. 40: 293-297.  
(L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini, I. Zini & G. Toffano)
559. Failure of neuropeptide Y in vitro to increase the number of  $\alpha_2$ -adrenergic binding sites in membranes of medulla oblongata of the spontaneous hypertensive rat. Acta Physiol. Scand. 119: 309-312.  
(L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini, A. Härfstrand, T. Hökfelt, L. Cavicchioli, K. Tatemoto & V. Mutt)
560. Rat growth hormone and hypothalamic catecholamine nerve terminal systems evidence for rapid and discrete reductions in dopamine and noradrenaline levels and turnover in the median eminence of the hypophysectomized male rat. European Journal of Pharmacology, 95(1983) 271-275.  
(K. Andersson, K. Fuxe, P. Eneroth, O. Isaksson, F. Nyberg & P. Roos)
561. Regional variations in 5-HT receptor populations and in <sup>3</sup>H-imipramine binding sites in their responses to chronic antidepressant treatment. In: Frontiers in Neuropsychiatric Research (E. Usdin, M. Goldstein, A.J. Friedhoff & A. Georgotas, eds.), pp. 33-54. MacMillan Press, London.  
(K. Fuxe, S.-O. Ögren, L.F. Agnati, F. Benfenati, L. Cavicchioli, B. Fredholm, K. Andersson, C. Farabegoli & P. Eneroth)
562. Receptor-receptor interactions: possible new mechanisms for the action of some antidepressant drugs. In: Frontiers in Neuropsychiatric Research (E. Usdin, M. Goldstein, A.J. Friedhoff & A. Georgotas, eds.), pp. 301-318. MacMillan Press, London.  
(L.F. Agnati, K. Fuxe, F. Benfenati, L. Calza, N. Battistini & S.-O. Ögren)
563. Effects of chronic administration of antidepressant drugs on central serotonergic receptor mechanisms. In: Frontiers in Neuropsychiatric Research (E. Usdin, M. Goldstein, A.J. Friedhoff & A. Georgotas, eds.), pp. 93-108. MacMillan Press, London.  
(S.-O. Ögren, K. Fuxe, O.G. Berge & L.F. Agnati)

564. Excitotoxins, Wenner-Gren International Symposium Series Vol. 39. MacMillan Press, London.  
(K. Fuxe, P. Roberts & R. Schwarcz)
565. Studies on excitatory amino acid receptors and their interactions and regulation of pre- and postsynaptic dopaminergic mechanism in the rat telencephalon. In: Excitotoxins (K. Fuxe, P. Roberts & R. Schwarcz eds.), pp. 138-156. MacMillan Press, London.  
(K. Fuxe, L.F. Agnati, M.F. Celani, F. Benfenati, K. Andersson & J. Collins)
566. Ibotenate as a tool in neurobiology. Studies on dopaminergic and cholecystokinin immunoreactive neurons after ibotenate induced lesions. In: Excitotoxins (K. Fuxe, P. Roberts & R. Schwarcz eds.), pp. 223-238. MacMillan Press, London.  
(K. Fuxe, L.F. Agnati, P. Frey, C. Köhler, M.F. Celani, K. Andersson, N. Battistini, C. Farabegoli & R. Schwarcz)
567. Characterization of striatal ibotenate lesions and of 6-hydroxydopamine induced nigral lesions by morphometric and densitometric approaches. In: Excitotoxins (K. Fuxe, P. Roberts & R. Schwarcz eds.), pp. 239-250. MacMillan Press, London.  
(L.F. Agnati, K. Fuxe, L. Calza, F. Benfenati, N. Battistini, I. Zini, L. Fabbri & M. Goldstein)
568. Effect of ibotenic acid stereotactically injected into striatum or hippocampus on local blood flow and glucose utilization in rats. In: Excitotoxins (K. Fuxe, P. Roberts & R. Schwarcz eds.), pp. 251-255.  
(Ch. Owman, J. Andersson, N.H. Diemer & K. Fuxe)
569. Neurotensin in vitro markedly reduces the affinity in subcortical limbic <sup>3</sup>H-N-propylnorapomorphine binding sites. Acta Physiol. Scand. 119: 459-461.  
(L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini)
570. Ganglioside increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol Scand., 119(4): 347-363, 1983.  
(L.F. Agnati, K. Fuxe, L. Calza, F. Benfenati, L. Cavicchioli, G. Toffano, M. Goldstein)
571. ~~Attaccamento~~ Attaccamento di cellule eterologhe nel tessuto cerebrale: un problema culturale e scientifico. In: Trapianto di cuore e trapianto di cervello (ed Orizzonte Medico). pp. 208-235.  
(K. Fuxe and L.F. Agnati)
572. Central Dopamine Neurons as Regulators of Prolactin Secretion and as Targets for Prolactin Action. In: Prolactin and prolactinomas. K. Andersson, K. Fuxe, C.A. Blake, P. Roos, K.A. Elias, P. Eneroth, S. Hendricks, L.F. Agnati, L. Calza, J.F. Rodrigues-Sierra, and F. Nyberg.
573. Subcortical limbic <sup>3</sup>H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro. Bioscience Reports 3, pp.1101-1105.  
(L.F. Agnati and K. Fuxe).

574. Evidence for the existence of a dopamine receptor of the D-1 type in the rat median eminence. Neuroscience Letters, 43:185-190, 1983.  
(K. Fuxe, L.F. Agnati, F. Benfenati, K. Andersson, M. Camurri and M. Zoli)
575. Morphometrical analysis of the distribution of luteinizing hormone-releasing hormone and tyrosine hydroxylase-immunoreactive nerve terminals within the lateral palisade zone of the median eminence of the male rat. Neuroscience Letters, 43:179-183, 1983.  
(L. Calza, L.F. Agnati, K. Fuxe, L. Giardino and M. Goldstein)
576. On the use of poly- and monoclonal antibodies in studies on the structure and function of the glucocorticoid receptor. In: Steroid Hormone Receptors: Structure and Function (H. Eriksson and J.-Å. Gustafsson eds), pp. 355-388. Elsevier Science Publishers B.V., 1983.  
(J.-Å. Gustafsson, S. Okret, A.-C. Wikström, B. Andersson, M. Radojcic, Ö. Wrange, W. Sachs, A.J. Doupe, P.H. Patterson, B. Cordell and K. Fuxe)
577. Neurochemical and Functional Studies with EMD 23 448, a Novel Dopamine Agonist. In: Symposium on Dopamine Receptor Agonists (eds. A. Carlsson & J.L.G. Nilsson), pp.243-247, Swedish Pharmaceutical Press, Stockholm, 1983.  
(C.A. Seyfried, K. Fuxe, H.P. Wolf and L.F. Agnati)

1984

578. Central catecholamine neurons and exposure to dichloromethane. Selective changes in amine levels and turnover in tel- and diencephalic DA and NA nerve terminal systems and in the secretion of anterior pituitary hormones in the male rat. Toxicology, 29:293-305, 1984.  
(K. Fuxe, K. Andersson, T. Hansson, L.F. Agnati, P. Eneroth & J.-Å. Gustafsson)
579. Transmitter and peptide systems in areas involved in the control of blood pressure. Clin. Exp. Hyper.-Theory and Practice, A6 (1&2) :23-41, 1984.  
(T. Hökfelt, B.J. Everitt, K. Fuxe, M. Kalia, L.F. Agnati, O. Johansson, A. Härfstrand, J.M. Lundberg, L. Terenius, E. Theodorsson-Norheim & M. Goldstein)
580. Aging brain and dopamine receptors: Abnormal regulation by CCK-8 of <sup>3</sup>H-spiroperone labeled dopamine receptors in striatal membranes. Acta Physiol. Scand., 120: 465-467, 1984.  
(L.F. Agnati, K. Fuxe, N. Battistini & F. Benfenati)
581. New concepts on the structure of the neuronal networks: The miniaturization and hierarchical organization of the central nervous system. Bioscience Reports 4:93-98, 1984.  
(L.F. Agnati & K. Fuxe)
582. Somatostatin produces apnea and is localized in medullary respiratory nuclei: a possible role in apneic syndromes. Brain Res., 296:339-344, 1984.  
(M. Kalia, K. Fuxe, L.F. Agnati, T. Hökfelt & A. Härfstrand)
583. Distribution of neuropeptide immunoreactive nerve terminals within the subnuclei of the nucleus of the tractus solitarius of the rat. J. Comp. Neurolog., 22:409-444, 1984.  
(M. Kalia, K. Fuxe, T. Hökfelt, O. Johansson, R. Lang, D. Ganten, C. Cuello & L. Terenius)
584. A method for rostrocaudal integration of morphometric information from transmitter-identified cell groups. A morphometrical identification and description of 5-HT cell groups in the medulla oblongata of the rat. J. Neurosci. Methods, 10:83-101, 1984.  
(L.F. Agnati, K. Fuxe, L. Calza, I. Zini, T. Hökfelt, A. Steinbusch & A. Verhofstad)
585. 1-Glutamate reduces the affinity of (<sup>3</sup>H)N-propylnorapomorphine binding sites in striatal membranes. Eur. J. Pharmacol., 100:127-130, 1984.  
(K. Fuxe, M.F. Celani, M. Martire, I. Zini, M. Zoli & L.F. Agnati)
586. Luteinizing hormone-releasing hormone increases dopamine turnover in the lateral palisade zone of the median eminence and reduces noradrenaline turnover in the nucleus preopticus medialis of the hypophysectomized male rat. Neurosci. Lett., 45:253-258, 1984.  
(K. Andersson, K. Fuxe, L.F. Agnati, P. Eneroth & M. Camurri)

587. Gangliosides as regulatory factors in central catecholamine neurons. In: Discussions in Neurosciences. Nervous system development and repair., (eds. P.J. Magistretti, J.H. Morrison & F.E. Bloom), FESN, Vol. 1, No. 2, pp. 84-89, 1984.  
(K. Fuxe & L.F. Agnati)
588. Differential effects of mecamylamine on the nicotine induced changes in amine levels and turnover in hypothalamic dopamine and noradrenaline nerve terminal systems and in the secretion of adenohipophyseal hormones in the castrated female rat. Evidence for involvement of cholinergic nicotine-like receptors. Acta Physiol. Scand., 120:489-498, 1984.  
(K. Andersson, K. Fuxe, P. Eneroth & L.F. Agnati)
589. Corticotropin-releasing factor increases noradrenaline turnover in the median eminence and reduces noradrenaline turnover in the paraventricular region of the hypophysectomized male rat. Acta Physiol. Scand., 120:621-624, 1984.  
(K. Andersson, L.F. Agnati, K. Fuxe, P. Eneroth, A. Härfstrand & F. Benfenati)
590. Computer assisted morphometry and microdensitometry of transmitter identified neurons with special reference to the mesostriatal dopamine pathway. I. Methodological aspects. Acta Physiol. Scand., Suppl. 532:5-36, 1984.  
(L.F. Agnati, K. Fuxe, F. Benfenati, I. Zini, M. Zoli, L. Fabbri & A. Härfstrand)
591. Computer assisted morphometry and microdensitometry of transmitter identified neurons with special reference to the mesostriatal dopamine pathway. II. Further studies on the effects of the GM<sub>1</sub> ganglioside on the degenerative and regenerative features of mesostriatal dopamine neurons. Acta Physiol. Scand., Suppl. 532:37-44, 1984.  
(L.F. Agnati, K. Fuxe, L. Calza, M. Goldstein, G. Toffano, L. Giardino & M. Zoli)
592. Computer assisted morphometry and microdensitometry of transmitter identified neurons with special reference to the mesostriatal dopamine pathway. III. Studies on aging processes. Acta Physiol. Scand., Suppl. 532:45-66.  
(L.F. Agnati, K. Fuxe, F. Benfenati, G. Toffano, M. Cimino, N. Battistini, L. Calza & E. Merlo Pich)
593. Central 5-HT neurons as targets for antidepressant drug action: Differential modulation of 5-HT receptor populations in the central nervous system of the rat. In: Frontiers in Biochemical and Pharmacological Research in Depression, (eds. E. Usdin, M. Åsberg, L. Bertilsson and F. Sjöqvist), Raven Press, New York, p. 271-284, 1984.  
(K. Fuxe, S.-O. Ögren, F. Benfenati & L.F. Agnati)

594. New mechanisms involved in the modulation of synaptic transmission. In: Neuromodulation and Brain Function. Proceedings of the Biannual Capo Boi Conference Villasimius, Italy, June 1983. (eds. G. Biggio, P.F. Spano, G. Toffano & G.L. Gessa), Pergamon Press, p. 13-23, 1984.  
(F. Benfenati, I. Zini, N. Battistini, K. Fuxe, G. Toffano, E. Merlo Pich & L.F. Agnati)
595. Modulation by chronic antidepressant treatment of central serotonergic receptors. In: Clinical Neuropharmacology, Vol 7, Suppl. 1. (eds. R. Racagni, R. Paoletti & P. Kielholz), Raven Press, p. 314-315, 1984.  
(S.-O. Ögren, K. Fuxe, M. Martire & L.F. Agnati)
596. Evidence for functional synaptic plasticity in the central nervous system and its alteration during aging and in physiopathological conditions. In: Clinical Neuropharmacology, Vol 7, Suppl. 1. (eds. G. Racagni, R. Paoletti & P. Kielholz), Raven Press, p. 590-591, 1984.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, M. Zoli, F. Benfenati, G. Toffano & E. Merlo Pich)
597. Evidence for structural plasticity in the nigrostriatal dopamine neurons: Morphometrical and biochemical evidence for a trophic action of gangliosides on partially lesioned nigrostriatal dopamine neurons. In: Clinical Neuropharmacology, Vol 7, Suppl. 1. (eds. G. Racagni, R. Paoletti & P. Kielholz), Raven Press, p. 594-595, 1984.  
(L.F. Agnati, K. Fuxe, G. Toffano, L. Calza, F. Benfenati, I. Zini, N. Battistini, M. Goldstein & M. Zoli)
598. Distribution of adrenaline neurons in the rat brain. In: Clinical Neuropharmacology, Vol 7, Suppl. 1. (eds. G. Racagni, R. Paoletti & P. Kielholz), Raven Press, p. 678-679, 1984.  
(T. Hökfelt, M. Goldstein, G. Foster, O. Johansson, M. Schultzberg, W. Staines, K. Fuxe & M. Kalia)
599. Receptor-receptor interactions in the central nervous system. Evidence for the existence of heterostatic synaptic mechanisms. In: Regulation of transmitter function: Basic and Clinical Aspects, Developments in Neuroscience Series, Vol 17, (eds. E.S. Vizi & K. Magyar), p. 129-140, 1984.  
(K. Fuxe, L.F. Agnati, K. Andersson, M. Martire, S.-O. Ögren, L. Giardino, N. Battistini, R. Grimaldi, C. Farabegoli, A. Härfstrand & G. Toffano)
600. Postsynaptic effects of neuropeptide comodulators at central monoamine synapses. In: Neurology and Neurobiology, Vol 8B, (eds. E. Usdin, A. Carlsson, A. Dahlström & J. Engel), Alan R. Liss Inc., New York, p. 191-198, 1984.  
(L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini, I. Zini, M. Camurri & T. Hökfelt)
601. Quantitative chemical neuroanatomy gives new insights into the catecholamine regulation of the peptidergic neurons projecting to the median eminence. Neurology and Neurobiology, Vol 8B, (eds. E. Usdin, A. Carlsson, A. Dahlström & J. Engel), Alan R. Liss Inc., New York, p. 141-149, 1984.  
(K. Fuxe, L.F. Agnati, L. Calza, K. Andersson, L. Giardino, F. Benfenati, M. Camurri & M. Goldstein)

602. A role for exogenous gangliosides in the functional recovery of adult lesioned nervous system. In: Neurology and Neurobiology, Vol. 8C, (eds. E. Usdin, A. Carlsson, A. Dahlström & J. Engel), Alan R. Liss Inc., New York, pp. 219-227, 1984.  
(G. Toffano, G. Savoini, C. Aldinio, M. Valenti, G. Lombardi, F. Moroni, L.F. Agnati and K. Fuxe)
603. Somatostatin-induced apnea: Interaction with hypoxia and hypercapnea in the rat. Neurosci. Lett., 50: 37-42, 1984.  
(A. Härfstrand, M. Kalia, K. Fuxe, L. Kaijser & L.F. Agnati).
604. Evidence for the existence of putative dopamine-, adrenaline- and nor-adrenaline-containing vagal motor neurons in the brainstem of the rat. Neurosci. Lett., 50: 57-62, 1984.  
(M. Kalia, K. Fuxe, M. Goldstein, A. Härfstrand, L.F. Agnati & J.T. Coyle).
605. Possible therapeutical approaches for parkinsonian disease: New mechanisms for the modulation of dopamine receptor sensitivity and new strategies for dopaminergic reinnervation of striatum. In: Lega Italiana per la lotta contro il morbo di parkinson e le malattie extrapiramidali, (eds. A. Agnoli & G. Bertolani), D. Guanella, Roma, pp. 11-27, 1984.  
(L.F. Agnati, K. Fuxe, I. Zini, L. Giardino, M. Zoli, F. Benfenati, L. Calza, G. Toffano, R. Toni & C.A. Seyfried).
606. Effects of gangliosides on the functional recovery of damaged brain. In: Ganglioside structure, function, and biomedical potential, (eds. R.W. Ledeen, R.K. Yu, M.M. Rapport, K. Suzuki), Plenum Publ. Corp., pp. 475-488, 1984.  
(G. Toffano, G. Savoini, C. Aldinio, G. Valenti, R. Dal Toso, A. Leon, L. Calza, I. Zini, L.F. Agnati & K. Fuxe).
607. Actions of centrally administered neuropeptide Y on EEG activity in different rat strains and in different phases of their circadian cycle. Acta Physiol Scand 122:71-77, 1984.  
(I. Zini, E. Merlo Pich, K. Fuxe, P.L. Lenzi, L.F. Agnati, A. Härfstrand, V. Mutt, K. Tatemoto & M. Moscara)
608. Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesion. Acta Physiol Scand 122:313-321, 1984.  
(G. Toffano, L.F. Agnati, K. Fuxe, C. Aldinio, A. Consolazione, G. Valenti & G. Savoini).
609. Computer-assisted morphometry in immunohistochemistry and receptor autoradiography: Impact on Neuroendocrine control. In: Computers in endocrinology (eds. D. Rodbard & G. Forti), Serono Symposia Publications from Raven Press, Vol 14, p. 171-185, 1984.  
(L.F. Agnati, K. Fuxe, F. Benfenati, L. Calzà & L. Fabbri)

610. Studies on neurotensin-catecholamine interactions in the hypothalamus and in the forebrain of the male rat. Neurochem. Int., Vol. 6, No. 6:737-750, 1984.  
(K. Fuxe, L.F. Agnati, K. Andersson, P. Eneroth, A. Härfstrand, M. Goldstein & M. Zoli).
611. Anatomi och patologi vid Parkinsons sjukdom. In: Parkinsons sjukdom -forskning och klinik (eds. G. Steg & B. Johnels), Sandoz, ISBN: 91-970140-9-5, p. 41-72, 1984.  
(K. Fuxe, O. Lindvall, S.-M. Aquilonius, G. Jonsson, K. Kristensson & Y. Olsson)
612. Studies on neuropeptide-Y catecholamine interactions in central cardiovascular regulation in the  $\alpha$ -chloralose anaesthetized rat. Evidence for a possible new way of activating the  $\alpha$ -2 adrenergic transmission line. Symposium on Neuropeptides and Blood Pressure Control, June 12-14, 1984 in Heidelberg, Germany. Clin. and Exp. Hypertension, Theory and Practice, A6 (10&11), 1947-1950, 1984.  
(A. Härfstrand, F. Fuxe, L.F. Agnati, D. Ganten, P. Eneroth, K. Tatemoto & V. Mutt)
613. Evidence for a modulation by neuropeptide Y of the  $\alpha$ -2 adrenergic transmission line in central adrenaline synapses. New possibilities for treatment of hypertensive disorders. Symposium on Neuropeptides and Blood Pressure Control, June 12-14, 1984 in Heidelberg, Germany. Clin. and Exp. Hypertension, Theory and Practice, A6 (10&11), 1951-1956, 1984.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, M. Martire, M. Goldstein, R. Grimaldi, P. Bernardi, I. Zini, K. Tatemoto & V. Mutt).
614. Distribution of neurophysin II immunoreactive nerve fibers within the subnuclei of the nucleus of the tractus solitarius of the rat. Brain Res. 321:71-83.  
(M. Kalia, K. Fuxe, T. Hökfelt, A. Härfstrand, R.E. Lang och D. Ganten)
615. Morphofunctional studies on the role of somatostatin-enkephalin interactions in the regulation of central respiratory mechanisms. In: Neurogenesis of central respiratory rhythm, eds. M.L. Bianchi and M. Denavit-Saubie, MTP Press, Ltd. Falcon House, Lancaster, England, pp. 322-336, 1984.  
(K. Fuxe, A. Härfstrand, M. Kalia, L.F. Agnati)



1985

616. The ergolene derivative MPME induces in the rat a behavioural syndrome associated with activation of dopamine D-1 receptors belonging to the dotted type of forebrain dopamine nerve terminals. Eur. J. of Pharmacol. 106: 79-89, 1985. (S.-O., Ögren, K. Fuxe, Ångeby, K. & Köhler, C.)
617. Immunocytochemistry of central neurons. In: Central nervous system plasticity and repair (eds. A. Bignami, F.E. Bloom, C.L. Bolis & A. Adeloye), Raven Press, New York, p. 47-56, 1985. (K. Fuxe, L.F. Agnati, T. Hökfelt, L. Calzà, F. Benfenati, F. Mascagni & M. Goldstein)
618. Effect of GM<sub>1</sub> ganglioside on the recovery of dopaminergic nigro-striatal neurons after lesion. In: Central nervous system plasticity and repair (eds. A. Bignami, F.E. Bloom, C.L. Bolis & A. Adeloye), Raven Press, New York, p. 75-84, 1985. (G. Savoini, K. Fuxe, L.F. Agnati, L. Calzà, F. Moroni, M.G. Lombardi, M. Goldstein and G. Toffano)
619. Central dopamine agonist activity on the 8- $\alpha$ -amino-ergoline CU 32-085. Brain Res., 328:325-332, 1985. (K. Fuxe, L.F. Agnati, F. Mascagni, S. Kuga, E. Helmer-Matyjek and M. Goldstein)
620. Rat medulla oblongata: I. Cytoarchitectonic considerations. J. Comp. Neurol., 233:285-307, 1985. (M. Kalia & K. Fuxe).
621. Rat medulla oblongata: II. Dopaminergic, noradrenergic (A1 and A2) and adrenergic neurons, nerve fibers, and presumptive terminal processes. J. Comp. Neurol., 233:308-332, 1985. (M. Kalia, K. Fuxe & M. Goldstein).
622. Rat medulla oblongata: III. Adrenergic (C1 and C2) neurons, nerve fibers and presumptive terminal processes. J. Comp. Neurol., 233:333-349, 1985. (M. Kalia, K. Fuxe & M. Goldstein).
623. Rat medulla oblongata: IV. Topographical distribution of catecholaminergic neurons with quantitative three-dimensional computer reconstruction. J. Comp. Neurol., 233:350-364, 1985. (M. Kalia, D.J. Woodward, W.K. Smith & K. Fuxe).
624. Effects of antidepressant drugs on cerebral serotonin receptor mechanisms. Acta Pharmacologica et Toxicologica, Vol. 56, Suppl. 1, pp. 105-127, 1985. (S.-O. Ögren, K. Fuxe, L.F. Agnati and M.F. Celani)
625. Determinations of catecholamine half-lives and turnover rates in discrete catecholamine nerve terminal systems of the hypothalamus, the preoptic region and the forebrain by quantitative histofluorimetry. Acta Physiol. Scand., 123:411-426, 1985. (K. Andersson, K. Fuxe & L.F. Agnati)

626. Morphometrical analysis of the distribution of corticotrophin releasing factor, glucocorticoid receptor and phenylethanolamine-N-methyltransferase immunoreactive structures in the paraventricular hypothalamic nucleus of the rat. Neurosci. Lett., 54:147-152, 1985.  
(L.F. Agnati, K. Fuxe, Z.-Y. Yu, A. Härfstrand, S. Okret, A.-C. Wikström, M. Goldstein, M. Zoli, W. Vale & J.-Å. Gustafsson)
627. Further evidence for the existence of interactions between receptors for dopamine and neurotensin. Dopamine reduces the affinity and increases the number of <sup>3</sup>H-neurotensin binding sites in the subcortical limbic fore-brain of the rat. Acta Physiol Scand., 124:125-128, 1985.  
(L.F. Agnati, K. Fuxe, N. Battistini, L. Giardino, F. Benfenati, M. Martire & M. Ruggeri)
628. Effects of acute intermittent exposure to cigarette smoke on catecholamine levels and turnover in various types of hypothalamic DA and NA nerve terminal systems as well as on the secretion of adenohipophyseal hormones and corticosterone. Acta Physiol. Scand., 124:277-285.  
(K. Andersson, K. Fuxe, P. Eneroth, F. Mascagni & L.F. Agnati)
629. Effects of lesions and ganglioside GM1 treatment on striatal polyamine levels and nigral DA neurons. A role of putrescine in the neurotropic activity of gangliosides. Acta Physiol. Scand., 124:499-506.  
(L.F. Agnati, K. Fuxe, I. Zini, P. Cavalli, A. Corti, L. Calza, G. Toffano, M. Zoli, G. Piccinini and M. Goldstein)
630. Considerazioni sulle interazioni fra sistema nervoso centrale e sistema endocrino. Crescita 14:34-38, 1985.  
(L.F. Agnati, K. Fuxe & M. Zoli)
631. Effects of antidepressant drugs on serotonin receptor mechanisms. In: Neuropharmacology of Serotonin (ed. A.R. Green), Oxford University Press, New York, pp. 131-180, 1985.  
(S.-O. Ögren & K. Fuxe)
632. The importance of brain serotonergic receptor mechanisms for the action of antidepressant drugs. Pharmacopsychiatry No. 2, Vol. 18:209-213, 1985.  
(S.O. Ögren, K. Fuxe & L.F. Agnati)
633. Cholecystokinin neuron systems and their interactions with the pre-synaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58. In: Neuronal Cholecystokinin (eds. J.-J. Vanderhaeghen & J.N. Crawley), Ann. N.Y. Acad. Sci., 448:231-254, 1985.  
(K. Fuxe, L.F. Agnati, J.-J. Vanderhaeghen, K. Tatemoto, K. Andersson, P. Eneroth, A. Härfstrand, G. von Euler, R. Toni, M. Goldstein & V. Mutt)
634. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Studies on their functional meaning. In: Neuronal Cholecystokinin (eds. J.-J. Vanderhaeghen & J.N. Crawley), Ann. N.Y. Acad. Sci., 448:315-333, 1985.  
(L.F. Agnati, K. Fuxe, L. Giardino, L. Calza, M. Zoli, N. Battistini, F. Benfenati, J.-J. Vanderhaeghen, D. Guidolin, M. Ruggeri & M. Goldstein)

635. Morphofunctional studies on central glucocorticoid and estrogen receptors: new openings for the understanding of the hormone regulation of brain function. Table Ronde Roussel Uclaf, No 53, Steroids and the brain, 17-21, 1985.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, A.C. Wikström, S. Okret, Z.-Y. Yu, M. Goldstein, A. Cintra, A.-M. Janson, M. Zoli, L.S. Miller, J.L. Greene & J.-Å. Gustafsson)
636. The external layer of the median eminence and the paraventricular hypothalamic nucleus represent two important levels of integration in the neuroendocrine regulation. Studies on peptide-catecholamine interactions give evidence for the existence of "medianosomes". In: Dopamine and Neuroendocrine Active Substances (Eds. E. del Pozo & E. Flückiger), Academic Press, London, pp. 11-18, 1985.  
(K. Fuxe, L.F. Agnati, K. Andersson, P. Eneroth, A. Härfstrand, M. Goldstein, B. Bernardi, W. Vale, Z.-Y. Yu & J.-Å. Gustafsson)
637. Dopaminergic systems in the brain and pituitary. In: Basic and Clinical Aspects of Neuroscience: The Dopaminergic Systems (Eds. E. Flückiger, E.E. Müller & M.O. Thorner), Springer-Verlag, Berlin, pp. 11-25, 1985.  
(K. Fuxe, L.F. Agnati, M. Kalia, M. Goldstein, K. Andersson & A. Härfstrand)
638. Effects of ganglioside GM1 treatment on striatal glucose metabolism, blood flow, and protein phosphorylation of the rat. Acta Physiol. Scand. 125:43-53, 1985.  
(L.F. Agnati, K. Fuxe, F. Benfenati, M. Zoli, C. Owman, N.H. Diemer, J. Kährström, G. Toffano and M. Cimino)
639. Somatostatin induced apnoea: prevention by central and peripheral administration of the opiate receptor blocking agent naloxone. Acta Physiol. Scand., 125: 91-95, 1985.  
(A. Härfstrand, K. Fuxe, M. Kalia & L.F. Agnati)
640. Striatal ornithine decarboxylase activity following neurotoxic and mechanical lesions of the mesostriatal dopamine system of the male rat. Acta Physiol Scand., 125: 173-175, 1985.  
(L.F. Agnati, K. Fuxe, P. Davalli, I. Zini, A. Corti and M. Zoli)
641. Acute continuous exposure to cigarette smoke produces discrete changes in cholecystokinin and substance P levels in the hypothalamus and preoptic area of the male rat. Acta Physiol. Scand., 125:437-443, 1985.  
(K. Fuxe, R. A. Siegel, K. Andersson, P. Eneroth, F. Mascagni and L.F. Agnati)
642. Evidence for a modulatory influence of centrally administered substance P on a 5-hydroxytryptamine-mediated behavioural response in the male rat. Acta Physiol. Scand., 125:743-745, 1985.  
(S.-O. Ögren, K. Fuxe and L.F. Agnati)

643. Effects of chronic exposure to cigarette smoke on amine levels and turn-over in various hypothalamic catecholamine nerve terminal systems and on the secretion of pituitary hormones in the male rat. Neuroendocrinology 41:462-466, 1985.  
(K. Andersson, P. Eneroth, K. Fuxe, F. Mascagni and L.F. Agnati)
644. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Medicinal Res. Rev., Vol. 5, No. 4, 441-482, 1985.  
(K. Fuxe and L.F. Agnati.)
645. Immunocytochemical studies on the localization of glucocorticoid receptor immunoreactive nerve cells in the lower brain stem and spinal cord of the male rat using a monoclonal antibody against rat liver glucocorticoid receptor. Neuroscience Letters, 60 (1):1-6, 1985.  
(K. Fuxe, A. Härfstrand, L.F. Agnati, Z.-Y. Yu, A. Cintra, A.-C. Wikström, S. Okret, E. Cantoni and J.-Å. Gustafsson)
646. Effects of neurotoxic and mechanical lesions of the mesostriatal dopamine pathway on striatal polyamine levels in the rat: Modulation by chronic ganglioside GM1 treatment. Neuroscience Letters, 61: 339-344, 1985.  
(L.F. Agnati, K. Fuxe, M. Zoli, P. Davalli, A. Corti, I. Zini and G. Toffano)
647. Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinol., Vol. 117, No.5: 1803-1812, 1985.  
(K. Fuxe, A.-C. Wikström, S. Okret, L.F. Agnati, A. Härfstrand, Z.-Y. Yu, Lars Granholm, M. Zoli, W. Vale & J.-Å. Gustafsson).
648. Morphometrical and microdensitometrical studies on monoaminergic and peptidergic neurons in the aging brain. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 91-112, 1985.  
(L.F. Agnati, K. Fuxe, L. Calza, L. Giardino, I. Zini, G. Toffano, M. Goldstein, P. Marraa, J.-Å. Gustafsson, Z.-Y. Yu, A.C. Cuello, L. Terenius, R. Lang & D. Ganten).
649. Topographic distribution of catecholaminergic neurons in the rat medulla oblongata using quantitative three-dimensional reconstruction. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 127-143, 1985.  
(M. Kalia, D.J. Woodward, W.K. Smith, K. Fuxe, T. Hökfelt and M. Goldstein)
650. Effects of chronic GM1 ganglioside treatment on nigral dopamine cell bodies and dendrites in experimental rats using image analysis - relationship to the pharmacokinetic properties. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 145-156.  
(L.F. Agnati, K. Fuxe, G. Toffano, L. Calza, I. Zini, L. Giardino, F. Mascagni & M. Goldstein).

651. Development of quantitative methods for the evaluation of the entity of coexistence of neuroactive substances in nerve terminal populations in discrete areas of the central nervous system: Evidence for hormonal regulation of cotransmission. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 157-174, 1985.  
(K. Fuxe, L.F. Agnati, M. Zoli, A. Härfstrand, R. Grimaldi, P. Bernardi, M. Camurri, F. Tucci & M. Goldstein).
652. Principles for the construction of the software for image analysis of transmitter-identified neurons. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 175-184, 1985.  
(P.L. Fabbri, L.F. Agnati, K. Fuxe, N. Battistini, I. Zini and M. Zoli)
653. Quantitative microfluorimetry and semiquantitative immunocytochemistry as tools in the analysis of transmitter identified neurons. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 331-348, 1985..  
(K. Fuxe, L.F. Agnati, K. Andersson, M. Zoli, F. Benfenati, P. Eneroth & C. Cuello).
654. Quantitative autoradiography as a tool to study receptors in neural tissue. Studies on 3H-Ouabain binding sites and correlation with synaptic protein phosphorylation in different brain areas. In: Quantitative Neuroanatomy in Transmitter Research, (eds. L.F. Agnati and K. Fuxe), Wenner-Gren Int. Symp. Series, Vol. 42, MacMillan Press, England, pp. 381-396, 1985.  
(F. Benfenati, L.F. Agnati, K. Fuxe, M. Cimino, N. Battistini, E. Merlo Pich, C. Farabegoli & I. Zini).
655. On the use of automatic image analysis in the demonstration of transmitter identified nerve cell clusters in the central nervous system. Acta Stereol, 4/2:171-174, 1985.  
(A.M. Janson, L.F. Agnati, K. Fuxe, I. Zini and A. Härfstrand).
656. Image analysis and the determination of the entity of coexistence of neuroactive substances in nerve cell body populations. Acta Stereol, 4/2:175-180, 1985.  
(L.F. Agnati, K. Fuxe, A.M. Janson, R. Grimaldi, I. Zini and A. Härfstrand).
657. Image analysis and the determination of codistribution and coexistence of neuroactive substances in nerve terminal populations. Acta Stereol, 4/2:181-186, 1985.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, M. Zoli and A.M. Janson).
658. Computer assisted image analysis of transmitter receptors. Acta Stereologica 4/2:187-192, 1986.  
(F. Benfenati, M. Cimino, K. Fuxe & L.F. Agnati)

659. Morphofunctional studies on the role of somatostatin-enkephalin interactions in the regulation of central respiratory mechanisms. In: Neurogenesis of central respiratory rhythm, (eds. A.L. Bianchi, M. Denavit-Saubié), Symposium of the Centre National de la Recherche Scientifique (CNRS), Ile de Bendor, Bandol, France, Sept. 18-22, 1985, MTP Press Limited, Boston, 57, pp. 322-335.  
(K. Fuxe, A. Härfstrand, L.F. Agnati and M. Kalia)

1986

660. Studies on neurotensin-dopamine receptor interactions in striatal membranes of the male rat. The influence of 6-hydroxydopamine-induced dopamine receptor supersensitivity. Acta Physiol Scand., 126:147-149, 1986. (K. Fuxe, L.F. Agnati, M. Martire, A. Neumeyer, F. Benfenati & P. Frey)
661. Intravenous uridine treatment antagonizes hypoglycaemia-induced reduction in brain somatostatin-like immunoreactivity. Acta Physiol Scand., 126:525-531, 1986. (L.F. Agnati, K. Fuxe, P. Eneroth, I. Zini, A. Härfstrand, R. Grimaldi and M. Zoli)
662. Computer-assisted morphometry of transmitter-identified neurons: New openings for the understanding of peptide-monoamine interactions in the mediobasal hypothalamus. Neurohistochemistry: Modern Methods and Applications, 137-172, 1986. (M. Zoli, K. Fuxe, L.F. Agnati, A. Härfstrand, L. Terenius, R. Toni and M. Goldstein)
663. Analysis of (<sup>3</sup>H)spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum. Neuroscience Letters, 64:163-168, 1986. (K. Fuxe, E. Meller, M. Goldstein, F. Benfenati and L.F. Agnati)
664. Studies on neuropeptide Y-catecholamine interactions in the hypothalamus and in the forebrain of the male rat. Relationship to neuroendocrine function. Neurochem. Int. 8/3:355-376, 1986. (A. Härfstrand, K. Fuxe, L.F. Agnati, P. Eneroth, I. Zini, M. Zoli, K. Andersson, G. von Euler, L. Terenius, V. Mutt and M. Goldstein)
665. Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat. Neurochem. Int., 8/3:429-434, 1986. (P. Frey, K. Fuxe, P. Eneroth and L.F. Agnati)
666. Medianosomes as integrative units in the external layer of the median eminence. Studies on GRF/catecholamine interactions in the hypothalamus of the male rat. Neurochem. Int. 9/1:155-170, 1986. (K. Fuxe, K. Andersson, A. Härfstrand, L.F. Agnati, P. Eneroth, A.M. Janson, W. Vale, M. Thorner and M. Goldstein)
667. Heterogeneities in the dopamine neuron systems and dopamine co-transmission in the basal ganglia and the relevance of receptor-receptor interactions. In: Recent Developments in Parkinson's Disease, (eds. S. Fahn, C.D. Marsden, P. Jenner, P. Teychenne), Raven Press, New York, pp. 17-32, 1986. (K. Fuxe, L.F. Agnati, A. Härfstrand, S-O. Ögren and M. Goldstein)
668. Selective dopamine agonists as putative antiparkinsonian agents. In: Recent Developments in Parkinson's Disease, (eds. S. Fahn, C.D. Marsden, P. Jenner, P. Teychenne), Raven Press, New York, pp. 183-203, 1986. (M. Goldstein, E. Helmer-Matyjek, J.Y. Lew, A. Lieberman and K. Fuxe)

669. Morphological and biochemical studies on neuropeptide Y (NPY) and adrenergic mechanisms and their interactions in central cardiovascular regulation. Central Nervous System Control of the Heart, (eds. T. Stober, K. Schimrigk, D. Ganten, D.G. Sherman), Martinus Nijhoff Publishing, pp. 49-81, 1986.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, M. Kalia, T.H. Svensson, A. Neume-  
yer, M. Zoli, R. Lang, d. Ganten, L. Terenius and M. Goldstein)
670. Further evidence for a vasodepressor role of neuropeptide Y (NPY) and adrenaline (A) in the central nervous system (CNS) of the rat. Central Nervous System Control of the Heart, (eds. T. Stober, K. Schimrigk, D. Ganten, D.G. Sherman), Martinus Nijhoff Publishing, pp. 93-109, 1986.  
(A. Härfstrand, L.F. Agnati, K. Fuxe, M. Kalia)
671. Studies on peptide comodulator transmission. New perspective on the treatment of disorders of the central nervous system. In:Progress in Brain Research, (eds. P.C. Emson, M.N. Rossor and M. Tohyama), Elsevier Science Publishers B.V. (Biomedical Division), 66:341-368.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, K. Andersson, F. Mascagni, M. Zoli, M. Kalia, N. Battistini, F. Benfenati, T. Hökfelt and M. Goldstein)
672. Increases in dopamine utilization in certain limbic dopamine terminal populations after a short period of intermittent exposure of male rats to cigarette smoke. J. Neural Transm. 67:15-29, 1986.  
(K. Fuxe, K. Andersson, A. Härfstrand, and L.F. Agnati)
673. Neuropeptide Y enhances the inhibitory effects of clonidine on <sup>3</sup>H-noradrenaline release in synaptosomes isolated from the medulla oblongata of the male rat. J. Neural Transm. 67:113-124, 1986.  
(M. Martire, K. Fuxe, G. Pistritto, P. Preziosi, and L.F. Agnati)
674. Nicotine-induced increases in brain luteinizing hormone releasing hormone-like immunoreactivity and in serum luteinizing hormone levels of the male rat. Neurosci. Lett. 71:289-292, 1986.  
(K. Andersson, P. Eneroth, K. Fuxe and A. Härfstrand)
675. Aspects on the information handling by the central nervous system: focus on cotransmission in the aged rat brain. In: Progress in Brain Research, Vol. 68. (eds. T. Hökfelt, K. Fuxe and B. Pernow), Elsevier Science Publishers B.V., pp. 291-301, 1986.  
(L.F. Agnati, K. Fuxe, E. Merlo Pich, F. Benfenati, I. Zini and M. Goldstein)
676. Morphofunctional studies on the neuropeptide Y/adrenaline costoring terminal systems in the dorsal cardiovascular region of the medulla oblongata. Focus on receptor-receptor interactions in cotransmission. In: Progress in Brain Research, Vol. 68. (eds. T. Hökfelt, L. Fuxe and B. Pernow), Elsevier Science Publishers, B.V., pp. 303-320, 1986.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, A.M. Janson, A. Neume-  
yer, K. Andersson, M. Ruggeri, M. Zoli and M. Goldstein).



677. Quantitative autoradiography of central neurotransmitter receptors: methodological and statistical aspects with special reference to computer-assisted image analysis. Acta Physiol. Scand., 128:129-146, 1986. (F. Benfenati, M. Cimino, L.F. Agnati and K. Fuxe)
678. Receptor autoradiographical evidence for high densities of <sup>125</sup>I-neuropeptide Y binding sites in the nucleus tractus solitarius of the normal male rat. Acta Physiol. Scand. 128:195-200, 1986. (A. Härfstrand, K. Fuxe, L.F. Agnati, F. Benfenati and M. Goldstein)
679. A correlation analysis of the regional distribution of central enkephalin and  $\beta$ -endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol. Scand. 128:201-207, 1986. (L.F. Agnati, K. Fuxe, M. Zoli, I. Zini, G. Toffano and F. Ferraguti).
680. Aspects on the role of neuropeptide Y and atrial peptides in control of vascular resistance. In: Central and Peripheral Mechanisms of Cardiovascular Regulation. (eds. A. Magro, W. Osswald, D. Reis and P. Vanhoutte), Plenum Publishing Corporation, pp. 503, 1986. (L.F. Agnati, K. Fuxe, R. Grimaldi, A. Härfstrand, M. Zoli, I. Zini, D. Ganten and P. Bernardi)
681. Evidence for a vasodepressor role of neuropeptide Y and adrenaline mechanisms in the medulla oblongata of the rat. In: Brain and blood pressure control, (ed. K. Nakamura), Elsevier Sci. Publ., Amsterdam, pp. 99-112, 1986. (K. Fuxe, A. Härfstrand, L.F. Agnati, M. Kalia, A. Neumeyer, A. Cintra, I. Zini, M. Zoli, L. Terenius and M. Goldstein)
682. On the cellular localization and distribution of estrogen receptors in the rat tel- and diencephalon using monoclonal antibodies to human estrogen receptor. Neurochem. Int., Vol. 8, No. 4, pp. 587-595, 1986. (A. Cintra, K. Fuxe, A. Härfstrand, L.F. Agnati, L.S. Miller, J.L. Greene and J.-Å. Gustafsson)
683. Neuroanatomical and biochemical evidence for a reduction in the functional capability of the "aged neuron". In: Modulation of central and peripheral transmitter function, (eds Biggio E., Spano, P.F., Toffano, G. and Gessa G.L.), Fidia Research Series, Liviana Press/Springer Verlag, Padova, pp. 234-243, 1986. (F. Benfenati, K. Fuxe, L.F. Agnati, M. Zoli, M. Cimino, C. Farabegoli, G. Von Euler, M. Goldstein and G. Toffano)
684. Chemical neuroanatomy of respiratory and cardiovascular nuclei in the medulla oblongata. In: Neurobiology of the control of breathing (eds. C. von Euler and H. Lagercrantz), Raven Press, New York, pp. 165-173, 1986. (M. Kalia, J.J. Viola, M.E. Hudson, K. Fuxe, D.W. Richter, A. Härfstrand and M. Goldstein)

685. On a possible role of neuropeptide Y, peptide YY, and opioid peptides in the regulation of central respiratory rhythm in the rat. In: Neurobiology of the control of breathing (eds. C. von Euler and H. Lagercrantz), Raven Press, New York, pp. 175-186, 1986.  
(A. Härfstrand, K. Fuxe, M. Kalia, L.F. Agnati, I. Zini and L. Terenius)
686. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc. Natl. Acad. Sci., Vol. 83, pp. 9779-9783, 1986.  
(A. Härfstrand, K. Fuxe, A. Cintra, L.F. Agnati, I. Zini, A.-C. Wikström, S. Okret, Z.-Y. Yu, M. Goldstein, H. Steinbusch, A. Verhofstad and J.-Å. Gustafsson)
687. Morphofunctional studies on the central nervous system by means of image analysis. In: Neural Regulation of Brain Circulation, (eds. C. Owman and J.E. Hardebo), Elsevier Sci. Publ., Amsterdam, pp. 95-110, 1986.  
(L.F. Agnati, K. Fuxe, A.M. Janson, M. Zoli, A. Härfstrand, I. Zini and M. Goldstein)
688. Morphofunctional studies on glucocorticoid receptor immunoreactivity in central nervous system. In: Monoclonal antibodies: Basic Principles, Experimental and Clinical Applications in Endocrinology, (eds. G. Forti, M. Serio and M.B. Lipsett), Serono Symposia Publications, Vol. 30, Raven Press, New York, pp. 159-170, 1986.  
(M. Zoli, L.F. Agnati, K. Fuxe, M. Tesini, E. Cantoni and J.-Å. Gustafsson)
689. Age induced changes in the trophic signals and information handling in the central nervous system. Focus on peptide transmission. In: Senile Dementias: Early Detection, (eds. A. Bès et al.), John Libbey Eurotext, pp. 273-280, 1986.  
(K. Fuxe, L.F. Agnati, M. Zoli, F. Benfenati, I. Zini, A. Härfstrand, P. Eneroth and G. Toffano)
690. Quantitative analysis: computer-assisted morphometry and microdensitometry applied to immunostained neurones. In: Immunocytochemistry: Modern Methods and Applications, (eds. J.M. Polak and S. Van Noorden), Wright, Bristol, pp. 205-224, 1986.  
(L.F. Agnati, K. Fuxe, A.M. Janson, M. Zoli and A. Härfstrand)
691. Glucocorticoid mechanism of action: Monoclonal antibodies as experimental tools. Med. Oncol. & Tumor Pharmacother, Vol. 3, No. 3/4, pp. 185-196, 1986.  
(A.-C. Wikström, S. Okret, O. Bakke, K. Fuxe and J.-Å. Gustafsson)
692. New vistas on the morphofunctional organization of the endocrine hypothalamus. Focus on aging induced changes in the arcuate nucleus and in the medianosomes of the rat. In: Neuroendocrine system and aging, (eds. P. Vezzadini, A. Facchini and G. Labò), Eurage, pp. 13-25.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, P. Eneroth, I. Kitayama, C. Farabegoli, M. Tesini, R. Toni and M. Goldstein)
693. Morphofunctional evidence for an alteration in central cardiovascular regulation in aging especially in relation to stress induced alterations in cardiovascular function. In: Neuroendocrine system and aging, (eds. P. Vezzadini, A. Facchini and G. Labò), Eurage, pp. 37-50.  
(L.F. Agnati, K. Fuxe, M. Zoli, R. Grimaldi, P. Bernardi, A. Härfstrand, I. Zini, G. Gavioli, M. Goldstein and J.-Å. Gustafsson)

694. New evidence for the morphofunctional recovery of striatal function by ganglioside GM1 treatment following a partial hemitransection of rats. Studies on dopamine neurons and protein phosphorylation. In: Gangliosides and Neuronal Plasticity, (eds. G. Tettamani, R.W. Ledeen, K. Sandhoff, Y. Nagai and G. Toffano), Fidia Research Series, Vol. 6, Liviana Press, Padova, pp. 347-364, 1986.  
(K. Fuxe, L.F. Agnati, F. Benfenati, I. Zini, G. Gavioli and G. Toffano)
695. Studies on the involvement of polyamines for the trophic actions of the ganglioside GM1 in mechanically and 6-hydroxydopamine lesioned rats. Evidence for a permissive role of putrescine. In: Gangliosides and Neuronal Plasticity, (eds. G. Tettamani, R.W. Ledeen, K. Sandhoff, Y. Nagai and G. Toffano), Fidia Research Series, Vol. 6, Liviana Press, Padova, pp. 381-396, 1986.  
(I. Zini, M. Zoli, L.F. Agnati, K. Fuxe, E. Merlo Pich, P. Davalli, A. Corti, G. Gavioli and G. Toffano)
696. Evidence that intracisternal injections of cholecystokinin-8 counteracts the cardiovascular effects of intracisternally injected adrenaline and neuropeptide Y in the  $\alpha$ -chloralose anaesthetized rat. J Hypertension 4(suppl 6): 251-253, 1986.  
(A. Härfstrand, K. Fuxe and L.F. Agnati)
697. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin MPTP. Neurosci. Lett. 68:51-62, 1986.  
(A.Y. Deutch, J.D. Elsworth, M. Goldstein, K. Fuxe, D.E. Redmond, Jr., J.R. Sladek, Jr., R.H. Roth)
698. I samma bok som 689: Zini et al. "Studies on cerebral ischemia in the rat  
.....

1987

699. Morphometrical and microdensitometrical studies on the mosaic organization of the striatum. Focus on neuropeptide/dopamine transmitter interactions at the pre- and postsynaptic level. In: Neurotransmitter Interactions in the Basal Ganglia, (eds. M. Sandler, C. Feuerstein and B. Scatton), Raven Press, New York, pp. 31-46, 1987.  
(K. Fuxe, L.F. Agnati, M. Zoli, A. Härfstrand, S.-O. Ögren, E. Merlo Pich, I. Zini and M. Goldstein)
700. Evidence for a vasodepressor role of neuropeptide Y / adrenaline costoring neurons of the dorsal subnuclei of the nuc. tractus solitarius and for their interactions with CCK peptides and their regulation by calcitonin gene-related peptide and substance P immunoreactive nerve terminal networks. In: Brain Peptides and Catecholamines in Cardiovascular Regulation, (eds. J.P. Buckley and C.M. Ferrario), Raven Press, New York, pp. 27-42, 1987.  
(K. Fuxe, A. Härfstrand, L.F. Agnati, M. Kalia, A. Cintra, I. Kitayama, A.M. Janson and M. Goldstein)
701. Chronic imipramine treatment reduces (+)2-(<sup>125</sup>I)iodolysergic acid, diethylamide but not <sup>125</sup>I-neuropeptide Y binding in layer IV of rat cerebral cortex. Neurosci. Lett., 75: 152-156, 1987.  
(J.T. Cummins, G. von Euler, K. Fuxe, S.-O. Ögren and L.F. Agnati)
702. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regulatory Peptides 17: 167-179, 1987.  
(A. Härfstrand, P. Eneroth, L.F. Agnati and K. Fuxe)
703. Intravenous administration of atriopeptin III affects arterial blood pressure differentially in young and old male rats. Acta Physiol Scand., 129: 525-528.  
(R. Grimaldi, I. Zini, L.F. Agnati, K. Fuxe and A. Härfstrand)
704. Partial di-mesencephalic hemitranssections produce disappearance of <sup>3</sup>H-nicotine binding in discrete regions of rat brain. Acta Physiol. Scand., 130: 161-163, 1987.  
(A. Härfstrand, K. Fuxe, K. Andersson, L.F. Agnati, A.M. Janson and A. Nordberg)
705. Effects of subacute treatment with toluene on cerebrocortical  $\alpha$ - and  $\beta$ -adrenergic receptors in the rat. Evidence for an increased number and a reduced affinity of  $\beta$ -adrenergic receptors. Acta Physiol Scand., 130: 307-311, 1987.  
(K. Fuxe, M. Martire, G. von Euler, L.F. Agnati, T. Hansson, K. Andersson, J.-Å. Gustafsson and A. Härfstrand)

706. Differential effect of ganglioside GM1 on rat brain phosphoproteins: potentiation and inhibition of protein phosphorylation regulated by calcium/calmodulin and calcium/phospholipid-dependent protein kinases. Acta Physiol. Scand., 130: 317-325, 1987.  
(M. Cimino, F. Benfenati, C. Farabegoli, F. Cattabeni, K. Fuxe, L.F. Agnati and G. Toffano)
707. Inhibitory effects of neuropeptide Y on cyclic AMP accumulation in slices of the nucleus tractus solitarius region of the rat. Neurosci. Lett., 76: 185-190.  
(A. Härfstrand, B. Fredholm and K. Fuxe)
708. Evidence for the existence of ornithine decarboxylase-immunoreactive neurons in the rat brain. Neurosci. Lett., 76: 269-274.  
(A. Cintra, K. Fuxe, L.F. Agnati, L. Persson, A. Härfstrand, M. Zoli, P. Eneroth and I. Zini)
709. Presence of glucocorticoid receptor immunoreactivity in corticotrophin releasing factor and in growth hormone releasing factor immunoreactive neurons of the rat di- and telencephalon. Neurosci. Lett., 77: 25-30.  
(A. Cintra, K. Fuxe, A. Härfstrand, L.F. Agnati, A.-C. Wikström, S. Okret, W. Vale and J.-Å. Gustafsson)
710. Intracisternal administration of cholecystokinin-8 counteracts the central cardiovascular effects of adrenaline and NPY. A study based on the coexistence of cholecystokinin, phenylethanolamine-N-methyltransferase and neuropeptide Y immunoreactivity in neurons of the nucleus tractus solitarius. Neurochem. Int., Vol. 10, No. 4: 481-494, 1987.  
(A. Härfstrand, K. Fuxe, L.F. Agnati, I. Kitayama, A. Cintra, A.M. Janson, M. Kalia, J.-J. Vanderhaegen, M. Goldstein and Lars Terenius)
711. Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized rat. Neurochem. Int., Vol. 10, No. 4: 509-520, 1987.  
(M. Ruggeri, U. Ungerstedt, L.F. Agnati, V. Mutt, A. Härfstrand and Kjell Fuxe)
712. Evidence for discrete alterations in central cardiovascular catecholamine and neuropeptide Y immunoreactive neurons in aged male rats and in genetically hypertensive male rats of the Lyon strain. Eur. Heart Journal, 8 (suppl B): 139-145, 1987.  
(K. Fuxe, L.F. Agnati, I. Kitayama, M. Zoli, A.M. Janson, A. Härfstrand, M. Vincent, M. Kalia, G. Goldstein and J. Sassard)
713. Effects of acute continuous exposure of the rat to cigarette smoke on amine levels and utilization in discrete hypothalamic catecholamine nerve terminal systems and on neuroendocrine function. Arch Pharmacol., 335: 521-528, 1987.  
(K. Andersson, K. Fuxe, P. Eneroth, L.F. Agnati and A. Härfstrand)

714. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocrine Reviews 8(2): 185-234, 1987.  
(J-Å. Gustafsson, J. Carlstedt-Duke, L. Poellinger, Sam Okret, A-C. Wikström, M. Brönnegård, M. Gillner, Y. Dong, K. Fuxe, A. Cintra, A. Härfstrand and L.F. Agnati)
715. Neuropeptide Y-immunoreactive perikarya and nerve terminals in the rat medulla oblongata: Relationship to cytoarchitecture and catecholaminergic cell groups. J Comp. Neurol., 260: 20-35, 1987.  
(A. Härfstrand, K. Fuxe, L. Terenius and M. Kalia)
716. Effects of nicotine and exposure to cigarette smoke on discrete dopamine and noradrenaline nerve terminal systems of the telencephalon and diencephalon of the rat: Relationship to reward mechanisms and neuroendocrine functions and distribution of nicotinic binding sites in brain. In: Tobacco smoking and nicotine (eds. W.R. Martin, G.R. Van Loon, E.T. Iwamoto and L. Davis), Advances in Behavioural Biology, Vol. 31, Plenum Publ. Corp., New York, pp. 225-262, 1987.  
(K. Fuxe, K. Andersson, P. Eneroth, A. Härfstrand, A. Nordberg and L.F. Agnati)
717. Evidence for a fast receptor turnover of D1 dopamine receptors in various forebrain regions of the rat. Neurosci Lett., 81: 183-187, 1987.  
(K. Fuxe, L.F. Agnati, E. Merlo Pich, E. Meller and M. Goldstein)
718. Receptor-receptor Interactions. A New Intramembrane Integrative Mechanism MacMillan Press, London, 1987.  
(K. Fuxe & L.F. Agnati)
719. Opening Address. In: Receptor-receptor Interactions. A New Intramembrane Integrative Mechanism, (eds. K. Fuxe & L.F. Agnati), MacMillan Press, London, xiv-xviii, 1987.  
(K. Fuxe & L.F. Agnati)
720. On the role of receptor-receptor interactions in synaptic transmission: Biochemical and autoradiographical studies on the interactions between  $\alpha_2$ -adrenergic and neuropeptide Y receptors in the nucleus tractus solitarius. In: Receptor-receptor Interactions. A New Intramembrane Integrative Mechanism, (eds. K. Fuxe & L.F. Agnati), MacMillan Press, London, pp. 222-235, 1987.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, B.B. Fredholm, M. Kalia and M. Goldstein)
721. Aspects on the integrative capabilities of the central nervous system: Evidence for "volume transmission" and its possible relevance for receptor-receptor interactions. In: Receptor-receptor Interactions. A New Intramembrane Integrative Mechanism, (eds. K. Fuxe & L.F. Agnati), MacMillan Press, London, pp. 236-249, 1987.  
(L.F. Agnati, K. Fuxe, E. Merlo Pich, M. Zoli, I. Zini, F. Benfenati, A. Härfstrand & M. Goldstein)

722. Effects of intraventricular injections of galanin on neuroendocrine functions in the male rat. Possible involvement of hypothalamic catecholamine neuronal systems. Acta Physiol. Scand. 131:25-32, 1987. (T. Melander, K. Fuxe, A. Härfstrand, P. Eneroth & T. Hökfelt)
723. Effects of subacute toluene exposure on protein phosphorylation levels in rat frontoparietal and striatal membranes. Acta Physiol. Scand., 131: 113-118, 1987. (G. von Euler, K. Fuxe, T. Hansson, F. Benfenati, L.F. Agnati & J.-Å. Gustafsson)
724. Ganglioside GM<sub>13</sub> treatment prevents the effects of subacute exposure to toluene on N-(<sup>3</sup>H)propylnorapomorphine binding characteristics in rat striatal membranes. Neurosci. Lett. 82:181-184, 1987. (G. von Euler, K. Fuxe, L.F. Agnati, T. Hansson & J.-Å. Gustafsson)
725. Neuropeptide Y receptors in pig spleen. Acta Physiol. Scand. 131:321-322, 1987. (A. Härfstrand, J.M. Lundberg and K. Fuxe)
726. Effects of acute and chronic treatment with imipramine on 5-hydroxytryptamine nerve cell groups and on bulbospinal 5-hydroxytryptamine/substance P/thyrotropin releasing hormone immunoreactive neurons in the rat. A morphometric and microdensitometric analysis. J. Neuroal Transm. 70:251-285, 1987. (I. Kitayama, A.M. Janson, K. Fuxe, L.F., Agnati, A. Cintra, S.O. Ögren, A. Härfstrand, P. Eneroth, T. Tsutsumi, G. Jonsson, H.W.M. Steinbusch and T.J. Visser)
727. On the role of receptor-receptor interactions in synaptic transmission. In: Neuronal Messengers in Vascular Function, (eds. A. Nobin, C. Owman and B. Arneklo-Nobin), Elsevier Science Publishers, Amsterdam, pp. 305-325, 1987. (K. Fuxe, L.F., Agnati, F. Benfenati, A. Härfstrand, G. von Euler, E. Merlo Pich and F. Fontana)
728. The characterization of the dopaminergic profile of EMD 23,448, an indolyl-3-butylamine: selective actions on presynaptic and supersensitive postsynaptic DA receptor populations. J. Neural Transm. 70:193-215, 1987. (M. Goldstein, K. Fuxe, E. Meller, C.A. Seyfried, L.F. Agnati and F.M. Mascagni)
729. Chronic haloperidol affects striatal D<sub>2</sub>-dopamine receptor reappearance after irreversible receptor blockade. Brain Research 435:147-152, 1987. (E. Merlo Pich, F. Benfenati, C. Farabegoli, K. Fuxe, E. Meller, M. Aronsson, M. Goldstein and L.F. Agnati)
730. Studies on the cellular localization and distribution of glucocorticoid receptor and estrogen receptor immunoreactivity in the central nervous system of the rat and their relationship to the monoaminergic and peptidergic neurons of the brain. J. Steroid Biochem. 27(1-3):159-170, 1987. (K. Fuxe, A. Cintra, L.F. Agnati, A. Härfstrand, A.-C. Wikström, S. Okret, M. Zoli, L.S. Miller, J.L. Greene and J.-Å. Gustafsson)

731. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand. 131:625-526, 1987.  
(G. von Euler, K. Fuxe)
732. On the role of receptor-receptor interactions in central cardiovascular regulation: Functional studies on the interactions between  $\alpha_2$ -adrenergic and neuropeptide Y receptors in the rat medulla oblongata. In: Receptor-receptor interactions. A new intramembrane Integrative Mechanism, (eds. K. Fuxe & L.F. Agnati), MacMillan Press, London. pp. 519-530.  
(A. Härfstrand, K. Fuxe & L.F. Agnati)
733. Simultaneous central administration of adrenaline and neuropeptide Y leads to antagonistic interactions in vasodepressor responses in awake male rats. Acta Physiol. Scand. 130:529-531, 1987.  
(A. Härfstrand & K. Fuxe)
734. Further studies on the interactions between gangliosides and polyamines in the mechanically lesioned rat brain. In: Neuroplasticity: a new therapeutic tool in the CNS pathology (eds. R.L. Masland, A. Portera-Sanchez, G. Toffano), Liviana Press, Padova, 12:55-64, 1987.  
(M. Zoli, I. Zini, L.F. Agnati, K. Fuxe, P. Davalli, A. Corti, A. Desiderio, G. Toffano)
735. Central catecholamine-neuropeptide Y interactions at the pre- and postsynaptic level in cardiovascular centers. J. Cardiovasc. Pharmacol. 10(12):1-13, 1987.  
(Fuxe, K., Härfstrand, A., Agnati, L.F., Kalia, M., Fredholm, B., Svensson, T., Gustafsson, J.-Å., Lang, R. and Ganten, D.)
736. Central glucocorticoid receptor immunoreactive neurons: New insights into the endocrine regulation of the brain. Ann. N.Y. Acad. Sci. 512:362-393.  
(K. Fuxe, A. Cintra, A. Härfstrand, L.F. Agnati, M. Kalia, M. Zoli, A.-C. Wikström, S. Okret, M. Aronsson & J.-Å. Gustafsson)
- \* Evidence for a cardiovascular role of central galanin neurons. Focus on interactions with  $\alpha_2$ -adrenergic and neuropeptide Y mechanisms. J. Cardiovasc. Pharmacol. 10, suppl. 12:199-204, 1987.  
(Härfstrand, A., Fuxe, Melander, T., Hökfelt, T. and Agnati, L.F.)



1988

737. Effects of acute haloperidol treatment on regional catecholamine levels and utilization in rats exposed to toluene. Acta Physiol. Scand. 132(2): 199-208, 1988.  
(G. von Euler, K. Fuxe, T. Hansson, P. Eneroth, L.F. Agnati, A. Härfstrand & J.-Å. Gustafsson)
738. Reduction of (<sup>3</sup>H)nicotine binding by clonidine in membrane preparations of the rat cerebral cortex. Acta Physiol. Scand. 132(2):265-266, 1988.  
(K. Fuxe, G. von Euler & L.F. Agnati)
739. Chronic uridine treatment reduces the level of (<sup>3</sup>H)spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Acta Physiol. Scand. 132:209-216, 1988.  
(C. Farabegoli, E. Merlo Pich, M. Cimino, L.F. Agnati & K. Fuxe)
740. Distribution of nicotinic cholinergic receptors in the rat tel- and diencephalon: a quantitative receptor autoradiographical study using (<sup>3</sup>H)-acetylcholine, ( $\alpha$ -<sup>125</sup>I)bungarotoxin and (<sup>3</sup>H)nicotine. Acta Physiol. Scand. 132:1-14, 1988.  
(A. Härfstrand, A. Adem, K. Fuxe, L. Agnati, K. Andersson & A. Nordberg)
741. Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci. Lett. 85:163-167, 1988.  
(K. Fuxe, G. von Euler, L.F. Agnati & S.-O. Ögren)
742. Development of computer-assisted simulation procedure to analyze receptor modulatory processes. J. Neuroal Transm. 71:143-158, 1988.  
(F. Benfenati, L.F. Agnati & K. Fuxe)
743. Antibodies to catecholamine synthesizing enzymes: Tools for neurochemical and immunohistochemical research. In: Perspectives in psychopharmacology. A collection of papers in honor of Earl Usdin, (eds. J.D. Barchas, W.E. Bunney, Jr.), Alan R. Liss, Inc., New York, pp. 43-53, 1988.  
(M. Goldstein, K. Fuxe & T. Hökfelt)
744. Effects of acute intermittent exposure to cigarette smoke on hypothalamic and preoptic catecholamine nerve terminal systems and on neuroendocrine function in the diestrous rat. Naunyn-Schmiedeberg's Arch Pharmacol 337:131-139, 1988.  
(K. Andersson, P. Eneroth, K. Fuxe and A. Härfstrand)
745. Evidence for the existence of angiotensinogen mRNA in magnocellular paraventricular hypothalamic neurons. Acta Physiol Scand 132:585-586, 1988.  
(M. Aronsson, K. Almasan, K. Fuxe, A. Cintra, A. Härfstrand, J.-Å. Gustafsson and D. Ganten)

746. GM1 ganglioside protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 132:587-588, 1988.  
(A.M. Janson, L.F. Agnati, K. Fuxe, A. Cintra, E. Sundström, I. Zini, G. Toffano and M. Goldstein)
747. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 132:589-591, 1988.  
(A.M. Janson, K. Fuxe, E. Sundström, L.F. Agnati and M. Goldstein)
748. Effects of acute and chronic treatment with imipramine on 5-hydroxytryptamine and 5-hydroxytryptamine comodulators in central 5-hydroxytryptamine neurons and on glucocorticoid receptors in central monoaminergic neurons: a morphometrical and microdensitometrical analysis. In: New Concepts in Depression (eds. M. Briley and G. Fillion), MacMillan Press, London, pp. 25-41, 1988.  
(K. Fuxe, I. Kitayama, A.M. Janson, L.F. Agnati, A. Cintra, S.O. Ögren, A. Härfstrand, P. Eneroth and J.-Å. Gustafsson)
749. Morphometric studies on epinephrine and neuropeptide (NPY)-costoring neurons in the rat brain. In: Epinephrine in the Central Nervous System (eds. J.M. Stolk, D.C. U'Prichard and K. Fuxe), Oxford University Press, New York, Oxford, pp. 32-45, 1988.  
(L.F. Agnati, K. Fuxe, M. Zoli, A. Härfstrand, M. Kalia, A.M. Janson, I. Zini, F. Benfenati, R. Grimaldi, M. Goldstein and J.-Å. Gustafsson)
750. Connectivity and ultrastructure of noradrenergic and adrenergic neurons in the medulla oblongata. In: Epinephrine in the Central Nervous System (eds. J.M. Stolk, D.C. U'Prichard and K. Fuxe), Oxford University Press, New York, Oxford, pp. 59-77, 1988.  
(M. Kalia, J.J. Viola, M.E. Hudson, K. Fuxe, A. Härfstrand and M. Goldstein)
751. Physiological and biochemical characteristics of epinephrine/neuropeptide Y-costoring neurons in the medulla oblongata of the rat, with particular reference to vasodepressor functions within the nucleus tractus solitarii. In: Epinephrine in the Central Nervous System (eds. J.M. Stolk, D.C. U'Prichard and K. Fuxe), Oxford University Press, New York, Oxford, pp. 346-365, 1988.  
(K. Fuxe, A. Härfstrand, L.F. Agnati, M. Kalia, A. Neumeyer, T.G. Svensson, G. von Euler, L. Terenius, P. Bernardi and M. Goldstein)
752. Principles for the hormone regulation of wiring transmission and volume transmission in the central nervous system. In: Current Topics in Neuroendocrinology, Vol. 8 (eds. D. Ganten and D. Pfaff), Springer Verlag, Berlin, Heidelberg, pp. 1-53, 1988.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, A. Cintra, M. Aronsson, M. Zoli & J.-Å. Gustafsson)

753. The opioid peptide systems: Their organization and role in volume transmission and neuroendocrine regulation. In: Regulatory Roles of Opioid Peptides (eds. P. Illes and C. Farsang), VCH, Weinheim, New York, pp. 33-68, 1988.  
(K. Fuxe, L.F. Agnati, M. Zoli, A. Cintra, A. Härfstrand, G. von Euler, R. Grimaldi, M. Kalia & P. Eneroth)
754. Regeneration in the central nervous system: Concepts and facts. Advances and Technical Standards in Neurosurgery Vol. 16: 3-50, 1988.  
(L.F. Agnati, I. Zini, M. Zoli, K. Fuxe, E. Merlo Pich, R. Grimaldi, G. Toffano & M. Goldstein)
755. Neurotransmitter systems in the central organization of reproduction. In: Fundamentals and Clinics in Pineal Research (eds. G.P. Trentini, D. De Gaetani & P. Pévet), Raven Press, New York, pp. 237-250, 1988.  
(M. Zoli, L.F. Agnati, K. Fuxe, M. Ruggeri, C. Carani, G. Toffano & H.G.W. Steinbusch)
756. Polyamines, ornithine decarboxylase, and diamine oxidase in the substantia nigra and striatum of the male rat after hemitransection. J Neurochem 51(1):25-31, 1988.  
(M.A. Desiderio, I. Zini, P. Davalli, M. Zoli, A. Corti, K. Fuxe & L.F. Agnati)
757. Neuroendocrine and trophic actions of nicotine. In: The Pharmacology of Nicotine (eds. M.J. Rand & K. Thurau), ISCU Press, Paris, IRL Press, Oxford, pp. 293-320, 1988.  
(K. Fuxe, K. Andersson, P. Eneroth, A. Härfstrand, A.M. Janson, G. von Euler, L.F. Agnati, B. Tinner, C. Köhler & L.B. Hersh)
758. Effects of toluene treatment in vivo and in vitro on the binding characteristics of (<sup>3</sup>H)neurotensin in rat striatal membranes. Toxicology 49:149-154, 1988.  
(G. von Euler, K. Fuxe, T. Hansson & J.-Å. Gustafsson)
759. D<sub>1</sub>- and D<sub>2</sub>-receptor antagonists induce catalepsy via different efferent striatal pathways. Neurosci Lett 85:333-338, 1988.  
(S.-O. Ögren & K. Fuxe)
760. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Research 455:332-345, 1988.  
(A.M. Janson, K. Fuxe, L.F. Agnati, I. Kitayama, A. Härfstrand, K. Andersson & M. Goldstein)
761. Toluene induces changes in the morphology of astroglia and neurons in striatal primary cell cultures. Toxicology 49:155-163, 1988.  
(E. Hansson, G. von Euler, K. Fuxe & T. Hansson)
762. The emerging complexity of the brain. Limits of brain-computer analogy. In: Traffic Engineering for ISDN Design and Planning (eds. M. Bonatti and M. Decina). Elsevier Science Publishers B.V., pp. 209-230, 1988.  
(L.F. Agnati, M. Zoli, E. Merlo Pich, M. Ruggeri & K. Fuxe)

763. Neuropeptide Y mechanisms in neuroendocrine regulation. Focus on neuropeptide Y-catecholamine interactions in regulation of LH and prolactin secretion. In: Frontiers in gynecological endocrinology series (eds. A.R. Genazzani, U. Montemagno, C. Nappi and F. Petraglia). The Parthenon Publishing Group. The First Capri Conference, Capri, Italy, May 1987. pp. 45-55, 1988.  
(K. Fuxe, A. Härfstrand, P. Eneroth, M. Zoli & L.F. Agnati)
764. Morphometrical and microdensitometrical studies on phenylethanolamine-N-methyltransferase- and neuropeptide Y-immunoreactive neurons in the rostral medulla oblongata of the adult and old male rat. Neuroscience 26:461-478, 1988.  
(L.F. Agnati, K. Fuxe, M. Zoli, I. Zini, A. Härfstrand, G. Toffano & M. Goldstein)
765. Morphometrical and microdensitometrical studies on phenylethanolamine-N-methyltransferase- and neuropeptide Y-immunoreactive nerve terminals and on glucocorticoid receptor-immunoreactive nerve cell nuclei in the paraventricular hypothalamic nucleus in adult and old male rats. Neuroscience 26:479-492, 1988.  
(M. Zoli, L.F. Agnati, K. Fuxe, I. Zini, E. Merlo Pich, R. Grimaldi, A. Härfstrand, M. Goldstein, A.C. Wikström & J.-Å. Gustafsson)
766. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J Neuroal Transm. 73:191-203, 1988.  
(I. Kitayama, A.M. Janson, A. Cintra, K. Fuxe, L.F. Agnati, S.-O. Ögren, A. Härfstrand, P. Eneroth & J.-Å. Gustafsson)
767. Involvement of D1 dopamine receptors in the nicotine-induced neuro-endocrine effects and depletion of diencephalic catecholamine stores in the male rat. Neuroendocrinology 48:188-200, 1988.  
(K. Andersson, K. Fuxe, P. Eneroth, A. Härfstrand & L.F. Agnati)
768. Intraventricular injections of galanin reduces 5-HT metabolism in the ventral limbic cortex, the hippocampal formation and the fronto-parietal cortex of the male rat. Acta Physiol. Scand. 133:579-581, 1988.  
(K. Fuxe, S.-O. Ögren, A. Jansson, A. Cintra, A. Härfstrand & L.F. Agnati)
769. Apomorphine and pergolide induce hypothermia by stimulation of dopamin D-2 receptors. Acta Phyciol. Scand. 133:91-95, 1988.  
(S.-O. Ögren & K. Fuxe)
770. Studies on central D1 receptors role in volume transmission, neuroendocrine regulation and release of noradrenaline. In: Advances in Experimental Medicine and Biology, vol. 235 (eds. M. Goldstein, K. Fuxe and I Tabachnick). Plenum Press, New York, London, pp. 83-119, 1988.  
(K. Fuxe, L.F. Agnati, A. Cintra, K. Andersson, P. Eneroth, A. Härfstrand, M. Zoli and M. Goldstein)

771. Enhanced striatal glucose metabolism by chronic nicotine treatment following meso-striatal lesions in rats. In: The Pharmacology of Nicotine (eds. M.J. Rand and K. Thurau). ICSU Press, Oxford, pp. 266-267, 1988. (Ch. Owman, K. Fuxe, A.M. Janson & J. Kährström)
772. Receptor autoradiographical evidence of a preferential reduction of binding sites for atrial natriuretic factor in renal papilla of the spontaneously hypertensive rat. Acta Physiol. Scand. 134, 61-64, 1988. (L.F. Agnati, K. Fuxe, Härfstrand, R.E. Lang, T. Unger & D. Ganten)
773. Studies on the relationship of tyrosine hydroxylase, dopamine and cyclic AMP-regulated phosphoprotein-32 immunoreactive neuronal structures and D1 receptor antagonist binding sites in various brain regions of the male rat - mismatches indicate a role of D1 receptors in volume transmission. Neurochem. Int. 13, 179-197, 1988. (K. Fuxe, A. Cintra, L.F. Agnati, A. Härfstrand and M. Goldstein)
774. Involvement of D1 dopamine receptors in the nicotine-induced noradrenaline release from hypothalamic and preoptic noradrenaline nerve terminal systems. Neurochem. Int. 13(2):159-163, 1988. (K. Andersson, K. Fuxe & P. Eneroth)
775. D1 receptor mechanisms in the median eminence and their inhibitory regulation of LHRH release. Neurochem. Int. 13(2):165-178, 1988. (K. Fuxe, L.F. Agnati, K. Andersson, A. Cintra, A. Härfstrand, M. Zoli, P. Eneroth & M. Goldstein)
776. Morphofunctional studies on neuronal plasticity in the striatum of the aging rat. In: Senile dementias. II International Symposium. (eds. A. Agnoli, J. Cahn, N. Lassen, R. Mayeux). John Libbey Eurotext, Paris, pp. 121-129, 1988. (E. Merlo Pich, M. Zoli, F. Ferraguti, P. Marrama, K. Fuxe & L.F. Agnati)
777. Angiotensin II reduces the affinity of (<sup>3</sup>H)para-aminoclonidine binding sites in membrane preparations from the rat dorsomedial medulla oblongata. Acta Physiol. Scand. 134: 317-318, 1988. (K. Fuxe, G. von Euler & L.F. Agnati)
778. Survival of adenohipophyseal homologous transplants in the rat striatum associated with prolactin-like immunoreactivity in the surrounding neuropil of the striatum. Neurosci. Lett. 93:139-145, 1988. (B. Bjelke, K. Fuxe & L.F. Agnati)
779. Effects of chronic toluene exposure on central monoamine and peptide receptors and their interactions in the adult male rat. Toxicology 52:103-126, 1988. (G. von Euler, K. Fuxe, T. Hansson, S.-O. Ögren, L.F. Agnati, P. Eneroth, A. Härfstrand & J.-Å. Gustafsson)

780. Localization and distribution of glucocorticoid receptor immunoreactivity and of glucocorticoid receptor mRNA in the rat brain using immunocytochemistry and in situ hybridization. In: Progress in endocrinology, Vol. 8 (eds. H. Imura, K. Shizoime, S. Uoshida). Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, pp. 875-883, 1988.  
(K. Fuxe, A. Cintra, M. Aronsson, L.F. Agnati, I. Kitayama, A.-C. Wikström, S. Okret & J.-Å. Gustafsson)
781. Evidence for selective changes in peptide and monoamine synapses and their interactions in the aging rat brain. Possible loss of homeostatic responses and of trophic signals. In: New Trends in Aging Research, Vol. 15 (eds. G. Pepeu, B. Tomlinsin, C.M. Wischik. Fidia Research Series, Liviana Press, Padova, pp. 3-20, 1988.  
(K. Fuxe, L.F. Agnati, I. Zini, E. Merlo Pich, A. Cintra, I. Kitayama, A. Härfstrand, G. von Euler, W. Vale, G. Toffano & . Goldstein)
782. Morphometrical evidence for a complex organization of tyrosine hydroxylase-, enkephalin- and DARPP-32-like immunoreactive patches and their codistribution at three rostrocaudal levels in the rat neostriatum. Neurosci., 27:785-797, 1988.  
(L.F. Agnati, K. Fuxe, M. Zoli, F. Ferraguti, F. Benfenati, C.C. Ouimet, S.I. Walaas, H.C. Hemmings Jr., M. Goldstein & P. Greengard)
783. Effects of chronic uridine treatment on regional neuropeptide and tyrosine hydroxylase-like immunoreactivities in th brain of 12 month-old male rats. Neurochem. Int., 13:499-508, 1988.  
(M. Zoli, L.F. Agnati, K. Fuxe, A. Cintra, R. Grimaldi, J.J. Vanderhaeghen, P. Eneroth and M. Goldstein)
784. Pre- and postsynaptic features of the central angiotensin systems. Indications for a role of angiotensin peptides in volume transmission and for interactions with central monoamine neurons. In: Clin. and Exper. Hypertensin - Theory and Practice A10(suppl.1):143-168, 1988.  
(K. Fuxe, B. Bunnemann, M. Aronsson, B. Tinner, A. Cintra, G. von Euler, L.F. Agnati, S. Nakanishi, H. Ohkubo and D. Ganten)
785. Studies on the functional role of central dopamine D1 and D2 receptors. Neurology and Neurobiology, 42B:27-31, 1988.  
(S.O. Ögren, K. Fuxe and C. Köhler)
786. Aspects on neuropeptide Y/epinephrine co-transmission in central cardiovascular regulation. Neurology and Neurobiology, 42B:225-232, 1988.  
(A. Härfstrand, K. Fuxe, A. Cintra and L.F. Agnati)
787. On the role of dopamine nerve terminals and tanycytes in the medianosomal organization of the median eminence: focus on the lutenizing hormone-releasing hormone medianosome. Neurology and Neurobiology, 42B:267-272, 1988.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, M. Zoli, P. Eneroth, K. Andersson, F. Benfenati, C. Ouimet and P. Greengard)

788. Mapping of the tuberionfundibular dopamine neurons as studied by dopamine and tyrosine hydroxylase immunocytochemistry. Neurology and Neurobiology, 42B:279-284, 1988. *Program in Cate ... se te per*  
(L.F. Agnati, K. Fuxe, H. Steinbusch, M. Zoli, I. Zini, A. Cintra and A. Härfstrand)
789. Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc. Natl. Acad. Sci. USA, 85:9331-9335, 1988.  
(M. Aronsson, K. Fuxe, Y. Dong, L.F. Agnati, S. Okret & J.-Å. Gustafsson)
- + *Morphofunctional studies on the interaction between dopamine, neuropeptide Y and beta-endorphin neuronal systems in the control of prolactin secretion. In: Opioid Peptides in Biological Fluids (Eds. A.R. Genazzani and M. Negri), The Parthenon Publ Group, New Jersey, USA, pp. 53-65.*  
(M. Zoli, I. Zini, P. Bernardi, F. Fontana, A. Härfstrand, L.F. Agnati and K. Fuxe)

1989

790. Reciprocal interactions between  $\alpha_2$ -adrenoceptor agonist and neuropeptide Y binding sites in the nucleus tractus solitarius of the rat. A biochemical and autoradiographic analysis. J. Neural transm., 75:83-99, 1989.  
(A. Härfstrand, K. Fuxe, L.F. Agnati & B.B. Fredholm)
791. Regional differences in glucocorticoid receptor immunoreactivity among neuropeptide Y immunoreactive neurons of the rat brain. Acta Physiol. Scand., 135:3-9, 1989.  
(A. Härfstrand, A. Cintra, K. Fuxe, M. Aronsson, A.-C. Wikström, S. Okret, J.-Å. Gustafsson & L.F. Agnati)
792. Centrally administered galanin reduces dopamine utilization in the median eminence and increases dopamine utilization in the medial neostriatum of the male rat. Acta Physiol. Scand., 135:199-200, 1989.  
(A. Jansson, K. Fuxe, P. Eneroth and L.F. Agnati)
793. Demonstration of NPY transmitter receptor mismatches in the central nervous system of the male rat. Acta Physiol. Scand., 135:201-202, 1989.  
(M. Zoli, L.F. Agnati, K. Fuxe and B. Bjelke)
794. Some aspects of the communicational and computational organization of the brain. Acta Physiol. Scand., 135:203-216.  
(K. Fuxe, L.F. Agnati, M. Zoli, B. Bjelke and I. Zini)
795. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene. Acta Physiol. Scand. 135:443-448, 1989.  
(G. von Euler, K. Fuxe, F. Benfenati, T. Hansson, L.F. Agnati & J.-Å. Gustafsson)
796. Persistent effects of neonatal toluene exposure on regional brain catecholamine levels and turnover in the adult male rat. Toxicology, 54:1-16, 1989.  
(G. von Euler, K. Fuxe, T. Hansson, P. Eneroth & J.-Å. Gustafsson)
797. Evidence for the existence of a population of arcuate neurons costoring choline acetyltransferase and tyrosine hydroxylase immunoreactivities in the male rat. Neurosci. Lett., 99:44-49, 1989.  
(B. Tinner, K. Fuxe, Ch. Köhler, L. Hersh, K. Andersson, A. Jansson, M. Goldstein & L.F. Agnati)
798. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology, 14:19-41, 1989.  
(K. Fuxe, K. Andersson, P. Eneroth, A. Härfstrand & L.F. Agnati)
799. Effects of withdrawal from chronic exposure to cigarette smoke on hypothalamic and preoptic catecholamine nerve terminal systems and on the secretion of pituitary hormones in the male rat. Naunyn-Schmiedeberg's Arch Pharmacol. 339:387-396, 1989.  
(K. Andersson, K. Fuxe, P. Eneroth, A. Hansson & A. Härfstrand)



800. Reduced inhibitory effects of clonidine and neuropeptide Y on <sup>3</sup>H-noradrenaline release from synaptosomes of the medulla oblongata of the spontaneously hypertensive rat. J. Neural Transm. 76:181-189, 1989. (M. Martire, K. Fuxe, G. Pistrutto, P. Preziosi & L.F. Agnati)
801. Chronic immobilization stress: evidence for decreases of 5-hydroxy-tryptamine immunoreactivity and for increases of glucocorticoid receptor immunoreactivity in various brain regions of the male rat. J. Neuroal Transm. 77:93-130, 1989. (I. Kitayama, A. Cintra, A.M. Janson, K. Fuxe, L.F. Agnati, P. Eneroth, M. Aronsson, A. Härfstrand, H.W.M. Steinbusch, T.J. Visser, M. Goldstein, W. Vale & J.-Å. Gustafsson)
802. Neuropeptide Y increases the inhibitory effects of clonidine on potassium evoked <sup>3</sup>H-noradrenaline but not <sup>3</sup>H-5-hydroxytryptamine release from synaptosomes of the hypothalamus and the frontoparietal cortex of the male Sprague-Dawley rat. J. Neural Transm. 78:61-72, 1989. (M. Martire, K. Fuxe, G. Pistrutto, P. Preziosi & L.F. Agnati)
803. Effects of transient forebrain ischaemia on vasoactive intestinal polypeptide-immunoreactive neuronal populations in the frontoparietal cortex and hippocampal formation of the male rat. Acta Physiol. Scand. 136:289-290, 1989. (R. Grimaldi, I. Zini, F. Ferraguti, P. Cortelli, K. Fuxe, L.F. Agnati & M. Zoli)
804. Reduction of (<sup>3</sup>H)nicotine binding in hypothalamic and cortical membranes by dopamine D1 receptors. Acta Physiol. Scand. 136:295-296, 1989. (K. Fuxe, G. von Euler, U.-B. Finnman & L.F. Agnati)
805. Intraventricular injections of galanin counteract development of head twitches induced by the 5-HT-2 agonist 1-(2,5-dimethoxyphenyl-4-bromo)-2-aminopropane. Acta Physiol. Scand. 136:297-298, 1989. (S.-O. Ögren & K. Fuxe)
806. Pertussis toxin treatment counteracts the cardiovascular effects of neuropeptide Y and clonidine in the awake unrestrained rat. Neurosci. Lett. 101:337-341, 1989. (K. Fuxe, G. von Euler, I. van der Ploeg, B.B. Fredholm & L.F. Agnati)
807. Centrally administered endothelin-1 produces lesions in the brain of the male rat. Acta Physiol Scand 137: 155-156, 1989. (K. Fuxe, A. Cintra, B. Andbjør, E. Änggård, M. Goldstein & L.F. Agnati)
808. Centrally administered endothelin-1 produces apnoea in the  $\alpha$ -chloralose-anaesthetized male rat. Acta Physiol Scand 137: 157-158. (K. Fuxe, B. Andbjør, M. Kalia & L.F. Agnati)
809. Intraventricular injection of neurotensin reduces the binding of dopamine D2 receptors in the rat forebrain. Acta Physiol Scand 137: 309-310, 1989. (G. von Euler, B. Meister, T. Hökfelt & K. Fuxe)

810. On the cellular localization and distribution of the ganglioside GM1 in the rat brain as revealed by immunofluorescence histochemistry of cholera toxin binding sites. Acta Physiol Scand 137: 551-552, 1989.  
(K. Fuxe, B. Tinner, A.M. Janson A. Cintra, W. Staines & L.F. Agnati)
811. Increased endothelin-like immunoreactivity in ibotenic acid-lesioned hippocampal formation of the rat brain. Acta Physiol Scand 137: 557-558, 1989.  
(A. Cintra, K. Fuxe, E. Ånggård, B. Tinner, W. Staines & L.F. Agnati)
812. Localization of <sup>125</sup>I-endothelin-1 and <sup>125</sup>I-endothelin-3 binding sites in the rat brain. Acta Physiol Scand 137: 563-564, 1989.  
(K. Fuxe, E. Ånggård, K. Lundgren, A. Cintra, L.F. Agnati, S. Galton & J. Vane)
813. Neurohistochemical studies on striatal lesions induced by transient forebrain ischemia. Evidence for protective effects of the ganglioside analogue AGF2. Neuroscience Res Comm Vol. 4(3): 153-158, 1989.  
(M. Zoli, R. Grimaldi, L.F. Agnati, I. Zini, E. Merlo Pich, G. Toffano & K. Fuxe)
814. Pertussis toxin treatment counteracts intramembrane interactions between neuropeptide Y receptors and  $\alpha 2$ -adrenoceptors. Eur J Pharmacol - Molecular Pharmacology Section, 172: 435-441, 1989.  
(G. von Euler, K. Fuxe, I. Van der Ploeg, B. Fredholm & L.F. Agnati)
815. Immunocytochemical studies on some brain regions in a rat model of incomplete cerebral ischemia. Relationship to behavior and aging. In: Cerebral Ischemia and Calcium, eds. A. Hartmann & W. Kuschinsky, Springer-Verlag, Berlin, pp. 83-96, 1989.  
(G. Németh, A. Cintra, K. Fuxe, L. Persson, L.F. Agnati, M. Goldstein & S. Hoyer)
816. Effects of transient global cerebral ischemia on peptide neuronal populations in different brain regions and on behavioral performances in rats. In: Cerebral Ischemia and Calcium, eds. A. Hartmann & W. Kuschinsky, Springer-Verlag, Berlin, pp. 97-104, 1989.  
(I. Zini, R. Grimaldi, E. Merlo Pich, V. Solfrini, G. Toffano, L.F. Agnati & K. Fuxe)
817. Related responses between dopamine synapses and astrocytes in the rat striatum after global cerebral ischemia: A morphometric and microdensitometric study. In: Cerebral Ischemia and Calcium, eds. A. Hartmann & W. Kuschinsky, Springer-Verlag, Berlin, pp. 105-110, 1989.  
(R. Grimaldi, I. Zini, M. Zoli, G. Biagini, M. Goldstein, K. Fuxe & L.F. Agnati)
818. Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats. Neurosci Lett 102: 279-283, 1989.  
(Ch. Owman, K. Fuxe, A.M. Janson & J. Kährström)
819. Acute treatment with clozapine blocks D1 dopamine receptor binding in discrete brain areas of the male rat. Neurosci Lett 106: 169-174, 1989.  
(K. Fuxe, G. von Euler, L.F. Agnati, C.F. Saller, A. Salama & M. Goldstein)

820. Increased diffusion of prolactin-like material into the brain neuropil from homologous adenohypophyseal transplants in the rat neostriatum after a 6-OH-dopamine induced degeneration of the mesostriatal dopamine neurons. Neurosci Lett 107: 33-38, 1989.  
(B. Bjelke, K. Fuxe & L.F. Agnati)
821. Integration of humoral and neuronal signals in neuroendocrine regulation. Focus on interaction of glucocorticoids with central neuropeptide and monoamine neurotransmission. In: Recent Advances in Basic and Clinical Neuroendocrinology (eds. F.F. Casanueva, D. Dieguez), Elsevier Science Publ, Amsterdam, pp. 109-126, 1989.  
(K. Fuxe, A. Cintra, S. Tanganelli, G. von Euler, U.-B. Finnman, K. Lundgren, J. Aguirre-Gomez, B. Bjelke, M. Zoli, P. Eneroth & L.F. Agnati)
822. Coexistence of glucocorticoid receptor-like immunoreactivity with neuropeptides in the hypothalamic paraventricular nucleus. Exp Brain Res 78: 33-42, 1989.  
(S. Ceccatelli, A. Cintra, T. Hökfelt, K. Fuxe, A.-C. Wikström & J.-Å. Gustafsson)
823. Transient forebrain ischemia produces multiple deficits in dopamine D1 transmission in the lateral neostriatum of the rat. Brain Res 498: 376-380, 1989.  
(F. Benfenati, E. Merlo Pich, R. Grimaldi, M. Zoli, K. Fuxe, G. Toffano & L.F. Agnati)
824. Evidence for nuclear ornithine decarboxylase activity in different brain regions of the male rat. Neurochem Int 15(4): 433-438, 1989.  
(R. Grimaldi, C.G. Eriksson, P. Eneroth, L.F. Agnati & K. Fuxe)
825. Morphofunctional studies on the effects of the ganglioside analogue AGF2 on striatal lesions induced by transient global cerebral ischemia. In: Pharmacology of Cerebral Ischemia 1988 (ed J. Kriegstein), Verlagsgesellschaft, Stuttgart, pp. 289-294, 1989.  
(L.F. Agnati, M. Zoli, I. Zini, E. Merlo Pich, R. Grimaldi, G. Toffano, F. Ferraguti & K. Fuxe)
826. Toluene treatment in vitro and calcium-regulated protein phosphorylation in primary astroglial cell cultures from the rat striatum. Toxic in Vitro 3(3): 235-240, 1989.  
(G. von Euler, E. Hansson & K. Fuxe)
827. NPY receptors and their interactions with other transmitter systems. In: Neuropeptide Y (eds. V. Mutt, K. Fuxe), Raven Press, New York, pp. 103-114, 1989.  
(L.F. Agnati, M. Zoli, E. Merlo Pich, F. Benfenati, R. Grimaldi, I. Zini, G. Toffano & K. Fuxe)
828. Studies on the neurochemical mechanisms underlying the neuroendocrine actions of neuropeptide Y. In: Neuropeptide Y (eds. V. Mutt, K. Fuxe), Raven Press, New York, pp. 115-136, 1989.  
(K. Fuxe, L.F. Agnati, A. Härfstrand, P. Eneroth, A. Cintra, B. Tinner, E. Merlo Pich, M. Aronsson, B. Bunnemann, R. Lang & D. Ganten)

829. On the role of NPY in central cardiovascular regulation. In: Neuropeptide Y (eds. V. Mutt, K. Fuxe), Raven Press, New York, pp. 201-214, 1989.  
(K. Fuxe, A. Härfstrand, L.F. Agnati, G. von Euler, T. Svensson & B. Fredholm)
830. New Aspects on the morphometrical characterization at cell body and terminal level of transmitter identified nerve populations using computer-assisted image analysis. In: Visualization of brain function (eds. D. Ottoson & W. Rostène), Wenner-Gren Int Series, MacMillan Press, Vol. 53, pp. 87-101, 1989.  
(L.F. Agnati, K. Fuxe, M. Zoli, D. Guidolin, E. Merlo Pich, B. Bjelke & I. Zini)
831. Possibilit  e limiti del trapianto de tessuto cerebrale sistema nervoso centrale. In: La Cura della Salute Verso il 2000 (ed P. Donati), F. Angeli Libri s.r.l., Milano, pp. 167-178, 1989.  
(E. Merlo Pich, I. Zini, K. Fuxe, B. Bjelke & L.F. Agnati)
832. Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res 502: 319-324, 1989.  
(S. Tanganelli, G. von Euler, K. Fuxe, L.F. Agnati & U. Ungerstedt)
833. Neurochemical mechanisms underlying the neuroendocrine actions of nicotine: focus on the plasticity of central cholinergic nicotinic receptors. Prog in Brain Res 79: 197-207, 1989.  
(K. Fuxe, K. Andersson, P. Eneroth, A. Jansson, G. von Euler, B. Tinner, B. Bjelke & L.F. Agnati)
834. Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat. Prog in Brain Res 79: 257-266, 1989.  
(A.M. Janson, K. Fuxe, L.F. Agnati, A. Jansson, B. Bjelke, E. Sundstr m, K. Andersson, A. H rfstrand, M. Goldstein & Ch. Owman)
835. Studies of protective actions of nicotine on neuronal and vascular functions in the brain of rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber systems, and the effect of a dopamine agonist. Prog in Brain Res 79: 267-276, 1989.  
(Ch. Owman, K. Fuxe, A.M. Janson & J. K hrstr m)
836. Immunohistochemical and biochemical studies on the temporal profile of rat brain incomplete cerebral ischemia. J Cerebral Blood Flow and Metabolism 9(1), New York, Raven Press, p. S652, 1989.  
(A. Cintra, G. N meth, K. Fuxe, L.F. Agnati & S. Hoyer)
837. Age-related temporal and regional differences in neuronal damage after bilateral incomplete cerebral ischemia. J Cerebral Blood Flow and Metabolism 9(1), New York, Raven Press, p. S661, 1989.  
(G. N meth, A. Cintra, K. Fuxe & S. Hoyer)

838. Effects of chronic treatment with uridine on striatal dopamine release and dopamine related behaviours in the absence or the presence of chronic treatment with haloperidol. Neurochem Int 15(1): 107-113, 1989.  
(L.F. Agnati, K. Fuxe, M. Ruggeri, E. Merlo Pich, F. Benfenati, V. Volterra, U. Ungerstedt & I. Zini)
839. Effects of combined pre- and postnatal treatment with nicotine on hypothalamic catecholamine nerve terminal systems and neuroendocrine function in the 4-week old and adult male and female diestrous rat. J Neuroendocrinology 1(6): 455-464, 1989.  
(A. Jansson, K. Andersson, K. Fuxe, B. Bjelke & P. Eneroth)
840. Receptor-receptor interactions and development of psychoactive drugs. In: Neurochemical Pharmacology - A Tribute to B.B. Brodie (eds. E. Costa), Raven Press, New York, pp. 211-227, 1989.  
(K. Fuxe, L.F. Agnati, G. von Euler, F. Benfenati, M. Zoli, A. Härfstrand and B. Fredholm)

1990

841. Effects of nicotine on synaptic transmission in the brain. In: *Nicotine Psychopharmacology. Molecular Cellular and Behavioural Aspects* (eds. S. Wonnacott, M.A.H. Russell & I.P. Stolerman) Oxford University Press, pp. 195-225, 1990.  
(K. Fuxe, K. Andersson, A. Härfstrand, P. Eneroth, M. Perez de la Mora & L.F. Agnati)
842. Evidence for thyrotropin-releasing hormone and glucocorticoid receptor-immunoreactive neurons in various preoptic and hypothalamic nuclei of the male rat. *Brain Res* 506: 139-144, 1990.  
(A. Cintra, K. Fuxe, A.-C. Wikström, T. Visser & J.-Å. Gustafsson)
843. Effects of central administration of neuropeptide Y on vigilance and pain threshold in spontaneously hypertensive rats. In: *Advances in Pain Research and Therapy* Vol. 13, (eds. S. Lipton, E. Tunks & M. Zoppi), New York, Raven Press, pp. 55-63, 1990.  
(E. Merlo Pich, M. Zoli, I. Zini, F. Ferraguti, V. Solfrini, M. Tiengo, K. Fuxe & L.F. Agnati)
844. Galanin/5-HT receptor interactions. A new integrative mechanism in the control of 5-HT neurotransmission in the central nervous system. In: *Serotonin from Cell Biology to Pharmacology and Therapeutics* (eds. R. Paoletti, P.M. Vannoutte, N. Brunello & F.M. Maggi). Dordrecht, Kluwer Academic Publ, pp. 169-185, 1990.  
(K. Fuxe, L.F. Agnati, G. von Euler, K. Lundgren, M. Zoli, B. Bjelke, P. Eneroth & S.O. Ögren)
845. Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen. *Neurosci Lett* 109: 325-330, 1990.  
(G. von Euler, P. Mailleux, J.-J. Vanderhaeghen and K. Fuxe)
846. Ganglioside GM1 prevents and reverses toluene-induced increases in membrane fluidity and calcium levels in rat brain synaptosomes. *Brain Res* 508: 210-214, 1990.  
(G. von Euler, K. Fuxe and S.C. Bondy)
847. Indole-pyruvic acid increases 5-hydroxyindoleacetic acid levels in the cerebrospinal fluid and frontoparietal cortex of the rat: a microdialysis study. *Acta Physiol Scand* 138: 97-98, 1990.  
(M. Ruggeri, E. Merlo Pich, I. Zini, K. Fuxe, U. Ungerstedt and L.F. Aganti)
848. Morphometrical and microdensitometrical studies on peptide- and tyrosine hydroxylase-like immunoreactivities in the forebrain of rats prenatally exposed to methylazoxymethanol acetate. *Developmental Brain Res* 51: 45-61, 1990.  
(M. Zoli, E. Merlo Pich, M. Cimino, G. Lombardelli, G. Peruzzi, K. Fuxe, L.F. Agnati and F. Cattabeni)

849. Regulation of endocrine function by the nicotinic cholinergic receptor. **In: The Biology of Nicotine Dependence**, Ciba Foundation Symposium 152. Wiley, Chichester, pp. 113-130, 1990. (Fuxe K, Agnati LF, Jansson A, von Euler G, Tanganelli S, Andersson K and Eneroth P)
850. Long-lasting reduction of glucocorticoid receptor immunoreactivity in the hippocampal field CA1 but not in the dentate gyrus after neonatal treatment with corticosterone in the rat. **Acta Physiol Scand** 138: 577-579, 1990. (Zoli M, Agnati L, Fuxe K, Ferraguti F, Biagini G, Cintra A and Gustafsson J-Å)
851. Changes in pituitary-adrenal activity affect the binding properties of striatal dopamine D2 receptors but not their modulation by neurotensin and cholecystokinin-8. **Neurochem Int** 16(3): 275-280, 1990. (von Euler G, Fuxe K, Tanganelli S, Finnman U-B and Eneroth P)
852. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. **Naunyn Schmiedeberg's Arch Pharmacol** 341: 171-181, 1990. (Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P and Agnati LF)
853. On the role of neuropeptide Y in information handling in the central nervous system in normal and physiopathological states. **Ann N.Y. Acad Sci** 579: 28-67, 1990. (Fuxe K, Agnati LF, Härfstrand A, Zoli M, von Euler G, Grimaldi R, Merlo Pich E, Bjelke B, Eneroth P, Benfenati F, Cintra A, Zini I and Martire M)
854. Monoaminergic and peptidergic innervation of the intermedio-lateral horn of the spinal cord. I. Distribution patterns of nerve terminal networks. **Eur J Neurosci** 2: 430-450, 1990. (Fuxe K, Tinner B, Bjelke B, Agnati LF, Verhofstad A, Steinbusch HGW, Goldstein M and Kalia M)
855. Monoaminergic and peptidergic innervation of the intermedio-lateral horn of the spinal cord. II. Relationship to preganglionic sympathetic neurons. **Eur J Neurosci** 2: 451-460, 1990. (Fuxe K, Tinner B, Agnati LF, Verhofstad A, Steinbusch HGW, Goldstein M, Hersh L and Kalia M)
856. Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. **Neurosci Lett** 114 (1990) 147-153. (Bunnemann B, Fuxe K, Metzger R, Mullins J, Jackson TR, Hanley MR and Ganten D)
857. Evidence for the existence of angiotensin II like immunoreactivity in subpopulations of tyrosine hydroxylase immunoreactive neurons in the A1 and C1 area of the ventral medulla of the male rat. **Neurosci Lett** 114 (1990) 160-166. (Covenas R, Fuxe K, Cintra A, Aguirre JA, Goldstein M and Ganten D)
858. Aspects of neural plasticity in the central nervous system. I. Computer-assisted image analysis methods. **Neurochem Int** 16(4) (1990) 383-418. (Zoli M, Zini I, Agnati LF, Guidolin D, Ferraguti F and Fuxe K)

859. Aspects of neural plasticity in the central nervous system. II. Numerical classification in neuroanatomy. **Neurochem Int** 16(4) (1990) 419-426. (Agnati LF, Zoli M, Benfenati F, Merlo Pich E, Grimaldi R and Fuxe K)
860. Aspects of neural plasticity in the central nervous system. III. Methodological studies on the microdialysis technique. **Neurochem Int** 16(4) (1990) 427-436. (Ruggeri M, Zoli M, Grimaldi R, Ungerstedt U, Eliasson A, Agnati LF and Fuxe K)
861. Aspects of neural plasticity in the central nervous system. IV. Chemical anatomical studies on the aging brain. **Neurochem Int** 16(4) (1990) 437-450. (Zoli M, Benfenati F, Merlo Pich E, Toffano G, Fuxe K and Agnati LF)
862. Aspects of neural plasticity in the central nervous system. V. Studies on a model of transient forebrain ischemia in male Sprague-Dawley rats. **Neurochem Int** 16(4) (1990) 451-468. (Zini I, Grimaldi R, Merlo Pich E, Zoli M, Fuxe K and Agnati LF)
863. Aspects of neural plasticity in the central nervous system. VI. Studies of the effects of gangliosides on brain metabolic lesions. **Neurochem Int** 16(4) (1990) 469 - 478. (Zoli M, Ruggeri M, Zini I, Grimaldi R, Merlo Pich E, Toffano G, Fuxe K and Agnati LF)
864. Aspects of neural plasticity in the central nervous system. VII. Theoretical aspects of brain communication and computation. **Neurochem Int** 16(4) (1990) 478 - 500. (Agnati LF, Zoli M, Merlo Pich E, Benfenati F and Fuxe K)
865. Effects of indole-pyruvic acid on sleep and food intake in the rat. **Acta Physiol Scand** 139(4) (1990) 583-589. (Merlo Pich E, Solfrini V, Biagini G, Fuxe K and Agnati LF)
866. Increased vasopressor potency of the centrally injected neuropeptide Y fragment 13-36 in the adult spontaneously hypertensive awake male rat of the Wistar-Kyoto strain. **Acta Physiol Scand** 139(4) (1990) 609-610. (Aguirre JA, Fuxe K and Agnati LF)
867. Chronic but not acute uridine treatment reduces haloperidol-induced dopamine release in neostriatum as studied by intracerebral microdialysis. **Neurosci Res Comm** 6(3) (1990) 187-192. (Ruggeri M, Zoli M, Ungerstedt U, Peruzzi G, Agnati LF and Fuxe K)
868. Cellular and synaptic alterations in the aging brain. **Aging** 2(1) (1990) 5-25. (Agnati LF, Zoli M, Grimaldi R, Fuxe K, Toffano G and Zini I)
869. Modulation of dopamine D1 and D2 transmission lines in the central nervous system. **Current Aspects of Neurosciences**, Vol. 1, N.N. Osborne (Ed), The Macmillan Press Ltd, London (1990) 203-243. (Fuxe K, Agnati LF, von Euler G, Benfenati F and Tanganelli S)
870. Nerve cell clusters in dorsal striatum and nucleus accumbens of the male rat demonstrated by glucocorticoid receptor immunoreactivity. **J Chem Neuroanat** 3 (1990) 355-366. (Zoli M, Cintra A, Zini I, Hersh LB, Gustafsson J-Å, Fuxe K and Agnati LF)
871. Distribution of glutamic acid decarboxylase messenger RNA-containing nerve cell populations of the male rat brain. **J Chem Neuroanat** 3 (1990) 377-396. (Ferraguti F, Zoli M, Aronsson M, Agnati LF, Goldstein M, Filer D and Fuxe K)



872. Acute and subchronic corticosterone treatment differentially modulates subcortical limbic and neostriatal nicotinic cholinergic receptors. **Brain Res** 526 (1990) 122-126. (von Euler G, Fuxe K, Finnmann U-B and Agnati LF)
873. Changes in pituitary-adrenal activity affect the apomorphine- and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis. **J Neural Transm** 81 (1990) 183-194. (Tanganelli S, Fuxe K, von Euler G, Eneroth P, Agnati LF and Ungerstedt U)
874. Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors. **Naunyn-Schmiedeberg's Arch Pharmacol** 342 (1990) 300-304. (Tanganelli S, Fuxe K, von Euler G, Agnati LF, Ferraro L and Ungerstedt U)
875. Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence. **Brain Res** 531 (1990) 253-262. (von Euler G, Meister B, Hökfelt T, Eneroth P and Fuxe K)
876. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. **Neurosci Lett** 118 (1990) 5-8. (Aguirre JA, Fuxe K, Agnati LF and von Euler G)
877. Vasopressor effects of intracerebroventricular injections of PEC-60, a novel porcine 60-residue intestinal peptide, in the awake unrestrained male rat. **Neurosci Lett** 119 (1990) 129-131. (Aguirre JA, Fuxe K, Agnati LF, Agerberth B and Mutt V)
878. Biology of Disease. Nigrostriatal dopamine neurons, D1 transmission in basal and ischemic states and protective effects of gangliosides. **Lab Invest** 63(3) (1990) 283-297. (Agnati LF and Fuxe K)
879. Evidence for a role of neosynthesized putrescine in the increase of glial fibrillary acidic protein immunoreactivity induced by a mechanical lesion in the rat brain. **Neurosci Lett** 120 (1990) 13-16. (Zini I, Zoli M, Grimaldi R, Merlo Pich E, Biagini G, Fuxe K and Agnati LF)
880. Morphofunctional studies on the interaction between dopamine, neuropeptide Y and beta-endorphin neuronal systems in the control of prolactin secretion. **In Opioid peptides in biological fluids** (AR Genazzani and M Negri, Eds) The Parthenon Publ Group, Park Ridge, NJ, USA (1990) 53-65. (Zoli M, Zini I, Eneroth P, Bernardi F, Fontana A, Härfstrand A, Agnati LF and Fuxe K)
881. Le basi neurochimiche del dolore: studi sugli effetti analgesici dell'imipramina. **In Cefalee da Farmaci** (E. Sternieri and G. Nappi, Eds) Cluster Press, Roma (1990) 3-22. (Zini I, Ruggeri M, Zoli M, Merlo Pich E, Tiengo M, Fuxe K and Agnati LF)
882. Effects of transient forebrain ischemia on peptidergic neurons and astroglial cells: evidence for recovery of peptide immunoreactivities in neocortex and striatum but not hippocampal formation. **Exp Brain Res** 82 (1990) 123-136. (Grimaldi R, Zoli M, Agnati LF, Ferraguti F, Fuxe K, Toffano G and Zini I)
883. Neuropeptide Y and central cardiovascular regulation. Focus on its role as a cotransmitter in cardiovascular adrenergic neurons. **Ann NY Acad Sci**, Vol 611 (1990)

111-132. (Fuxe K, Aguirre JA, Agnati LF, von Euler G, Hedlund P, Covenas R, Zoli M, Bjelke B and Eneroth P)

884. Evidence for different types of glucocorticoid receptor immunoreactive cell populations in the rat testis with differential sensitivity to neonatal corticosterone treatment. In **Hormonal Communicating events in the testis** (A Isidori, A Fabbri and ML Dufau, Eds) Raven Press, New York (1990) pp 127-136. (Biagini G, Merlo Pich E, Marrama P, Fuxe K, Agnati LF and Gustafsson JÅ)

**1991**

885. Regional increases in ornithine decarboxylase mRNA levels in the rat brain after partial mesodiencephalic hemitranssection as revealed by in situ hybridization histochemistry. **Neurochem Int** (1991) 18(3) 347-352. (Zoli M, Bettuzzi S, Ferraguti F, Ingletti MC, Zini I, Fuxe K, Agnati LF and Corti A)
886. Morphofunctional studies on transmitter-identified neurons and on protective effects of gangliosides (siagoside) on forebrain dopamine transmission after transient forebrain ischemia. In **Proceedings of a Satellite Symposium on Protection from Ischemic Neuronal Damage** held during the 1st International Stroke Congress, Kyoto, October 19, 1989. Excerpta Medica, Ltd. Tokyo, 1991. (Fuxe K, Agnati LF, Zoli M, Grimaldi R, Benfenati F, Merlo Pich E, Toffano G and Zini I)
887. Stimulation of high-affinity adenosine A<sub>2</sub> receptors decreases the affinity of dopamine D<sub>2</sub> receptors in rat striatal membranes. **Proc Natl Acad Sci, USA** 88 (1991) 7238-7241. (Ferré S, von Euler G, Johansson B, Fredholm BB and Fuxe K)
888. Central peptidergic neurons as targets for glucocorticoid action. Evidence for the presence of glucocorticoid receptor immunoreactivity in various types of classes of peptidergic neurons. **J Steroid Biochem Molec Biol** Vol 40 No 1-3 (1991) 93-103. (Cintra A, Fuxe K, Solfrini V, Agnati LF, Tinner B, Wikström A-C, Staines W, Okret S and Gustafsson J-Å)
889. Prominent expression of acidic fibroblast growth factor in motor and sensory neurons. **Neuron** 7 (1991) 349-364. (Elde R, Cao Y, Cintra A, Brelje TC, Pelto-Huikko M, Junttila T, Fuxe K, Pettersson RF and Hökfelt T)
890. Endothelin-1-induced lesions in the brain as a new model of focal ischemia. In **Methods in Neurosciences**, Vol. 7: Transplantations, Lesions, and Surgical Techniques (P. Michael Conn, Ed), Academic Press Inc, Orlando, Florida, (1991) pp 256-282. (Fuxe K, Kurosawa M, Cintra A, Goiny M, Hallström Å, Rosén L, Ungerstedt U and Agnati LF)
891. Strongly glucocorticoid receptor immunoreactive neurons in the neonatal rat brain. **NeuroReport** 2 (1991) 85-88. (Cintra A, Solfrini V, Agnati LF, Gustafsson J-Å and Fuxe K)
892. Basic FGF is present in dopaminergic neurons of the ventral midbrain of the rat. **NeuroReport** 2 (1991) 597-600. (Cintra A, Cao Y, Oellig C, Tinner B, Bortolotti F, Goldstein M, Pettersson RF and Fuxe K)
893. Two principal modes of electrochemical communication in the brain: Volume versus wiring transmission. In **Advances in Neuroscience, Vol. 1, Volume Transmission in**

- the Brain. Novel Mechanisms for Neural Transmission** (K Fuxe and LF Agnati, Eds), Raven Press, New York (1991) pp 1-9. (Fuxe K and Agnati LF)
894. On the existence of volume transmission in the central neuropeptide Y neuronal systems. Studies on transmitter receptor mismatches and on biological effects of neuropeptide Y fragments. In **Advances in Neuroscience, Vol. 1, Volume Transmission in the Brain. Novel Mechanisms for Neural Transmission** (K Fuxe and LF Agnati, Eds), Raven Press, New York (1991) pp 105-130. (Fuxe K, Agnati LF, Aguirre JA, Bjelke B, Tinner B, Merlo Pich E and Eneroth P)
895. The brain renin-angiotensin-system and its possible involvement in volume transmission. In **Advances in Neuroscience, Vol. 1, Volume Transmission in the Brain. Novel Mechanisms for Neural Transmission** (K Fuxe and LF Agnati, Eds), Raven Press, New York (1991) pp 131-158. (Bunnemann B, Fuxe K, Bjelke B and Ganten D)
896. Neuron-astroglia interactions in physiopathological conditions. Possible role of volume transmission. In **Advances in Neuroscience, Vol. 1, Volume Transmission in the Brain. Novel Mechanisms for Neural Transmission** (K Fuxe and LF Agnati, Eds), Raven Press, New York (1991) pp. 247-256. (Grimaldi R, Zini I, Zoli M, Merlo Pich E, Ferraguti F, Davalli P, Toffano G, Fuxe K and Agnati LF)
897. Experimental evidence for volume transmission by analysis of host graft interaction using intrastriatal adenohipophyseal transplants in the rat in combination with 3-dimensional reconstruction. In **Advances in Neuroscience, Vol. 1, Volume Transmission in the Brain. Novel Mechanisms for Neural Transmission** (K Fuxe and LF Agnati, Eds), Raven Press, New York (1991) pp 463-478. (Bjelke B, Agnati LF and Fuxe K)
898. Changes in pituitary-adrenal activity regulate the central vasodepressor responses induced by Y and adrenaline in the awake unrestrained male rat. **Acta Physiol Scand** 141 (1991) 35-44. (Aguirre JA, Fuxe K, Andbjør B, Eneroth P and Agnati LF)
899. Chronic imipramine treatment increases the affinity of <sup>125</sup>Igalanin binding sites in the tel- and diencephalon of the rat and alters the 5-HT<sub>1A</sub>/galanin receptor. **Acta Physiol Scand** 141 (1991) 137-138. (Hedlund P and Fuxe K)
900. PEC-60, a novel porcine 60-residue intestinal peptide, reduces dopamine utilization in discrete parts of the neostriatum of the male rat following an intracerebroventricular injection. **Acta Physiol Scand** 141 (1991) 139-140. (Fuxe K, Aguirre A, Tinner B, Agnati LF, Agerberth B and Mutt V)
901. Neurochemical effects of nicotine on glutamate and GABA mechanisms in the rat brain. **Acta Physiol Scand** 141 (1991) 241-250. (Pérez de la Mora P, MéndezFranco J, Salceda R, Aguirre JA and Fuxe K)
902. Preferential increases of [<sup>125</sup>I]NPY 1-36 binding in the hippocampal formation produced by the NPY Y<sub>2</sub> receptor agonist NPY 13-36. **Acta Physiol Scand** 141 (1991) 279-280. (Hedlund P, Bjelke B, Aguirre J.A. and Fuxe K)
903. The unique effect of remoxipride on dopamine utilization in the basal ganglia. **Acta Physiol Scand** 141 (1991) 577-578. (Fuxe K and Ögren SO)

904. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. **J Neurochem** 56(1) (1991) 178-183. (von Euler G, van der Ploeg I, Fredholm BB and Fuxe K)
905. Galanin increases potassium evoked release of [<sup>3</sup>H]5-hydroxytryptamine from rat hypothalamic synaptosomal preparations. **Neurosci Lett** 122 (1991) 87-90. (Martire M, Fuxe K, Agnati LF, Pistritto G and Preziosi P)
906. Neuroplasticity of mesotelencephalic dopamine neurons at the network and receptor level: New aspects of the role of dopamine in schizophrenia and possible pharmacological treatments. In **Advances in Neuropsychiatry and Psychopharmacology, Vol. 1: Schizophrenia Research** (Tamminga CA and Schultz SC, Eds), Raven Press, New York (1991) pp 51-76. (Fuxe K, Agnati LF, Zoli M, Merlo Pich E, Grimaldi R, Bjelke B, Tanganelli S, von Euler G and Janson AM)
907. Mechanisms underlying the protective effects of chronic nicotine treatment against degeneration of central dopamine neurons by mechanical lesions. In **Advances in Pharmacological Sciences: Effects of Nicotine on Biological Systems** (Adlkofer F and Thureau K, Eds), Birkhäuser Verlag, Basel (1991) pp 307-322. (Fuxe K, Janson AM, Grenhoff J, Andersson K, Kåhrström J, Andbjør B, Owman Ch, Svensson Tand Agnati LF)
908. The effects of chronic nicotine treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. In **Advances in Pharmacological Sciences: Effects of Nicotine on Biological Systems** (Adlkofer F and Thureau K, Eds), Birkhäuser Verlag, Basel (1991) pp 322-329. (Janson AM, Fuxe K, Agnati LF, Sundström E and Goldstein M)
909. Effects of postnatal exposure to cigarette smoke on hypothalamic catecholamine nerve terminal systems and neuroendocrine function in weanling and adult male rats. In **Advances in Pharmacological Sciences: Effects of Nicotine on Biological System**. (Adlkofer F and Thureau K, Eds), Birkhäuser Verlag, Basel (1991) pp 331-337. (Andersson K, Jansson A, Bjelke B, Eneroth P and Fuxe K)
910. Demonstration and nature of endothelin-3-like immunoreactivity in somatostatin and choline acetyltransferase-immunoreactive nerve cells of the neostriatum of the rat. **Neurosci Lett** 123 (1991) 107-111. (Fuxe K, Tinner B, Staines W, Hemsén A, Hersh L and Lundberg JM)
911. Subacute exposure to low concentrations of toluene affects dopamine-mediated locomotor activity in the rat. **Toxicology** 67 (1991) 333-349. (von Euler G, Ögren SO, Bondy SC, McKee M, Warner M, Gustafsson J-Å, Eneroth P and Fuxe K)
912. On the role of neuropeptide Y receptors of the Y<sub>2</sub> type in the control of hypothalamic catecholamine mechanisms and neuroendocrine function. Central effects of the NPY fragment (13-36). **Neurochem Int** 19(3) (1991) 261-270. (Aguirre JA, Fuxe K, Tinner B, Andbjør B, Agnati LF and Eneroth P)
913. Ganglioside GM1 modulation of calcium/calmodulin-dependent protein kinase II activity and autophosphorylation. **Neurochem Int** 19(3) (1991) 271-279. (Benfenati F, Fuxe K and Agnati LF)

914. A trypsin inhibitor-like peptide PEC-60 reduces the affinity of dopamine D2 agonist binding sites in rat neostriatal membranes. **Eur J Pharmacol - Mol Pharmacol Section 207** (1991) 365-366. (von Euler G, Ferré S, von Euler M, Agerberth B, Mutt V and Fuxe K)
915. Computer-assisted image analysis techniques allow a characterization of the compartments within the basal ganglia. Focus on functional compartments produced by d-amphetamine activation of the c-fos gene and its relationship to the glucocorticoid receptor. **J Chem Neuroanat** 4 (1991) 355-372. (Fuxe K, Agnati LF, Rosén L, Bjelke B, Cintra A, Bortolotti F, Tinner B, Andersson C, Hasselrot U, Steinbusch H, Gustafsson JÅ and Benfenati F)
916. Regulatory peptides in the neuroendocrine system. In **Brain Endocrinology**, Second Edition (M Motto, Ed), Raven Press, New York (1991) pp 31-69. (Fuxe K, Agnati LF, Zoli M, Biagini G, Cintra A and Eneroth P)
917. Responses of blood flow, extracellular lactate, and dopamine in the striatum to intrastriatal injection of endothelin-1 in anesthetized rats. **J Cardiovasc Pharmacol** 17 (Suppl 7) (1991) S340-342. (Kurosawa M, Fuxe K, Hallström Å, Gojny M, Cintra A and Ungerstedt U)
918. Changes in striatal dopamine neurohistochemistry and biochemistry after incomplete transient cerebral ischemia in the rat. **Exp Brain Res** 86 (1991) 545-554. (Németh G, Cintra A, Herb J-M, Ding A, Goldstein M, Agnati LF, Hoyer S and Fuxe K)
919. Stimulation of adenosine A2 receptors induces catalepsy. **Neurosci Lett** 130 (1991) 162-164. (Ferré S, Rubio A and Fuxe K)
920. Central integration of chemical signals involved in the control of prolactin and LH secretion. Focus on the medianosomes. **New Trends in Gynecology and Obstetrics**, Vol VII-No 3-4/1 (1991) 237-259. (Fuxe K, Agnati LF, Bjelke B, Zoli M, Aguirre A, Cintra A, Hedlund P, von Euler G, Andersson K and Eneroth P)
921. Galanin/5-HT interactions in the rat central nervous system. Relevance for depression. In **Galanin. A new Multifunctional peptide in the neuroendocrine system** (T Hökfelt, T Bartfai, D Jacobowitz, D Ottoson, Eds) Wenner-Gren Int Series Vol 58, Macmillan Press, London (1991) 221-235. (Fuxe K, Hedlund P, von Euler G, Lundgren K, Martire M, Ögren SO, Eneroth P and Agnati LF)
922. Centrally coinjected galanin and a 5-HT 1A agonist act synergistically to produce vasodepressor responses in the rat. **Eur J Pharmacol** 204 (1991) 87-95. (Hedlund P, Aguirre JA, Narvaez JA and Fuxe K)
923. Age-related decrease of galanin immunoreactivity in discrete forebrain areas of the male rat assessed by semiquantitative immunocytochemistry. **Neurosci Res Comm** 9(2) (1991) 83-89. (Ferraguti F, Zoli M, Fuxe K and Agnati LF)
924. Corticosterone treatment counteracts lesions induced by neonatal treatment with monosodium glutamate in the mediobasal hypothalamus of the male rat. **Neurosci Lett** 132 (1991) 225-228. (Zoli M, Ferraguti F, Biagini G, Cintra A, Fuxe K and Agnati LF)

925. A new model of focal brain ischemia based on the intracerebral injection of endothelin-1. **Ital J Neurol Sci**, Suppl 2 (1991) 49-53. (Agnati LF, Zoli M, Kurosawa M, Benfenati F, Biagini G, Zini I, Hallström Å, Ungerstedt U, Toffano G and Fuxe K)
926. Selective reduction of glucocorticoid receptor immunoreactivity in the hippocampal formation and central amygdaloid nucleus of the aged rat. **Brain Res** 545 (1991) 199-207. (Zoli M, Ferragutti F, Gustafsson J-Å, Toffano G, Fuxe K and Agnati LF)
927. Changes in striatal  $\mu$  and  $\delta$  opioid receptors after transient forebrain ischemia: a quantitative autoradiographic study. **Brain Res** 546 (1991) 171-175. (Benfenati F, Merlo Pich E, Zoli M, Grimaldi R, Fuxe K and Agnati LF)
928. Compartmentation and receptor interactions in the basal ganglia. Two basic features of striatal operation. **New Issues in Neurosciences** Vol III, No 2 (1991) 271-295. (Fuxe K, Agnati LF, Bjelke B, Tinner B, Cintra A, Steinbusch H, Ferré S, von Euler G, Benfenati F, Ponzoni S, Ögren SO and Goldstein M)
929. Limited distribution of pertussis toxin in rat brain after injection into the lateral cerebral ventricles. **Neuroscience** Vol 44(1) (1991) 205-214. (van der Ploeg I, Cintra A, Altiok N, Askelöf P, Fuxe K and Fredholm B)
930. Activation of 5-hydroxytryptamine 1A receptors increases the affinity of galanin receptors in di- and telencephalic areas of the rat. **Brain Res** 560 (1991) 251-259. (Hedlund P, von Euler G and Fuxe K)
931. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitranssected at the meso-diencephalic junction. **Brain Res** 562 (1991) 347-351. (Grenhoff J, Janson AM, Svensson TH and Fuxe K)
932. Hypertrophy of dopamine neurons in the primate following ventromedial mesencephalic tegmentum lesion. **Exp Brain Res** 87 (1991) 232-238. (Janson AM, Fuxe K, Goldstein M and Deutch AY)
933. Reserpine treatment increases PEC-60-like immunoreactivity in the substantia nigra of the male rat as determined by radioimmunoassay. **Acta Physiol Scand** 143 (1991) 357-358. (Fuxe K, Östenson C-G, Aguirre JA, Efendic S, Agerberth B and Mutt V)
934. Neuropeptide Y/angiotensin II interactions in central cardiovascular regulation of the rat. **Brain Res** 566 (1991) 61-69. (Aguirre JA, Fuxe K, Hedlund P, Narvaéz JA, Cintra A, Rosén L and Agnati LF)
935. Pain, analgesia, and stress: An integrated view. **Clin J Pain** 7(Suppl 1) (1991) S23-S37. (Agnati LF, Tiengo M, Ferraguti F, Biagini G, Benfenati F, Benedetti C, Rigoli M and Fuxe K)
936. Dopamine-neurotensin interactions in the neostriatum: evidence for a substrate of neuronal plasticity. **PINS** Vol. 1, No. 1 (1991) 13-17. (O'Connor WT, Fuxe K, Antonelli T, Osborne PG, Tanganelli S, Agnati LF and Ungerstedt U)

1992

937. Evidence for the protective action of vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. **Exp Brain Res** 88 (1992) 117-130. (Fuxe K, Janson AM, Rosén L, Finnman U-B, Tanganelli S, Morari M, Goldstein M and Agnati LF)
938. Involvement of local ischemia in endothelin-1 induced lesions of the neostriatum of the anaesthetized rat. **Exp Brain Res** 88 (1992) 131-139. (Fuxe K, Kurosawa N, Cintra A, Hallström Å, Goiny M, Rosén L, Agnati LF and Ungerstedt U)
939. High blood pressure in transgenic mice carrying the rat angiotensinogen gene. **The EMBO Journal** 11(3) (1992) 821-827. (Kimura S, Mullins JJ, Bunnemann B, Metzger R, Hilgenfeldt U, Zimmermann F, Jacob H, Fuxe K, Ganten D and Kaling M)
940. Involvement of gangliosides in neuroplasticity of the central nervous system in physiological and pathological conditions. In **Current Aspects of the Neurosciences**, Vol. 4 (N.N. Osborn, ed) The Macmillan Press Ltd (1992) pp 33-86. (Agnati LF, Zoli M, Biagini G, Benfenati F, Toffano G and Fuxe K)
941. Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. **Neuroendocrinology** 55 (1992) 451-459. (Honkaniemi J, Pelto-Huikko M, Rechart L, Isola J, Lammi A, Fuxe K, Gustafsson J-Å, Wikström A-C and Hökfelt T)
942. Siagoside selectively attenuates morphological and functional striatal impairments induced by transient forebrain ischemia in rats. **Stroke** 23 (1992) 234-241. (Merlo Pich E, Grimaldi R, Zoli M, Biagini G, Solfrini V, Toffano G, Fuxe K and Agnati LF)
943. The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: an in vivo microdialysis study. **Brain Res** 573 (1992) 209-216. (O'Connor WT, Tanganelli S, Ungerstedt U and Fuxe K)
944. Feeding and drinking responses to neuropeptide Y injections in the paraventricular hypothalamic nucleus of aged rats. **Brain Res** 575 (1992) 265-271. (Merlo Pich E, Messori B, Zoli M, Ferraguti F, Marrama P, Biagini G, Fuxe K and Agnati LF)
945. Coactivation of dopamine D1 and D2 receptors increases the affinity of cholecystinin-8 receptors in membranes from post-mortem human caudate-putamen. **Brain Res** 584 (1992) 157-162. (von Euler G, Mailleux P, von Euler M, Schiffmann SN, Vanderhaeghen J-J and Fuxe K)
946. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. **Proc Natl Acad Sci USA**, 89 (1992) 5591-5595. (Fuxe K, O'Connor WT, Antonelli T, Osborne PG, Tanganelli S, Agnati LF and Ungerstedt U)
947. Effects of postnatal exposure to cigarette smoke on hypothalamic catecholamine nerve terminal system and on neuroendocrine function in the postnatal and adult male rat. Evidence for longterm modulation of anterior pituitary function. **Acta Physiol Scand** 144 (1992) 453-462. (Jansson A, Andersson K, Bjelke B, Eneroth P and Fuxe K)

948. Failure of integrative mechanisms in the aging brain. In Treatment of Age-Related Cognitive Dysfunction: Pharmacological and Clinical Evaluation. **Int Acad Biomed Drug Res** 2(S.Z. Langer, J. Mendlewicz and G. Racagni, Eds.), S. Karger, Basel (1992) pp 1-18. (Fuxe K, Agnati LF, Hedlund P, Ögren SO, Bortolotti F, Carani C and Biagini G)
949. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. **Clin Investig** 70 (1992) 232-238. (Janson AM, Fuxe K and Goldstein M)
950. Inhibitory effects of the psychoactive drug modafinil on g-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. **Naunyn-Schmiedeberg's Arch Pharmacol** 345 (1992) 461-465. (Tanganelli S, Fuxe K, Ferraro L, Janson AM and Bianchi C)
951. The semi-quantitative distribution and cellular localization of angiotensinogen mRNA in the rat brain. **J Chem Neuroanat** 5 (1992) 245-262. (Bunnemann B, Fuxe K, Metzger R, Bjelke B and Ganten D)
952. Volume Transmission in the Brain. Do brain cells communicate solely through synapses? A new theory proposes that information also flows in the extracellular space. **Am Sci** 80 (1992) 362-374. (Agnati LF, Bjelke B and Fuxe K)
953. Central glucocorticoid receptors, dopamine and their involvement in stress responses in postnatal rats. **In: Stress: Neuroendocrine and Molecular Approaches** (R. Kvetnansky, R. McCarty and J. Axelrod, Eds.), Gordon and Breach Science Publ. S.A., New York, USA (1992) pp 751-763. (Agnati LF, Cintra A, Biagini G, Zoli M, Maramba P, Carani C, Gustafsson J-Å and Fuxe K)
954. Muscarinic modulation of acetylcholine release from slices of guinea pig nucleus basalis magnocellularis. **Neurosci Lett** 140 (1992) 235-238. (Siniscalchi A, Badini I, Cintra A, Fuxe K, Bianchi C and Beani L)
955. Intracerebroventricularly administered pertussis toxin blocks the central vasopressor action of neuropeptide Y (13-36) in the awake unrestrained male rat. **Neurosci Lett** 140 (1992) 273-276. (Narváez JA, Aguirre JA, van der Ploeg I and Fuxe K)
956. The distribution of angiotensin II AT1 receptor subtype mRNA in the rat brain. **Neurosci Lett** 142 (1992) 155-158. (Bunnemann B, Iwai N, Metzger R, Fuxe K, Inagami T and Ganten D)
957. Neuronal plasticity and ageing processes in the frame of the "Red Queen Theory". **Acta Physiol Scand** 145 (1992) 301-309. (Agnati LF, Zoli M, Biagini G and Fuxe K)
958. Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. **Brain res**, 594 (1992) 124-130. (Ferré S and Fuxe K)
959. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. **Ann NY Acad Sci** 668 (1992) 186-204. (Fuxe K, von Euler G, Agnati LF, Merlo Pich E, O'Connor WT, Tanganelli S, Li XM, Tinner B, Cintra A, Carani C and Benfenati F)



960. Adenosine-dopamine interactions in the brain. **Neuroscience** 51(3) (1992) 501-512. (Ferré S, Fuxe K, von Euler G, Johansson B and Fredholm BB)
961. Evidence for specific N-terminal galanin fragment binding sites in the rat brain. **Eur J Pharmacol** 224 (1992) 203-205. (Hedlund P, Yanaihara N and Fuxe K)
962. Molecular cloning of PEC-60 and expression of its mRNA and peptide in the gastrointestinal tract and immune system. **J Biol Chem** 267 (1992) 19829-19832. (Metsis M, Cintra A, Solfrini V, Ernfors P, Bortolotti F, Morrasutti DG, Östenson C-G, Efendic S, Agerberth B, Mutt V, Persson H and Fuxe K)
963. Colocalization of fos- and glucocorticoid receptor-like immunoreactivities in the rat amygdaloid complex after immobilization stress. **J Neuroendocrinol** 4(5) (1992) 547-555. (Honkaniemi J, Fuxe K, Rechart L, Koistinaho J, Isola J, Gustafsson J-Å, Okret S and Pelto-Huikko M)
964. Ganglioside GM1 counteracts the enhancing effects of subacute toluene exposure on apomorphine-induced locomotor activity. **Toxicology Lett** 63 (1992) 165-169. (von Euler G, Ögren S-O, Fuxe K and Gustafsson J-Å)
965. Steroidal regulation of coexisting neuronal messengers: Focus on double and triple immunolabeling procedures and on indirect evaluation of coexistence. **Neuroprotocols** 1(1) (1992) 77-86. (Cintra A, Coveñas R, de Leon M, Bjelke B, Gustafsson J-Å, Agnati LF and Fuxe K)
966. The brain renin-angiotensin system: Localization and general significance. **J Cardiovasc Pharmacol** 19(Suppl 6) (1992) S51-S62. (Bunnemann B, Fuxe K and Ganten G)
967. Neurotrophic factors and central dopamine neurons. **Neuroscience Facts** 3(21) (1992) 81. (Fuxe K and Agnati LF)
968. Regional increase in ornithine decarboxylase mRNA levels in the rat brain after partial mesodiencephalic hemistransection as revealed by in situ hybridization histochemistry. **Neurochem Int** 18 (1992) 347-352. (Zoli M, Bettuzzi S, Ferraguti F, Ingletti MC, Zini I, Fuxe K, Agnati LF and Corti A)
969. Brain aging and neuronal plasticity. In *Physiological Processes of Aging. Towards a Multicausal Interpretation*. **Ann NY Acad Sci** 673 (1992) pp 180-186. (Agnati LF, Benfenati F, Solfrini V, Biagini G, Fuxe K, Giodolin D, Carani C and Zini I)
970. Neuropeptides, excitatory amino acid and adenosine A2 receptors regulate D2 receptors via intramembrane receptor-receptor interactions. Relevance for Parkinson's disease and schizophrenia. **Neurochem. Int.** 20 (1992) 215-224. (Fuxe K, Agnati LF, von Euler G, Tanganelli S, O'Connor WT, Ferré S, Hedlund P and Zoli M)
- 1993**
971. Intramembrane receptor-receptor interactions: Integration of signal transduction pathways in the nervous system. **Neurochem Int** 22 (1993) 213-222. (Agnati LF, Fuxe K, Benfenati F, von Euler G and Fredholm B)

972. Coexistence of c-fos and glucocorticoid receptor immunoreactivities in the CRF immunoreactive neurons of the paraventricular hypothalamic nucleus of the rat after acute immobilization stress. **Neurosci Lett** 149 (1993) 149-152. (Coveñas R, de Leon M, Cintra A, Bjelke B, Gustafsson J-Å and Fuxe K)
973. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. **Eur J Pharmacol** 230 (1993) 159-166. (Tanganelli S, Li X-M, Ferraro L, von Euler G, O'Connor WT, Bianchi C, Beani L and Fuxe K)
974. Region-specific inhibition of potassium-evoked <sup>3</sup>H-noradrenaline release from rat brain synaptosomes by neuropeptide Y (13-36). Involvement of NPY receptors of the Y<sub>2</sub> type. **Eur J Pharmacol** 230 (1993) 231-234. (Martire M, Pistritto G, Mores N, Agnati LF and Fuxe K)
975. The C-terminal neurotensin-(8-13) fragment potently modulates rat neostriatal dopamine D2 receptors. **Eur J Pharmacol** 234 (1993) 125-128. (Li X-M, von Euler G, Hedlund P, Finnman U-B and Fuxe K)
976. Opposing actions of an adenosine A<sub>2</sub> receptor agonist and a GTP analogue on the regulation of dopamine D<sub>2</sub> receptors in rat neostriatal membranes. **Eur J Pharmacol-Molecular Pharmacology Section** 244 (1993) 311-315. (Ferré S, Snaprud P and Fuxe K)
977. Cellular localization of angiotensin type 1 receptor and angiotensinogen mRNAs in the subfornical organ of the rat brain. **Neurosci Lett** 150 (1993) 153-158. (Lippoldt A, Bunnemann B, Iwai N, Metzger R, Inagami T, Fuxe K and Ganten G)
978. Subpicomolar amounts of NPY (13-36) injected into the nucleus tractus solitarius of the rat counteract the cardiovascular responses to L-glutamate. **Neurosci Lett** 151 (1993) 182-186. (Narvaéz JA, Aguirre JA and Fuxe K)
979. Antagonistic A<sub>2a</sub>/D<sub>2</sub> receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. **Drug Dev Res** 28 (1993) 374-380. (Fuxe K, Ferré S, Snaprud P, von Euler G, Johansson B and Fredholm B)
980. Persistent effects of subchronic toluene exposure on spatial learning and memory, dopamine-mediated locomotor activity and dopamine D<sub>2</sub> agonist binding in the rat. **Toxicology** 77 (1993) 223-232. (von Euler G, Ögren S-O, Li XM, Fuxe K and Gustafsson J-Å)
981. Induction of c-fos immunoreactivity in tyrosine hydroxylase and phenylethanolamine-N-methyltransferase immunoreactive neurons of the medulla oblongata of the rat after phosphate-buffered saline load in the urethane-anaesthetized rat. **Brain Res** 602 (1993) 342-349. (Narvaéz JA, Coveñas R, de Leon M, Aguirre JA, Cintra A, Goldstein M and Fuxe K)
982. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. **Exp Brain**

- Res 93** (1993) 259-270. (Ueki A, Rosén L, Andbjør B, Finnman U-B, Altamimi U, Janson AM, Goldstein M, Agnati LF and Fuxe K)
983. Neurochemical alterations but not nerve cell loss in aged rat neostriatum. **J Chem Neuroanat** 6 (1993) 131-145. (Zoli M, Ferraguti F, Toffano G, Fuxe K and Agnati L F)
984. Distribution of dopamine-immunoreactive neurons and their relationship to transmitter and hypothalamic hormone-immunoreactive neuronal systems in the rat mediobasal hypothalamus. A morphometric and microdensitometric analysis. **J Chem Neuroanat** 6 (1993) 293-310. (Zoli M, Agnati LF, Tinner B, Steinbusch HWM and Fuxe K)
985. N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study **J Neurochem** 60 (1993) 1884-1893. (Morari M, O'Connor WT, Ungerstedt U and Fuxe K)
986. Regional expression of angiotensinogen mRNA in the brain of one-week-old, adult and old male rats. **Dev. Brain Res** 73 (1993) 41-45. (Bunnemann B, Metzger R, Fuxe K and Ganten D)
987. Extrarenal renin systems: The brain. **In Renin-Angiotensin System** (JI Robertson and MG Nicholls, Eds), Gower Med Publ, Plymouth, UK (1992) 41.1-41.17. (Bunnemann B, Fuxe K and Ganten D)
988. Novel aspects on central 5-hydroxytryptamine neurotransmission: Focus on the cerebellum. **In: Serotonin, the Cerebellum and Ataxia** (P. Trouillas and K. Fuxe, Eds), Raven Press Ltd, New York (1993) 1-36. (Fuxe K, Agnati LF, Bjelke B, Hedlund P, Ueki A, Tinner B, Bunnemann B, Steinbusch H, Ganten D and Cintra A)
989. Neurophysiological aspects of pain. **Anaesthetic Pharmacology Review** 2 (1993) 101-113. (Agnati LF, Zoli M, Biagini G, Bjelke B, Fuxe K and Benfenati F)
990. Indole-pyruvic acid treatment reduces damage in striatum but not in hippocampus after transient forebrain ischemia in the rat. **Neurochem Int** 23 (1993) 139-148. (Zoli M, Merlo Pich E, Ferraguti F, Biagini G, Fuxe K and Agnati LF)
991. Indole-pyruvic acid, a tryptophan ketoanalogue, antagonizes the endocrine but not the behavioral effects of repeated stress in a model of depression. **Biol Psychiatry** 33 (1993) 712-719. (Biagini G, Merlo Pich E, Carani C, Marrama P, Gustafsson J-Å, Fuxe K and Agnati LF)
992. Corticosterone increases FGF-2 (bFGF) immunoreactivity in the substantia nigra of the rat. **NeuroReport** 4 (1993) 783-786. (Chadi G, Rosén L, Cintra A, Tinner B, Zoli M, Pettersson R and Fuxe K)
993. Codistribution of cholera toxin binding sites and tyrosine hydroxylase/FGF-2 immunoreactive nigral nerve cells. **NeuroReport** 4 (1993) 857-860. (Fuxe K, Tinner B, Janson AM and Agnati LF)
994. L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. **NeuroReport** 4 (1993) 955-958. (Biagini G, Zoli M, Fuxe K and Agnati LF)

995. Fast and widespread increase of basic fibroblast growth factor messenger RNA and protein in the forebrain after kainate-induced seizures. **Neuroscience** 57 (1993) 913-922. (Humpel C, Lippoldt A, Chadi G, Ganten D, Olson L and Fuxe K)
996. Prenatal development of glucocorticoid receptor gene expression and immunoreactivity in the rat brain and pituitary gland: A combined in situ hybridization and immunocytochemical analysis. **Neuroendocrinology** 57 (1993) 1133-1147. (Cintra A, Solfrini V, Bunnemann B, Okret S, Bortolotti F, Gustafsson J-Å and Fuxe K)
997. Microinjections of subpicomolar amounts of NPY(13-36) into the nucleus tractus solitarius of the rat counteract the vasodepressor responses of NPY(1-36) and of a NPY Y1 receptor agonist. **Brain Res** 621 (1993) 126-132. (Yang S-N, Narvaéz JA, Bjelke B, Agnati LF and Fuxe K)
998. Photochemically induced focal cerebral ischemia in rat: time dependent and global increase in expression of basic fibroblast growth factor mRNA. **Brain Res** 625 (1993) 45-56. (Lippoldt A, Andbjør B, Rosén L, Richter E, Ganten D, Cao Y, Pettersson FF and Fuxe K)
999. Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat. **Exp Brain Res** 96 (1993) 89-99. (Ueki A, Rosén L, Andbjør B, Agnati LF, Hallström Å, Goigny M, Tanganelli S, Ungerstedt U and Fuxe K)
1000. Receptor-receptor interactions as an integrative mechanism in nerve cells. **Mol Neurobiol** Vol. 7 (1993) 293-334. (Zoli M, Agnati LF, Hedlund P, Li XM, Ferré S and Fuxe K)
1001. Immobilization stress induces vasodepressor and altered neuroendocrine responses in the adult stroke-prone spontaneously hypertensive male rat. **Acta Physiol Scand** 149 (1993) 491-501. (Narvaéz JA, Aguirre JA, Härfstrand A, Eneroth P, Ganten D, Agnati LF and Fuxe K)
1002. Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes. **Neurosci Lett** 155 (1993) 121-124. (Li X-M, Finnman U-B, von Euler G, Hedlund P and Fuxe K)
1003. Basic fibroblast growth factor (bFGF, FGF-2) immunoreactivity exists in the noradrenaline, adrenaline and 5-HT nerve cells of the rat brain. **Neurosci Lett** 160 (1993) 171-176. (Chadi G, Tinner B, Agnati LF and Fuxe K)
1004. Autoradiographic evidence for a bradykinin/angiotensin II receptor-receptor interactions in the rat brain. **Neurosci Lett** 163 (1993) 58-62. (Fior D, Hedlund P and Fuxe K)
1005. Intraventricular b-endorphin accumulates in DARPP-32 immunoreactive tanycytes. **NeuroReport** 5 (1993) 265-268. (Bjelke B and Fuxe K)
1006. Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. **NeuroReport** 5 (1993) 277-280. (Sommer W, Bjelke B, Ganten D and Fuxe K)

1007. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. **Exp Brain Res** 97 (1993) 145-158. (Chadi G, Møller A, Rosén L, Janson AM, Agnati LF, Goldstein M, Ögren SO, Pettersson RF and Fuxe K)
1008. The renin-angiotensin system in the brain: an update 1993. **Reg Peptides** 46 (1993) 487-509. (Bunnemann B, Fuxe K and Ganten D)
1009. Cholecystokinin-8 increases K<sup>+</sup>-evoked [<sup>3</sup>H]g-aminobutyric acid release in slices from various brain areas. **Eur J Pharmacol** 250 (1993) 423-430. (Pérez de la Mora M, Hernandez-Gómez A-M, Méndez-Franco J and Fuxe K)
1010. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. **J Neurosci** 13 (1993) 5402-5406. (Ferré S, O'Connor WT, Fuxe K and Ungerstedt U)
1011. Colocalization of Fos- and glucocorticoid receptor immunoreactivities is present only in a very restricted population of dorsal horn neurons of the rat spinal cord after nociceptive stimulation. **Brain Res** 632 (1993) 334-338. (Cintra A, Molander C and Fuxe K)
1012. Cellular expression of angiotensin type-1 receptor mRNA in the kidney. **Kidney Int** 44 (1993) 331-336. (Meister B, Lippoldt A, Bunnemann B, Inagami T, Ganten D and Fuxe K)
- 1994**
1013. Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-d-aspartic acid. **Eur J Pharmacol** 256 (1994) 23-30. (Morari M, O'Connor WT, Ungerstedt U and Fuxe K)
1014. Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT. **Eur J Pharmacol** 257 (1994) 257-265. (Narváez, JA, Diaz Z, Aguirre JA, González-Barón S, Yanaihara N, Fuxe K and Hedlund P)
1015. Cholecystokinin receptor subtypes regulate dopamine D2 receptors in rat neostriatal membranes. **Ann NY Acad Sci, USA** 713 (1994) 386-387. (Li XM, Hedlund P and Fuxe K)
1016. Evidence for a regional distribution of hyaluronic acid in the rat brain using a highly specific hyaluronic acid recognizing protein. **Neurosci Lett** 169 (1994) 25-30. (Fuxe K, Tinner B, Chadi G, Härfstrand A and Agnati LF)
1017. Adrenalectomy alters discrete galanin mRNA levels in the hypothalamus and mesencephalon of the rat. **Neurosci Lett** 170 (1994) 77-82. (Hedlund PB, Koenig JI and Fuxe K)
1018. Coinjections of NPY(1-36) or [Leu<sup>31</sup>,Pro<sup>34</sup>]NPY with adrenaline in the nucleus tractus solitarius of the rat counteract the vasodepressor responses to adrenaline. **Neurosci Lett** 171 (1994) 27-31. (Yang S, Fior DR, Hedlund PB, Narváez JA, Agnati LF and Fuxe K)

1019. 6-Hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea pig. **Neurosci Lett** 171 (1994) 201-204. (Tanganelli S, Ferraro L, Bianchi C and Fuxe K)
1020. Volume transmission in transmitter peptide costoring neurons in the medulla oblongata. **In: Nucleus of the Solitary Tract** (I.R.A. Barraco, ed), CRC Press, Boca Raton, Florida (1994) pp 75-89. (Fuxe K, Agnati LF, Coveñas R, Narvaez JA, Bunnemann B and Bjelke B)
1021. **Trophic regulation of the basal ganglia. Focus on dopamine neurons.** Wenner-Gren International Series, Vol. 66, Elsevier Science Ltd., Oxford (1994). (Eds. Fuxe K, Agnati LF, Bjelke B and Ottoson D)
1022. Fibroblast growth factor-2, ganglioside GM1 and the trophic regulation of the basal ganglia. Focus on the nigrostriatal dopamine neurons. **In Trophic regulation of the basal ganglia. Focus on dopamine neurons** (Fuxe K, Agnati LF, Bjelke B and Ottoson D, Eds.). Elsevier Science Ltd., Oxford, 1994, pp. 1-41. (Fuxe K, Chadi G, Agnati LF, Tinner B, Rosén L, Janson AM, Møller A, Cintra A, Cao Y, Goldstein M, Lindahl U, David G, Ögren SO, Toffano G, Baird A and Pettersson RF)
1023. Neurochemical and behavioral studies on L-dopa toxicity in the model of manganese lesioned nigrostriatal pathway in the rat: Evidence for a protective effect of the GM1 lactone siagoside. **In Trophic regulation of the basal ganglia. Focus on dopamine neurons** (Fuxe K, Agnati LF, Bjelke B and Ottoson D, Eds.). Elsevier Science Ltd., Oxford, 1994, pp. 381-407. (Biagini G, Ferraguti F, Ponzoni S, Zoli M, Alboni L, Toffano G, Fuxe K and Agnati LF)
1024. The MPTP model of Parkinson's disease in the mouse. Modafinil - a new potential neuroprotective agent. **In Trophic regulation of the basal ganglia. Focus on dopamine neurons** (Fuxe K, Agnati LF, Bjelke B and Ottoson D, Eds.). Elsevier Science Ltd., Oxford, 1994, pp. 409-423. (Janson AM, Fuxe K, Goldstein M and Agnati LF)
1025. Responses of neostriatal dopaminoreceptive cells to the ischemic insult. **In Trophic regulation of the basal ganglia. Focus on dopamine neurons** (Fuxe K, Agnati LF, Bjelke B and Ottoson D, Eds.). Elsevier Science Ltd., Oxford, 1994, pp. 517-533. (Benfenati F, Cimino M, Onofri F, Fuxe K and Agnati LF)
1026. Increase of basic fibroblast growth factor (bFGF, FGF-2) messenger RNA and protein following implantation of a microdialysis probe into rat hippocampus. **Exp Brain Res** 98 (1994) 229-237. (Humpel C, Chadi G, Lippoldt A, Ganten D, Fuxe K and Olson L)
1027. Human angiotensinogen is highly expressed in astrocytes in human cortical grafts. **Glia** 10 (1994) 186-192. (Humpel C, Lippoldt A, Strömberg I, Bygdeman M, Wagner J, Hilgenfeldt U, Ganten D, Fuxe K and Olson L)
1028. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. **Neuroscience** 60(3) (1994) 649-657. (Tanganelli S, O'Connor WT, Ferraro L, Bianchi C, Beani L, Ungerstedt U and Fuxe K)

1029. Galanin-(1-15), but not galanin-(1-29), modulates 5-HT<sub>1A</sub> receptors in the dorsal hippocampus of the rat brain: possible existence of galanin receptor subtypes. **Brain Res** 634 (1994) 163-167. (Hedlund PB, Finnman U-B, Yanaihara N and Fuxe K)
1030. On the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain. **Brain Res** 636 (1994) 131-138. (Fuxe K, Chadi G, Tinner B, Agnati LF, Pettersson R and David G)
1031. Subpopulations of primary sensory neurons show coexistence of neuropeptides and glucocorticoid receptors in the rat spinal and trigeminal ganglia. **Brain Res** 636 (1994) 338-342. (DeLeón M, Coveñas R, Chadi G, Narvaez JA, Fuxe K and Cintra A)
1032. Adrenalectomy increases the number of substance P and somatostatin immunoreactive nerve cells in the rat lumbar dorsal root ganglia. **Brain Res** 640 (1994) 352-356. (Coveñas R, DeLeón M, Chadi G, Cintra A, Gustafsson J-Å, Narvaez JA and Fuxe K)
1033. Dopamine D<sub>1</sub> receptors are involved in the modulation of D<sub>2</sub> receptors induced by cholecystinin receptor subtypes in rat neostriatal membranes. **Brain Res** 650 (1994) 289-298. (Li XM, Hedlund P, Agnati LF and Fuxe K)
1034. Selective modulation of the NPY receptors of the Y<sub>2</sub> subtype by  $\alpha_2$  receptors in the nucleus tractus solitarii of the rat. A cardiovascular and quantitative receptor autoradiographical analysis. **Brain Res** 654 (1994) 137-144. (Yang S-N, Fior D, Hedlund P, Agnati LF and Fuxe K)
1035. Chronic nicotine treatment counteracts dopamine D<sub>2</sub> receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. **Brain Res** 655 (1994) 25-32. (Janson A-M, Hedlund P, Fuxe K and von Euler G)
1036. PEC-60 increases dopamine but not GABA release in the dorsolateral neostriatum of the halothane anaesthetized rat. An in vivo microdialysis study. **Neurosci Lett** 177 (1994) 53-57. (Rimondini R, O'Connor WT, Ferré S, Sillard R, Agerberth B, Mutt V, Ungerstedt U and Fuxe K)
1037. The dopamine D<sub>2</sub> antagonist remoxipride acts in vivo on a subpopulation of dopamine D<sub>2</sub> receptors. **Neuroscience** 61(2) (1994) 269-283. (Ögren SO, Rosén L and Fuxe K)
1038. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: Evidence for L-deprenyl-induced activation of reactive astrocytes. **Neurochem Int** 25(1) (1994) 17-22. (Biagini G, Frasoldati A, Fuxe K and Agnati LF)
1039. Basic fibroblast growth factor and steroid receptors in the aging hippocampus of the brown Norway rat: Immunocytochemical analysis in combination with stereology. **Neurochem Int** 25(1) (1994) 39-45. (Cintra A, Lindberg J, Chadi G, Tinner B, Möller A, Gustafsson JÅ, DeKloet ER, Oitzl M, Nishikawa K, Agnati LF and Fuxe K)
1040.  $\alpha_2$ /angiotensin II receptor interactions in the nucleus tractus solitarius lead to an enhancement of angiotensin II receptor transduction. **Pharm Pharmacol Lett** 3 (1994) 237-240. (Fior D, Yang S-N, Hedlund P, Narvaez JA, Agnati LF and Fuxe K)
1041. Strong effects of NT/NN peptides on DA D<sub>2</sub> receptors in rat neostriatal sections. **NeuroReport** 5 (1994) 1621-1624. (Li X-M, Hedlund P and Fuxe K)

1042. Generalized presence of a PEC-60-like peptide in catecholamine neurones. **NeuroReport** 5 (1994) 1817-1821. (Fuxe K, Tinner B, Metsis M, Staines W, Morassutti D, Agnati LF, Östenson C-G, Efendic S, Agerberth B, Goldstein M and Mutt V).
1043. Evidence for an antagonistic angiotensin II/a<sub>2</sub>-adrenoceptor interaction in the nucleus tractus solitarii. **Eur J Pharmacol** 262 (1994) 271-282. (Fior D, Yang S-N, Hedlund P, Narvaez JA, Agnati LF and Fuxe K)
1044. A<sub>2a</sub>/D<sub>2</sub> receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D<sub>2</sub> and adenosine A<sub>2a</sub> receptor cDNA. **Biochem Pharmacol** 48(11) (1994) 2043-2047. (Snaprud P, Gerwins P, Caron MG, Libert F, Persson H, Fredholm B and Fuxe K)
1045. Evidence for volume transmission in the dopamine denervated neostriatum of the rat after a unilateral nigral 6-OHDA microinjection. Studies with systemic D-amphetamine treatment. **Brain Res** 662 (1994) 11-24. (Bjelke B, Strömberg I, O'Connor WT, Andbjer B, Agnati LF and Fuxe K)
1046. Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons. **Neuroscience** 61(4) (1994) 891-910. (Chadi G, Cao Y, Pettersson RF and Fuxe K)
1047. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. **Neuroscience** 62(3) (1994) 843-897. (Cintra A, Zoli M, Rosén L, Agnati LF, Okret S, Wikström A-C, Gustafsson J-Å and Fuxe K)
1048. Antagonistic interaction between adenosine A<sub>2a</sub> receptors and dopamine D<sub>2</sub> receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. **Neuroscience** 63(3) (1994) 765-773. (Ferré S, O'Connor WT, Snaprud P, Ungerstedt U and Fuxe K)
1049. Antagonistic regulation of a<sub>2</sub>-adrenoceptors by neuropeptide Y receptor subtypes in the nucleus tractus solitarii. **Eur J Pharmacol** 271 (1994) 201-212. (Yang S-N, Fior D, Hedlund PB, Agnati LF and Fuxe K)
1050. Immunocytochemical studies on glucocorticoid receptor. In **Methods in Neuroscience Vol. 22 Neurobiology of Steroids** (deKloet ER and Sutanto W, Eds), Academic Press, San Diego, CA, 1994, pp. 143-161. (Cintra A, Akner G, Coveñas R, de León M, Wikström A-C, Agnati LF, Gustafsson J-Å and Fuxe K)
1051. Central glucocorticoid receptors and neuronal plasticity. In **Methods in Neuroscience Vol. 22 Neurobiology of Steroids** (deKloet ER and Sutanto W, Eds), Academic Press, San Diego, CA, 1994, pp. 372-382. (Fuxe K, Cintra A, Chadi G, Gustafsson J-Å and Agnati LF)
1052. Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A<sub>2</sub> and dopamine D<sub>2</sub> receptors in the neostriatum. **Psychopharmacology** 116 (1994) 279-284. (Ferré S, Schwarcz R, Li XM, Snaprud P, Ögren SO and Fuxe K)



1053. Persistent effects of 80 ppm toluene on dopamine-regulated locomotor activity and prolactin secretion in the male rat. **NeuroToxicology** 15(3) (1994) 621-624. (von Euler G, Ögren SO, Eneroth P, Fuxe K and Gustafsson J-Å)
1054. Different classes of volume transmission signals exist in the central nervous system and are affected by metabolic signals, temperature gradients and pressure waves. **NeuroReport** 6 (1994) 9-12. (Agnati L, Cortelli P, Biagini G, Bjelke B and Fuxe K)
1055. Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. **NeuroReport** 6 (1994) 73-76. (Ferré S, Popoli P, Giménez-Llort L, Finnman U-B, Martinez E, Scotti de Carolis A and Fuxe K)
1056. Possible mechanisms for the powerful actions of neuropeptides. **Ann NY Acad Sci** 739 (1994) 42-59. (Fuxe K, Li XM, Bjelke B, Hedlund P, Biagini G and Agnati L)
1057. On the plasticity of the cerebellar renin-angiotensin system: localization of components and effects of mechanical perturbation. **Brain Res** 668 (1994) 144-159. (Lippoldt A, Bunnemann B, Ueki A, Rosén L, Cintra A, Hasselrot U, Metzger R, Hilgenfeldt U, Brosnihan B, Ganten D and Fuxe K)
1058. PEC-60 and related peptides as hormones in the gastrointestinal tract and the immune system and as generalized cotransmitters in catecholamine neurons. **Biomedical Res** 15, Suppl 2 (1994) 103-113. (Fuxe K, Metsis M, Ferré S, O'Connor WT, Tinner B, Cintra A, Östensson CG, Efendic S, Agerberth B, Tanganelli S, Goldstein M, Staines W, Agnati LF and Mutt V)
1059. Glial and neuronal glucocorticoid receptor immunoreactive cell populations in developing, adult and aging brain. **Ann NY Acad Sci** 746 (1994) 42-63. (Cintra A, Bhatnagar M, Chadi G, Tinner B, Lindberg J, Gustafsson J-Å, Agnati L and Fuxe K)
1060. Chronic continuous infusion of nicotine increases the disappearance of choline acetyltransferase immunoreactivity in the cholinergic cell bodies of the medial septal nucleus following a partial unilateral transection of the fimbria fornix. **Clin Invest** 72 (1994) 262-268. (Fuxe K, Rosén L, Lippoldt A, Andbjør B, Hasselrot U, Finnman U-B and Agnati LF)

## 1995

1061. Differential brain area vulnerability to long-term subcortical excitotoxic lesions. **Neuroscience** 65 (1995) 15-25. (Mahy N, Bendahan G, Boatell M, Bjelke B, Tinner B, Olson L and Fuxe K)
1062. Volume versus wiring transmission in the brain: A new theoretical frame for neuro-psychopharmacology. **Med Res Rev** 15 (1995) 33-45. (Agnati L, Bjelke B and Fuxe K)
1063. Modafinil and cortical g-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins. **Eur J Pharmacol** 273 (1995) 63-71. (Tanganelli S, Pérez de la Mora M, Ferraro L, Méndez-Franco J, Beani L, Rambert F and Fuxe K)
1064. Counteraction of NPY-induced c-fos expression in the nucleus tractus solitarii by  $\alpha_2$  receptor agonists. **NeuroReport** 6 (1995) 384-388. (Yang S-N, Bjelke B, Narváez J, Cintra A, Agnati L and Fuxe K)

1065. On the cellular localization and distribution of carbonic anhydrase II immunoreactivity in the rat brain. **Brain Res** 676 (1995) 10-24. (Agnati L, Tinner B, Staines W, Väänänen K and Fuxe K)
1066. Evidence for the existence of antagonistic intramembrane adenosine A2a/dopamine D2 receptor interactions in the basal ganglia: analysis from the network to the molecular level. In **Adenosine and adenine nucleotides: From molecular biology to integrative physiology** (Belardinelli L and Pelleg A, Eds), Kluwer Academic Publ, Boston, MA, pp. 499-507. (Fuxe K, Ferré S, Dasgupta S, O'Connor WT, Snaprud P, Arenas E, Persson H, Ungerstedt U and Fredholm B)
1067. A single (-)nicotine injection causes change with a time delay in the affinity of striatal D2 receptors for antagonist, but not for agonist, nor in the D2 receptor mRNA levels in the rat substantia nigra. **Brain Res** 679 (1995) 157-167. (Li XM, Zoli M, Finnman U-B, LeNovère, Changeux J-P and Fuxe K)
1068. Evidence for a differential modulation of the alpha-2 adrenoceptors by angiotensin II in the nucleus tractus solitarii of the spontaneously hypertensive and the Wistar-Kyoto normotensive rats. **Brain Res** 679 (1995) 168-177. (Fior D, Yang S-N, Ganten U, Ganten D and Fuxe K)
1069. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections. **Eur J Neuroscience** 7 (1995) 962-971. (Li XM, Hedlund PB and Fuxe K)
1070. Nicotine and animal models of Parkinson's disease. In **Effects of Nicotine on Biological Systems II. Advances in Pharmacological Sciences** (Clarke PBS, Quik M, Adlkofer F and Thurau K, Eds), Birkhäuser Verlag, Basel, pp 321-328. (Janson AM, Møller A, Hedlund PB, von Euler G and Fuxe K)
1071. 5-HT<sub>1A</sub> receptor-mediated activation of high-affinity GTPase in rat hippocampal membranes. **Eur J Pharmacol** 288 (1995) 385-388. (Odagaki Y and Fuxe K)
1072. Presynaptic A<sub>2</sub>-adrenoceptors and neuropeptide Y Y<sub>2</sub> receptors inhibit [<sup>3</sup>H]noradrenaline release from rat hypothalamic synaptosomes via different mechanisms. **Neurosci Lett** 188 (1995) 9-12. (Martire M, Pistritto G, Mores N, Agnati LF and Fuxe K)
1073. A brief appraisal on some aspects of the receptor-receptor interaction. **Neurochem Int** 27, 2 (1995) 139-146. (Agnati LF, Ferré S, Cortelli P and Fuxe K)
1074. Long distance pathways of diffusion for dextran along fibre bundles in brain. Relevance for volume transmission. **NeuroReport** 6 (1995) 1005-1006. (Bjelke B, England R, Nicholson C, Rice M, Lindberg J, Zoli M, Agnati L and Fuxe K)
1075. Functional coupling of dopamine D2 and muscarinic cholinergic receptors to their respective G proteins assessed by agonist-induced activation of high-affinity GTPase activity in rat striatal membranes. **Biochem Pharmacol** 50(3) (1995) 325-335. (Odagaki Y and Fuxe K)
1076. Increased vasopressor actions of intraventricular neuropeptide Y-(13-36) in spontaneously hypertensive versus normotensive Wistar-Kyoto rats. Possible relationship to increases in Y<sub>2</sub> receptor binding in the nucleus tractus solitarius. **Brain**

- Res** 684 (1995) 159-164. (Aguirre J, Hedlund P, Narváez J, Bunnemann B, Ganten D and Fuxe K)
1077. Cholecystokinin octapeptide and the D2 antagonist raclopride induce Fos-like immunoreactivity in the shell part of the nucleus accumbens via different mechanisms. **Brain Res** 684 (1995) 225-229. (Li X-M, Chadi G and Fuxe K)
1078. Prenatal corticosterone increases spontaneous and d-amphetamine induced locomotor activity and brain dopamine metabolism in prepubertal male and female rats. **Neuroscience** 66 (1995) 467-473. (Diaz R, Ögren S, Blum M and Fuxe K)
1079. Pharmacological characterization of the 5-hydroxytryptamine-1A receptor-mediated activation of high-affinity GTP hydrolysis in rat hippocampal membranes. **J Pharmacol Exp Ther** 274 (1995) 337-344. (Odagaki Y and Fuxe K)
1080. Receptor-receptor interactions and their relevance for receptor diversity. In: **Diversity of interacting receptors** (Abood, L. and Lajtha, A.), **Ann N.Y. Acad Sci** 757 (1995) 365-376. (Fuxe K, Li X-M, Tanganelli S, Hedlund P, O'Connor W, Ferraro L, Ungerstedt U and Agnati L)
1081. The concept of trophic units in the central nervous system. **Prog in Neurobiol** 46 (1995) 561-574. (Agnati L, Cortelli P, Pettersson R and Fuxe K)
1082. Neurotensin-like immunoreactivity in odontoblasts and their processes in rat maxillary molar teeth and the effect of pulpotomy. **Reg Peptides** 58 (1995) 141-147. (Bhatnagar M, Cintra A, Tinner B, Agnati L, Kerezoudis N, Edwall L and Fuxe K)
1083. Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. **Synapse** 20 (1995) 362-364. (Ferraro L, Tanganelli S, O'Connor W, Bianchi C, Ungerstedt U and Fuxe K)
1084. 5-HT<sub>1A</sub>, GABA(B) and pirenzepine-insensitive muscarinic receptors are functionally coupled to distinct pools of the same kind of G proteins in rat hippocampus. **Brain Res** 689 (1995) 129-135. (Odagaki Y and Fuxe K)
1085. Reduction of dopamine D<sub>2</sub> receptor transduction by activation of adenosine A<sub>2A</sub> receptors in stably A<sub>2A</sub>/D<sub>2</sub> (long-form) receptor co-transfected mouse fibroblast cell lines: Studies on intracellular calcium levels. **Neuroscience** 68 (1995) 729-736. (Yang S-N, Dasgupta S, Lledo P-M, Vincent J-D and Fuxe K)
1086. The brain renin-angiotensin system - Molecular mechanisms of cell to cell interactions. **Clin Exp Hypertension** 17 (1995) 251-266. (Lippoldt A, Paul M, Fuxe K and Ganten D)
1087. Localization of thioredoxin in the rat brain and functional implications. **J Neurosci** 15 (1995) 6747-6756. (Lippoldt A, Padilla C, Gerst H, Andbjør B, Richter E, Holmgren A and Fuxe K)
1088. Functional coupling between A<sub>1</sub> adenosine receptors and G-proteins in rat hippocampal membranes assessed by high-affinity GTPase activity. **Br J Pharmacol** 116 (1995) 2691-2697. (Odagaki Y and Fuxe K)

1089. Additivity and non-additivity between dopamine-, norepinephrine-, carbochol- and GABA-stimulated GTPase activity. **Eur J Pharmacol, Mol Pharm Sec** 291 (1995) 245-253. (Odagaki Y, Dasgupta S and Fuxe K)
1090. Intercellular communication in the brain: Wiring versus volume transmission. **Neuroscience** 69 (1995) 711-726. (Agnati L, Zoli M, Strömberg I and Fuxe K)
1091. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. **J Neural Transm** 102 (1995) 125-137. (Li X, Ferraro L, Tanganelli s, O'Connor W, Hasselrot U, Ungerstedt U and Fuxe K)
1092. **Challenges and Perspectives in Neuroscience.** Wenner-Gren International Series, Vol. 66. Pergamon, Elsevier Science Ltd., Oxford (1995) (Eds. Ottoson D, Bartfai T, Hökfelt T and Fuxe K)
1093. Bradykinin modulation of  $\alpha_2$ -adrenoceptors in the nucleus tractus solitarius of the rat. An in vitro autoradiographical study. **Neuropharmacology** 34 (1995) 81-88. (Fior D and Fuxe K)
- 1996**
1094. The secretory trypsin inhibitor like-peptide, PEC-60 increases dopamine D2 receptor agonist induced inhibition of GABA release in the dorsolateral neostriatum of the awake freely moving rat. An in vivo microdialysis study. **Reg Peptides** 61 (1996) 111-117. (Rimondini R, O'Connor W, Sillard R, Mutt V, Ungerstedt U and Fuxe K)
1095. Galanin and 5-HT<sub>1A</sub> receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. In: **Neuropeptides: Basic and Clinical Advances.** (Crawley, J. and McLean, S.), Ann. N.Y. Acad. Sci. 780 (1996) 193-212. (Hedlund P and Fuxe K)
1096. Regulation of dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells cotransfected with human CCK<sub>B</sub> and D<sub>2L</sub> receptor cDNAs. **Mol Brain Res** 36 (1996) 292-299. (Dasgupta S, Li X-M, Jansson A, Finnman U-B, Matsui T, Rinken A, Arenas E, Agnati L and Fuxe K)
1097. Chronic continuous infusion of (-)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat. **Neuroscience** 70 (1996) 169-177. (Blum M, Wu G, Mudó G, Belluardo N, Andersson K, Agnati L and Fuxe K)
1098. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat. I. Effects of perfusion with tetrodotoxin and low-calcium medium. **Neuroscience** 72 (1996) 79-87. (Morari M, O'Connor W, Darvelid M, Ungerstedt U, Bianchi C and Fuxe K)
1099. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat. II. Evidence for a striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. **Neuroscience** 72 (1996) 89-97. (Morari M, O'Connor W, Ungerstedt U, Bianchi C and Fuxe K)

1100. Integrative aspects of brain function: Receptor-receptor interactions in dopamine transmission of the basal ganglia. In: **CNS Neurotransmitters and Neuromodulators. Dopamine.** (Stones, T. W.), CRC Press Ltd., Boca Raton, Florida (1996) 89-106. (Fuxe K, Li X-M, Hedlund P, Benfenati F, Agnati L and Ferré S)
1101. Localization of neuropeptide Y Y1 receptor-like immunoreactivity in catecholaminergic neurons of the rat medulla oblongata. **Neuroscience** 73 (1996) 519-530. (Yang S-N, Bunnemann B, Cintra A and Fuxe K)
1102. Evidence for a differential cholecystokinin-B and -A receptor regulation of GABA release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms. **Neuroscience** 73 (1996) 941-950. (Ferraro L, O'Connor W, Li X-M, Rimondini R, Beani L, Ungerstedt U, Fuxe K and Tanganelli S)
1103. On the role of glucocorticoid receptors in brain plasticity. **Cell Mol Neurobiol** 16 (1996) 239-258. (Fuxe K, Diaz R, Cintra A, Bhatnagar M, Tinner B, Gustafsson J-Å, Ögren S and Agnati L)
1104. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding site. **Neurosci Lett** 208 (1996) 109-112. (Ferré S, Popoli P, Tinner-Staines B and Fuxe K)
1105. Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopeduncular pathway and its modulation of adenosine A1 receptor-mediated mechanisms. **Eur J Neurosci** 8 (1996) 1545-1553. (Ferré S, WT OC, Svenningsson P, Björklund L, Lindberg J, Tinner B, Strömberg I, Goldstein M, Ögren S, Ungerstedt U, Fredholm B and Fuxe K)
1106. Kinetic evidence for isomerization of the dopamine receptor-raclopride complex. **Neurochem Int** 28 (1996) 591-595. (Lepiku M, Rincken A, Järv J and Fuxe K)
1107. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. **Eur J Pharmacol** 306 (1996) 33-39. (Ferraro L, Tanganelli S, O'Connor W, Antonelli T, Rambert F and Fuxe K)
1108. Preclinical studies with modafinil. Evidence for vigilance enhancement and neuroprotection. **Drugs of Today** 32 (1996) 313-326. (Fuxe K, Rambert F, Ferraro L, O'Connor W, Laurent P, Agnati L and Tanganelli S)
1109. Computer-assisted mapping of basic fibroblast growth factor immunoreactive nerve cell populations in the rat brain. **J Chem Neuroanat** 11 (1996) 13-35. (Fuxe K, Tinner B, Zoli M, Pettersson R, Baird A, Biagini G, Chadi G and Agnati L)
1110. Stimulation of adenosine A1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits. **Eur J Pharmacol** 305 (1996) 123-126. (Popoli P, Ferré S, Pèzzola A, Reggio R, Scotti de Carolis A and Fuxe K)
1111. Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. **Eur J Pharmacol** , 316 (1996) 325-331. (Dasgupta S, Ferré S, Kull B, Hedlund P, Finnman U-B, Ahlberg S, Arenas E, Fredholm B and Fuxe K)

1112. Basic fibroblast growth factor expression and tenascin C immunoreactivity after partial unilateral hemitranssection of the rat brain. **Brain Res** 730 (1996) 1-16. (Lippoldt A, Andbjør B, Gerst H, Ganten D and Fuxe K)
1113. Expression of cytochrome P45011B1 mRNA in the brain of normal and hypertensive transgenic rats. **Brain Res** 733 (1996) 73-82. (Erdmann B, Gerst H, Lippoldt A, Bülow H, Ganten D, Fuxe K and Bernhardt R)
1114. Evidence for receptors for hyaluronan in discrete nerve cell populations of the brain. **Brain Res** 736 (1996) 329-337. (Fuxe K, Agnati L, Tinner B, Forsberg N, McCourt P and Gustafson S)
1115. Intrastrially injected c-fos antisense oligonucleotide interferes with striatonigral but not striatopallidal g-aminobutyric acid transmission in the conscious rat. **Proc Natl Acad Sci USA** 93 (1996) 14134-14139. (Sommer W, Rimondini R, O'Connor W, Hansson A, Ungerstedt U and Fuxe K)
1116. Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. **Hypertension** 28 (1996) 818-824. (Erdmann B, Fuxe K and Ganten D)
1117. Ibotenic acid in the medial septum increased brain-derived neurotrophic factor mRNA levels in the dorsal rat hippocampal formation. **Neurosci Lett** 213 (1996) 169-172. (Mahy N, Diaz R, Andres N and Fuxe K)
1118. The non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226 blocks the [Leu31,Pro34]neuropeptide Y-induced modulation of  $\alpha_2$ -adrenoceptors in the nucleus tractus solitarii of the rat. **NeuroReport** 7 (1996) 2701-2705. (Yang S-N, Finnman U-B and Fuxe K)
1119. Dopaminergic transmission in the rat retina: evidence for volume transmission. **J Chem Neuroanat** 12 (1996) 37-50. (Bjelke B, Goldstein M, Tinner B, Andersson C, Sesack S, Steinbusch H, Lew J, He X, Watson S, Tengroth B and Fuxe K)
1120. Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat. **Neurosci Lett** 217 (1996) 61-65. (Cintra A, Andbjør B, Finnman U-B, Hagman M, Agnati L, Höglund G and Fuxe K)
1121. The receptor mosaic hypothesis of the engram: Possible relevance of Boolean network modeling. **Int J Neural Systems** 7 (1996) 363-368. (Zoli M, Guidolin D, Fuxe K and Agnati L)
1122. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. **Neurosci Lett** 218 (1996) 209-213. (Popoli P, Giménez-Llort L, Pezzola A, Reggio R, Martínez E, Fuxe K and Ferré S)
1123. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT<sub>3</sub> receptor. **Neurosci Lett** 220 (1996) 5-8. (Ferraro L, Tanganelli S, O'Connor W, Antonelli T, Rambert F and Fuxe K)
1124. **Molecular Mechanisms of Neuronal Communication.** Wenner-Gren International Series, Vol. 68. Pergamon, Oxford (1996). (Eds. Fuxe K, Hökfelt T, Olson L, Ottoson D, Dahlström A and Björklund A)

1125. The impact of histological techniques in revealing brain function. Volume transmission: from fluorescence histochemistry to confocal laser microscopy. In: **Molecular Mechanisms of Neuronal Communication**. (Fuxe, K., Hökfelt, T., Olson, L., Ottoson, D., Dahlström, A. and Björklund, A.), Wenner-Gren International Series, Vol. 68 (1996) 251-277. (Agnati LF and Fuxe K)
1126. Centrally infused galanin-(1-15) but not galanin-(1-29) reduces the baroreceptor reflex sensitivity in the rat. **Brain Res** 741 (1996) 32-37. (Díaz Z, Narváez JA, Hedlund P, Aguirre JA, González-Barón S and Fuxe K)
1127. Neuropharmacology of the adenosine A2a receptors. **Drug Dev Res** 39 (1996) 450-460. (Ongini E, Dionisotti S, Morelli M, Ferré S, Svenningsson P, Fuxe K and Fredholm BB)

### 1997

1128. Regional distribution of neural cell adhesion molecule immunoreactivity in the adult rat telencephalon and diencephalon. Partial colocalization with heparan sulfate proteoglycan immunoreactivity. **Brain Res** 746 (1997) 25-33. (Fuxe K, Tinner B, Staines W, David G and Agnati LF)
1129. Comparative localization of fibroblast growth factor receptor-1,-2 and -3 mRNAs in the rat brain: In situ hybridization analysis. **J Comp Neurol** 379 (1997) 226-246. (Belluardo N, Wu G, Mudo G, Hansson AC, Pettersson R and Fuxe K)
1130. Increased potency of neuropeptide Y to antagonize  $\alpha_2$ -adrenoceptor function in the nucleus tractus solitarii of the spontaneously hypertensive rat. **Neuroscience** 78 (1997) 803-813. (Yang S-N, Fior DR, Hansson AC, Cintra A, Castellano M, Ganten U, Ganten D, Agnati LF and Fuxe K)
1131. Mechanism of modulation of [3H]raclopride binding to dopaminergic receptors in rat striatal membranes by sodium ions. **Neurochem Int** 30 (1997) 575-581. (Lepiku M, Järv J, Rincken A and Fuxe K)
1132. NPY Y1 receptor like immunoreactivity exists in a subpopulation of b-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. **Neurosci Lett** 225 (1997) 49-52. (Fuxe K, Tinner B, Caberlotto L, Bunnemann B and Agnati LF)
1133. Codistribution of the dopamine D3 receptor and glucocorticoid receptor mRNAs during striatal prenatal development in the rat. **Neurosci Lett** 227 (1997) 119-122. (Diaz R, Sokoloff P and Fuxe K)
1134. Possible involvement of G-proteins in the regulation of striatal dopamine D2 receptor affinity by cholecystinin octapeptide. **Neurosci Lett** 228 (1997) 171-174. (Li X-M, Jansson A, Finnman U-B, Agnati L and Fuxe K)
1135. Adenosine A2A agonists: A potential new type of atypical antipsychotic. **Neuropsychopharmacology** 17 (1997) 82-91. (Rimondini R, Ferré S, Ögren SO and Fuxe K)

1136. On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach. **Neurochem Int** 31 (1997) 425-436. (Sommer W and Fuxe K)
1137. Agonist-induced high-affinity GTP hydrolysis as an index of receptor-mediated G protein activation in mammalian brain membranes. In: **Methods in Molecular Biology, Vol. 83: Receptor Signal Transduction Protocols**. (Challiss, R. A. J.), (1997) 133-141. (Odagaki Y and Fuxe K)
1138. Neurochemical changes in the hippocampus of the brown Norway rat during aging. **Neurobiology of Aging** 18 (1997) 319-327. (Bhatnagar M, Cintra A, Chadi G, Lindberg J, Oitzl M, De Kloet ER, Möller A, Agnati LF and Fuxe K)
1139. Endothelin-1 induced lesions of the frontoparietal cortex of the rat. A possible model of focal cortical ischemia. **NeuroReport** 8 (1997) 2623-2629. (Fuxe K, Bjelke B, Andbjør B, Grahn H, Rimondini R and Agnati LF)
1140. Chronic nicotine treatment differentially regulates substance P and tyrosine hydroxylase immunoreactivity in substantia nigra ipsilateral to a unilateral lesion. **Exp Neurol** 146 (1997) 575-586. (Janson AM and Fuxe K)
1141. Localization of neuropeptide Y Y1 mRNA in the human brain: Abundant expression in cerebral cortex and striatum. **Eur J Neurosci** 9 (1997) 1212-1225. (Caberlotto L, Fuxe K, Sedvall G and Hurd YL)
1142. Prenatal corticosterone treatment induces long-term changes in spontaneous and apomorphine-mediated motor activity in male and female rats. **Neuroscience** 81 (1997) 129-140. (Diaz R, Fuxe K and Ögren SO)
1143. The antinarcotic drug modafinil increases glutamate release in thalamic areas and hippocampus. **NeuroReport** 8 (1997) 2883-2887. (Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F and Fuxe K)
1144. Localization of angiotensin II AT1 receptor-like immunoreactivity in catecholaminergic neurons of the rat medulla oblongata. **Neuroscience** 81 (1997) 503-515. (Yang SN, Lippoldt A, Jansson A, Phillips MI, Ganten D and Fuxe K)
1145. Prolonged treatment with haloperidol and clozapine in the rat: differential effects on spontaneous and theophylline-induced motor activity. **Neurosci Lett** 232 (1997) 21-24. (Ögren SO, Ferré S, Schwarcz R and Fuxe K)
1146. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. **Trends Neurosci** 20 (1997) 482-487. (Ferré S, Fredholm B, Morelli M, Popoli P and Fuxe K)
1147. GABA-dopamine receptor-receptor interactions in neostriatal membranes of the rat. **Neurochem Res** 22 (1997) 1051-1054. (Pérez de la Mora M, Ferré S and Fuxe K)
1148. Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. **Eur J Neurosci** 9 (1997) 1838-1846. (Ferraro L, O'Connor WT, Antonelli T, Fuxe K and Tanganelli S)



1149. Modafinil: An antinarcotic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. **Biol Psych** 42 (1997) 1181-1183. (Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA and Fuxe K)
1150. Extracellular sodium removal increases release of neuropeptide Y-like immunoreactivity from rat brain hypothalamic synaptosomes: Involvement of intracellular acidification. **Synapse** 27 (1997) 191-198. (Martire M, Preziosi P, Cannizzaro C, Mores N and Fuxe K)
1151. Identification, isolation, and characterization of dantain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats. **PNAS** 94 (1997) 13879-13884. (Chen Z-W, Ahren B, Östenson C-G, Cintra A, Bergman T, Möller C, Fuxe K, Mutt V, Jörnvall H and Efendic S)
1152. Modulation of [<sup>3</sup>H]quinpirole binding to dopaminergic receptors by adenosine A<sub>2A</sub> receptors. **Neurosci Lett** 239 (1997) 61-64. (Lepiku M, Rinken A, Järv J and Fuxe K)

## 1998

1153. Obituary: Menek Goldstein (1926-1997). **TIPS** 19 (1998) 1. (Fuxe K and Hökfelt T)
1154. Acetylcholine receptors containing the b2 subunit are involved in the reinforcing properties of nicotine. **Nature** 391 (1998) 173-177. (Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Merlo Pich E, Fuxe K and Changeux J-P)
1155. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. **J Biol Chem** 273 (1998) 4718-4724. (Ferré S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas E, Fredholm BB and Fuxe K)
1156. Brain Communication. In: **Solemne Investidura de Doctor Honoris Causa al professor Kjell G. Fuxe** Publicacions de la Universitat de Barcelona, Barcelona (1998) 17-52. (Fuxe K)
1157. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. **Neuroscience** 83 (1998) 723-740. (Belluardo N, Blum M, Mudo G, Andbjer B and Fuxe K)
1158. Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human post mortem brain. **Neuroscience** 86 (1998) 167-178. (Caberlotto L, Fuxe K, Rimland JM, Sedvall G and Hurd YL)
1159. On the relationship of neuropeptide Y Y1 receptor immunoreactive neuronal structures to the neuropeptide Y-immunoreactive nerve terminal networks. A double immunolabelling analysis in the rat brain. **Neuroscience** 86 (1998) 827-845. (Caberlotto L, Tinner B, Bunnemann B, Agnati LF and Fuxe K)
1160. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. **Eur J Pharmacol** 347 (1998) 153-158. (Rimondini R, Ferré S, Giménez-Llort L, Ögren SO and Fuxe K)

1161. Existence of striatal nerve cells coexpressing CCK<sub>B</sub> and D<sub>2</sub> receptor mRNAs. **NeuroReport** 9 (1998) 2035-2038. (Hansson AC, Andersson A, Tinner B, Cui X, Sommer W and Fuxe K)
1162. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. **Mol Brain Res** 59 (1998) 58-65. (Caberlotto L, Fuxe K, Overstreet D, Gerrard P and Hurd Y)
1163. Age-related alteration of the adenosine/dopamine balance in the rat striatum. **Brain Res** 795 (1998) 297-300. (Popoli P, Betto P, Rimondini R, Reggio R, Pézzola A, Ricciarello G, Fuxe K and Ferré S)
1164. On the relationship of 5-hydroxytryptamine neurons to 5-hydroxytryptamine 2A receptor-immunoreactive neuronal processes in the brain stem of rats. A double immunolabelling analysis. **NeuroReport** 9 (1998) 2505-2511. (Jansson A, Tinner B, Steinbusch HWM, Agnati LF and Fuxe K)
1165. The emergence of the volume transmission concept. **Brain Res Reviews** 26 (1998) 136-147. (Zoli M, Torri C, Ferrari R, Jansson A, Zini I, Fuxe K and Agnati LF)
1166. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. **Brain Res Reviews** 26 (1998) 258-273. (Fuxe K, Ferré S, Zoli M and Agnati LF)
1167. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: Functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. **J Neurosci** 18(17) (1998) 6977-6989. (Ferraro L, Antonelli T, O'Connor W, Fuxe K, Soubrié P and Tanganelli S)
1168. Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. **Neurosci Lett** 251 (1998) 201-204. (Popoli P, Reggio R, Pézzola A, Fuxe K and Ferré S)
1169. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. **Neurosci Lett** 253 (1998) 135-138. (Ferraro L, Antonelli T, O'Connor W, Tanganelli S, Rambert F and Fuxe K)
1170. Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. **Eur J Neurosci** 10 (1998) 1716-1722. (Morari M, Sbrenna S, Marti M, O'Connor W, Bianchi C, Fuxe K and Beani L)
1171. Intraventricular galanin modulates a 5-HT1A receptor mediated behavioural response in the rat. **Eur J Neurosci** 10 (1998) 1230-1240. (Misane I, Razani H, Wang FH, Jansson A, Fuxe K and Ögren SO)
1172. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. **Neurochem Int** 33 (1998) 383-397. (Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C and Beani L)

1173. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. **Antisense & Nucleic Acid Drug Development** 8 (1998) 75-85. (Sommer W, Cui X, Erdmann B, Wiklund L, Bricca G, Heilig M and Fuxe K)
1174. Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine<sub>1A</sub> receptor interactions in the brain. In: **Galanin: Basic Research Discoveries and Therapeutic Implications**. (Hökfelt, T., Bartfai, T. and Crawley, J.), 863, Ann. N.Y. Acad. Sci., New York (1998) 274-290. (Fuxe K, Jansson A, Diaz-Cabiale Z, Andersson A, Tinner B, Finnman U-B, Misane I, Razani H, Wang F-H, Agnati LF and Ögren SO)
1175. Galanin and NH<sub>2</sub>-terminal galanin fragments in central cardiovascular regulation. In: **Galanin: Basic Research Discoveries and Therapeutic Implications**. (Hökfelt, T., Bartfai, T. and Crawley, J.), 863, Ann. N.Y. Acad. Sci., New York (1998) 421-424. (Díaz-Cabiale Z, Narváez J, Marcos P, Cordon M, Coveñas R, Fuxe K and Gonzalez-Baron S)
1176. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. **NeuroReport** 9 (1998) 4209-4213. (Antonelli T, Ferraro L, Hillion J, Tomasini M, Rambert F and Fuxe K)
- 1999**
1177. On the distribution patterns of D<sub>1</sub>, D<sub>2</sub>, tyrosine hydroxylase and dopamine transporter immunoreactivities in the ventral striatum of the rat. **Neuroscience** 89 (1999) 473-489. (Jansson A, Goldstein M, Tinner B, Zoli M, Meador-Woodruff J, Lew J, Levey A, Watson S, Agnati L and Fuxe K)
1178. Effects of nitric oxide inhibition on the spread of biotinylated dextran and on extracellular space parameters in the neostriatum of the male rat. **Neuroscience** 91 (1999) 69-80. (Jansson A, Mazel T, Andbjør B, Rosén L, Guidolin D, Zoli M, Syková E, Agnati L and Fuxe K)
1179. Pharmacological characterization of dopamine-stimulated [<sup>35</sup>S]-guanosine 5'-(γ-thiotriphosphate) ([<sup>35</sup>S]GTPγS) binding in rat striatal membranes. **Biochem Pharmacol** 57 (1999) 155-162. (Rinken A, Finnman U-B and Fuxe K)
1180. Serotonergic agonists behave as partial agonists at the dopamine D<sub>2</sub> receptor. **NeuroReport** 10 (1999) 493-495. (Rinken A, Ferré S, Terasmaa A, Owman C and Fuxe K)
1181. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. **Neurosci Lett** 259 (1999) 181-185. (Pérez de la Mora M, Aguilar-García A, Ramon-Frias T, Ramirez-Ramirez R, Méndez-Franco J, Rambert F and Fuxe K)
1182. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABA<sub>A</sub> receptor blockade. **Neuropsychopharmacology** 20 (1999) 346-356. (Ferraro L, Antonelli T, Tanganelli S, O'Connor W, Perez de la Mora M, Mendez-Franco J, Rambert F and Fuxe K)

1183. Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. **Neurochem Int** 34 (1999) 235-244. (Lillrank S, Lipska B, Weinberger D, Fredholm B, Fuxe K and Ferré S)
1184. Alterations in neuropeptide Y levels and Y1 binding sites in the flinders sensitive line rats, a genetic animal model of depression. **Neurosci Lett** 265 (1999) 191-194. (Caberloto L, Jimenez P, Overstreet D, Hurd Y, Mathé A and Fuxe K)
1185. Reciprocal interactions between adenosine A<sub>2A</sub> and dopamine D<sub>2</sub> receptors in Chinese hamster ovary cells co-transfected with the two receptors. **Biochem Pharmacol** 58 (1999) 1035-1045. (Kull B, Ferré S, Arslan G, Svenningsson P, Fuxe K, Owman C and Fredholm B)
1186. Multiple intramembrane receptor-receptor interactions in the regulation of striatal dopamine D<sub>2</sub> receptors. **NeuroReport** 10 (1999) 2051-2054. (Rimondini R, Fuxe K and Ferré S)
1187. Volume transmission in the CNS and its relevance for neuropsychopharmacology. **TIPS** 20 (1999) 142-150. (Zoli M, Jansson A, Syková E, Agnati L and Fuxe K)
1188. Stimulation of adenosine A<sub>1</sub> receptors attenuates dopamine D<sub>1</sub> receptor-mediated increase of NGF1-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D<sub>1</sub> receptor-mediated turning behaviour. **Eur J Neurosci** 11 (1999) 1-9. (Ferré S, Rimondini R, Popoli P, Reggio R, Pèzzola A, Hansson A, Andersson A and Fuxe K)
1189. Adenosine A<sub>2A</sub> and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D<sub>2</sub> receptors in the rat striatum. **Neuropharmacology** 38 (1999) 129-140. (Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J and Fuxe K)
1190. The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. **NeuroReport** 10 (1999) 3909-3913. (Belluardo N, Mudó G, Caniglia G, Cheng Q, Blum M and Fuxe K)
1191. Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat. **Neurosci Lett** 274 (1999) 5-8. (Cintra A, Aguirre JA, Andbjør B, Finnman U-B, Hagman M, Agnati LF, Höglund C, Möller A and Fuxe K)
1192. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. **Neurosci Lett** 275 (1999) 215-218. (Aguirre JA, Cintra A, Hillion J, Narváez JA, Jansson A, Antonelli T, Ferraro L, Rambert FA and Fuxe K)
1193. The nicotinic acetylcholine receptor agonist (±)epibatidine increases FGF-2 mRNA and protein levels in the rat brain. **Mol Brain Res** 74 (1999) 98-110. (Belluardo N, Mudó G, Blum M, Cheng Q, Caniglia G, Dell'Albani P and Fuxe K)

1194. Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated increase of NGF1-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1 receptor-mediated turning behaviour. **Eur J Neurosci** 11 (1999) 3884-3892. (Ferré S, Rimondini R, Popoli P, Reggio R, Pèzzola A, Hansson A, Andersson A and Fuxe K)

**2000**

1195. Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. **J Neurochem** 74 (2000) 432-439. (Salim H, Ferré S, Dalal A, Peterfreund RA, Fuxe K, Vincent J-D and Lledo P-M)
1196. Internalization of intracerebrally administered porcine galanin (1-29) by a discrete nerve cell population in the hippocampus of the rat. **Exp Neurol** 161 (2000) 153-166. (Jansson A, Tinner B, Andbjør B, Razani H, Wang F-H, Schött PA, Agnati LF, Ögren SO and Fuxe K)
1197. Ontogeny of the motor inhibitory role of dopamine D3 receptor subtype in rats. **Eur J Pharmacol** 392 (2000) 35-39. (Diaz Heijtz R, Ögren S and Fuxe K)
1198. Modulation of [<sup>35</sup>S]GTPγS binding to Chinese hamster ovary cell membranes by D<sub>2(short)</sub> dopamine receptors. **Neurosci Lett** 280 (2000) 135-138. (Terasmaa A, Finnman U-B, Owman C, Ferré S, Fuxe K and Rincken A)
1199. Phorbol ester induced changes in tight and adherens junctions in the choroid plexus epithelium and in the ependyma. **Brain Res** 854 (2000) 197-206. (Lippoldt A, Jansson A, Kniesel U, Andbjør B, Andersson A, Wolburg H, Fuxe K and Haller H)
1200. Galanin/alpha2-receptor interactions in central cardiovascular control. **Neuropharmacology** 39 (2000) 1377-1385. (Diaz-Cabiale Z, Narváez JA, Yanaihara N, González-Barón S and Fuxe K)
1201. Oxytocin/alpha2-adrenoceptor interactions in feeding responses. **Neuroendocrinology** 71 (2000) 209-218. (Diaz-Cabiale Z, Narváez JA, Petersson M, Uvnäs-Moberg K and Fuxe K)
1202. Galanin(1-16) modulates 5-HT1A receptors in the ventral limbic cortex of the rat. **NeuroReport** 11 (2000) 151-159. (Diaz-Cabiale Z, Narváez JA, Finnman U-B, Bellido I, Ögren SO and Fuxe K)
1203. Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and -5 expression by protein kinase c. **NeuroReport** 11 (2000) 1427-1431. (Lippoldt A, Liebner S, Andbjør B, Kalbacher H, Wolburg H, Haller H and Fuxe K)
1204. Striatal dopamine denervation decreases the GDP binding affinity in rat striatal membranes. **NeuroReport** 11 (2000) 2691-2694. (Terasmaa A, Andbjør B, Fuxe K and Rincken A)

1205. Intraventricular galanin produces a time-dependent modulation of 5-HT<sub>1A</sub> receptors in the dorsal raphe of the rat. **NeuroReport** 11 (2000) 3943-3948. (Razani H, Diaz-Cabiale Z, Fuxe K and Ögren SO)
1206. Neurotrophic effects of central nicotinic receptor activation. **J Neural Transm (Suppl)** 60 (2000) 203-221. (Belluardo N, Mudo G, Blum M, Amato G and Fuxe K)
1207. Antagonistic oxytocin/ $\alpha$ 2-adrenoreceptor interactions in the nucleus tractus solitarii: Relevance for central cardiovascular control. **J Neuroendocrinology** 12 (2000) 1167-1173. (Diaz-Cabiale Z, Narváez JA, Garrido R, Petersson M, Uvnäs-Moberg K and Fuxe K)
1208. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. **Neuropharmacology** 39 (2000) 1974-1983. (Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert F and Antonelli T)
1209. Fetal ventral mesencephalic grafts functionally reduce the dopamine D<sub>2</sub> receptor supersensitivity in partially dopamine reinnervated host striatum. **Exp Neurology** 164 (2000) 154-165. (Strömberg I, Kehr J, Andbjør B and Fuxe K)
1210. Intracerebral infusion of 3H-dopamine and 3H-mannitol in the striatum of halothane-anaesthetized male rats. A dual-probe microdialysis study of long-distance diffusion. **Eur J Neurosci** 12 (2000) 2505-2514. (Höistad M, Kehr J, Andbjør B, Jansson A and Fuxe K)
1211. Gluco- and mineralocorticoid receptor-mediated regulation of neurotrophic factor gene expression in the dorsal hippocampus and the neocortex of the rat. **Eur J Neurosci** 12 (2000) 2918-2934. (Hansson AC, Cintra A, Belluardo N, Sommer W, Bhatnagar M, Bader M, Ganten D and Fuxe K)
1212. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A<sub>2A</sub> receptors in dopamine D<sub>2</sub> receptor regulation in the rat dopamine-denervated striatum. **Eur J Neurosci** 12 (2000) 4033-4037. (Strömberg I, Popoli P, Müller CE, Ferré S and Fuxe K)
1213. Central nicotinic receptors, neurotrophic factors and neuroprotection. **Behav Brain Res** 113 (2000) 21-34. (Belluardo N, Mudo G, Blum M and Fuxe K)
1214. Systemic oxytocin treatment modulates  $\alpha$ 2-adrenoreceptors in telencephalic and diencephalic regions of the rat. **Brain Res** 887 (2000) 421-425. (Diaz-Cabiale Z, Petersson M, Narváez JA, Uvnäs-Moberg K and Fuxe K)
1215. K<sup>+</sup>-evoked [<sup>3</sup>H]-aspartate release in rat spinal cord synaptosomes: Modulation by neuropeptide Y and calcium channel antagonists. **J Neurosci Res** 62 (2000) 722-729. (Martire M, Altobelli D, Maurizi S, Preziosi P and Fuxe K)
1216. Volume transmission as a key feature of information handling in the central nervous system possible new interpretative value of the Turing's B-type machine. **Prog Brain Res** 125 (2000) 3-19. (Agnati LF and Fuxe K)
1217. Diffusion of radiolabeled dopamine, its metabolites and mannitol in the rat striatum studied by dual-probe microdialysis. **Prog Brain Res** 125 (2000) 179-190. (Kehr, J., Höistad M. and Fuxe, K.)

- 1218 Evidence for the existence of pulses of dopamine in the extracellular space of the striatum. **Prog Brain Res** 125 (2000) 303-308. (Agnati LF, Zoli M, Ferrari R, Di Paola L, Torri C, Fuxe K and Zini I)
1219. Restoration of dopamine transmission in graft reinnervated striatum. Evidence for regulation of dopamine D2 receptor function in regions lacking dopamine. **Prog Brain Res** 125 (2000) 309-15. (Stromberg, I., Kehr, J. and Fuxe, K.)
1220. Adenosine as a volume transmission signal. A feedback detector of neuronal activation. **Prog Brain Res** 125 (2000) 353-361. (Ferre, S. and K. Fuxe)
1221. Long distance signalling in volume transmission. Focus on clearance mechanisms." **Prog Brain Res** 125 (2000) 399-413. (Jansson, A., Lippoldt, A., Mazel, T., Bartfai, T., Ögren, S. O., Sykova, E., Agnati, L. F. and Fuxe, K.)
1222. The galanin receptor antagonist M40 blocks the central cardiovascular actions of the galanin N-terminal fragment (1-15). **Eur J Pharmacol** 399 (2000) 197-203. (Narváez JA, Díaz-Cabiale Z, Hedlund P, Aguirre JA, Coveñas R, González-Barón S and Fuxe K)
1223. Evidence for adenosine/dopamine receptor interactions. Indications for heteromerization. **Neuropsychopharmacology** 23 (2000) 50-59. (Franco R, Ferré S, Agnati LF, Torvinen M, Gines S, Hillion J, Casado V, Lledo P, Zoli M, Lluís C and Fuxe K)
1224. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala and striatum. **J Chem Neuroanat** 20 (2000) 327-337 (Caberlotto L, Fuxe K and Hurd Y)
1225. Dopamine D1 and adenosine A1 receptors assemble into functionally interacting heteromeric complexes. **Proc Natl Acad Sci** 97 (2000) 8606-8611. (Ginés S, Hillion J, Torvinen M, LeCrom S, Casado V, Canela E, Rondin S, Lew J, Watson S, Zoli M, Agnati L, Vernier P, Lluís C, Ferré S, Fuxe K and Franco R)
1226. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. **J Drug Targeting** 8 (2000) 319-334. (Khan A, Sommer W, Fuxe K and Akhtar S)
- 2001**
1227. Induction of hippocampal glial cells expressing basic fibroblast growth factor RNA by corticosterone. **NeuroReport** 12 (2001) 141-145. (Hansson A, Sommer W, Andbjør B, Bader M, Ganten D and Fuxe K)
1228. Prolonged effects of intraventricular galanin on a 5-hydroxytryptamine 1A receptor mediated function in the rat. **Neurosci Lett** 299 (2001) 145-149. (Razani H, Diaz-Cabiale Z, Misane I, Wang F-H, Fuxe K and Ögren SO)
1229. Voltage-operated Ca<sup>2+</sup> channels involved in K<sup>+</sup>-evoked release of vasoactive intestinal polypeptide from the rat hypothalamus. **Neurochemistry** 38 (2001) 359-365. (Martire M, Curró D, Altobelli D, Preziosi P and Fuxe K)

1230. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. **Parkinsonism and Related Disorders** 7 (2001) 235-241. (Ferré S, Popoli P, Giménez-Llort L, Rimondini R, Müller CE, Strömberg I, Ögren SO and Fuxe K)
1231. Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs. **Brain Res** 894 (2001) 307-310. (Ferraro L, Tanganelli S, Fuxe K, Bebe WB, Tomasini MC, Rambert FA and Antonelli T)
1232. Galanin/a2-adrenoceptor interactions in telencephalic and diencephalic regions of the rat. **NeuroReport** 12 (2001) 151-155. (Díaz-Cabiale Z, Narváez JA, Garcia-Coronel M and Fuxe K)
1233. Adenosine receptors and Parkinson's Disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. In: **Parkinson's Disease** (Calne, D. and Calne, S.), Advances in Neurology 86, Lippincott Williams & Wilkins, Philadelphia (2001) 345-353. (Fuxe K, Strömberg I, Popoli P, Rimondini-Giorgini R, Torvinen M, Ögren SO, Franco R, Agnati LF and Ferré S)
1234. D2 dopamine receptor - G protein coupling. Cross-regulation of agonist and guanosine nucleotide binding sites. **Neurosci Lett** 302 (2001) 5-8. (Rinken A, Terasmaa A, Raidaru G and Fuxe K)
1235. Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: biochemical and functional correlates. **Peptides** 22 (2001) 1229-1234. (Tanganelli S, Fuxe K, Antonelli T, O'Connor WT and Ferraro L)
1236. A view of renin in the brain. **J Mol Med** 79 (2001) 71-73. (Lippoldt A, Fuxe K and Luft C)
1237. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. **Neuroscience** 102 (2001) 113-120. (Ferraro L, Tomasini MC, Fernandez M, Bebe BW, O'Connor WT, Fuxe K, Glennon JC, Tanganelli S and Antonelli T)
1238. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury. **Neuroreport** 12(12) (2001) 2615-2617. (Aguirre, J. A., Andbjør, B., Gonzalez-Baron, S., Hansson, A., Stromberg, I., Agnati, L. F., Fuxe, K.)
1239. Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. **Neuroreport** 12(9) (2001) 1831-1834. (Diaz-Cabiale, Z., Hurd, Y., Guidolin, D., Finnman, U. B., Zoli, M., Agnati, L. F., Vanderhaeghen, J. J., Fuxe, K., Ferre, S.)
1240. Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain." **J Chem Neuroanat** 22(3) (2001) 185-203. (Jansson, A., Tinner, B., Bancila, M., Verge, D., Steinbusch, H. W., Agnati, L. F., Fuxe, K.)
1241. Central galanin and N-terminal galanin fragment induce c-Fos immunoreactivity in the medulla oblongata of the anesthetized rat. **Peptides** 22(9) (2001) 1501-9. (Marcos, P., Diaz-Cabiale, Z., Cordon, M. P., Covenas, R., Yanaihara, N., Fuxe, K., Gonzalez-Baron, S., Narvaez, J. A.)



1242. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors." **Neuropsychopharmacology** 25(4) (2001) 505-13. (Popoli, P., Pezzola, A., Torvinen, M., Reggio, R., Pintor, A., Scarchilli, L., Fuxe, K., Ferre, S.)

## 2002

1243. Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. **Neurosci Lett** 317(2) (2002) 101-105. (Bellido I, Diaz-Cabiale Z, Jiménez-Vasquez PA, Andbjør B, Mathé A and Fuxe K)
1244. Quantitative dual-probe microdialysis: evaluation of [<sup>3</sup>H]mannitol diffusion in agar and rat striatum. **J Neurochem** 81 (2002) 80-93. (Höistad M, Chen KC, Nicholson C, Fuxe K and Kehr J)
1245. Quantitative dual-probe microdialysis: mathematical model and analysis. **J Neurochem** 81 (2002) 94-107. (Chen KC, Höistad M, Kehr J, Fuxe K and Nicholson C)
1246. Theory relating in vitro and in vivo microdialysis with one or two probes. **J Neurochem** 81 (2002) 108-121. (Chen KC, Höistad M, Kehr J, Fuxe K and Nicholson C)
1247. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: Possible relevance for wakefulness and depression. **J Neurosci Res** 68(1) (2002) 107-12. (Ferraro, L., K. Fuxe, et al.)
1248. Transmitter-receptor mismatches in central dopamine, serotonin and neuropeptide systems.. Further evidence for volume transmission. **In The Neuronal Environment: Brain Homeostasis in Health and Disease** (eds. W. Walz) Human Press Inc., Totowa, NJ (2002) pp. 83-108. (Jansson A, Descarries L, Cornea-Hébert, Riad M, Vergé D, Bancila M, Agnati LF and Fuxe K)
1249. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors. **Neurosci Lett** 324 (2002) 154-158. (Díaz-Cabiale Z, Vivó M, Del Arco A, O'Connor WT, Harte MK; Müller CE, Martínez E, Popoli P, Fuxe K and Ferré S)
1250. Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: Counteraction by a NTRI-like receptor antagonist. **NeuroReport** 13 (2002) 763-766. (Díaz-Cabiale Z, Fuxe K, Narváez JA, Finetti S, Antonelli T, Tanganelli S and Ferraro L)
1251. Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. **J Biol Chem** 277 (2002) 18091-18097. (Hillion J, Canals M, Torvinen M, Casadó V, Scott R, Terasmaa A, Hansson A, Watson S, Olah M, Mallo J, Canela E, Zoli M, Agnati LF, Ibanez C, Lluís C, Franco R, Ferré S and Fuxe K)
1252. Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons. **Neuroscience** 113 (3) (2002) 709-719. (Torvinen M, Ginés S, Hillion J, Latini S, Canals M, Ciruela F, Bordini F, Staines W, Pedata F, Agnati LF, Lluís C, Franco R, Ferré S and Fuxe K)

1253. Synergistic interaction between adenosine A2A and glutamate mGluR5 receptors: Implications for striatal neuronal function. **Proc Natl Acad Sci USA** 99 (2002) 11940-11945. (Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K, Goldberg SR, Lluís C, Franco R and Ciruela F)
1254. Biphasic autoregulation of mineralocorticoid receptor mRNA in the medial septal nucleus by aldosterone. **Neuroendocrinology** 75 (2002)58-66. (Hansson AC and Fuxe K)
1255. Reversible and irreversible components of [3H]-N-propylnorapomorphine interaction with rat striatum membranes. **Neurosci Lett** 325 (2002) 111-114. (Lepiku M, Järv J, Fuxe K and Rincken A)
1256. Propranolol blocks the tachycardia induced by galanin (1-15) but not by galanin (1-29). **Regulatory Peptides** 107 (2002) 29-36. (Diaz-Cabiale Z, Cordon MP, Covenas R, Rivera A, Yanaihara N, Fuxe K, Gonzalez-Baron S, Narvaez JA)
1257. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. **Behav Pharmacol** 13 (2002):639-44 (Andersen MB, Fuxe K, Werge T, Gerlach J)
1258. Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture. **J Neurosci Res** 70(6) (2002) 766-773. (Antonelli T, Tomasini MC, Finetti S, Giardino L, Calza L, Fuxe K, Soubrie P, Tanganelli S, Ferraro L)
1259. Molecular basis of learning and memory: Modelling based on receptor mosaics. **In: From Synapses to Rules** (Apolloni and Kurfess, eds), Kluwer Academic/Plenum Publishers, New York, 2002, p. 165-195 (Agnati LF, Santarossa LM, Benfenati F, Ferri M, Morpurgo A, Apolloni B and Fuxe K)
1260. Heteromerization of adenosine and dopamine receptor subtypes. Relevance for neuronal integration in normal and pathological states.. **Advances in Behavioural Biology** Vol 53: Catecholamine Research: from Molecular Insights to Clinical Medicine (T. Nagatsu, T. Nabeshima, R. McCarty, D.S. Goldstein, eds), Kluwer Academic/Plenum Publishers, Hardbound, 2002. (Fuxe K, Ferré S, Torvinen M, Hillion J, Strömberg I, Franzén O, Ibanéz C, Zoli M, Lluís C, Agnati LF, Franco R)
1261. Regulation of FGF-2 gene by nicotinic receptors and its intracellular signaling mechanisms in the rat brain. **Eur Neuropsychopharm** (2002) 12(3):S.20.03, p. 144. (Fuxe K, Belluardo N, Olsson P-A, Mudo G)

## 2003

1262. Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse. **Curr Med Chem – Central Nervous System Agents** 3 (2003) 1-26. (Ferré S, Ciruela F, Woods AS, Canals M, Burgueno J, Marcellino D, Karcz-Kubichal M, Hope BT, Morales M, Popoli P, Goldberg SR, Fuxe K, Lluís C, Franco R, Agnati LF)
1263. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the

- striatopallidal GABA neurons. **Pharmacological Reviews** 55 (2003) 509-550. (Agnati LF, Ferré S, Lluís C, Franco R and Fuxe K)
1264. Novel strategies for the treatment of Parkinson's Disease. Focus on receptor-receptor interactions in the basal ganglia. Proceedings of the 10<sup>th</sup> International Conference on In Vivo Methods " **Monitoring Molecules in Neuroscience** (2003) 199-202. (Fuxe K, Ferré S, Woods A, Rivera A, Höistad M, Franco R, Kehr J and Agnati LF)
1265. Receptor heteromerization in adenosine A(2A) receptor signaling: Relevance for striatal function and Parkinson's disease. **Neurology** (2003) 61(11 Suppl 6): S19-23. (Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluís C, Ciruela F, Franco R, Ferré S)
1266. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. **J Biol Chem** (2003) 278(47): 46741-9. (Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferré S, Lluís C, Bouvier M, Franco R)
1267. Angiotensin II modulates the cardiovascular responses to microinjection of NPY Y1 and NPY Y2 receptor agonists into the nucleus tractus solitarii of the rat. **Brain Res** (2003) 983(1-2): 193-200. (Diaz-Cabiale Z, Fuxe K, Covenas R, Gonzalez-Baron S, Narvaez JA)
1268. Determination of histamine in microdialysis samples from rat brain by microbore column liquid chromatography following intramolecular excimer-forming derivatization with pyrene-labeling reagent. **J Neurosci Methods** (2003) 127(1): 11-17. (Yoshitake T, Yamaguchi M, Nohta H, Ichinose F, Yoshida H, Yoshitake S, Fuxe K, Kehr J)
1269. c-fos reduces corticosterone-mediated effects on neurotrophic factor expression in the rat hippocampal CA1 region. **J Neurosci** (2003) 23(14): 6013-22. (Hansson AC, Sommer W, Rimondini R, Andbjør B, Stromberg I, Fuxe K)
1270. The dopamine D1 receptor-rich main and paracapsular intercalated nerve cell groups of the rat amygdala: relationship to the dopamine innervation. **Neuroscience** (2003) 119(3): 733-746. (Fuxe K, Jacobsen KX, Höistad M, Tinner B, Jansson A, Staines WA, Agnati LF)
1271. Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. **Trends Biochem Sci** (2003) 28(5): 238-43. (Franco R, Canals M, Marcellino D, Ferré S, Agnati L, Mallol J, Casado V, Ciruela F, Fuxe K, Lluís C, Canela EI)
1272. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. **Neuropsychopharmacology** (2003) 28(7): 1281-91. (Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z, Pezzola A, Reggio R, Müller CE, Fuxe K, Goldberg SR, Popoli P, Ferré S)
1273. Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions? . **J Neurochem** 85 (2003) 23-33..(Del Arco A, Segovia A, Fuxe K, Mora F)

1274. Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. **J Neural Transm** 65 (2003) 1-28. (Agnati LF, Franzén O, Ferré S, Franco R, Fuxe K)

## 2004

1275. Hyperactivity to novelty induced by social isolation is not correlated with changes in D2 receptor function and binding in striatum. **Psychopharmacology** (Berl). (2004)171(2): 148-55. (Del Arco A, Zhu S, Terasmaa A, Mohammed AH, Fuxe K)

1276. Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. **J Neurochem** (2004) 88(3): 726-734. (Canals M, Burgueno J, Marcellino D, Cabello N, Canela EI, Mallol J, Agnati L, Ferre S, Bouvier M, Fuxe K, Ciruela F, Lluís C, Franco R)

1277. Acute intermittent nicotine treatment produces a reduction in the total number of FGF-2 immunoreactive astroglial cells in the substantia nigra of the rat. A stereological analysis. **Neurosci Lett** (2004) 355:181-184. (Liu FL, Fuxe K, Belluardo N, Leo G, Agnati LF and Aguirre A)

1278. The distribution and morphological characteristics of catecholaminergic cells in the diencephalon and midbrain of the bottlenose dolphin (*Tursiops truncatus*). **Brain Behav Evol** (2004) 64(1): 42-60. (Manger PR, Fuxe K, Ridgway SH, Siegel JM)

1279. Neurotensin enhances endogenous extracellular glutamate levels in primary cultures of rat cortical neurons: Involvement of neurotensin receptor in NMDA induced excitotoxicity. **Cereb Cortex** (2004) 14(4): 466-473. (Antonelli T, Ferraro L, Fuxe K, Finetti S, Fournier J, Tanganelli S, De Mattei M, Tomasini MC)

1280. Long-term modulation by postnatal oxytocin of the  $\alpha_2$ -adrenoceptor agonist binding sites in central autonomic regions and the role of prenatal stress. **J Neuroendocrinology** (2004) 16: 183-190. (Diaz-Cabiale Z, Olausson H, Sohlström A, Agnati LF, Narváez JA, Uvnäs-Moberg K and Fuxe K)

1281. On the molecular basis of the receptor mosaic hypothesis of the engram. **Cell Mol Neurobiol**,(2004) 24: 501-516. (Agnati LF, Ferré S, Leo G, Lluís C, Canela EI, Franco R and Fuxe K)

1282. Editorial Introduction. **In Parkinsonism and Related Disorders**, (Eds K. Fuxe and S-M. Aquilonius), Elsevier 2004, Vol 10, 257-258. (Aquilonius S-M and Fuxe K)

1283. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuropsychiatric disorders. **In Parkinsonism and Related Disorders**, (Eds K. Fuxe and S-M. Aquilonius), Elsevier 2004, Vol. 10, 265-271. (Ferré S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casadó V, Hillion J, Torvinen M, Fanelli F, de Benedetti P, Goldberg S, Bouvier M, Fuxe K, Agnati LF, Lluís C, Franco R and Woods A)

1284. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. **In Parkinsonism and Related Disorders**, (Eds K. Fuxe and S-M. Aquilonius), Elsevier 2004, Vol 10, 273-280. (Tanganelli S, Sandager Nielsen K, Ferraro L, Antonelli T, Kehr J, Franco R, Ferré S, Agnati LF, Fuxe K and Scheel-Krüger)
1285. Striatal plasticity and motor learning-importance of circadian rhythms, sleep stages and dreaming .. **In Parkinsonism and Related Disorders**, (Eds K. Fuxe and S-M. Aquilonius), Elsevier 2004, Vol 10, 315-317. (Horowski R, Benes H and Fuxe K)
1286. Neuronal A1 receptors mediate increase in extracellular kynurenic acid after local intrastriatal adenosine infusion. **J Neurochem** (2004) 90, 621-628. (Wu H-Q, Fuxe K and Schwarcz R)
1287. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor. **J Mol Neurosci** ((2004) 24, 173-180. (Torvinen M, Kozell LB, Neve KA, Agnati LF and Fuxe K)
1288. Energy gradients for VT-signal migration in the CNS: studies on melanocortin receptors, mitochondrial uncoupling proteins and food intake. **J Endocrin Invest** (2004) 27 (suppl 6), 23-34. (Agnati LF, Vergoni AV, Leo G, Genedani S, Franco R, Bertolini A and Fuxe K)
1289. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease and in Parkinson's disease patients. **Neurotox Res** (2004) 6(4), 327-332. (Genedani S, Rasio G, Cortelli P, Antonelli F, Guidolin D, Galantucci M, Fuxe K and Agnati LF)
1290. Corticosterone strongly increases the affinity of dorsal raphe 5-HT1A receptors. **NeuroReport** (2004) 15(9), 1457-1459. (Bellido I, Hansson A, Gómez-Luque AJ, Andbjør B., Agnati LF and Fuxe K)
1291. Motor responses to amphetamine treatment, task-specific training, and limited motor experience in a postacute animal stroke model. **Exp Neurol** (2004) 190, 102-108. (Brown AW, Bjelke B and Fuxe K)
1292. Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging. **Neurobiol Aging** (2004) 25, 1333-1342. (Belluardo N, Mudo G, Blum M, Itoh N, Agnati LF and Fuxe K)
1293. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. **Anal Chem** (2004) 76, 5354-5363. (Ciruela F, Burgueno J, Casado V, Canals M, Marcellino D, Goldberg SR, Bader M, Fuxe K, Agnati LF, Lluís C, Franco R, Ferré S and Woods AS)
1294. Neuroprotective effect of L-DOPA co-administration with the adenosine A2A receptor agonist CGS 21680 in animal model of Parkinson's disease. **Brain Res Bull** (2004) 64, 155-164. (Agnati LF, Leo G, Vergoni A-V, Martínez E, Hockemeyer J, Lluís C, Franco R, Fuxe K and Ferré S)

**2005**

1295. Trafficking of Adenosine A2A and Dopamine D2 Receptors. **J Mol Neurosci** 25(2):191-200, 2005. (Torvinen M, Torri C, Tombesi A, Marcellino D, Watson S, Lluís C, Franco R, Fuxe K, Agnati LF)
1296. Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat. **Neurosci Lett** 377(2): 101-105, 2005. (Perez de la Mora M, Cardenas-Cachon L, Vazquez-Garcia M, Crespo-Ramirez M, Jacobsen K, Höistad M, Agnati LF, Fuxe K)
1297. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. **Brain Res** 1033(2): 216-220, 2005. (Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Andbjør B, Leo G, Medhurst AD, Agnati LF, Fuxe K)
1298. Intracisternal galanin/angiotensin II interactions in central cardiovascular control. **Regulatory Peptides** 127(1-3): 133-140, 2005. (Diaz-Cabiale Z, Parrado C, Vela C, Covenas R, Yahaihara N, Fuxe K, Gonzales-Baron S, Narvaez JA)
1299. Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. **Life Sci** 76(13):1513-1526, 2005. (Uustare A, Vonk A, Terasmaa A, Fuxe K, Rincken A)
1300. In memoriam. **J Endocrinol Invest** 27(6): 3-8, 2005. (Azzali G, Lanza GG, Martini L, Agnati LF, Fuxe K, Benfenati F, Toni R, Vitale M)
1301. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. **Synapse** 55(4): 230-241, 2005. (Ferraro L, Fuxe K, Agnati LF, Tanganelli S, Tomasini MC, Antonelli T)
1302. Molecular mechanisms involved in the adenosine A2A and A1 receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. **J Neurochem** 92(2): 337-348, 2005. (Canals M, Angulo E, Casado V, Canela EI, Mallol J, Vinals F, Staines W, Tinner B, Hillion J, Agnati LF, Fuxe K, Ferré S, Lluís C, Franco R)
1303. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. **J Neural Transm** 112(1): 163-169, 2005. (Agnati LF, Genedani S, Rasio G, Galantucci M, Saltini S, Filafferro M, Franco R, Mora F, Ferré S, Fuxe K)
1304. Dynamics of volume transmission in the brain. Focus on catecholamine and opioid peptide communication and the role of uncoupling protein 2. **J Neural Transm** 112(1): 65-76, 2005. (Fuxe K, Rivera A, Jacobsen KX, Höistad M, Leo G, Horvath TL, Staines W, De la Calle A, Agnati LF)
1305. Energy gradients for the homeostatic control of brain ECF composition and for VT signal migration: introduction of the tide hypothesis. **J Neural Transm** 112(1): 45-63, 2005. (Agnati LF, Genedani S, Lenzi PL, Leo G, Mora F, Ferré S, Fuxe K)
1306. Preface – Special Issue. Neural Communication, NeuroTransmitters and Aging. **J Neural Transm** 112(1): 1-2, 2005. (Mora F, Fuxe K)
1307. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence for

- functional A2A/D3 heteromeric complexes. **Mol Pharmacol** 67(2): 400-407, 2005. (Torvinen M, Marcellino D, Canals M, Agnati LF, Lluís C, Franco R, Fuxe K)
- 1308 How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. **Trends Biochem Sci.** 30:188-93, 2005 (Agnati LF, Fuxe K, Ferre S.)
- 1309 Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. **Brain Res.** 1041:167-80, 2005. (Hoistad M, Samskog J, Jacobsen KX, Olsson A, Hansson HA, Brodin E, Fuxe K.)
- 1310 Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. **Neuroscience.** 133:787-96, 2005. (Belluardo N, Olsson PA, Mudo' G, Sommer WH, Amato G, Fuxe K.)
- 1311 Role of galanin and galanin(1-15) on central cardiovascular control. **Neuropeptides.** 39:185-90, 2005. (Diaz-Cabiale Z, Parrado C, Vela C, Razani H, Covenas R, Fuxe K, Narvaez JA.)
- 1312 Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. **J Neurosci Res.** 82:264-72, 2005. (Andersson M, Terasmaa A, Fuxe K, Stromberg I.)
- 1313 Effects of sarizotan on the corticostriatal glutamate pathways. **Synapse.** 58(3):193-9, 2005. (Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L.)
- 1314 New methods to evaluate colocalization of fluorophores in immunocytochemical preparations as exemplified by a study on A2A and D2 receptors in Chinese hamster ovary cells. **J Histochem Cytochem.** 53:941-53, 2005. (Agnati LF, Fuxe K, Torvinen M, Genedani S, Franco R, Watson S, Nussdorfer GG, Leo G, Guidolin D.)
- 1315 Existence and theoretical aspects of homomeric and heteromeric dopamine receptor complexes and their relevance for neurological diseases. **Neuromolecular Med.** 7:61-78, 2005. (Agnati LF, Ferre S, Burioni R, Woods A, Genedani S, Franco R, Fuxe K.)
- 1316 Concluding remarks. **J Mol Neurosci.** 26:299-302, 2005. (Agnati LF, Fuxe K.)
- 1317 Partners for adenosine A1 receptors. **J Mol Neurosci.** 26:221-32, 2005. (Franco R, Ciruela F, Casado V, Cortes A, Canela EI, Mallol J, Agnati LF, Ferre S, Fuxe K, Lluís C.)
- 1318 Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. **J Mol Neurosci.** 26:209-20, 2005. (Fuxe K, Ferre S, Canals M, Torvinen M, Terasmaa A, Marcellino D, Goldberg SR, Staines W, Jacobsen KX, Lluís C, Woods AS, Agnati LF, Franco R.)
- 1319 Receptor-receptor interactions, receptor mosaics, and basic principles of molecular network organization: possible implications for drug development. **J Mol Neurosci.** 26:193-208, 2005 (Agnati LF, Tarakanov AO, Ferre S, Fuxe K, Guidolin D.)
- 1320 Computer-assisted image analysis of caveolin-1 involvement in the internalization process of adenosine A2A-dopamine D2 receptor heterodimers. **J Mol Neurosci.** 26:177-84, 2005. (Genedani S, Guidolin D, Leo G, Filaferrero M, Torvinen M, Woods

AS, Fuxe K, Ferre S, Agnati LF.)

- 1321 How proteins come together in the plasma membrane and function in macromolecular assemblies: focus on receptor mosaics. **J Mol Neurosci.** 26:133-54, 2005. (Agnati LF, Guidolin D, Genedani S, Ferre S, Bigiani A, Woods AS, Fuxe K.)
- 1322 Role of electrostatic interaction in receptor-receptor heteromerization. **J Mol Neurosci.** 26:125-32, 2005. (Woods AS, Ciruela F, Fuxe K, Agnati LF, Lluís C, Franco R, Ferre S.)
- 1323 Introductory remarks. **J Mol Neurosci.** 26:109-12, 2005. (Agnati LF, Fuxe K. )
- 1324 Oxytocin increases the density of high affinity alpha(2)-adrenoceptors within the hypothalamus, the amygdala and the nucleus of the solitary tract in ovariectomized rats **Brain Res.** (2005) 12;1049(2):234-9. (Petersson M, Diaz-Cabiale Z, Angel Narvaez J, Fuxe K, Uvnas-Moberg K.)
- 1325 Dimer-based model for heptaspanning membrane receptors. **Trends Biochem Sci.** 30:360-6, 2005 (Franco R, Casado V, Mallol J, Ferre S, Fuxe K, Cortes A, Ciruela F, Lluís C, Canela EI.)
- 2006**
- 1326 Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. **J Neurol Sci.** 248(1-2):16-22, 2006. (Antonelli T, Fuxe K, Agnati L, Mazzoni E, Tanganelli S, Tomasini MC, Ferraro L.)
- 1327 Volume transmission and wiring transmission from cellular to molecular networks: history and perspectives. **Acta Physiol (Oxf).** 187(1-2):329-44, 2006. (Agnati LF, Leo G, Zanardi A, Genedani S, Rivera A, Fuxe K, Guidolin D)
- 1328 Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. **Brain Res.** 1077(1):67-80, 2006. (Filip M, Frankowska M, Zaniewska M, Przegalinski E, Muller CE, Agnati L, Franco R, Roberts DC, Fuxe K.)
- 1329 The two-state dimer receptor model: a general model for receptor dimers. **Mol Pharmacol.** 69(6):1905-12, 2006. (Franco R, Casado V, Mallol J, Ferrada C, Ferre S, Fuxe K, Cortes A, Ciruela F, Lluís C, Canela EI.)
- 1330 On the existence of a global molecular network enmeshing the whole central nervous system: physiological and pathological implications. **Curr Protein Pept Sci.** 7(1):3-15, 2006. (Agnati LF, Zunarelli E, Genedani S, Fuxe K.)
- 1331 Corticosterone actions on the hippocampal brain-derived neurotrophic factor expression are mediated by exon IV promoter. **J Neuroendocrinol.** 18(2):104-14, (2006) (Hansson AC, Sommer WH, Metsis M, Stromberg I, Agnati LF, Fuxe K.)
- 1332 Uncoupling protein 2/3 immunoreactivity and the ascending dopaminergic and noradrenergic neuronal systems: relevance for volume transmission. **Neuroscience.** 137(4):1447-61, 2006. (Rivera A, Agnati LF, Horvath TL, Valderrama JJ, de La Calle A, Fuxe K)



- 1333 Allosteric Modulation of Dopamine D(2) Receptors by Homocysteine. **J Proteome Res.** 5(11):3077-3083, 2006 (Agnati LF, Ferre S, Genedani S, Leo G, Guidolin D, Filafarro M, Carriba P, Casado V, Lluís C, Franco R, Woods AS, Fuxe K)
- 1334 Targeting adenosine A(2A) receptors in Parkinson's disease. **Trends Neurosci.** 29(11):647-54. 2006. (Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M.)
- 1335 The nigrostriatal DA pathway and Parkinson's disease. **J Neural Transm Suppl.** (70):71-83, 2006. (Fuxe K, Manger P, Genedani S, Agnati L.)
- 1336 Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype. **Eur J Neurosci.** 24(2):499-508, 2006. (Diaz-Cabiale Z, Parrado C, Rivera A, de la Calle A, Agnati L, Fuxe K, Narvaez JA )
- 1337 Uncoupling protein-2 promotes nigrostriatal dopamine neuronal function. **Eur J Neurosci.** 24(1):32-6, 2006 (Andrews ZB, Rivera A, Elsworth JD, Roth RH, Agnati L, Gago B, Abizaid A, Schwartz M, Fuxe K, Horvath TL.)
- 1338 The distribution of dopamine D1 receptor and mu-opioid receptor 1 receptor immunoreactivities in the amygdala and interstitial nucleus of the posterior limb of the anterior commissure: relationships to tyrosine hydroxylase and opioid peptide terminal systems. **Neuroscience.** 141(4):2007-18, 2006. (Jacobsen KX, Hoistad M, Staines WA, Fuxe K.)
- 1339 Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety. **Eur J Neurosci.** (10):2749-59, 2006. (Perez de la Mora M, Lara-Garcia D, Jacobsen KX, Vazquez-Garcia M, Crespo-Ramirez M, Flores-Gracia C, Escamilla-Marvan E, Fuxe K)
- 1340 Choline acetyltransferase immunoreactive cortical interneurons do not occur in all rodents: A study of the phylogenetic occurrence of this neural characteristic. **J Chem Neuroanat.** 32(2-4) :208-16, 2006. (Bhagwandin A, Fuxe K, Manger PR.)
- 1341 On the Neurobiological Basis of Consciousness: the Multiple Mirror Network Hypothesis. In: **New Research on Consciousness.** J.T. Locks, ed. Nova Science Publishers, Inc., Hauppauge, NY, pp. 65-81, 2006. (Agnati, L.F., Ferre, S., Fuxe, K.)
- 1342 Neurosciences from hodology to function: the vital legacy of Golgi and Cajal. **Leadership medica.** 2006 No 6: 4-21 (Agnati LF and Fuxe K )
- 1343 Protein conformational diseases in the frame of the concepts of pathological protein mosaics and "Nosferatu's effect". **Leadership medica.** 2006 No.6 24-33 (Agnati LF, Genedani S, Leo G, Andreoli N, Filafarro M, Forni A, Guidolin D, Mora F, Fuxe K )
- 2007**
- 1344 Working memory deficits in transgenic rats overexpressing human adenosine A(2A) receptors in the brain. **Neurobiol Learn Mem.** 2007. 87(1):42-56. (Gimenez-Llort L, Schiffmann SN, Schmidt T, Canela L, Camon L, Wassholm M, Canals M, Terasmaa A, Fernandez-Teruel A, Tobena A, Popova E, Ferre S, Agnati L, Ciruela F, Martinez E, Scheel-Kruger J, Lluís C, Franco R, Fuxe K, Bader M)

- 1345 Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption. **Neuropharmacology**. 2007; 52, 684-692. (Parrado C, Diaz-Cabiale Z, Garcia-Coronel M, Agnati LF, Covenas R, Fuxe K, Narvaez)
- 1346 Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. **J Neural Transm**. 2007; 114, 49-75. (Fuxe K, Canals M, Torvinen M, Marcellino D, Terasmaa A, Genedani S, Leo G, Guidolin D, Diaz-Cabiale Z, Rivera A, Lundstrom L, Langel U, Narvaez J, Tanganelli S, Lluís C, Ferre S, Woods A, Franco R, Agnati LF)
- 1347 Receptor-receptor interactions in central cardiovascular regulation. Focus on neuropeptide/alpha(2)-adrenoreceptor interactions in the nucleus tractus solitarius. **J Neural Transm**. 2006; 114,115-125. (Diaz-Cabiale Z, Parrado C, Fuxe K, Agnati L, Narvaez JA)
- 1348 Receptor-receptor interactions as studied with microdialysis. Focus on NTR/D2 interactions in the basal ganglia. **J Neural Transm**. 2007; 114, 105-113. (Antonelli T, Tomasini MC, Fuxe K, Agnati LF, Tanganelli S, Ferraro L.)
- 1349 Amyloidbeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease. **J Neural Transm**. 2007; 114:21-31. (Agnati LF, Genedani S, Leo G, Forni A, Woods AS, Filafèrro M, Franco R, Fuxe K.)
- 1350 A boolean network modelling of receptor mosaics relevance of topology and cooperativity. **J Neural Transm**. 2007, 114(1):77-92. (Agnati LF, Guidolin D, Leo G, Fuxe K)
- 1351 Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. **J Neural Transm**. 2007, 114(1):135-47. (Mudo G, Belluardo N, Fuxe K.)
- 1352 The brain as a system of nested but partially overlapping networks. Heuristic relevance of the model for brain physiology and pathology. **J Neural Transm**. 2007 Jan;114(1):3-19. (Agnati LF, Guidolin D, Fuxe K.)
- 1353 Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. **Eur Neuropsychopharmacol**. 2007, 17(4):298-308. (Jimenez-Vasquez PA, Diaz-Cabiale Z, Caberlotto L, Bellido I, Overstreet D, Fuxe K, Mathe AA.)
- 1354 Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens. **J Neural Transm**. 2007 114(2):185-93. (Del Arco A, Mora F, Mohammed AH, Fuxe K)
- 1355 Acute intermittent nicotine treatment induces fibroblast growth factor-2 in the subventricular zone of the adult rat brain and enhances neuronal precursor cell proliferation. **Neuroscience**. 2007; 145(2):470-83. (Mudò G, Belluardo N, Mauro A, Fuxe K.)
- 1356 Opposite patterns of age-associated changes in neurons and glial cells of the thalamus

- of human brain. **Neurobiol Aging**. 2007. (Guidolin D, Zunarelli E, Genedani S, Trentini GP, De Gaetani C, Fuxe K, Benegiamo C, Agnati LF.)
- 1357 Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. **Brain Res**. 2007 1143:208-20. (Marcellino D, Roberts DC, Navarro G, Filip M, Agnati L, Lluís C, Franco R, Fuxe K.)
- 1358 Dopamine D(4) receptor activation decreases the expression of mu-opioid receptors in the rat striatum. **J Comp Neurol**. 2007 502(3):358-66. (Gago B, Fuxe K, Agnati L, Peñafiel A, De La Calle A, Rivera A.)
- 1359 Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. **Brain Res Rev**. 2007, 55(1):55-67. (Ferré S, Agnati LF, Ciruela F, Lluís C, Woods AS, Fuxe K, Franco R.)
- 1360 On the role of receptor-receptor interactions and volume transmission in learning and memory. **Brain Res Rev**. 2007; 55(1):119-33. (Guidolin D, Fuxe K, Neri G, Nussdorfer GG, Agnati LF.)
- 1361 From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. **Brain Res Rev**. 2007, 55(1):17-54. (Fuxe K, Dahlström A, Höistad M, Marcellino D, Jansson A, Rivera A, Diaz-Cabiale Z, Jacobsen K, Tinner-Staines B, Hagman B, Leo G, Staines W, Guidolin D, Kehr J, Genedani S, Belluardo N, Agnati LF.)
- 1362 Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides. **Brain Res Rev**. 2007, 55(1):144-54. (Ferraro L, Tomasini MC, Fuxe K, Agnati LF, Mazza R, Tanganelli S, Antonelli T.)
- 1363 One century of progress in neuroscience founded on Golgi and Cajal's outstanding experimental and theoretical contributions. **Brain Res Rev**. 2007, 55(1):167-89. (Agnati LF, Genedani S, Leo G, Rivera A, Guidolin D, Fuxe K.)
- 1364 Does the human brain have unique genetically determined networks coding logical and ethical principles and aesthetics? From Plato to novel mirror networks. **Brain Res Rev**. 2007, 55(1):68-77. (Agnati LF, Agnati A, Mora F, Fuxe K.)
- 1365 The human histamine H3 receptor couples to GIRK channels in *Xenopus* oocytes. **Eur J Pharmacol**. 2007, 567(3):206-10. (Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.)
- 1366 Distribution and morphology of putative catecholaminergic and serotonergic neurons in the medulla oblongata of a sub-adult giraffe, *Giraffa camelopardalis*. **J Chem Neuroanat**. 2007, 34(3-4):69-79. (Badlangana NL, Bhagwandin A, Fuxe K, Manger PR.)
- 1367 Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. **Physiol Behav**. 2007, 92(1-2):210-7. (Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF.)

- 1368 Distribution and morphology of catecholaminergic and serotonergic neurons in the brain of the highveld gerbil, *Tatera brantsii*. **J Chem Neuroanat.** 2007, 34(3-4):134-44. (Moon DJ, Maseko BC, Ihunwo AO, Fuxe K, Manger PR.)
- 1369 Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. **Mov Disord.** 2007, 22(14):1990-2017. (Fuxe K, Marcellino D, Genedani S, Agnati L.)
- 1370 Possible relevance of receptor-receptor interactions between viral- and host-coded receptors for viral-induced disease. **ScientificWorldJournal.** 2007, 7:1073-81. (Agnati LF, Leo G, Genedani S, Guidolin D, Andreoli N, Fuxe K.)
- 1371 Hyper-homocysteinemia alters amyloid peptide-clusterin interactions and neuroglial network morphology and function in the caudate after intrastriatal injection of amyloid peptides. **Curr Alzheimer Res.** 2007, 4(3):305-13. (Leo G, Genedani S, Filaferrero M, Carone C, Andreoli N, Astancolle S, Davalli P, Fuxe K, Agnati LF.)
- 1372 Observations on the giraffe central nervous system related to the corticospinal tract, motor cortex and spinal cord: what difference does a long neck make? **Neuroscience.** 2007, 148(2):522-34. (Badlangana NL, Bhagwandin A, Fuxe K, Manger PR.)
- 1373 Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. **Prog Neurobiol.** 2007, 83(2):92-109. (Antonelli T, Fuxe K, Tomasini MC, Mazzoni E, Agnati LF, Tanganelli S, Ferraro L.)
- 1374 Role of cooperativity in protein folding and protein mosaic assemblage relevance for protein conformational diseases. **Curr Protein Pept Sci.** 2007, 8(5):460-70. (Agnati LF, Guidolin D, Leo G, Genedani S, Arhem P, Fornì A, Andreoli N, Fuxe K.)
- 1375 Adenosine receptor heteromers and their integrative role in striatal function. **ScientificWorldJournal.** 2007; 7:74-85. (Ferré S, Ciruela F, Quiroz C, Luján R, Popoli P, Cunha RA, Agnati LF, Fuxe K, Woods AS, Lluís C, Franco R.)
- 1376 Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [(3)H]GABA release. **Eur J Neurosci.** 2007, 26(12):3614-30. (Pérez de la Mora M, Hernández-Gómez AM, Arizmendi-García Y, Jacobsen KX, Lara-García D, Flores-Gracia C, Crespo-Ramírez M, Gallegos-Cari A, Nuche-Bricaire A, Fuxe K.)
- 2008**
1377. On the key role played by altered protein conformation in Parkinson's disease. **J Neural Transm** 115(9): 1285-99, 2008. (Agnati LF, Baldelli E, Andreoli N, Woods AS, Vellani V, Marcellino D, Guidolin D, Fuxe K.)
1378. Receptor mosaics of neural and immune communication: possible implications for basal ganglia functions. **Brain Res Rev** 58(2): 400-14, 2008. (Agnati LF, Fuxe KG, Goncharova LB, Tarakanov AO.)

1379. Understanding neuronal molecular networks builds on neuronal cellular network architecture. **Brain Res Rev** 58(2): 379-99, 2008. (Agnati LF, Guidolin D, Carone C, Dam M, Genedani S, Fuxe K.)
1380. Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains. **Brain Res Rev** 58(2): 459-74, 2008. (Agnati LF, Leo G, Genedani S, Andreoli N, Marcellino D, Woods A, Piron L, Guidolin D, Fuxe K.)
1381. Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein. **J Neural Transm** 116(8): 953-74, 2008. (Agnati LF, Leo G, Genedani S, Piron L, Rivera A, Guidolin D, Fuxe K.)
1382. The novel cyclooxygenase-2 inhibitor GW637185X protects against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. **Neuroreport** 19(6): 657-60, 2008. (Aguirre, J. A., G. Leo, Cueto, R, Andjer B, Naylor A. Medhurst AD, Agnati, LF, Fuxe K.)
1383. Neurotensin receptor involvement in the rise of extracellular glutamate levels and apoptotic nerve cell death in primary cortical cultures after oxygen and glucose deprivation. **Cereb Cortex** 18(8): 1748-57, 2008. (Antonelli T, Tomasini MC, Fournier J, Mazza R, Tanganelli S, Pironi S, Fuxe K, Luca F.)
1384. Nicotine-induced fibroblast growth factor-2 restores the age-related decline of precursor cell proliferation in the subventricular zone of rat brain. **Brain Res** 1193: 12-24, 2008. (Belluardo N, Mudo' G, Bonomo A, Di Liberto V, Frinchi M, Fuxe K.)
1385. Nuclear organization and morphology of cholinergic, putative catecholaminergic and serotonergic neurons in the brains of two species of African mole-rat. **J Chem Neuroanat** 35(4): 371-87, 2008. (Bhagwandin A, Fuxe K, Bennett NC, Manger PR.)
1386. Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. **Neuropharmacology** 54(1): 31-5, 2008. (Borgkvist A, Marcellino D, Fuxe K, Greengard P, Fisone G.)
1387. Detection of heteromerization of more than two proteins by sequential BRET-FRET. **Nat Methods** 5(8): 727-33, 2008. (Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, Lluís C, Franco R.)
1388. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain. **Brain Res** 1190: 23-38, 2008. (Chadi G, Silva C, Maximino JR, Fuxe K, da Silva GO.)
1389. Distribution and morphology of putative catecholaminergic and serotonergic neurons in the brain of the greater canerat, *Thryonomys swinderianus*. **J Chem Neuroanat** 35(1): 108-22, 2008. (Dwarika S, Maseko BC, Ihunwo AO, Fuxe K, Manger PR.)
1390. Neurotensin receptors as modulators of glutamatergic transmission. **Brain Res Rev** 58(2): 365-73, 2008. (Ferraro L, Tomasini MC, Mazza R, Fuxe K, Fournier J, Tanganelli S, Antonelli T.)

1391. Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. **Neurosci Lett** 447(1): 20-5, 2008. (Frinchi M, Bonomo A, Trovato-Salinaro A, Condorelli DF, Fuxe K, Spampinato MG, Mudò G.)
1392. The basal ganglia-from neuronal systems to molecular networks. Preface. **Brain Res Rev** 58(2): 247-8, 2008. (Fuxe, K., L. F. Agnati, et al.)
1393. Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. **Physiology** (Bethesda) 23: 322-32, 2008. (Fuxe, K., D. Marcellino, et al.)
1394. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. **Brain Res Rev** 58(2): 415-52, 2008. (Fuxe, K., D. Marcellino, et al.)
1395. A new road to neuroinflammation in Parkinson's disease? **Brain Res Rev** 58(2): 453-8, 2008. (Fuxe, K. G., A. O. Tarakanov, et al.)
1396. Opposite patterns of age-associated changes in neurons and glial cells of the thalamus of human brain. **Neurobiol Aging** 29(6): 926-36, 2008. (Guidolin D, Zunarelli E, Genedani S, Trentini GP, De Gaetani C, Fuxe K, Benegiamo C, Agnati LF.)
1397. Time-course of immediate early gene expression in hippocampal subregions of adrenalectomized rats after acute corticosterone challenge. **Brain Res** 1215: 1-10, 2008. (Hansson, A. C. and K. Fuxe.)
1398. Nuclear organization and morphology of cholinergic, putative catecholaminergic and serotonergic neurons in the brain of the Cape porcupine (*Hystrix africaeaustralis*): increased brain size does not lead to increased organizational complexity. **J Chem Neuroanat** 36(1): 33-52, 2008. (Limacher A, Bhagwandin A, Fuxe K, Manger PR.)
1399. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. **Neuropharmacology** 54(5): 815-23, 2008. (Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K.)
1400. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. **J Biol Chem** 283(38): 26016-25, 2008. (Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, Barnes C, Goldberg SR, Lluis C, Fuxe K, Franco R.)
1401. Wiring and volume transmission in rat amygdala. Implications for fear and anxiety. **Neurochem Res** 33(8): 1618-33, 2008. (Pérez de la Mora M, Jacobsen KX, Crespo-Ramírez M, Flores-Gracia C, Fuxe K.)
1402. Cellular localization and distribution of dopamine D(4) receptors in the rat cerebral cortex and their relationship with the cortical dopaminergic and noradrenergic nerve terminal networks. **Neuroscience** 155(3): 997-1010, 2008. (Rivera A, Peñafiel A, Megías M, Agnati LF, López-Téllez JF, Gago B, Gutiérrez A, de la Calle A, Fuxe K.)

1403. Nuclear organization and morphology of serotonergic neurons in the brain of the Nile crocodile, *Crocodylus niloticus*. **J Chem Neuroanat** 35(1): 133-45, 2008. (Rodrigues SL, Maseko BC, Ihunwo AO, Fuxe K, Manger PR.)
1404. Differential voltage-sensitivity of D2-like dopamine receptors. **Biochem Biophys Res Commun** 374(3): 496-501, 2008. (Sahlholm K, Marcellino D, Nilsson J, Fuxe K, Arhem P.)
1405. Voltage-sensitivity at the human dopamine D2S receptor is agonist-specific. **Biochem Biophys Res Commun** 377(4): 1216-21, 2008. (Sahlholm K, Marcellino D, Nilsson J, Fuxe K, Arhem P.)
1406. Electrophysiology-based analysis of human histamine H(4) receptor pharmacology using GIRK channel coupling in *Xenopus* oocytes. **Eur J Pharmacol** 591(1-3): 52-8, 2008. (Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.)
1407. Voltage-dependence of the human dopamine D2 receptor. **Synapse** 62(6): 476-80, 2008. (Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.)
1408. How calmodulin interacts with the adenosine A(2A) and the dopamine D(2) receptors. **J Proteome Res** 7(8): 3428-34, 2008. (Woods AS, Marcellino D, Jackson SN, Franco R, Ferré S, Agnati LF, Fuxe K.)
1409. Book review on “ Starting with serotonin :how a high-rolling father of drug discovery repeatedly beat the odds” by Fuxe K **N ENGL J MED** 2008, 359, 24 p 2622.
1410. The Nigro-Striatal DA Neurons and Mechanisms of Their Degeneration in Parkinson's Disease in “ From Development to Degeneration and Regeneration of the Nervous System” eds C. Ribak et al. **Oxford University Press** 119-141, 2008 (Fuxe K, Marcellino D, Antonelli T, Mudo,G, Manger P,Genedani S, Ferraro L, Belluardo N, Tanganelli S, Agnati L)
1411. Receptor Heteromers: Building a New Language to Fit Emerging Concepts **Nature Chemical Biology** 2009 ,5, 131-4, 2008. (Sergi Ferré, Ruben Baler, Michel Bouvier, Marc G. Caron, Lakshmi A. Devi, Thierry Durroux, Kjell Fuxe, Susan R. George, Jonathan A. Javitch, Martin J. Lohse, Ken Mackie, Graeme Milligan, Kevin D.G. Pflieger, Jean-Philippe Pin, Nora Volkow, Maria Waldhoer, Amina S. Woods & Rafael Franco.)

## 2009

1412. Implications of the 'Energide' concept for communication and information handling in the central nervous system. **J Neural Transm** 116(8): 1037-52, 2009. (Agnati, L. F., K. Fuxe, et al.)
1413. Receptor-receptor interactions: A novel concept in brain integration. **Prog Neurobiol** 90(2): 157-75, 2009. (Agnati, L. F., D. Agnati LF, Guidolin D, Leo G, Carone C, Genedani S, Fuxe K.)
1414. Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein. **J Neural Transm** 116(8): 953-74, 2009. (Agnati LF, Leo G, Genedani S, Piron L, Rivera A, Guidolin D, Fuxe K.)

1415. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. **J Pharmacol Exp Ther** 329(2): 708-17, 2009. (Antonelli T, Tomasini MC, Mazza R, Fuxe K, Gaetani S, Cuomo V, Tanganelli S, Ferraro L.)
1416. Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment. **Neuromolecular Med** 12(3): 248-59, 2009. (Baldelli E, Leo G, Andreoli N, Fuxe K, Biagini G, Agnati LF.)
1417. Organization of cholinergic, putative catecholaminergic and serotonergic nuclei in the diencephalon, midbrain and pons of sub-adult male giraffes. **J Chem Neuroanat** 39(3): 189-203, 2009. (Bux F, Bhagwandin A, Fuxe K, Manger PR.)
1418. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. **Prog Neurobiol** 90(2): 198-216, 2009. (de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K.)
1419. Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceuticals in neurodegenerative disorders. **Mini Rev Med Chem** 9(12): 1429-38, 2009. (Ferraro L, Tomasini MC, Beggiato S, Guerrini R, Salvadori S, Fuxe K, Calzà L, Tanganelli S, Antonelli T.)
1420. Building a new conceptual framework for receptor heteromers. **Nat Chem Biol** 5(3): 131-4, 2009. (Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pflieger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R.)
1421. The discovery of central monoamine neurons gave volume transmission to the wired brain. **Prog Neurobiol** 90(2): 82-100, 2009. (Fuxe K., A. B. Dahlstrom, et al.)
1422. Brain receptor mosaics and their intramembrane receptor-receptor interactions: molecular integration in transmission and novel targets for drug development. **J Acupunct Meridian Stud** 2(1): 1-25, 2009. (Fuxe K., D. Marcellino, et al.)
1423. Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. **Curr Opin Pharmacol** 10(1): 14-22, 2009. (Fuxe K., D. Marcellino, et al.)
1424. Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. **J Neural Transm** 116(8): 923-39, 2009. (Fuxe K., D. Marcellino, et al.)
1425. Nuclear organization and morphology of cholinergic, putative catecholaminergic and serotonergic neurons in the brain of the rock hyrax, *Procavia capensis*. **J Chem Neuroanat** 38(1): 57-74, 2009. (Gravett N, Bhagwandin A, Fuxe K, Manger PR.)
1426. An international conference on Brain Plasticity, Aging and Neuropsychiatric disorders hosted by the Ramon Areces Foundation. Preface. **J Neural Transm** 116(8): 921-2, 2009. (Mora F, Agnati LF, Fuxe K.)
1427. The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. **J Neural Transm** 116(8): 995-1005, 2009. (Mudò G, Bonomo A, Di Liberto V, Frinchi M, Fuxe K, Belluardo N.)



1428. Cell-Cell Communications through the Extracellular Space. In: Squire LR (ed.) **Encyclopedia of Neuroscience** 2009 volume 2, pp. 665-664. Oxford: Academic Press. (Fuxe K and Agnati LF.)
1429. Interactions between calmodulin, adenosine A<sub>2A</sub>, and dopamine D<sub>2</sub> receptors. **J Biol Chem** 284(41): 28058-68, 2009. (Navarro G, Aymerich MS, Marcellino D, Cortés A, Casadó V, Mallol J, Canela EI, Agnati L, Woods AS, Fuxe K, Lluís C, Lanciego JL, Ferré S, Franco R.)
1430. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair. **J Neural Transm Suppl**(73): 185-202, 2009. (Silva, C., K. Fuxe, et al.)
1431. Triplet puzzle: homologies of receptor heteromers. **J Mol Neurosci** 41(2): 294-303, 2009. (Tarakanov, A. O. and K. G. Fuxe)
1432. Possible role of receptor heteromers in multiple sclerosis. **J Neural Transm** 116(8): 989-94, 2009. (Tarakanov, A. O., K. G. Fuxe, et al.)
- 2010**
1433. An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A<sub>2A</sub>, dopamine D<sub>2</sub>, cannabinoid CB<sub>1</sub>, and metabotropic glutamate mGlu<sub>5</sub> receptors. **J Recept Signal Transduct Res** 30(5): 355-69, 2010. (Agnati LF, Guidolin D, Albertin G, Trivello E, Ciruela F, Genedani S, Tarakanov A, Fuxe K.)
- <sup>1434.</sup> Understanding wiring and volume transmission. **Brain Res Rev** 64(1): 137-59, 2010. (Agnati LF, Guidolin D, Guescini M, Genedani S, Fuxe K.)
1435. Receptor-receptor interactions: A novel concept in brain integration. **Prog Neurobiol** 90(2): 157-75, 2010. (Agnati LF, Guidolin D, Leo G, Carone C, Genedani S, Fuxe K.)
1436. On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers. **J Recept Signal Transduct Res** 30(5): 287-303, 2010. (Agnati LF, Guidolin D, Vilardaga JP, Ciruela F, Fuxe K.)
1437. Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment. **Neuromolecular Med** 12(3): 248-59, 2010. (Baldelli E, Leo G, Andreoli N, Fuxe K, Biagini G, Agnati LF.)
- <sup>1438.</sup> Impaired M<sub>3</sub> muscarinic acetylcholine receptor signal transduction through blockade of binding of multiple proteins to its third intracellular loop. **Cell Physiol Biochem** 25(4-5): 397-408, 2010. (Borroto-Escuela DO, Correia PA, Perez Alea M, Narvaez M, Garriga P, Fuxe K, Ciruela F.)
1439. The M<sub>5</sub> muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization. **Biochim Biophys Acta** 1803(7): 813-25, 2010. (Borroto-Escuela DO, García-Negredo G, Garriga P, Fuxe K, Ciruela F.)
1440. A serine point mutation in the adenosine A<sub>2A</sub> R C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D<sub>2</sub>R. **Biochem Biophys**

- Res Commun** 394(1): 222-7, 2010. (Borrito-Escuela DO, Marcellino D, Narvaez M, Flajolet M, Heintz N, Agnati L, Ciruela F, Fuxe K.)
1441. Galanin receptor-1 modulates 5-hydroxytryptamine-1A signaling via heterodimerization. **Biochem Biophys Res Commun** 393(4): 767-72, 2010. (Borrito-Escuela DO, Narvaez M, Marcellino D, Parrado C, Narvaez JA, Tarakanov AO, Agnati LF, Díaz-Cabiale Z, Fuxe K.)
1442. Characterization of the A(2a)R-D(2)R interface: focus on the role of the C-terminal tail and the transmembrane helices. **Biochem Biophys Res Commun**. 2010. (Borrito-Escuela DO, Romero-Fernandez W, Tarakanov AO, Gómez-Soler M, Corrales F, Marcellino D, Narvaez M, Frankowska M, Flajolet M, Heintz N, Agnati LF, Ciruela F, Fuxe K.)
1443. Dopamine D2 and 5-hydroxytryptamine 5-HT(A) receptors assemble into functionally interacting heteromers. **Biochem Biophys Res Commun** 401(4): 605-10, 2010. (Borrito-Escuela DO, Romero-Fernandez W, Tarakanov AO, Marcellino D, Ciruela F, Agnati LF, Fuxe K.)
1444. Organization of cholinergic, putative catecholaminergic and serotonergic nuclei in the diencephalon, midbrain and pons of sub-adult male giraffes. **J Chem Neuroanat** 39(3): 189-203, 2010. (Bux F, Bhagwandin A, Fuxe K, Manger PR.)
1445. G protein-coupled receptor oligomerization for what? **J Recept Signal Transduct Res** 30(5): 322-30, 2010. (Ciruela F, Vallano A, Arnau JM, Sánchez S, Borrito-Escuela DO, Agnati LF, Fuxe K, Fernández-Dueñas V.)
1446. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. **Prog Neurobiol** 90(2): 198-216, 2010. (de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K.)
1447. The Galanin N-terminal fragment (1-15) interacts with neuropeptide Y in central cardiovascular control: Involvement of the NPY Y2 receptor subtype. **Regul Pept** 163(1-3): 130-6, 2010. (Díaz-Cabiale Z, Parrado C, Narvaez M, Millón C, Puigcerver A, Fuxe K, Narvaez JA.)
1448. Nanomolar concentrations of cocaine enhance D2-like agonist-induced inhibition of the K<sup>+</sup>-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine. **J Neural Transm** 117(5): 593-7, 2010. (Ferraro L, Beggiano S, Marcellino D, Frankowska M, Filip M, Agnati LF, Antonelli T, Tomasini MC, Tanganelli S, Fuxe K.)
1449. GABA(A) rho receptor mechanisms in the rat amygdala and its role in the modulation of fear and anxiety. **Psychopharmacology** (Berl). 2010. (Flores-Gracia C, Nuche-Bricaire A, Crespo-Ramírez M, Miledi R, Fuxe K, Pérez de la Mora M.)
1450. FGF-2/FGFR1 neurotrophic system expression level and its basal activation do not account for the age-dependent decline of precursor cell proliferation in the subventricular zone of rat brain. **Brain Res** 1358: 39-45, 2010. (Frinchi M, Di Liberto V, Olivieri M, Fuxe K, Belluardo N, Mudò G.)
1451. The discovery of central monoamine neurons gave volume transmission to the wired brain. **Prog Neurobiol** 90(2): 82-100, 2010. (Fuxe K., A. B. Dahlstrom, et al.)

1452. The changing world of G protein-coupled receptors. **J Recept Signal Transduct Res** 30(5): 271, 2010. (Fuxe, K. and T. Kenakin)
1453. The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. **J Recept Signal Transduct Res** 30(5): 272-83, 2010. (Fuxe, K., D. Marcellino, et al.)
1454. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. **CNS Neurosci Ther** 16(3): e18-42, 2010. (Fuxe, K., D. Marcellino, et al.)
1455. Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. **Curr Opin Pharmacol** 10(1): 14-22, 2010. (Fuxe, K., D. Marcellino, et al.)
1456. Differential sensitivity of A(2A) and especially D (2) receptor trafficking to cocaine compared with lipid rafts in cotransfected CHO cell lines. Novel actions of cocaine independent of the DA transporter. **J Mol Neurosci** 41(3): 347-57, 2010. (Genedani S, Carone C, Guidolin D, Filaferrero M, Marcellino D, Fuxe K, Agnati LF.)
1457. Bioinformatics and mathematical modelling in the study of receptor-receptor interactions and receptor oligomerization Focus on adenosine receptors. **Biochim Biophys Acta**. 2010. (Guidolin D, Ciruela F, Genedani S, Guescini M, Tortorella C, Albertin G, Fuxe K, Agnati LF.)
1458. International Workshop at the Nobel Forum, Karolinska Institutet on G protein-coupled receptors: finding the words to describe monomers, oligomers, and their molecular mechanisms and defining their meaning. Can a consensus be reached? **J Recept Signal Transduct Res** 30(5): 284-6, 2010. (Kenakin T, Agnati LF, Caron M, Fredholm B, Guidoli D, Kobilka B, Lefkowitz RW, Lohse M, Woods A, Fuxe K.)
1459. Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. **Neurobiol Dis** 40(2): 460-6, 2010. (Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D.)
1460. Cocaine produces D2R-mediated conformational changes in the adenosine A(2A)R-dopamine D2R heteromer. **Biochem Biophys Res Commun** 394(4): 988-92, 2010. (Marcellino D, Navarro G, Sahlholm K, Nilsson J, Agnati LF, Canela EI, Lluís C, Rhem P, Franco R, Fuxe K.)
1461. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. **J Neural Transm** 117(6): 681-7, 2010. (Marcellino D, Suárez-Boomgaard D, Sánchez-Reina MD, Aguirre JA, Yoshitake T, Yoshitake S, Hagman B, Kehr J, Agnati LF, Fuxe K, Rivera A.)
1462. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. **Proc Natl Acad Sci U S A** 107(43): 18676-81, 2010. (Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortés A, Casadó V, Canela EI, Ortiz J, Fuxe K, Lluís C, Ferré S, Franco R.)
1463. Nuclear organization of cholinergic, putative catecholaminergic and serotonergic nuclei in the brain of the eastern rock elephant shrew, *Elephantulus myurus*. **J Chem Neuroanat** 39(3): 175-88, 2010. (Pieters RP, Gravett N, Fuxe K, Manger PR.)

1464. Triplet puzzle: homologies of receptor heteromers. **J Mol Neurosci** 41(2): 294-303. 2010. (Tarakanov, A. O. and K. G. Fuxe)